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ABSTRACT 
The antimicrobial resistance data among zoonotic and indicator bacteria in 2011, submitted by 26 European 
Union Member States, were jointly analysed by the European Food Safety Authority and the European Centre 
for Disease Prevention and Control. Data covered resistance in zoonotic Salmonella and Campylobacter isolates 
from humans, food and animals, and in indicator Escherichia coli and enterococci isolates from animals and 
food. Data on methicillin-resistant Staphylococcus aureus in animals and food were also presented. Resistance in 
isolates  from  humans  were  mainly  interpreted  using  clinical  breakpoints,  while  animal  and  food  isolate 
resistance was interpreted using epidemiological cut-off values. Resistance was commonly found in isolates 
from humans, animals and food, although disparities in resistance were frequently observed between Member 
States. High resistance levels were recorded to ampicillin, tetracyclines and sulfonamides in Salmonella isolates 
from  humans,  while  resistance  to  third-generation  cephalosporins  and  fluoroquinolones  remained  low.  In 
Salmonella  and  indicator  Escherichia coli  isolates  from  fowl,  pigs,  cattle  and  meat  thereof,  resistance  to 
ampicillin, tetracyclines and sulfonamides was also commonly detected, while resistance to third-generation 
cephalosporins was low. Moderate to high resistance to (fluoro)quinolones was observed in Salmonella isolates 
from turkeys, fowl and broiler meat. In Campylobacter isolates from human cases, resistance to ampicillin, 
ciprofloxacin, nalidixic acid and tetracyclines was high, while resistance to erythromycin was low to moderate. 
High resistance to ciprofloxacin, nalidixic acid and tetracyclines was observed in Campylobacter isolates from 
fowl, broiler meat, pigs and cattle, whereas much lower levels were observed for erythromycin and gentamicin. 
Among the indicator enterococci isolates from animals and food, resistance to tetracyclines and erythromycin 
was commonly detected. The report also presents for the first time results on multi-resistance and co-resistance 
to critically important antimicrobials in both human and animal isolates. Very few isolates from animals were 
co-resistant to critically important antimicrobials. 
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About EFSA 
The European Food Safety Authority (EFSA), located in Parma, Italy, was established and funded by the 
European Union (EU) as an independent agency in 2002 following a series of food scares that caused the 
European  public  to  voice  concerns  about  food  safety  and  the  ability  of  regulatory  authorities  to  protect 
consumers. EFSA provides objective scientific advice on all matters, in close collaboration with national 
authorities and in open consultation with its stakeholders, with a direct or indirect impact on food and feed 
safety,  including  animal  health  and  welfare  and  plant  protection.  EFSA  is  also  consulted on  nutrition  in 
relation to EU legislation. EFSA’s work falls into two areas: risk assessment and risk communication. In 
particular, EFSA’s risk assessments provide risk managers (EU institutions with political accountability, i.e. 
the  European  Commission,  the  European  Parliament  and  the  Council)  with  a  sound  scientific  basis  for 
defining  policy-driven  legislative  or  regulatory  measures  required  to  ensure  a  high  level  of  consumer 
protection with regard to food and feed safety. EFSA communicates to the public in an open and transparent 
way on all matters within its remit. Collection and analysis of scientific data, identification of emerging risks 
and scientific support to the Commission, particularly in the case of a food crisis, are also part of EFSA’s 
mandate, as laid down in the founding Regulation (EC) No 178/2002
4 of 28 January 2002. 
About ECDC 
The  European  Centre  for  Disease  Prevention  and Control  (ECDC), an  EU  agency based in  Stockholm, 
Sweden,  was  established  in  2005.  The  objective  of  ECDC  is  to  strengthen  Europe’s  defences  against 
infectious diseases. According to Article 3 of the founding Regulation (EC) No 851/2004
5 of 21 April 2004, 
ECDC’s  mission  is  to  identify,  assess  and  communicate  current  and  emerging  threats  to  human  health 
posed by infectious diseases. In order to achieve this mission, ECDC works in partnership with national 
public  health  bodies  across  Europe  to  strengthen  and  develop  EU-wide  disease  surveillance  and  early 
warning systems. By working with experts throughout Europe, ECDC pools Europe’s knowledge in health so 
as  to  develop  authoritative  scientific  opinions  about  the  risks  posed  by  current  and  emerging  infectious 
diseases. 
About the report 
Based on Article 33 in the Regulation (EC) 178/2002, EFSA’s Zoonoses Unit is responsible for examining 
data on zoonoses, antimicrobial resistance and food-borne outbreaks collected from the Member States in 
accordance with Directive 2003/99/EC
6 and for preparing the  European Union  Summary Report from the 
results. Regarding antimicrobial resistance data from   2011, this  European Union  Summary Report was 
produced in collaboration with ECDC and the Animal Health and Veterinary Laboratories Agency (AHVLA), 
United Kingdom and the University of Hasselt in Belgium, contracted by EFSA. 
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Summary 
Zoonoses are infections and diseases that are transmissible between animals and humans. Infection can be 
acquired directly from animals, or through the ingestion of contaminated foodstuffs. The severity of these 
diseases in humans can vary from mild symptoms to life-threatening conditions. The zoonotic bacteria that 
are resistant to antimicrobials are of special concern since they might compromise the effective treatment of 
infections  in  humans.  In  order  to  follow  the  occurrence  of  antimicrobial  resistance  in  zoonotic  bacteria 
isolated  from  animals  and  food  in  the  European  Union,  information  is  collected  and  analysed  from  the 
European Union Member States. 
In 2011, 26 Member States submitted information on the occurrence of antimicrobial resistance in zoonotic 
bacteria to the European Commission and the European Food Safety Authority, and 21 Member States 
submitted information to the European Centre for Disease Prevention and Control. In addition, three other 
European  countries  provided  information.  Assisted  by  its  contractors,  the  Animal  Health  and  Veterinary 
Laboratories Agency in the United Kingdom and the University of Hasselt in Belgium, the European Food 
Safety Authority and the European Centre for Disease Prevention and Control analysed the data, the results 
of which are published in this European Union Summary Report on antimicrobial resistance. Information on 
resistance was reported regarding Salmonella and Campylobacter isolates from human cases, food and 
animals, whereas data on indicator Escherichia coli and indicator enterococci isolates related only to animals 
and  food.  Information  was  reported  by  some  Member  States  on  the  occurrence  of  methicillin-resistant 
Staphylococcus aureus  in  animals  and  food;  the  antimicrobial  susceptibility  of  methicillin-resistant 
Staphylococcus aureus isolates was additionally reported by two countries. Data on antimicrobial resistance 
in isolates from human cases were mainly interpreted by using clinical breakpoints, while the quantitative 
data  on  antimicrobial  resistance  in  isolates  from  food  and  animals  were  interpreted  using  harmonised 
epidemiological cut-off values that detect microbiological resistance.  
The reporting of antimicrobial resistance data at isolate-based level by an important number of Member 
States  has  allowed  the  first  analysis  at  the  European  Union  level  of  multi-resistance  and  co-resistance 
patterns to critically important antimicrobials in both human and animal isolates, which is a new feature of the 
present report. Also, for certain bacterial species, antimicrobial resistance data could be analysed at the 
production-type level, such as broilers and laying hens of Gallus gallus, which allows the analysis of the data 
to be fine-tuned. 
Antimicrobial resistance was commonly detected in isolates of Salmonella and Campylobacter from human 
cases as well as from food-producing animals and food in the European Union. This was also the case for 
indicator (commensal) Escherichia coli and enterococci isolated from animals and food. For many of the 
antimicrobials, the levels of resistance varied greatly between different Member States.  
In the European Union, the occurrence of resistance in Salmonella isolates from cases of salmonellosis in 
humans  was  high  for  ampicillin,  tetracyclines  and  sulfonamides  and  moderate  for  nalidixic  acid  and 
streptomycin, with high levels of multi-drug resistance observed in some countries. However, resistance to 
the critically important antimicrobials for human medicine, cefotaxime (a third-generation cephalosporin) and 
ciprofloxacin  (a  fluoroquinolone),  was  relatively  low,  although  for  ciprofloxacin  reported  resistance  levels 
were higher in countries where epidemiological cut-off values were used as the interpretive criteria. Co-
resistance to ciprofloxacin and cefotaxime among Salmonella isolates was low. The resistance levels also 
differed substantially between serovars, with higher resistance to ciprofloxacin and nalidixic acid observed in 
Salmonella Enteritidis than in Salmonella Typhimurium and the opposite for the other antimicrobials. There 
was  a  high  level  of  resistance  to  ampicillin,  ciprofloxacin,  nalidixic  acid  and  tetracyclines  among 
Campylobacter isolates from human cases, with high and very high levels of multi-drug resistance observed 
in some countries. However, relatively low resistance was recorded to erythromycin, which is the clinically 
most important antimicrobial for treatment of campylobacteriosis in humans. In addition, co-resistance to 
ciprofloxacin and erythromycin was low among Campylobacter jejuni isolates.  
The  high  proportions  of  Salmonella,  Campylobacter  and  indicator  Escherichia  coli  isolates  exhibiting 
resistance to fluoroquinolones (ciprofloxacin) remain of concern. In Salmonella spp. isolates of food and 
animal origin, the highest occurrence of resistance to ciprofloxacin was noted in turkeys, fowl (Gallus gallus) 
and broiler meat, where the proportion of resistant isolates varied between 29 % and 50 % in the reporting 
Member State group. Ciprofloxacin resistance was recorded more often in broilers than in laying hens. Three 
Member States demonstrated a significant increasing trend for ciprofloxacin and nalidixic acid resistance and 
one a decreasing trend for both antimicrobials in Salmonella species from Gallus gallus over the period 2005 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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to 2011. Considering the indicator Escherichia coli isolates, the levels of ciprofloxacin resistance observed in 
isolates from broilers and pigs were 53.1 % and 8.3 %, respectively. Furthermore, high to extremely high 
resistance to fluoroquinolones was commonly observed in Campylobacter isolates from Gallus gallus and 
broiler meat, as well as from pigs and cattle, at levels ranging from 36 % to 78 %.  
Resistance  to  the  third-generation  cephalosporin  cefotaxime  was  observed  in  Salmonella  isolates  from 
Gallus gallus, turkeys, pigs, cattle and meat derived from broilers, at very low or low levels varying between 
0 % and 3 %, as well as in indicator Escherichia coli isolates from Gallus gallus, pigs and cattle at levels 
ranging  from  <1 %  to  6.4 %.  Resistance  to  erythromycin  was  detected  in  Campylobacter  isolates  from 
Gallus gallus, poultry meat and pigs at levels of 2 % to 25 %. 
Among Salmonella isolates from meat and animals, resistance to tetracyclines, ampicillin and sulfonamides 
was reported at levels of 7 % to 61 % and it was higher in isolates from pigs and turkeys than in those from 
broilers,  laying  hens  and  cattle.  Resistance  to  ciprofloxacin  and  nalidixic  acid  was  higher  in  Salmonella 
isolates from broilers and turkeys (33–50 %) than it was in isolates from laying hens, pigs or cattle (1–13 %). 
In isolates of Campylobacter from meat and animals, resistance was commonly detected to tetracyclines at 
levels up to 75 %, whereas much lower resistance was reported to gentamicin (levels lower than 7 %).  
Among  indicator  Escherichia coli  from  broilers  and  pigs,  resistance  to  tetracyclines,  ampicillin  and 
sulfonamides was commonly reported at levels of 37 % to 57 %, resistance levels being lower in laying hens 
(14 % to 18 %). In the case of cattle, levels of resistance to these antimicrobials fell within the range 20 % to 
74 % in younger age groups, mainly fattening veal calves, but values were much lower in older cattle, mainly 
adult cows. In general, resistance levels were lower among isolates from cattle and layers than in isolates 
from broilers and pigs. 
Among  indicator enterococci, resistance to tetracyclines and  erythromycin was common  in  isolates  from 
Gallus gallus, pigs and cattle at levels of 23 % to 79 %, the resistance being the lowest for isolates from 
cattle. Resistance to vancomycin continued to be detected, albeit at very low levels (maximum 0.7 %), in 
enterococcal isolates from animals. 
Multi-resistance (reduced susceptibility to at least three antimicrobial classes according to epidemiological 
cut-off  values)  was  high  in  Salmonella  isolates  from  broilers,  turkeys  and  pigs  and  in  indicator 
Escherichia coli isolates from broilers and pigs in those countries reporting isolate-based data. However, co-
resistance to the clinically important antimicrobials ciprofloxacin and cefotaxime was detected in very few 
isolates  of  Salmonella  species  and  indicator  Escherichia coli.  Multi-resistance  was  generally  low  in 
Campylobacter jejuni isolates from broilers, and co-resistance to ciprofloxacin and erythromycin was either 
not detected or recorded at low levels. 
Several statistically significant national trends in resistance levels in isolates from animals and food were 
observed. Among Salmonella isolates more decreasing than increasing trends were found, whereas, in the 
case of Campylobacter, the statistically significant national trends were mostly increasing.  
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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1. INTRODUCTION 
The antimicrobial agents used in food-producing animals in Europe are frequently the same, or belong to the 
same classes, as those used in human medicine. Antimicrobial resistance is the main undesirable side effect 
of  antimicrobial  use  in  both  humans  and  animals  and  results  from  the  continuous  positive  selection  of 
resistant bacterial clones, whether these are pathogenic, commensal or even environmental bacteria. This 
will modify the population structure of microbial communities, leading to accelerated evolutionary trends with 
unpredictable consequences for human health. The use of antimicrobials can differ in humans and food-
producing animals, in terms of both the methods of administration and the quantities administered; there are 
important variations between and within food-producing animal species, as well as between countries. 
Bacterial resistance to antimicrobials occurring in food-producing animals can spread to people not only via 
food-borne routes but also by routes such as water or environmental contamination as well as through direct 
animal contact. Campylobacter, Salmonella and some strains of Escherichia coli (E. coli) are examples of 
zoonotic  bacteria  which  can  infect  people  by  the  food-borne  route.  Infections  with  bacteria  which  are 
resistant to antimicrobials may result in treatment failures or necessitate the use of second-line antimicrobials 
for therapy. The commensal bacterial flora can also form a reservoir of resistance genes which may transfer 
between bacterial species, including transference to organisms capable of causing disease in both humans 
and animals (EFSA, 2008a).  
The monitoring of antimicrobial resistance in zoonotic and commensal bacteria in food-producing animals 
and food thereof is a prerequisite for understanding the development and diffusion of resistance, providing 
relevant risk assessment data, and evaluating targeted interventions. Resistance monitoring entails specific 
and  continuous  data  collection,  analysis  and  reporting  that  quantitatively  follow  temporal  trends  in  the 
occurrence  and  distribution  of  resistance  to  antimicrobials,  and  should  also  allow  the  identification  of 
emerging or specific patterns of resistance. 
1.1. AMR monitoring and reporting at EU level 
According  to  Directive  2003/99/EC  on  the  monitoring  of  zoonoses  and  zoonotic  agents,  Member  States 
(MSs) are obliged to monitor and report antimicrobial resistance in Salmonella and Campylobacter isolates 
from animals and food. In addition, Commission Decision 2007/407/EC
7 lays down detailed requirements on 
the harmonised monitoring and reporting of antimicrobial resistance of  Salmonella  isolates  from  various 
poultry populations and pigs, sampled under the corresponding national control and monitoring programmes 
of Salmonella. The monitoring and reporting of antimicrobial resistance data from the indicator organisms 
E. coli and enterococci is voluntary. 
Decision  2119/98/EC
8  on  setting  up  a  network  for  the  epidemiological  surveillance  and  control  of 
communicable  diseases  in  the   EU,  as  complemented  by  Decision  2000/96/EC
9  with  amendment 
2003/542/EC
10 on the diseases to be progressively covered by the network, established the basis  for data 
collection on human diseases from MSs. The decisions foresee that data from the networks shall be used in 
the EU Summary Reports. Consequently, the European Centre for Disease Prevention and Control (ECDC) 
has provided data on zoonotic infections in humans, as well as their analyses, for the Community Summary 
Reports since 2005. Starting  in  2007, data on human cases have been reported from The European 
Surveillance System (TESSy), maintained by ECDC. 
This EU Summary Report 2011 includes data related to the occurrence of antimicrobial resistance  both in 
isolates from animals and foodstuffs, collected in the framework of Directive 2003/99/EC, and in isolates from 
human cases, derived from the networks under Decision 2119/98/EC.  This report  is a joint collaboration 
between the European Food Safety Authority (EFSA) and ECDC with the assistance of EFSA’s contractors, 
the Animal Health and Veterinary Laboratories Agency (AHVLA) in the United Kingdom and the University of 
                                                 
7  Decision 2007/407/EC: Commission Decision of 12 June 2007 on a harmonised monitoring of antimicrobial resistance in Salmonella 
in poultry and pigs. OJ L153, 14.6.2007, pp. 26–29. 
8  Decision  2119/98/EC  of  the  European  Parliament  and  of  the  Council  of  24  September  1998  setting  up  a  network  for  the 
epidemiological surveillance and control of communicable diseases in the Community. OJ L268, 3.10.1998, pp. 1–7. 
9  Decision  2000/96/EC  on  communicable  diseases  to  be  progressively  covered  by  the  Community  network  under  Decision 
No 2119/98/EC of the European Parliament and of the Council. OJ L180, 11.7.2009, pp. 22–23. 
10 Decision 2003/542/EC Commission Decision of 17 July 2003 amending Decision 2000/96/EC as regards the operation of dedicated 
surveillance networks. OJ L185, 24.7.2003, pp. 55–58. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Hasselt  in  Belgium.  MSs,  other  reporting  countries,  the  European  Commission  (EC)  and  the  relevant 
European Union Reference Laboratories  (EU-RL) were consulted while preparing the report. The efforts 
made by MSs, the reporting non-MSs as well as by the EC in the reporting of zoonoses data and in the 
preparation of this report are gratefully acknowledged. 
The main issues when comparing antimicrobial resistance data originating from different countries are the 
use of different laboratory methods and different interpretative criteria of resistance. These issues have been 
addressed  by  the  development  of  the  EFSA’s  guidelines  for  harmonised  monitoring  and  reporting  of 
resistance in food-producing animals and food thereof. The resistance monitoring performed under these 
guidelines utilises epidemiological cut-off values (ECOFFs) which separate the naïve, susceptible wild-type 
bacterial populations from isolates that have developed reduced susceptibility to a given antimicrobial agent 
(Kahlmeter et al., 2003). The ECOFFs may differ from breakpoints used for clinical purposes, which are 
defined against a background of clinically relevant data, including therapeutic indication, clinical response 
data,  dosing  schedules,  pharmacokinetics  and  pharmacodynamics.  In  the  EU  Summary  Reports  on 
antimicrobial resistance from 2004 to 2010, ECOFFs were applied to minimum inhibitory concentration (MIC) 
data to define resistant Salmonella, Campylobacter, indicator E. coli and indicator enterococci isolates from 
animals and food. The use of harmonised methods and ECOFFs ensured the comparability of data over time 
at country level and also facilitated the comparison of the occurrence of resistance between MSs. The same 
methods and principles have been applied in this 2011 Summary Report on antimicrobial resistance. 
The antimicrobial susceptibility data reported to EFSA for the year 2011 for Campylobacter, Salmonella, 
indicator E. coli and indicator enterococci isolates from animals and food were analysed and all quantitative 
data were interpreted using ECOFFs. This report also includes results of phenotypic monitoring of resistance 
caused  by  extended-spectrum  beta-lactamases  (ESBLs)  in  Salmonella  and  indicator  E. coli,  conferring 
resistance  to  third-generation  cephalosporins,  as  well  as  the  first  investigation  at  the  EU  level  of  the 
occurrence  of  complete  susceptibility  and  multi-resistance  in  data  reported  at  isolate  level.  A  list  of  the 
antimicrobials  included  in  this  evaluation  of  multi-resistance  can  be  found  in  Chapter  11–Materials  and 
methods. The majority of antimicrobial resistance data reported to EFSA by MSs comprised data collected in 
accordance  with  EFSA’s  monitoring  guidelines;  quantitative  disc  diffusion  data  constituted  only  a  small 
percentage of the total data and were analysed in the report as qualitative data only. This has circumvented 
the problem that ECOFFs are not available for the different disc diffusion methods used by MSs. 
The report also encompasses resistance in Salmonella and Campylobacter isolates from human cases of 
salmonellosis and campylobacteriosis, respectively. These data were reported as qualitative data, mostly 
interpreted using clinical breakpoints, by MSs to TESSy. An important general feature of this report is that 
human data are largely based on susceptibility testing of clinical isolates, whereas animal data are based 
mainly on the testing of isolates from healthy animals, where testing has been performed in accordance with 
EFSA’s  recommendations.  The  data  on  zoonotic  bacteria  from  humans  have  largely  been  collated  and 
collected using clinical breakpoints. Such data are therefore not always directly comparable with data from 
food-producing animals and food, which have been analysed using ECOFFs. Indeed, the use of ECOFFs in 
animal and food isolates generally conveys the picture of ‘microbiological resistance’ levels in these isolates 
higher than ‘clinical resistance’ levels recorded in human isolates, where clinical breakpoints have been 
used.  These  issues  are  discussed  further  in  the  chapters  on  Campylobacter  and  Salmonella.  Universal 
adoption  and  understanding  of  the  distinction  between  clinical  breakpoints  and  ECOFFs  would  enable 
clinicians to choose the appropriate treatment based on information relevant to the individual patient, yet 
would recognise that epidemiologists need to be aware of small changes in bacterial susceptibility, which 
may indicate emerging resistance and allow for appropriate control measures to be considered. ECOFFs, 
clinical breakpoints and related concepts regarding antimicrobial resistance/susceptibility are presented in 
detail hereafter. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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1.2. Epidemiological cut-off values and clinical breakpoints 
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) has defined clinical breakpoints 
and epidemiological cut-off values. A micro-organism is defined as clinically resistant when the degree of 
resistance  shown  is  associated  with  a  high  likelihood  of  therapeutic  failure.  The  micro-organism  is 
categorised as resistant by applying the appropriate clinical breakpoint in a defined phenotypic test system, 
and this breakpoint may alter with legitimate changes in circumstances (for example, alterations in dosing 
regime, drug formulation, patient factors). 
A micro-organism is defined as wild-type for a bacterial species when no acquired or mutational resistance 
mechanisms are present to the antimicrobial in question. A micro-organism is categorised as wild-type for a 
given bacterial species by applying the appropriate ECOFF value in a defined phenotypic test system. This 
cut-off value will not be altered by changing circumstances (such as alterations in frequency of antimicrobial 
administration). Wild-type micro-organisms may or may not respond clinically to antimicrobial treatment. A 
micro-organism is defined as non-wild-type for a given bacterial species by the presence of an acquired or 
mutational resistance mechanism to the antimicrobial in question. A micro-organism is categorised as non-
wild-type for a given bacterial species by applying the appropriate ECOFF value in a defined phenotypic test 
system; non-wild-type organisms are considered to show ‘microbiological resistance’ (as opposed to ‘clinical 
resistance’).  Clinical  breakpoints  and  ECOFFs  may  be  the  same,  although  it  is  often  the  case  that  the 
ECOFF is lower than the clinical breakpoint. 
Comparative advantages and disadvantages of the use of clinical breakpoints  versus ECOFFs (see box 
hereafter) have been taken into account in the detailed specifications for harmonised monitoring schemes on 
antimicrobial  resistance  in  animals  and  food  devised  by  EFSA.  These  guidelines  have  been  published 
(EFSA, 2007, 2008a) and the terminology used is that devised by EUCAST (Kahlmeter et al., 2003). As far 
as possible, ECOFFs have been used in this report, as recommended in the guidelines, to determine non-
wild-type  organisms  also  termed  ‘microbiologically  resistant’  organisms,  and  to  ensure  that  results  from 
different MSs are comparable. Hereafter in this report, ‘microbiologically antimicrobial-resistant’ organisms 
are referred to as ‘resistant’ for brevity. 
 
CLINICAL BREAKPOINTS (CLINICAL RESISTANCE) 
The clinician, or veterinarian, choosing an antimicrobial agent to treat humans or animals with a bacterial 
infection requires information that the antimicrobial selected is effective against the bacterial pathogen. 
Such information will be used, together with clinical details such as the site of infection, ability of the 
antimicrobial to reach the site of infection, formulations available and dosage regimes, when determining 
an appropriate therapeutic course of action. The in vitro susceptibility of the bacterial pathogen can be 
determined  and  clinical  breakpoints  used  to  ascertain  whether  the  organism  is  likely  to  respond  to 
treatment.  Clinical  breakpoints  will  take  into  account  the  clinical  behaviour  of  the  drug  following 
administration and assume that a clinical response will be obtained if the drug is given as recommended 
and there are no other adverse factors which affect the outcome. Conversely, if the clinical breakpoint 
indicates resistance, then it is likely that treatment will be unsuccessful. Frequency of dosing is one 
factor that can affect the antimicrobial concentration achieved at the site of infection. Therefore, different 
dosing regimes can lead to the development of different clinical breakpoints, as occurs in some countries 
for certain antimicrobials where different therapeutic regimes are in place. Although the rationale for the 
selection of different clinical breakpoints may be clear, their use makes the interpretation of results from 
different countries in reports of this type problematic, as the results are not directly comparable between 
those different countries. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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The  EUCAST  ECOFFs which should  be  applied  to  interpret the  results  obtained by MSs  are  quoted  in 
Commission  Decision  2007/407/EC.  However,  since  this  Decision  was  adopted,  there  have  been  some 
minor changes to a few of the ECOFFs for some antimicrobials. This occurs because, as more data are 
collected relating to more bacterial isolates, the normal distribution of the wild-type population can in some 
cases  be  better  defined.  This  2011  EU  Summary  Report  interprets  the  antimicrobial  resistance  data  in 
accordance with the current Decision. The Decision is currently undergoing review by the EC, notably on the 
basis  of  the  technical  specifications  proposed  for  harmonised  monitoring  of  antimicrobial  resistance  in 
animals and food recently issued by the EFSA (EFSA 2012a, b, c), and the expected revision in the future 
will update a number of the ECOFFs to be used. 
EPIDEMIOLOGICAL CUT-OFF VALUES (MICROBIOLOGICAL RESISTANCE) 
For a given bacterial species, the pattern of the Minimum inhibitory concentration (MIC) distribution or the 
inhibition zone diameter distribution (i.e. the frequency of occurrence of each given MIC or zone diameter 
plotted against the MIC value or zone diameter obtained) can enable the separation of the wild-type 
population of micro-organisms from those populations which show a degree of resistance. The wild-type 
susceptible population is assumed to have no acquired or mutational resistance and commonly shows a 
normal distribution. 
When  bacteria  acquire  resistance  by  a  clearly  defined  and  efficacious  mechanism,  such  as  the 
acquisition  of  a  plasmid  bearing  a  gene  which  produces  an  enzyme  capable  of  destroying  the 
antimicrobial, then the MIC or zone diameter distribution commonly shows two major sub-populations, 
one a fully susceptible normal distribution of isolates and the other a fully resistant population which has 
acquired the resistance mechanism. Resistance may be achieved by a series of small steps, such as 
changes in the permeability of the bacterial cell wall to the antimicrobial or other mechanisms which 
confer a degree of resistance. In this case, there may be populations of organisms which occur lying 
between  the  fully  susceptible  population  and  more  resistant  populations.  The  epidemiological  cut-off 
value indicates the MIC or zone diameter above which the pathogen has some detectable reduction in 
susceptibility. Epidemiological cut-off values are derived by testing an adequate number of isolates to 
ensure that the wild-type population can be confidently identified for a given antimicrobial. The clinical 
breakpoint, which is set to determine the therapeutic effectiveness of the antimicrobial, may fail to detect 
emergent resistance. Conversely, the epidemiological cut-off value detects any deviation in susceptibility 
from  the  wild-type  population,  although  it  may  not  be  appropriate  for  determining  the  likelihood  of 
success or failure for clinical treatment. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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1.3. Developments in the harmonised monitoring of antimicrobial resistance 
The EFSA, at the request of the EC, has prepared detailed specifications for the harmonised monitoring of 
antimicrobial  resistance  in  food-producing  animals.  These  were  developed  by  an  expert  working  group, 
established under the Task Force on Zoonoses Data Collection,  which recommended guidelines for the 
monitoring of antimicrobial resistance in Salmonella and Campylobacter (EFSA, 2007) and also in indicator 
E. coli and enterococci
11 (EFSA, 2008a). These guidelines include detailed protocols on sampling strategies, 
the method of susceptibility testing, the antimicrobials to be tested and the criteria for categorising isolates as 
susceptible or resistant, as well as making recommendations on quality control and reporting. The guidelines 
have been developed for use in all 27 EU MSs and hav e been progressively implemented.   Information 
collected using these guidelines has formed the majority of the data on antimicrobial resistance in bacteria 
from animals and food published in previous reports. 
The EFSA, at the  further request of the  EC, has reviewed and revised the  detailed specifications for the 
harmonised monitoring of antimicrobial resistance in food-producing animals in 2012, again assembling an 
expert working group to carry out the tasks. The working group also focused on refining and developing the 
monitoring of multiple antimicrobial resistance (which has been facilitated by the collection of data which can 
be related to an individual isolate ), while  two further working groups have produced recommendations 
describing in detail the detection and characterisation of beta-lactamase and carbapenemase resistance and 
the monitoring of MRSA. Three reports have been produced (EFSA 2012a, b, c) (see box below). 
 
                                                 
11 E. coli and enterococci (i.e. Enterococcus faecium and E. faecalis) can be used as indicator organisms of, respectively, the Gram-
negative and Gram-positive commensal intestinal flora. These three bacteria are commonly isolated from animal faeces; and most 
resistance phenotypes present in the animal populations are present in these species. In addition, the effects of use patterns of 
antibiotics in a given country and animal species, as well as trends in the occurrence of resistance, can be studied more accurately in 
indicator organisms than in food-borne pathogens because all food animals generally carry these indicator bacteria. 
DEVELOPMENTS IN THE MONITORING OF ANTIMICROBIAL RESISTANCE 
EFSA has published three reports (EFSA, 2012a, b, c) describing proposals and aims for developing and 
enhancing the future monitoring of antimicrobial resistance. A brief synopsis of these reports is presented 
below. 
TECHNICAL  SPECIFICATIONS  FOR  THE  ANALYSIS  AND  REPORTING  OF  DATA  ON  ANTIMICROBIAL 
RESISTANCE IN THE EUROPEAN UNION SUMMARY REPORT (EFSA, 2012a) 
This  report  describes  proposals  to  improve  the  harmonisation,  analysis  and  reporting  of  data  on 
antimicrobial resistance in animals and food collected from the MSs, based on a critical review of the 
EU Summary Reports which have been previously issued. It reinforces the use of epidemiological cut-off 
values  in  the  monitoring  programmes  and  makes  proposals  to  complement  the  harmonised  panel  of 
antimicrobials used for susceptibility testing. A logistic regression modelling approach is recommended to 
assess  trend  significance,  and  this  has  been  adopted in  the current  report.  It  suggests  that weighted 
indicators of resistance should be designed at EU level, accounting for prevalence of bacteria, occurrence 
of resistance and monitoring design at national level. It considers it essential that resistance data should 
no longer be reported in an aggregate fashion but at isolate level in order to address the phenomenon of 
multi-resistance. It provides a definition and an approach to the analysis of multi-resistance as well as a list 
of important co-resistance patterns. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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TECHNICAL SPECIFICATIONS ON THE HARMONISED MONITORING AND REPORTING OF ANTIMICROBIAL 
RESISTANCE  IN  SALMONELLA,  CAMPYLOBACTER  AND  INDICATOR  ESCHERICHIA  COLI  AND 
ENTEROCOCCUS SPP. BACTERIA TRANSMITTED THROUGH FOOD (EFSA, 2012b) 
These recommendations introduce the concept of a threshold for animal populations and meat derived 
therefrom,  to  determine  whether  monitoring  of  those  populations  and  the  meat  produced  from  them 
should  be  mandatory  or  optional.  The  volume  of  production  will  affect  the  degree  of  exposure  of 
consumers and the threshold attempts to prioritise the types of production which should be monitored, 
based on consumer exposure. The antimicrobials for inclusion in the monitoring programme have been 
broadened to include additional substances which either are important from the public health perspective 
or  provide  additional  information  for  epidemiological  purposes,  for  example  providing  an  insight  into 
resistance mechanisms involved. Thus, carbapenems are extremely important antimicrobials in human 
medicine  and  constitute  one  of  the  antimicrobial  options  of  last  resort  in  certain  multi-drug-resistant 
bacterial  infections.  A  carbapenem  has  been  included  in  the  recommended  monitoring  programme, 
which is tiered, so that resources can be targeted cost-effectively. Analytical methods are suggested for 
the  characterisation  of  Salmonella  and  E. coli  isolates  which  are  resistant  to  third-generation 
cephalosporins, in particular to distinguish between ESBL and AmpC enzyme-producing organisms, on 
both phenotypic and molecular grounds. The recommendations also suggest protocols for the specific 
monitoring of ESBL-producing E. coli using selective procedures, rather than utilising randomly selected 
E. coli from non-selective culture plates. The recommendations include the inclusion of teicoplanin in the 
monitoring of enterococci, since the genotype relating to glycopeptide resistance may be inferred from 
the  susceptibility  to  vancomycin  and  teicoplanin.  The  dilution  range  for  ciprofloxacin  is  deliberately 
recommended  to  be  wide,  since  multiple  resistance  mechanisms  can  contribute  to  fluoroquinolone 
resistance and these mechanisms may be acquired in a step-wise fashion. The recent emergence of 
Salmonella Kentucky with high-level resistance to ciprofloxacin (above or equal to 8 mg/L) illustrates the 
value of this recommended measure. 
TECHNICAL SPECIFICATIONS ON THE HARMONISED MONITORING AND REPORTING OF ANTIMICROBIAL 
RESISTANCE IN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (EFSA, 2012c) 
This report contains proposals to improve the harmonisation of monitoring of the prevalence, genetic 
diversity and antimicrobial resistance of methicillin-resistant Staphylococcus aureus (MRSA) from food-
producing animals and food derived from those animals by the EU MSs. The primary route of zoonotic 
transmission  of  MRSA  is  considered  to  be  the  occupational  contact  of  livestock  professionals  with 
colonised animals; the role of food as a source of human colonisation or infection with MRSA is presently 
considered  to  be  low.  The  sampling  recommendations  therefore  prioritise  food-producing  animal 
populations previously described as reservoirs of MRSA and to a lesser extent meat produced from 
these animals. Monitoring of broiler flocks, fattening pigs and dairy cattle, as well as fattening veal calves 
and fattening turkey flocks in those countries where the domestic production exceeds 10,000,000 tons 
slaughtered/year  is  recommended  every  third  year  on  a  rotating  basis.  It  is  proposed  that  breeding 
poultry flocks and breeding pigs, as well as meat and raw milk products, should be monitored on a 
voluntary basis. The report puts forward cost-effective methods whereby MRSA monitoring could be 
carried  out  at  the  same  time  as  other  monitoring  (for  example  the  National  Salmonella  Control 
Programmes)  and  describes  harmonised  analytical  methods  for  the  identification,  typing  and  further 
characterisation  of  MRSA.  The  use  of  a  microdilution  method  applied  to  a  harmonised  set  of 
antimicrobials  and  interpreted  using  EUCAST  epidemiological  cut-off  values  for  antimicrobial 
susceptibility testing of MRSA is recommended. Full support is given to the collection and reporting of 
isolate-based data, in order to enable more in-depth analyses to be conducted, in particular regarding the 
occurrence of multi-resistance. Ongoing evolution and development of the situation relating to MRSA in 
animals may occur and is exemplified by the recent description of MRSA ST49 in Switzerland (Overesch 
et al., 2011) (see Chapter 8 for more information). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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2. MAIN FINDINGS 
2.1. Main findings of the European Union Summary Report on antimicrobial resistance 2011 
  In 2011, MSs reported qualitative data on antimicrobial resistance in Salmonella and Campylobacter 
isolates from human cases mostly interpreted by using clinical breakpoints to define the resistant 
isolates. In contrast, quantitative data (minimum inhibitory concentrations (MICs) and/or inhibition 
zone diameter (IZD) results) on antimicrobial resistance, reported for isolates from food and animals, 
were interpreted by using epidemiological cut-off values. Epidemiological cut-off values are often 
lower than clinical breakpoints, and this can result in more isolates being classified as resistant, 
depending on the MIC distribution. 
  Antimicrobial resistance was regularly observed in isolates of Salmonella and Campylobacter from 
human cases as well as from food-producing animals and food in the EU. This was also the case for 
indicator (commensal) Escherichia coli (E. coli) and enterococci isolated from animals and food. For 
many of the antimicrobials, the levels of resistance varied greatly between different MSs and animal 
production types.  
  Fluoroquinolones, such as ciprofloxacin, and third-generation cephalosporins, such as cefotaxime, 
are considered critically important antimicrobials in the treatment of severe salmonellosis in humans. 
Likewise, fluoroquinolones and macrolides, such as erythromycin, are considered critically important 
for  treating severe Campylobacter  infections.  Therefore, special attention was paid  to  resistance 
against these substances in the analyses of the data. 
  Resistance at the EU level in Salmonella spp. isolates from human cases was high (between 20 % 
and  30 %)  to  ampicillin,  tetracyclines  and  sulfonamides.  In  contrast,  resistance  to  the  critically 
important  antimicrobials  ciprofloxacin  and  cefotaxime  was  relatively  low  (on  average  <10 %  and 
<1 %,  respectively). Higher  resistance levels  to  ciprofloxacin  were reported by the few  countries 
using epidemiological cut-off values as interpretative criteria in human data.  
  Multi-resistance (defined as reduced susceptibility to at least three antimicrobial classes) was high in 
human Salmonella isolates in some countries; however, there were low levels of co-resistance to 
ciprofloxacin  and  cefotaxime.  Furthermore,  more  than  half  of  all  Salmonella  isolates  were 
susceptible to the complete range of antimicrobials tested. 
  In  food  and  animal  isolates,  the  highest  occurrence  of  resistance  to  ciprofloxacin  was  noted  in 
Salmonella spp. isolates from fowl (Gallus gallus), broiler meat and turkeys (from 28.7 % to 50.4 % 
at the MS group level). The further sub-division of the Gallus gallus species into production types 
revealed higher overall resistance to ciprofloxacin in Salmonella spp. isolates from broilers (35.1 %) 
than in those from laying hens (12.7 %). In cattle, pigs and pig meat, low resistance levels were 
observed (from 1.7 % to 7.4 %).  
  Resistance  to  cefotaxime  (a  third-generation  cephalosporin)  was  observed  in  Salmonella spp. 
isolates from Gallus gallus, turkeys and pigs and in the meat derived from broilers and pigs, but at 
low or very low levels (0.4 % to 3.3 %), when all reporting MSs were considered. However, even low 
levels of resistance to this critically important antimicrobial are important, and increases in resistance 
to cefotaxime compared with 2010 data were observed in some MSs. Resistance to cefotaxime was 
not detected in Salmonella strains isolated from cattle in the reporting countries in 2011. 
  Resistance  to  tetracyclines,  ampicillin  and  sulfonamides  was  frequently  reported  among 
Salmonella spp.  isolates  from  meat  and  animals  (from  7.1 %  to  60.5 %  at  MS  group  level). 
Resistance to these antimicrobials was higher in isolates from pigs, turkeys and cattle (29.1 % to 
60.5 %) than in isolates from Gallus gallus (17.8 % to 25.3 %). 
  Multi-resistance  (reduced  susceptibility  to  at  least  three  antimicrobial  classes  according  to 
epidemiological cut-off values) was high in Salmonella spp. isolates from animals in some countries 
reporting  isolate-based  data;  however,  co-resistance  to  the  clinically  important  antimicrobials, 
ciprofloxacin and cefotaxime, was at very low to low levels.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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  The  resistance  among  Campylobacter  spp.  isolates  from  human  cases  was  high  to  very  high 
(between  30 %  and  50 %)  for  ampicillin,  ciprofloxacin,  nalidixic  acid  and  tetracyclines.  Low 
resistance  levels  (average  3.5 %)  were  observed  to  the  clinically  important  antimicrobial, 
erythromycin.  Multi-resistance  in  human  Campylobacter  isolates  was  high  or  very  high  in  some 
countries.  Levels  of  co-resistance  to  the  clinically  important  antimicrobials,  ciprofloxacin  and 
erythromycin, were on average low among Campylobacter jejuni (C. jejuni) isolates and moderate 
among Campylobacter coli (C. coli) isolates. 
  Extremely  high  resistance  to ciprofloxacin  (a  fluoroquinolone) was commonly  observed  in  C. coli 
isolates  from  broilers  (Gallus  gallus)  and  broiler  meat  (76.6 %  and  77.7 %,  respectively),  with 
somewhat lower levels in C. jejuni (57.2 % and 59.2 %, respectively). High levels were also reported 
for isolates from pigs and cattle (35.5 % to 38.8 %). Important differences were observed between 
animal species and MSs. 
  Resistance  to  erythromycin  was  detected  at  low  levels  in  Campylobacter  isolates  from  broilers 
(Gallus gallus) and poultry meat (1.6 % to 9.8%), except for C. coli in broilers, in which moderate 
resistance was detected (15.5 %). The highest level of resistance to erythromycin at the reporting 
MS group level was observed in C. coli isolates from pigs (24.5 %), while the level of erythromycin 
resistance in isolates of C. jejuni from cattle across reporting MSs was very low (0.8 %).  
  Resistance  to  nalidixic  acid  and  tetracyclines  was  common  among  Campylobacter  isolates  from 
meat and animals (from 32.4 % to 74.6 %), whereas resistance to gentamicin was low (from 0.8 % to 
7.2 %). As for Salmonella, levels of resistance to nalidixic acid followed closely those observed for 
ciprofloxacin. 
  Multi-resistance  (reduced  susceptibility  to  at  least  three  antimicrobial  classes  according  to 
epidemiological cut-off values) was generally low in C. jejuni isolates from broilers and meat thereof, 
and co-resistance to the clinically important antimicrobials, ciprofloxacin and erythromycin, was, in 
the same isolates, either not detected or recorded at low levels. Multi-resistance and co-resistance 
levels were generally higher in C. coli isolates from broilers. 
  Among indicator (commensal) E. coli isolates from animals, resistance to tetracyclines, ampicillin, 
streptomycin and sulfonamides was commonly reported in Gallus gallus and pigs (from 36.6 % to 
57.0 %),  moderate  levels  being  reported  in  cattle  (from  to  13.3 %  to  20.2 %).  Resistance  to 
ciprofloxacin and nalidixic acid was highest among E. coli isolates from Gallus gallus (40.5 % and 
33.7 %,  respectively),  while  levels  were  low  in  pigs  and  cattle  (4.8 %  to  8.3 %).  Cefotaxime 
resistance was low in all species (0.9 % to 6.4 %), and highest in isolates from Gallus gallus (6.4 %), 
considering all reporting MSs. At the MS level, resistance to cefotaxime in indicator E. coli showed 
wider  variation  in  some  species  or  production  types,  for  example  between  0 %  and  20.8 %  in 
broilers.  In  general,  resistance  to  third-generation  cephalosporins  in  E. coli  was  higher  than  that 
observed in Salmonella spp. for the same species of animals, which is consistent with the hypothesis 
that  E. coli  may  provide  a  reservoir  of  cephalosporin  resistance  genes  for  organisms  such  as 
Salmonella. 
  Multi-resistance was high in indicator (commensal) E. coli isolates from animals in some countries 
reporting  isolate-based  data;  however,  co-resistance  to  the  clinically  important  antimicrobials, 
ciprofloxacin and cefotaxime, was generally reported at very low to low levels. 
  Among indicator (commensal) enterococci, resistance to tetracyclines and erythromycin remained 
common in isolates from broilers (Gallus gallus), pigs and cattle (from 22.9 % to 78.9 %), with the 
lowest  levels  of  resistance  occurring  in  isolates  from  cattle  (22.9 %  to  35.6  %).  Vancomycin 
resistance continued to be detected in some animal species, but at very low levels (0.4 % to 0.7 %), 
although none of the meat samples tested yielded bacteria resistant to this antimicrobial.  
  Several statistically significant national trends in resistance levels in isolates from animals and food 
were  observed.  Among  Salmonella  spp.  isolates,  more  decreasing  than  increasing  trends  were 
found, whereas, in Campylobacter isolates, the statistically significant national trends were mostly 
increasing. 
  More countries reported data for indicator (commensal) E. coli and enterococci in 2011 than in 2010.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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2.2. Zoonotic and indicator agent-specific summaries 
Salmonella 
The  Salmonella spp.  data  presented  in  this  report  comprise  results  for  all  reported  Salmonella  serovars 
which have been amalgamated to represent the overall occurrence of antimicrobial resistance in Salmonella 
within the various animal and food categories. The differences in the distribution and prevalence of particular 
serovars and phage types of Salmonella in different countries and in different animal species, and their 
associated  patterns  of  resistance,  may  explain  some  of  the  differences  in  the  levels  of  antimicrobial 
resistance observed as well as in those of multi-resistance. The spread of particularly resistant clones, and 
the occurrence of resistance genes within these clones, can be exacerbated by the use of antimicrobials in 
human and animal population and the selective pressure this exerts. Other factors, such as foreign travel by 
humans, animal movements, farming systems, animal husbandry and the pyramidal structure of some types 
of animal primary production can also influence the spread of resistant clones. 
In addition to the amalgamated data for Salmonella spp., resistance data for the most important Salmonella 
serovars  for  public  health,  Salmonella  Enteritidis  (S. Enteritidis)  and  S. Typhimurium,  were  analysed 
separately. A selection of other serovars of public health importance were also analysed in a specific chapter 
of the report. 
In humans 
In 2011, 19 MSs and one non-MS provided information on antimicrobial resistance in Salmonella isolates 
from cases of salmonellosis in humans. 
The reported data represented 26.6 % of the confirmed salmonellosis cases reported in the EU in 2011. 
Resistance  in  human  Salmonella  isolates  was  high  for  ampicillin  (26.6 %),  tetracyclines  (27.1 %)  and 
sulfonamides (21.5 %) and moderate for streptomycin (18.4 %) and nalidixic acid (15.3 %), and high levels of 
multi-resistance were observed in some countries (24.1 % overall). For these first four antimicrobials this 
was  largely  due  to  the  high  to  extremely  high  resistance  levels  observed  among  S. Typhimurium  and 
monophasic S. Typhimurium isolates. However, more than half of all isolates tested were susceptible to the 
complete range of antimicrobials in the human data collection. In addition, the resistance to the clinically 
important  antimicrobials  ciprofloxacin  and  cefotaxime  was  relatively  low  (9.1 %  and  0.8 %,  respectively), 
albeit reported level of resistance to ciprofloxacin were, as expected, markedly higher in countries using 
epidemiological cut-off values or similar values for interpretation of resistance results than in those using 
clinical breakpoints, with the exception of Italy. Co-resistance to ciprofloxacin and cefotaxime among isolates 
was very low (0.3 %). Resistance to quinolones (ciprofloxacin and nalidixic acid) was generally higher in 
S. Enteritidis isolates than in S. Typhimurium isolates.  
Among other prevalent serovars, S. Kentucky isolates exhibited very high or extremely high resistance to all 
tested  antimicrobials,  when  compared  with  all  non-typhoidal  Salmonella  isolates,  except  for  cefotaxime. 
There  was  notably  higher  resistance  to  ciprofloxacin,  nalidixic  acid,  sulfonamides  and  tetracyclines  in 
S. Infantis  isolates  than  in  all  non-typhoidal  Salmonella  isolates.  Conversely,  S.  Newport  isolates  had  a 
comparatively low level of resistance to all antimicrobials. It is important to note that for some serovars, 
sufficient data for making separate country estimates was often available from only one or two countries. 
When assessed  by geographical region,  Salmonella  spp. isolates  acquired  within  the  EU/EEA countries 
exhibited greater resistance to ampicillin and streptomycin, while the highest level of resistance to six of the 
antimicrobials tested was observed in isolates acquired from Asia.   
In animals and food 
In 2011, information on antimicrobial resistance in Salmonella isolates from animals and food was reported 
by 20 MSs and one non-MS. 
Among  Salmonella spp.  isolates  from  Gallus  gallus,  the  resistance  level  to  tetracyclines,  ampicillin  and 
sulfonamides  in  all  reporting  MSs  was  at  moderate  level,  17.8 %,  18.9 %  and  25.3 %,  respectively. 
Resistance to ciprofloxacin and nalidixic acid was higher (28.7 % and 27.9 %, respectively), for all reporting 
MSs. In general, there  were  large  variations  in  the  levels  of resistance to these  antimicrobials  between 
different reporting MSs. The occurrence of resistance to cefotaxime in all reporting MSs was low, at 1.5 %. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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For the first year, data were presented at production type level, where possible, throughout the report. In 
2011,  13  MSs  reported  quantitative  data  from  broilers,  and  in  general  the  levels  of  resistance  in  this 
production  type  were  slightly  higher  than  those  reported  when  all  Gallus  gallus  production  types  were 
considered. Twelve MSs reported quantitative data from laying hens in 2011, and in contrast to the data from 
broilers, the levels of resistance in this production type were lower than those reported when all Gallus gallus 
were considered.  
Multi-resistance  levels  (reduced  susceptibility  to  at  least  three  different  antimicrobial  classes  using 
epidemiological cut-off values) were generally high in Salmonella spp. isolates from broilers and low in those 
from laying hens. Co-resistance to ciprofloxacin and cefotaxime was very low, and not detected when using 
clinical breakpoints. 
Some MSs showed statistically significant increasing trends in resistance among Salmonella spp. isolates 
from Gallus gallus over the years 2005–2011, whereas other MSs exhibited decreasing trends. Statistically 
significant decreasing trends were more frequently observed than significant increasing trends. Three MSs 
demonstrated  a  significant  increasing  trend  for  ciprofloxacin  and  nalidixic  acid  resistance  and  one  a 
decreasing trend for both antimicrobials. In particular, resistance to cefotaxime remained generally low, very 
low or absent in reporting MSs between 2005 and 2011. 
Resistance in S. Enteritidis was generally lower than in Salmonella spp. isolates from Gallus gallus, except 
to  ciprofloxacin  and  nalidixic  acid,  for  which  resistance  is  at  the  same  levels  as  for  Salmonella  spp.  In 
S. Enteritidis  the  occurrence  of  resistance  for  all  reporting  MSs  was  2.5 %  for  tetracyclines,  5.5 %  for 
ampicillin and 4.8 % for sulfonamides, whereas the level of resistance to both ciprofloxacin and nalidixic acid 
was 30.8 %. 
In Salmonella spp. isolates from broiler meat, resistance levels for all reporting MSs for tetracyclines and 
sulfonamides were high at 43.7 % and 44.8 %, respectively. Resistance to ciprofloxacin and nalidixic acid 
resistance  was  also  very  high,  with  overall  resistance  levels  of  50.1 %  and  48.8 %,  respectively.  The 
resistance level for cefotaxime was low, at 3.3 %. 
Among  Salmonella  spp.  isolates  from  turkeys,  the  level  of  resistance  to  tetracyclines,  ampicillin  and 
sulfonamides  in  all  reporting  MSs  was  high  at  52.2 %,  43.6 %  and  51.0 %,  respectively.  The  levels  of 
resistance  to  ciprofloxacin  and  nalidixic  acid  were  also  high,  at  50.4 %  and  36.9 %,  respectively,  for  all 
reporting MSs. There were commonly large variations in the levels of resistance to these antimicrobials 
among the different reporting MSs. The occurrence of resistance to cefotaxime in all reporting MSs was very 
low, at 0.4 %. Multi-resistance was generally high in Salmonella spp. isolates from turkeys; however, co-
resistance to ciprofloxacin and cefotaxime (interpreted using clinical breakpoints) was not detected. 
For  Salmonella spp.  isolates  from pigs,  resistance  levels  in  the reporting  group of MSs  were  very high: 
60.5 % for tetracyclines, 54.2 % for ampicillin and 60.5 % for sulfonamides. Ciprofloxacin and nalidixic acid 
resistance levels remained low, at 4.0 % and 3.4 % respectively, and the level of resistance to cefotaxime 
was also very low, at 1.0 % overall. Resistance to tetracyclines, ampicillin and sulfonamides was common in 
Salmonella spp. from pig meat, 52.8 %, 56.2 % and 54.5 %, respectively, considering all reporting MSs. 
Resistance  to  ciprofloxacin  and  nalidixic  acid  was  at  a  low  level  (7.4 %  and  6.1 %,  respectively)  and 
cefotaxime resistance was very low, at 0.9 %. The trends in resistance observed in Salmonella spp. isolates 
from pigs over the years 2005–2011 remained stable in some countries, while fluctuation was observed in 
others. Among the few statistically significant national trends, slightly more decreasing trends were observed 
than increasing ones. However, it is noteworthy that the level of resistance to cefotaxime remained generally 
low, very low or absent in reporting MSs over the period 2005 to 2011. Multi-resistance was generally high in 
Salmonella spp. isolates from pigs; however, co-resistance to ciprofloxacin and cefotaxime was very low and 
not detected when using clinical breakpoints. 
Among Salmonella spp. isolates from cattle, the occurrence of resistance to tetracyclines, ampicillin and 
sulfonamides  in  all  reporting  MSs  was  high  at  31.1%,  29.1 %  and  33.4 %,  respectively.  The  level  of 
resistance to ciprofloxacin and nalidixic acid was low, 1.7 % and 1.4 % respectively, for all reporting MSs, 
while cefotaxime resistance was not observed among the reporting MSs. Although variation was observed 
between MSs in the level of resistance to some antimicrobials, overall trends in resistance between 2005 
and  2011  were  mainly  decreasing  ones  among  Salmonella spp.  from  cattle.  Important  variability  was 
observed  in  multi-resistance  levels  in  Salmonella  spp.  isolates  from  cattle;  however,  co-resistance  to 
ciprofloxacin and cefotaxime was not detected. The few statistically significant trends observed in resistance 
levels among Salmonella isolates from cattle were all decreasing ones. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Campylobacter 
In humans 
Overall,  13  MSs  and  onr  non-MS  provided  information  on  antimicrobial  resistance  in  isolates  from 
campylobacteriosis cases in humans for the year 2011. 
Data from antimicrobial susceptibility testing represented 17.1 % of the total confirmed campylobacteriosis 
cases reported in the EU in 2011. Fewer countries reported results for Campylobacter than for Salmonella. 
The  variety  of  methods  and  interpretative  criteria  used  by  MSs  in  antimicrobial  susceptibility  testing  for 
Campylobacter  was  still  large,  even  though  some  harmonisation  towards  the  use  of  EUCAST  clinical 
breakpoints could be observed. The launch of clinical breakpoints for disc diffusion by EUCAST in 2012 will 
most likely facilitate this harmonisation further, as many countries use disc diffusion for testing of human 
isolates. The resistance levels in human Campylobacter isolates were highest for nalidixic acid (47.8 %) and 
ciprofloxacin (44.4 %) followed by ampicillin (35.3 %) and tetracyclines (30.5 %), with high levels of multi-
resistance observed in some countries. Resistance to the clinically important antimicrobial erythromycin was 
low overall (3.5 %), but moderately high in C. coli (10.3 %), although the number of isolates of this species 
tested was small. 
Sufficient  data  were  available  for  levels  of  resistance  to  be  compared  by  geographical  region  for 
ciprofloxacin, erythromycin, nalidixic acid and tetracyclines. Isolates acquired in EU/EEA countries had the 
lowest frequency of resistance to all these antimicrobials, with resistance to erythromycin notably lower than 
in Asia and Africa. However, the number of isolates tested that originated from outside of the EU/EEA was 
very low.  
In animals and food 
In 2011, 17 MSs and two non-MSs reported quantitative MIC data for Campylobacter isolates from food and 
animals. Seven MSs additionally reported qualitative data where the method of testing was not specified; 
however these data are not presented in the report. When considering all host species, the highest levels of 
resistance  were  seen  for  the  (fluoro)quinolones  (ciprofloxacin  and  nalidixic  acid)  and  tetracyclines. 
Resistance to erythromycin and gentamicin was comparatively low among Campylobacter isolates from food 
and  animals.  Resistance  was  generally  higher  in  C. coli  than  in  C. jejuni  from  the  same  host  species 
(Gallus gallus). 
For C. jejuni isolates from Gallus gallus, resistance ranged from high to very high for ciprofloxacin (57.2 %), 
nalidixic acid (55.5 %) and tetracyclines (40.6 %), while levels of resistance to erythromycin and gentamicin 
were low and very low at 1.6 % and 0.9 %, respectively. A similar pattern was seen for C. coli isolates from 
Gallus  gallus;  however,  levels  of  resistance  were  higher  overall.  Levels  of  resistance  to  ciprofloxacin, 
nalidixic acid and tetracyclines were extremely high, at 76.6 %, 70.2 % and 74.6 %, respectively, while levels 
of resistance to erythromycin and gentamicin were moderate (15.5 %) and low (3.8 %), respectively. Multi-
resistance (reduced susceptibility to at least three antimicrobial classes according to epidemiological cut-off 
values) was generally low in C. jejuni isolates from broilers, and co-resistance to the clinically important 
antimicrobials ciprofloxacin and erythromycin in the same isolates was either not detected or recorded at low 
levels in the reporting MSs. 
Although resistance to tetracyclines, ciprofloxacin and nalidixic acid in Gallus gallus varied greatly among 
reporting  MSs  over  the  period  2005–2011,  some  statistically  increasing  trends  in  resistance  to  these 
antimicrobials were observed for several MSs. Resistance to erythromycin, however, remained absent to low 
in C. jejuni isolates over this period. The statistically significant trends observed among isolates from pigs 
were generally increasing trends. 
For C. jejuni isolates from broiler meat, resistance ranged from high to very high for ciprofloxacin (59.2 %), 
nalidixic acid (56.9 %) and tetracyclines (46.9 %), while levels of resistance to erythromycin and gentamicin 
were low at 3.1 % and 1.7 %, respectively. A similar pattern was seen for C. coli isolates from broiler meat; 
however, levels of resistance were higher overall. Levels of resistance to ciprofloxacin, nalidixic acid and 
tetracyclines were extremely high, at 77.7 %, 72.2 % and 71.5 %, respectively, while levels of resistance to 
erythromycin and gentamicin were low at 9.8 % and 1.8 %, respectively. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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C. coli isolates from pigs were isolated at the slaughterhouse. Resistance to ciprofloxacin, nalidixic acid and 
tetracyclines  ranged  from  high  to  very  high,  at  35.5 %,  32.8 %  and  64.8 %,  respectively.  Resistance  to 
erythromycin was high (24.5 %) and to gentamicin was low (7.2 %).  
C. jejuni isolates from cattle were also considered. Overall, resistance was high for ciprofloxacin (38.8 %), 
nalidixic acid (39.2 %) and tetracyclines (32.4 %), while resistance to erythromycin and gentamicin was very 
low at 0.8 % for both. Few statistically significant decreasing trends were observed in cattle, but resistance to 
erythromycin remained absent to low in C. jejuni isolates over the period 2005–2011. 
Indicator (commensal) Escherichia coli 
Twelve  MSs  and  two  non-MSs  reported  quantitative  data  on  antimicrobial  resistance  in  indicator  E. coli 
isolates from animals and food in 2011. Most of the data related to isolates from Gallus gallus, pigs and 
cattle; three MSs reported results for meat derived from those species.  
Most data on Gallus gallus referred to broilers, although two MSs provided data on E. coli from laying hens. 
Resistance  levels  were  in  general  higher  among  E. coli  from  broilers  than  from  laying  hens.  Regarding 
broilers, the highest overall resistance levels observed at the reporting MS group level were to ciprofloxacin 
(53.1 %),  ampicillin  (54.4 %),  sulfonamides  (50.8 %),  streptomycin  (47.2  %),  tetracyclines  (45.2 %)  and 
nalidixic  acid  (42.6 %).  The  isolates  from  laying  hens  were  also  most  commonly  resistant  to  these 
antimicrobials  but  resistance  levels  were  lower,  ranging  between  9.7 %  and  18.1 %.  Resistance  to 
cefotaxime was low in both broilers (8.2 %) and layers (1.9 %). There was substantial variation in the level of 
resistance  to  these  antimicrobials  between  reporting  MSs.  Countries  mostly  reported  relatively  stable 
resistance in E. coli isolates from Gallus gallus between 2005 and 2011. However, statistically significant 
trends in resistance to all of these antimicrobials, except cefotaxime, have been identified: these trends have 
more commonly been increasing ones than decreasing ones.  
Concerning indicator E. coli from pigs, the highest overall resistance levels in the reporting group of MSs 
were  observed  for  tetracyclines  (57.0 %),  streptomycin  (53.1 %),  sulfonamides  (45.8 %)  and  ampicillin 
(37.1 %).  Resistance  to  both  ciprofloxacin  and  nalidixic  acid  was  low  at  8.3 %  and  4.8 %,  respectively, 
although resistance levels in the individual countries reached up to 30.6 %. Overall, only 1.7 % of isolates 
were resistant to cefotaxime. There were large differences in the occurrence of resistance between MSs. 
There were fewer statistically significant trends than in isolates from Gallus gallus. No significant trends were 
observed for cefotaxime, ciprofloxacin, nalidixic acid or streptomycin. 
Multi-resistance  levels  (reduced  susceptibility  to  at  least  three  antimicrobial  classes  according  to 
epidemiological cut-off values) were generally high in indicator E. coli isolates from broilers and pigs, and in 
a number of reporting countries. Co-resistance to the clinically important antimicrobials, ciprofloxacin and 
cefotaxime, was also detected in very few isolates from these species. 
In the reporting group of MSs, resistance levels in indicator E. coli isolates from cattle were generally lower 
than  among  isolates  from  Gallus  galllus  and  pigs.  The  highest  resistance  levels  observed  were  to 
tetracyclines (20.2 %), sulfonamides (19.5 %), streptomycin (17.4 %) and ampicillin (13.3 %). Resistance to 
ciprofloxacin and nalidixic acid was low, at 6.0 % and 4.8 %, respectively. Overall, only very few isolates 
(0.9 %) expressed resistance to cefotaxime. The occurrence of resistance was variable between MSs for 
most of the antimicrobials. As for Salmonella some MSs presented data at production type level for cattle, 
although only four MSs did so. One of these MSs reported much higher resistance among younger animals, 
mainly fattening veal calves, compared to older cattle, mainly adult cows, but this was not observed in the 
other countries. There have been numerous statistically significant trends in resistance since 2005, always of 
a decreasing nature. The only antimicrobial for which no significant trends were observed was cefotaxime. 
Indicator (commensal) enterococci 
In 2011, 10 MSs and two non-MSs reported antimicrobial resistance data regarding enterococcal isolates 
from animals and food. Most of the data concerned isolates from broilers (Gallus gallus), pigs and cattle, 
although three MSs reported results for isolates from meat derived from those species.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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There was substantial variation in the resistance levels observed in the different MSs. The highest resistance 
levels  among  Enterococcus faecium  (E. faecium)  and  Enterococcus  faecalis  (E. faecalis)  isolates  from 
broilers (Gallus gallus) were observed for tetracyclines (59.7 % and 61.9 %, respectively) and erythromycin 
(54.6 %  and  65.2 %,  respectively).  The  isolates  from  pigs  expressed  greater  resistance  to  tetracyclines 
(63.6 % in E. faecium and 78.9 % in E. faecalis) but lower resistance to erythromycin (34.8 % in E. faecium 
and 49.0 % in E. faecalis). Multi-resistance levels differed substantially between reporting MSs in E. faecium 
from  pigs  and  Gallus  gallus.  Regarding  the  isolates  from  cattle,  34.2 %  of  E. faecium  and  35.6 %  of 
E. faecalis  isolates  were  resistant  to  tetracyclines,  while  30.5 %  of  E. faecium  and  22.9 %  of  E. faecalis 
isolates were resistant to erythromycin. As in E. coli, one MS reported much higher resistance levels among 
younger animals, but this was not observed in the other country that reported data at production type level. 
Numerous statistically significant trends have been identified for these, and other, antimicrobials since 2005: 
those identified for isolates from pigs and cattle were predominantly decreasing trends. 
Resistance  levels  in  E. faecium  to  the  combination  of  antimicrobials  quinupristin/dalfopristin  has  been 
analysed in this report for the various animal species and was found to be at very high to extremely high 
levels (64.1 % to 86.5 %). This has however to be considered in relation to the very low levels of resistance 
to vancomycin observed in all animal species (maximum 0.7 %). 
Owing to cross-resistance between avoparcin and the human antimicrobial vancomycin, the use of avoparcin 
as an antimicrobial growth promoter was banned in the EU in 1997. In 2011, vancomycin resistance was 
found in only 0.7 % of E. faecium isolates from broilers, 0.6 % of E. faecalis isolates from broilers, 0.4 % of 
E. faecium isolates from pigs and 0.4 % of E. faecalis isolates from cattle. Resistance was not detected in 
the E. faecalis isolates from pigs and E. faecium isolates from cattle tested. 
Methicillin-resistant Staphylococcus aureus 
As regards healthy food-producing animals, a number of MSs and one non-MS detected MRSA in broilers 
(3.3 %, respectively 29.2 %), fattening pigs (from 5.6 % to 84.1 %), beef cattle at slaughter (8.7 %), cattle at 
slaughter (83.0 %) and bulk milk from dairy cattle (1.5 %) in 2011. Where several countries had examined 
the same type of animal, the prevalence could differ markedly between reporting countries.  
The most common type of MRSA detected was MRSA ST 398. However, some countries detected ST1 and 
ST49. Two countries reported longitudinal data on the occurrence of MRSA in pigs at slaughter in the years 
2010 and 2011; an increase in the numbers of pigs testing positive from one year to another was observed in 
both countries. 
Farm-to-fork analyses 
The association between the observed resistance to certain antimicrobials in isolates of S. Typhimurium, 
S. Enteritidis and Campylobacter from humans, food and animals was analysed by using the same clinical 
breakpoints to determine resistance. It appeared that, when resistance to erythromycin and ciprofloxacin was 
observed in human isolates in a country, resistant isolates were also found in animals and food, mostly at the 
same  levels.  Resistance  to  ciprofloxacin  in  S.  Typhimurium  was  rare  in  animal  and  food  isolates  when 
interpreted using clinical breakpoints, although some resistance was detected in human isolates. This could 
reflect  other  sources  of  human  infection  with  these  resistant  isolates,  such  as  infection  through  other 
alimentary sources than pork, chicken or beef, consumption of imported foods, infection associated with 
foreign travel or contact with pets.  
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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3. ANTIMICROBIAL RESISTANCE IN SALMONELLA 
3.1. Introduction 
Salmonella is an important zoonotic pathogen of economic significance in both humans and animals. The 
genus  Salmonella  is  divided  into  two  species:  S. enterica  and  S. bongori.  There  are  six  sub-species  of 
S. enterica  and  most  Salmonella  belong  to  the  sub-species  S. enterica  subsp.  enterica.  Salmonella  are 
further sub-divided into serovars based on the serological reactions of their somatic O-antigens and flagellar 
H-antigens. Different serovars have often been named based on the location where the serovar was first 
isolated. In this report, the organisms are identified by genus followed by serovar, e.g.  S. Typhimurium. 
There  are  more  than  2,500  serovars  of  zoonotic  Salmonella  which  have  been  recognised,  and  the 
prevalence of these different serovars can change over time. Within a given serovar, further sub-division of 
the isolates can be done, e.g. using bacteriophages (bacterial viruses). The pattern of lysis obtained with a 
standard panel of Salmonella bacteriophages (the lyso type) can be used to assign different phage types to 
a given serovar. 
Human  salmonellosis  is  usually characterised  by the  acute  onset  of fever, abdominal  pain, nausea and 
sometimes vomiting. The majority of Salmonella infections result in mild, self-limiting, gastrointestinal illness 
and usually do not require antimicrobial treatment. In some patients the infection may be more serious and 
the associated dehydration can be life-threatening. Invasive disease, such as Salmonella bacteraemia or 
meningitis,  can  occur  in  a  smaller  subset  of  patients,  with  a  higher  risk  in  patients  who  are  immuno-
compromised. In cases of severe enteric disease, or when Salmonella invades and causes a bloodstream 
infection, effective antimicrobials are essential for treatment and can be life-saving. The treatment of choice 
for  Salmonella  infection  is  fluoroquinolones  for  adults  and  third-generation  cephalosporins  for  children. 
Resistance  in  Salmonella  to  these  first-line  treatments,  resulting  in  infections  with  antimicrobial-resistant 
strains,  may  cause  treatment  failure,  which  in  turn  can  lead  to  more  severe  outcomes  in  patients. 
Salmonellosis has also been associated with long-term or chronic sequelae, e.g. reactive arthritis. 
The common reservoir of non-typhoidal Salmonella strains is the intestinal tract of a wide range of domestic 
and wild animals. A wide variety of food stuffs of both animal and plant origin can be contaminated with 
Salmonella,  which  may  cause  infection  in  humans.  Transmission  usually  occurs  when  the  bacteria  are 
introduced during food preparation or are allowed to multiply in food (for example because of inadequate 
storage temperature, inadequate cooking or cross-contamination of ready-to-eat food and uncooked food). 
Salmonella may also be transmitted through direct contact with infected animals or humans, or by contact 
with contaminated environments. 
Overall, considering all Salmonella infections in the EU, S. Enteritidis and S. Typhimurium are the serovars 
most  frequently  associated  with  human  illness.  S. Enteritidis  cases  in  humans  are  most  commonly 
associated with the consumption of contaminated eggs and poultry meat, while S. Typhimurium cases are 
mostly associated with the consumption of contaminated pig, bovine and poultry meat.  
In animals, particularly of certain species, sub-clinical infections or heathy carriage can be common. The 
organism may spread rapidly and easily between animals in a herd or flock without the animals showing any 
clinical signs in some cases and animals may become intermittent or persistent carriers. In other species, 
clinical disease may occur following Salmonella infection and, in particular, cattle may succumb to fever, 
diarrhoea and abortion following infection, particularly with some serovars, such as  S. Dublin. In calves, 
Salmonella can cause outbreaks of diarrhoea with high mortality. Fever and diarrhoea are less common in 
pigs than in cattle and sheep and poultry may also show no signs of infection. 
Salmonella spp. comprises the amalgamated results for all Salmonella serovars reported by a reporting MS. 
In the case of sampling in animals performed in accordance with EFSA’s recommendations (EFSA, 2007) 
and related to National Salmonella Control Programmes, there is a defined method of selecting isolates for 
inclusion in the monitoring. The relative contribution of different serovars possessing a particular resistance 
should  ideally  be  considered  when  interpreting  the  results,  in  order  to  evaluate  the  influence  of  clonal 
dissemination of serovars. If a MS has reported the susceptibility of particular serovars and excluded others, 
then this would introduce a source of bias in the susceptibility figures relating to Salmonella spp. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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3.2. Overview of reported resistance data in Salmonella from humans, animals and food 
Nineteen  MSs  and  Iceland  provided  data  for  2011  from  Salmonella  human  cases  isolates.  Countries 
reported  qualitative  data,  i.e.  interpreted  antibiotic  susceptibillity  testing  (AST)  results  for  tested  isolates 
(susceptible (S), intermediate (I) or resistant (R)), but no minimum inhibitory concentration (MIC) values or 
inhibition zone diameters (IZDs). Twenty MSs and one non-MS (Norway) reported quantitative MIC data on 
the antimicrobial resistance of Salmonella isolates recovered from animals and food in 2011. Table SA1 
presents an overview of the MSs reporting on antimicrobial resistance, either MIC or IZD data, on Salmonella 
spp. from humans and various animal and food categories in 2011. 
Table SA1.  Overview  of  countries  reporting  antimicrobial  resistance  data  using  MICs  and  disc 
inhibition  zones  on  Salmonella  spp.  (all  serovars)  from  humans  and  various  animal  and  food 
categories in 2011 
Method  Origin  Total number of 
MSs reporting  Countries 
Diffusion 
Human  12 
MSs: AT, EE, GR, HU, IT, LT
4, LU, LV
4, RO, 
SK
4, SI, ES 
Non-MS: IS 
Gallus gallus (fowl)  6 
MSs: AT
1, CY
2, LU
1, PL
2, RO, SI
3 
Non-MS: IS
1 
Turkeys  5  MSs: AT
1, CY
2, PL
2, RO, SI
3 
Pigs  6 
MSs: AT
1, IE
2, PL
2, PT
3, RO, SI
3 
Non-MS: IS
1 
Cattle (bovine animals)  3  MSs: AT
1, IE
2, LU
1 
Meat from broilers (Gallus gallus)  8 
MSs: AT
1, ES
2, HU
3, LT
3, LU
2, NL
3, PL
2, SI
3 
Non-MS: IS
1 
Meat from turkey  1  MS: HU
3 
Meat from pig  8 
MSs: AT
1, ES
2, HU
3, LT
3, LU
2, NL
3, PL
2, SI
3 
Non-MS: IS
1 
Meat from bovine animals  6  MSs: AT
1, ES
2, HU
3,
 LU
2, PL
2, SI
3 
Dilution 
Human  12  MSs: DK, DE, EE, IE, IT, LT
4, LV
4, MT, NL, 
RO, SK
4, UK 
Gallus gallus (fowl)  19 
MSs: AT, BE, DE, DK, EE, ES, FI, FR, GR, 
HU, IE, IT, LV, NL, PL, PT, SE, SK, UK 
Non-MS: NO 
Turkeys  13 
MSs: AT, DE, DK, ES, FI, FR, HU, IE, IT, PL, 
PT, SK, UK 
Non-MS: NO 
Pigs  11 
MSs: DE, DK, EE, ES, FI, HU, IE, IT, NL, 
SE, SK 
Non-MS: NO 
Cattle (bovine animals)  9 
MSs: DE, EE, ES, FI, IE, IT, NL, SE, SK 
Non-MS: NO 
Meat from broilers (Gallus gallus)  11  MSs: BE, DE, GR, HU, IE, IT, LV, NL, PT, 
RO, SK 
Meat from turkey  9  MSs: DE, EE, FI, HU, IE, IT, NL, PL, RO 
Meat from pig  11  MSs: BE, DE, DK, EE, HU, IE, IT, NL, PT, 
RO, SK 
Meat from bovine animals  8  MSs: DE, EE, FI, IE, IT, NL, PT, RO 
Note: Cyprus  provided  human  data  for  only  one  isolate  tested  for  one  antimicrobial  and  no  information  was  provided  regarding 
interpretive criteria. Cyprus is therefore not represented in the table. 
1. These data were submitted with no test method specified but are believed to have been tested by disc diffusion based on information 
in the National Zoonoses Reports. 
2. These data were submitted with no test method specified and this information could not be obtained from the National Zoonoses 
Reports. 
3. These data were submitted with the test method listed as dilution but no MIC distribution data were supplied. 
4. Clinical breakpoints shown are from the 2010 report; clinical breakpoints for 2011 were not reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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3.3. Antimicrobial resistance in Salmonella isolates from humans 
METHODS AND INTERPRETATIVE THRESHOLDS OF RESISTANCE IN SALMONELLA IN HUMANS 
The method of testing for antimicrobial susceptibility and the selection of the isolates to be tested varied 
between countries. In several countries, the reference laboratories perform antimicrobial susceptibility 
testing on only a subset of the isolates. The remainder may be subjected to susceptibility testing by 
hospitals or local laboratories and the methods used by these may not be reported. The methods and 
interpretative criteria used for antimicrobial susceptibility testing (AST) of Salmonella are presented in 
Table MM1 in Materials and Methods. At present there is a lack of standardisation of AST methods and 
interpretive criteria both between and within countries. Most countries used clinical breakpoints for the 
interpretation of test results as provided by the Clinical and Laboratory Standards Institute (CLSI) or a 
combination  of  clinical  breakpoints  from  CLSI  and  the  European  Committee  on  Antimicrobial 
Susceptibility Testing (EUCAST), depending on the antimicrobial. A few countries used other criteria such 
as epidemiological cut-off values (ECOFFs) provided by EUCAST.  
Of the 10 antimicrobials reported from both human and animal/food isolates, four MIC values or zone 
diameters  differ  markedly  between  the  clinical  breakpoints  and  the  ECOFFs  for  four:  cefotaxime, 
ciprofloxacin, gentamicin and trimethoprim. In particular, the ECOFF for ciprofloxacin is three dilution 
steps  lower  than  the  EUCAST  clinical  breakpoint  and  five  dilution  step  lower  than  the  CLSI  clinical 
breakpoint  (Figure  SA1).  The  results  for  these  four  antimicrobials  must  therefore  be  interpreted  with 
caution and no direct comparison between countries should be made. Where countries have used the 
same method over the time period covered by the report, the trends in occurrence of resistance are likely 
to be valid, although sensitivity may vary depending on the specific thresholds used. 
Figure  SA1.  Comparison  of  clinical  breakpoints  and  epidemiological  cut-off  values  used  to 
interpret MIC data reported for Salmonella spp. from humans, animals or food 
 
Note: CLSI from 2011, EUCAST from 2011, EUCAST ECOFFS as utilised by EFSA in 2011. 
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3.3.1. Antimicrobial resistance in Salmonella spp. 
Nineteen MSs and Iceland submitted antimicrobial resistance data from human non-typhoidal Salmonella 
isolates to ECDC for 2011. In total, 25,199 isolates were tested for resistance to one or more antimicrobials, 
representing 26.4 % (N=95,548) of the confirmed human salmonellosis cases reported in the EU in 2011 
(EFSA and ECDC, 2013).  
The highest level of resistance in all human Salmonella isolates from 2011 was observed for tetracyclines 
(27.1 %), closely followed by ampicillin (26.6 %) (Table SA2). However, as in previous years, wide variability 
in  percentages  of  resistance  to  different  antimicrobials  was  observed  among  the  reporting  countries. 
Salmonella  Enteritidis and  S. Typhimurium  were, in 2011  as  in previous  years,  the  two  most commonly 
reported Salmonella serovars, representing 44.4 % and 24.9 % respectively of all confirmed human cases for 
which serover information was provided (EFSA and ECDC, 2013). Furthermore, harmonisation of reporting 
of  monophasic  S. Typhimurium  1,4,[5],12:i:-  in  2010  resulted  in  this  serotype  becoming  the  third  most 
commonly reported serovar, representing 4.7 % of all confirmed reported cases in 2011.  
Multi-drug resistance of human Salmonella spp. to 10 antimicrobials are presented. The 10 antimicrobials 
included were ampicillin, cefotaxime, chloramphenicol, ciprofloxacin/nalidixic acid, gentamicin, kanamycin, 
streptomycin, sulfonamides, tetracyclines and trimethoprim. Of these, only kanamycin is not on the list of 
antimicrobials tested for in food and animal isolates. Multi-drug resistance of an isolate is defined as non-
susceptibility  to  at  least  three  different  antimicrobial  classes  (Magiorakos  et  al.,  2012).  Co-resistance  to 
ciprofloxacin  and  cefotaxime  was  also  estimated  as  these  two  antimicrobials  are  considered  the  most 
important for treatment of severe salmonellosis (EFSA, 2009d). 
The AST results for a total of 14 serovars (the top 10 serovars in humans and some additional serovars of 
importance in animals) are presented in a separate chapter. In order to assess whether there were any 
differences in resistance levels between human Salmonella infections aquired within the EU/EEA and those 
aquired when travelling outside of the EU/EEA, resistance data are presented by region based on most likely 
country of infection. Multi-drug resistance and co-resistance of human Salmonella spp. are also presented. 
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Table SA2.  Antimicrobial resistance in Salmonella spp. (all non-typhoidal serovars) from humans per country in 2011, using clinical breakpoints, with 
some exceptions
1  
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  2,235  12.7  2,235  0.7  2,235  4.0  2,235  0.7  2,235  0.9  2,235  0.6 
Cyprus  1  NA  -  -  -  -  -  -  -  -  -  - 
Denmark
1  1,149  25.8  1,149  1.6  1,149  6.6  1,149  14.6  1,149  3.7  1,149  1.2 
Estonia  286  15.7  266  1.1  222  1.8  359  1.1  220  0.9  219  0.5 
Germany  1,933  38.6  1,933  1.1   -  -  1,933  1.1  1,933  2.2  1,933  1.7 
Greece  273  13.2  53  0  214  3.3  270  0  58  86.2  214  4.2 
Hungary  697  55.4  697  0.1  697  12.2  697  0.1  697  0.3  697  0.9 
Ireland  305  31.5  304  3.0  305  19.0  304  1.0  304  3.6  304  2.3 
Italy  1,563  59.2  1,287  1.8  353  9.6  1,522  11.3  1,163  45.7  225  4.4 
Latvia  126  0  18  NA  3  NA  105  0  1  NA  -  - 
Lithuania  2,265  17.7  1,922  0.2  1,049  0.9  1,800  0.7  1,044  0.2  944  0 
Luxembourg  123  38.2  123  0  123  4.9  123  4.1  123  1.6  122  0 
Malta  120  30.8  -  -  -  -  120  9.2  120  58.3  -  - 
Netherlands
1  1,115  37.9  1,115  0.4  1,115  8.4  1,115  10.2  1,115  1.3  -  - 
Romania  281  27.8  281  0.4  281  8.2  281  0.7  281  1.4  281  1.1 
Slovakia  600  10.8  230  3.0  110  1.8  249  3.2  195  93.8  -  - 
Slovenia  400  15.3  400  0  400  3.8  400  0.3  400  0.8  400  0.8 
Spain  2,112  38.1  2,111  0.6  2,111  7.7  2,110  0.7  2,111  1.6  2,109  1.1 
United Kingdom  9,320  20.3  9,239  0.9  9,284  5.6  9,354  17.6  9,295  2.6  9,243  1.9 
Total (19 MSs)  24,904  26.6  23,363  0.8  19,651  6.0  24,126  9.1  22,444  5.6  20,075  1.5 
Iceland  44  22.7  1  NA  44  4.5  44  4.5  1  NA  -  - 
Table continued overleaf. 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
– = no data reported. 
NA = not applicable: if fewer than 20 isolates were tested resistance was not calculated. 
1. ECOFFs were used for interpretation. 
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Table  SA2  (continued).  Antimicrobial  resistance  in  Salmonella  spp.  (all  non-typhoidal  serovars)  from  humans  per  country  in  2011,  using  clinical 
breakpoints, with some exceptions
1 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  2,235  11.1  2,235  13.1  2,235  13.5  2,235  14.8  2,235  2.8 
Cyprus  -  -  -  -  -  -  -  -  -  - 
Denmark
1  1,149  11.5  1,149  29.5  1,149  27.9  1,149  29.7  1,148  5.7 
Estonia  217  6.9  215  5.6  221  6.8  220  5.0  294  3.1 
Germany  1,933  6.9  1,933  42.9  -  -  -  -  1,931  5.3 
Greece  257  2.7  214  15.4  -  -  215  14.9  44  11.4 
Hungary  697  26.8  697  49.2  697  63.8  697  54.8  697  6.9 
Ireland  304  11.8  305  28.5  305  32.5  305  36.4  304  10.5 
Italy  351  7.4  232  51.3  208  51.9  473  61.9  1,379  8.3 
Latvia  -  -  -  -  -  -  1  NA  107  0 
Lithuania  968  12.2  946  7.7  943  9.4  942  9.3  2,256  7.5 
Luxembourg  123  5.7  123  33.3  123  36.6  123  32.5  123  7.3 
Malta  -  -  -  -  -  -  -  -  120  10.8 
Netherlands
1  1,115  8.9  1,115  37.8  1,115  37.3  1,115  39.1  -  - 
Romania  281  16.4  281  23.5  281  45.6  281  27.8  281  15.7 
Slovakia  4  NA  11  NA  33  9.1  373  10.5  -  - 
Slovenia  400  10.0  400  13.3  400  15.3  400  12.5  400  1.0 
Spain  2,110  21.7  2,112  29.1  2,110  0.3  2,110  36.9  2,110  0.1 
United Kingdom  9,309  18.5  9,284  6.3  9,240  22.3  9,240  25.7  9,344  10.1 
Total (19 MSs)  21,453  15.3  21,252  18.4  19,060  21.5  19,879  27.1  22,773  7.2 
Iceland  44  13.6  -  -  -  -  -  -  44  2.3 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
– = no data reported. 
NA = not applicable: if fewer than 20 isolates were tested resistance was not calculated. 
1.   ECOFFs were used for interpretation. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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3.3.2. Antimicrobial resistance in S. Enteritidis 
As in previous years, S. Enteritidis was the most common Salmonella serovar isolated in Europe in 2011, 
with 34,385 cases (EFSA and ECDC, 2013). Data on antimicrobial resistance of S. Enteritidis isolates were 
submitted by 19 MSs and Iceland for 2011. 
The  highest  levels  of  resistance  among  S. Enteritidis  isolates  were  observed  for  nalidixic  acid  (23.2 %; 
N=6,811),  and  ciprofloxacin  (12.7 %;  N=7,965)  (Table  SA3).  Both  of  these  antimicrobials  belong  to  the 
quinolones, a family of synthetic broad-spectrum antimicrobials. Whereas nalidixic acid is a first-generation 
quinolone (and not normally used for the treatment of salmonellosis), ciprofloxacin belongs to the second-
generation of fluoroquinolones and is today the antimicrobial of choice for treatment of severe or invasive 
Salmonella infections in humans (EFSA, 2009d). As in 2009 and 2010, the highest resistance to ciprofloxacin 
was found in the United Kingdom (33.7 %; N=2,596) and Denmark (23.6 %; N=288), which both used more 
sensitive breakpoints. Italy reported the third highest resistance to ciprofloxacin in 2011 (15.5 %; N=148) 
which was a substantial increase compared with 2010 (1.4 %; N=207). This unexpected result, and those 
that follow, may be due to a lack of standardisation in AST methods and interpretive criteria. The United 
Kingdom  reported  a  marked  increase  in  ciprofloxacin  resistance  among  S. Enteritidis  from  the  19.0 % 
(N=2,784) observed in 2010, reflecting a return to the levels of resistance observed in 2009. A high level of 
resistance among S. Enteritidis to nalidixic acid was observed in the United Kingdom (34.4 %; N=2,587), 
Ireland (25.9 %; N=58) and Denmark (22.2 %; N=288) with very high resistance observed in Spain (56.4 %; 
N=612) (Table SA3). 
For the country-specific five-year trends for ciprofloxacin resistance over the 2007–2011 period, the countries 
were presented individually owing to wide diversity of AST methods and breakpoints/cut-off values used for 
interpreting resistance data (Figure SA2). The more sensitive breakpoints (ECOFFs or similar) were used in 
the United Kingdom, Denmark, the Netherlands and, since 2011, Estonia. Most of the countries using CLSI 
breakpoints reported very low to low levels of resistance, with the exception of Italy.  
The second most clinically important group of antimicrobials for the treatment of human salmonellosis are the 
cephalosporins,  especially  for  treatment  of  severe  infections  in  children  (EFSA,  2009d).  In  the  panel  of 
antimicrobials  tested,  this  group  of  antimicrobials  is  represented  by  cefotaxime,  a  third-generation 
cephalosporin. As in previous years, resistance to cefotaxime was generally very low in the reporting MSs, 
0.3 % (N=7,700) in 2011. The highest resistance was observed in Slovakia (3.0 %; N=169) followed by Italy 
(1.7 %; N=120) (Table SA3). The five-year 2007–2011 trends in cefotaxime resistance were generally at a 
very low level in reporting MSs (Figure SA3). The fact that CLSI changed the breakpoint for cefotaxime from 
≥64 mg/L to ≥4 mg/L in 2010 did not result in any visible increases in resistance in the countries adapting to 
this change in either 2010 or 2011. 
Other  noteworthy  observations  are  the  extremely  high  resistance  to  gentamicin  among  S. Enteritidis  in 
Slovakia (94.8 %; N=135) and Greece (83.3 %; N=42), while Malta reported a rise from 0 % (N=72) in 2010 
to 55.3 % (N=47) in 2011, although this can be attributed to the use of a more sensitive breakpoint in 2011 
(Table SA3).  
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Table SA3.  Antimicrobial resistance in S. Enteritidis from humans per country in 2011, using clinical breakpoints, with some exceptions
1 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  1,266  1.6  1,266  0.2  1,266  0.2  1,266  0.1  1,266  0  1,266  0 
Cyprus  1  NA  -  -  -  -  -  -  -  -  -  - 
Denmark
1  288  7.6  288  0.7  288  0  288  23.6  288  0  288  0 
Estonia  206  13.6  185  1.1  153  0.7  217  1.4  151  0  150  0.7 
Germany  191  1.0  191  0  -  -  191  0  191  0  191  0.5 
Greece  112  5.4  39  0  70  0  111  0  42  83.3  70  0 
Hungary  20  65.0  20  0  20  25.0  20  0  20  0  20  0 
Ireland  58  5.2  58  0  58  0  58  0  58  0  58  0 
Italy  147  8.8  120  1.7  28  0  148  15.5  124  37.9  23  0 
Latvia  116  0  12  NA  1  NA  97  0  -  -  -  - 
Lithuania  1,759  12.1  1,496  0.2  894  0.2  1,464  0.6  879  0  812  0 
Luxembourg  30  3.3  30  0  30  0  30  3.3  30  0  29  0 
Malta  47  10.6  -  -  -  -  47  6.4  47  55.3  -  - 
Netherlands
1  317  3.5  317  0  317  0.3  317  9.1  317  0  -  - 
Romania  120  7.5  120  0  120  2.5  120  0  120  0  120  0 
Slovakia  460  3.3  169  3.0  68  0  172  1.7  135  94.8  -  - 
Slovenia  210  3.3  210  0  210  0  210  0  210  0  210  0 
Spain  614  9.3  613  0.2  614  0.2  613  0.2  614  0.2  613  0 
United Kingdom  2,589  3.2  2,566  0.3  2,575  0.3  2,596  33.7  2,577  0.2  2,566  0 
Total (19 MSs)  8,551  5.9  7,700  0.3  6,712  0.4  7,965  12.7  7,069  3.4  6,416  0 
Iceland  19  NA  -  -  19  NA  19  NA  -  -  -  - 
Table continued overleaf. 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
– = no data reported. 
NA = not applicable: if fewer than 20 isolates were tested resistance was not calculated. 
1. ECOFFs were used for interpretation. 
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Table SA3 (continued). Antimicrobial resistance in S. Enteritidis from humans per country in 2011, using clinical breakpoints, with some exceptions
1  
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  1,266  4.9  1,266  0.6  1,266  0.8  1,266  1.1  1,266  0.4 
Cyprus  -  -  -  -  -  -  -  -  -  - 
Denmark
1  288  22.2  288  2.1  288  3.1  288  5.2  288  1.7 
Estonia  150  8.0  146  0  149  0.7  151  1.3  210  0.5 
Germany  191  3.7  191  0.5  -  -  -  -  191  0 
Greece  108  1.9  70  1.4  -  -  71  1.4  26  7.7 
Hungary  20  5.0  20  50.0  20  50.0  20  50.0  20  10.0 
Ireland  58  25.9  58  0  58  1.7  58  13.8  58  1.7 
Italy  38  5.3  23  0  21  0  43  9.3  113  4.4 
Latvia  -  -  -  -  -  -  -  -  99  0 
Lithuania  812  13.1  813  0.2  810  0.6  811  1.8  1,761  6.3 
Luxembourg  30  13.3  30  3.3  30  3.3  30  6.7  30  0 
Malta  -  -  -  -  -  -  -  -  47  6.4 
Netherlands
1  317  9.1  317  0.6  317  1.6  317  2.5  -  - 
Romania  120  20.0  120  3.3  120  20.0  120  2.5  120  4.2 
Slovakia  4  NA  4  NA  24  0  289  4.2  -  - 
Slovenia  210  6.7  210  1.9  210  4.3  210  0  210  0 
Spain  612  56.4  614  1.0  613  0  613  2.6  614  0 
United Kingdom  2,587  34.4  2,575  0.5  2,566  1.8  2,566  3.0  2,594  0.8 
Total (19 MSs)  6,811  23.2  6,745  0.8  6,492  1.9  6,853  2.7  7,647  2.1 
Iceland  19  NA  -  -  -  -  -  -  19  NA 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
– = no data reported. 
NA = not applicable: if fewer than 20 isolates were tested resistance was not calculated. 
1. ECOFFs were used for interpretation. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure SA2.  Resistance  to  ciprofloxacin  in  S. Enteritidis  in  humans  in  reporting  MSs,  2007-2011, 
using clinical breakpoints, with some exceptions
1 
Direct comparisons between countries should be avoided owing to use of different interpretive criteria
2 
 
Note: Data for at least four years from 2007 to 2011 were also available for Ireland, but are not shown as no resistant cases were 
observed in this period. 
1.   ECOFFs were used for interpretation in Denmark and the Netherlands. 
2.   Guidelines used for AST: Denmark (Danmap), Estonia (EUCAST), Germany (DIN), Italy (CLSI), Lithuania (CLSI), Luxembourg 
(CLSI), Malta (EUCAST), the Netherlands (EUCAST), Romania (CLSI), Slovenia (CLSI), Spain (CLSI), UK (HPA). See also Table 
MM1.  
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Figure SA3.  Resistance to cefotaxime in S. Enteritidis in humans in reporting MSs, 2007-2011, using 
clinical breakpoints, with some exceptions
1 
Direct comparisons between countries should be avoided owing to use of different interpretive criteria
2 
 
Note: Data for at least four years from 2007 to 2011 were also available for Lithuania and Luxembourg, but are not shown as few 
resistant cases were observed in this period in these countries. 
1.  ECOFFs were used for interpretation in Denmark and the Netherlands. 
2.  Guidelines  used  for  AST:  Denmark  (Danmap),  Estonia  (EUCAST),  Germany  (DIN),  Ireland  (EUCAST)  Italy  (CLSI),  the 
Netherlands (EUCAST), Romania (CLSI), Slovenia (CLSI), Spain (CLSI), UK (HPA). See also Table MM1.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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3.3.3. Antimicrobial resistance in S. Typhimurium 
Antimicrobial  resistance  in  S. Typhimurium  isolates  reported  for  2011  differed  from  that  in  S. Enteritidis. 
S. Typhimurium  was  the second  most  common  Salmonella  serovar  isolated  in  2011,  with  19,250  cases 
(excluding monophasic S. Typhimurium which is presented in Section 4.2.1) (EFSA and ECDC, 2013). Data 
were reported by 18 MSs and Iceland. The highest resistance in S. Typhimurium was observed for ampicillin 
(61.5 %;  N=5,617),  tetracyclines  (59.5 %;  N=4,241),  sulfonamides  (53.9 %;  N=4,031)  and  streptomycin 
(38.0 %; N=4,921) (Table SA4). The occurrence of resistance to these antimicrobials was generally high to 
extremely high in the majority of reporting MSs. In 2011, resistance observed in S. Typhimurium isolates to 
the two clinically most important antimicrobials was 4.8 % (N=5,562) for ciprofloxacin and 1.0 % (N=5,337) 
for  cefotaxime.  The  percentage  of  resistance  to  ciprofloxacin  increased  from  0.8 %  (N=824)  in  2010  to 
13.0 % (N=486) in Italy in 2011, but decreased from 20.1 % (N=388) in 2010 to 12.7 % (N=314) in the 
Netherlands. The highest levels of resistance to cefotaxime were observed in Slovakia (4.8 %; N=21) and 
Italy (2.7 %; N=412) (Table SA4). 
The  five-year  trend  (2007–2011)  in  resistance  to  ciprofloxacin  by  country  showed  that  most  reporting 
countries using CLSI clinical breakpoints reported consistently low levels of resistance to ciprofloxacin, with 
the exception of Italy. Countries using ECOFFs or similar interpretative criteria (Denmark, the Netherlands 
and  the  United  Kingdom)  generally  reported  higher  levels  of  resistance  over  the  five-year  period,  even 
though  the  trend  in  the  Netherlands  was  notably  inconsistent  (Figure  SA4).  For  the  five-year  trends  for 
cefotaxime resistance over 2007 to 2011, resistance was low overall in reporting MSs independent of the 
breakpoints used. The highest resistance (13.8 %; N=87) was observed in Romania in 2007, followed by a 
considerable decline to 2011 (1.1 %; N=94) (Figure SA5). 
Other noteworthy observations were the high resistance in S. Typhimurium to gentamicin in Italy (49.1 %, 
N=377) and extremely high resistance in Slovakia (82.6 %; N=23), while Malta reported a rise from 0 % 
(N=37) in 2010 to 60.0 % (N=25) in 2011, although this can be attributed to the use of a more sensitive 
breakpoint in 2011 and a small sample size (Table SA4). 
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Table SA4.  Antimicrobial resistance in S. Typhimurium from humans per country in 2011, using clinical breakpoints, with some exceptions
1 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  302  46.0  302  1.3  302  22.5  302  0  302  0.3  302  0 
Denmark
1  244  32.4  244  0.4  244  17.2  244  4.9  244  0.4  244  0.8 
Estonia  37  27.0  38  0  29  10.3  39  0  29  3.4  29  0 
Germany  811  79.0  811  1.1  -  -  811  0.4  811  1.6  811  2.6 
Greece  55  23.6  9  NA  44  9.1  54  0  10  NA  44  2.3 
Hungary  320  68.8  320  0  320  21.9  320  0  320  0.3  320  1.3 
Ireland  88  56.8  87  0  88  51.1  87  0  87  1.1  87  1.1 
Italy  507  76.7  412  2.7  115  24.3  486  13.0  377  49.1  47  2.1 
Latvia  7  NA  3  NA  -  -  7  NA  -  -  -  - 
Lithuania  215  63.7  174  0  104  6.7  194  0  99  0  92  0 
Luxembourg  31  51.6  31  0  31  16.1  31  3.2  31  0  31  0 
Malta  25  64.0  -  -  -  -  25  4.0  25  60.0  -  - 
Netherlands
1  314  55.1  314  0  314  24.5  314  12.7  314  0.6  -  - 
Romania  94  55.3  94  1.1  94  20.2  94  0  94  1.1  94  3.2 
Slovakia  62  50.0  21  4.8  25  8.0  29  10.3  23  82.6  -  - 
Slovenia  56  51.8  56  0  56  26.8  56  0  56  3.6  56  1.8 
Spain  274  82.5  274  0.7  273  26.4  273  0  273  1.8  273  3.3 
United Kingdom  2,175  56.7  2,147  1.2  2,169  14.8  2,196  6.6  2,171  2.2  2,150  1.6 
Total (18 MSs)  5,617  61.5  5,337  1.0  4,208  18.5  5,562  4.8  5,266  5.8  4,580  1.7 
Iceland  9  NA  1  NA  9  NA  9  NA  1  NA  -  - 
Table continued overleaf. 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
– = no data reported. 
NA = not applicable: if fewer than 20 isolates were tested, resistance was not calculated. 
1. ECOFFs were used for interpretation.  
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Table SA4 (continued). Antimicrobial resistance in S. Typhimurium from humans per country in 2011, using clinical breakpoints, with some exceptions
1 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  302  4.6  302  42.4  302  49.0  302  48.3  302  9.3 
Denmark
1  244  3.3  244  38.1  244  39.8  244  41.0  244  4.9 
Estonia  29  3.4  29  17.2  29  24.1  29  13.8  39  12.8 
Germany  811  4.8  811  78.2  -  -  -  -  809  7.3 
Greece  48  2.1  44  25.0  -  -  44  43.2  9  NA 
Hungary  320  1.9  320  43.8  320  51.3  320  44.4  320  13.4 
Ireland  87  8.0  88  59.1  88  62.5  88  63.6  87  12.6 
Italy  110  8.2  47  63.8  36  61.1  171  76.6  454  7.3 
Latvia  -  -  -  -  -  -  -  -  7  NA 
Lithuania  92  5.4  92  65.2  92  83.7  91  74.7  211  22.7 
Luxembourg  31  3.2  31  38.7  31  48.4  31  35.5  31  12.9 
Malta  -  -  -  -  -  -  -  -  25  0 
Netherlands
1  314  11.8  314  51.3  314  52.9  314  55.4  -  - 
Romania  94  5.3  94  43.6  94  73.4  94  50.0  94  26.6 
Slovakia  -  -  6  NA  5  NA  37  27.0  -  - 
Slovenia  56  19.6  56  53.6  56  48.2  56  46.4  56  3.6 
Spain  274  10.6  274  59.1  273  0  273  83.2  272  0 
United Kingdom  2,178  6.2  2,169  14.2  2,147  61.6  2,147  63.4  2,195  12.8 
Total (18 MSs)  4,990  6.2  4,921  38.0  4,031  53.9  4,241  59.5  5,155  10.7 
Iceland  9  NA  -  -  -  -  -  -  9  NA 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
– = no data reported. 
NA = not applicable; if fewer than 20 isolates were tested, resistance was not calculated. 
1. ECOFFs were used for interpretation.  
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Figure SA4.  Resistance to ciprofloxacin in S. Typhimurium in humans in reporting MSs, 2007–2011, 
using clinical breakpoints, with some exceptions
1 
Direct comparisons between countries should be avoided owing to use of different interpretive criteria
2 
 
Note: Data for at least four years from 2007 to2011 were also available for Malta, Romania and Slovenia, but are not shown as few, if 
any, resistant cases were observed in this period in these countries. 
1.  ECOFFs were used for interpretation in Denmark and the Netherlands. 
2.  Guidelines used for AST: Denmark (Danmap), Estonia (EUCAST), Germany (DIN), Ireland (EUCAST), Italy (CLSI), Lithuania 
(CLSI), Luxembourg (CLSI), the Netherlands (EUCAST), Spain (CLSI), UK (HPA). See also Table MM1.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure SA5.  Resistance to  cefotaxime  in  S. Typhimurium  in humans  in reporting  MSs,  2007-2011, 
using clinical breakpoints, with some exceptions
1 
Direct comparisons between countries should be avoided owing to use of different interpretive criteria
2 
 
1.  ECOFFs were used for interpretation in Denmark and the Netherlands. 
2.  Guidelines used for AST: Denmark (Danmap), Estonia (EUCAST), Germany (DIN), Ireland (EUCAST), Italy (CLSI), Lithuania 
(CLSI), the Netherlands (EUCAST), Romania (CLSI), Slovenia (CLSI), Spain (CLSI), UK (HPA). See also Table MM1. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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3.3.4. Multi-drug resistance in Salmonella isolates from humans 
Twelve MSs had tested isolates for the full range of antimicrobials included in the human data collection for 
Salmonella spp., and these isolates were included in the multi-drug resistance analysis. About half of the 
human Salmonella spp. isolates in the 12 MSs were susceptible to all 10 antimicrobials (55.6 %; N=17,833), 
varying from 17.1 % (N=697) in Hungary to 79.0 % (N=209) in Estonia (Table SA5). Multi-drug resistance 
was high (24.1 %; N=17,833; country average 28.2 %) at the EU level, with the highest levels reported from 
Hungary (60.7 %; N=697) and Italy (54.6 %; N=183) (Table SA5). The proportions of isolates susceptible to 
all and resistant (or non-susceptible) to any one up to 10 antimicrobials are presented by MSs in Figure SA6. 
The proportions differed substantially between countries. Isolates resistant to as many as seven or eight 
antimicrobials  were  reported  from  all  12  MSs,  and  four  MSs  (Austria,  Denmark,  Italy  and  the  United 
Kingdom) even reported a few isolates resistant to nine or all 10 antimicrobials. The serotypes of those 
isolates  resistant  to  nine  or  ten  antimicrobials  included  S. Bovismorbificans,  S. Concord,  S. Haifa, 
S. Kentucky, S. Newport, S. Typhimurium, monophasic S. Typhimurium and S. Virchow. 
Few isolates exhibited co-resistance to both ciprofloxacin and cefotaxime at the EU level (0.3 %; N=17,833) 
(Table SA6). The highest co-resistance was observed in isolates from Denmark (1.3 %; N=1,148). It should 
be noted however that Denmark used ECOFFs as interpretive criteria, which are more sensitive, in particular 
for ciprofloxacin (see Figure SA1). 
Table SA5.  Complete  susceptibility,  multi-resistance  and  co-resistance  (non-susceptibility)  to 
ciprofloxacin and cefotaxime as determined by clinical breakpoints
1 in Salmonella spp. from humans 
by MS, 2011 
Country  Susceptible to all (%)  Multi-resistant (%)  Co-resistant to  
CIP and CTX (%) 
Austria (N=2,235)  73.0  14.4  0.1 
Denmark
1 (N=1,148)  52.7  26.9  1.3 
Estonia (N=209)  78.9  6.2  0 
Hungary (N=697)  17.1  60.7  0 
Ireland (N=304)  53.6  31.9  0 
Italy (N=183)  42.1  54.6  0.5 
Lithuania (N=914)  70.5  9.3  0 
Luxembourg (N=122)  48.4  35.2  0 
Romania (N=281)  27.8  35.9  0 
Slovenia (N=400)  70.5  12.0  0 
Spain (N=2,102)  35.0  32.7  0 
United Kingdom (N=9,238)  58.0  22.4  0.4 
Total (12 MSs) (N=17,833)  55.6  24.1  0.3 
N = total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella. 
CIP = ciprofloxacin; CTX = cefotaxime. 
Susceptible to all = proportion of isolates clinically susceptible to all antimicrobial substances of the ECDC common set for Salmonella. 
Multi-resistant =  proportion of isolates clinically  non-susceptible (resistant  and intermediate) to at least three different antimicrobial 
substances belonging to any three antimicrobial families from the ECDC common antimicrobial set for Salmonella. 
Co-resistant to CIP and CTX = proportion of isolates clinically non-susceptible to both ciprofloxacin and cefotaxime. 
1. Denmark used ECOFFs for interpreting AST results. 
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Figure SA6.  Frequency distribution of Salmonella spp. isolates completely susceptible or resistant 
to 1 to 10 antimicrobials, as determined by clinical breakpoints,
* from humans by MS, 2011 
 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances for Salmonella. 
Susceptible = total number of isolates susceptible to all antimicrobial substances of the common set for Salmonella. 
res1/res10 = total number of isolates non-suscpetible (resistant and intermediate) to between 1 and 10 antimicrobial substances of the 
common set for Salmonella. 
* Denmark used ECOFFs for interpreting AST results. 
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3.3.5. Antimicrobial resistance in Salmonella isolates from humans by geographical region 
In 2011, overall,  the proportion of isolates tested for any antimicrobial among salmonellosis cases reported 
as imported (from other EU/EEA countries or outside of EU/EEA) was higher than in cases reported as 
domestically acquired (62.5 % versus 20.9 % in reporting countries, unknown importation status excluded). 
Varying  levels  of  resistance  were  observed  among  Salmonella  spp.  infections  acquired  from  different 
geographical regions around the world.
12 Data were submitted on ≥10 isolates from infections acquired in six 
geographical  regions  (EU/EEA,  non-EU/EEA,  Africa,  Asia,  Northern  and  Central  America,  and  Southern 
America). Only for infections acquired in Oceania were an insufficient number of isolates tested (Table SA6).  
For all antimicrobials, isolates acquired in Europe contributed to at least 75 % of the isolates tested. Isolates 
acquired within EU/EEA countries had a much greater level of resistance to both streptomycin (24.6 %; 
N=11,523) and ampicillin (27.8 %; N=12,619) than isolates acquired in other regions (Table SA15). Isolates 
acquired  from  Asia  exhibited  the  highest  level  of  resistance  to  six  antimicrobials,  most  notably  to 
ciprofloxacin (31.1 %; N=913), nalidixic acid (30.0 %; N=908) and tetracyclines (33.2 %; N=889). Infections 
acquired in South America exhibited the highest level of resistance to cefotaxime (4.3 %; N=23), although 
only a few isolates were tested (Table SA6).  
 
 
                                                            
12 Regional classification from United Nations Statistical Division http://unstats.un.org/unsd/methods/m49/m49regin.htm EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table SA6.  Antimicrobial  resistance  in  Salmonella  spp.  (all  non-typhoidal  serovars)  from  humans  by  geographical  region  in  2011,  using  clinical 
breakpoints, with some exceptions
1  
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Europe (EU/EEA countries)  12,619  27.8  11,739  0.8  9,757  6.2  12,342  5.0  11,805  4.2  10,462  1.2 
Europe (non-EU/EEA countries)  33  21.2  29  0  29  0  33  12.1  28  0  28  0 
Africa  1,028  12.4  1,013  0.9  1,009  4.7  1,034  19.1  1,017  5.6  948  1.2 
Asia  910  20.1  904  2.3  897  7.1  913  31.1  906  7.1  875  5.9 
North and Central America  158  3.8  157  1.9  156  3.8  158  11.4  157  0.6  155  1.3 
South America  23  8.7  23  4.3  21  4.8  23  17.4  23  8.7  20  20.0 
Oceania  7  NA  6  NA  6  NA  6  NA  6  NA  5  NA 
 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Europe (EU/EEA countries)  11,611  13.2  11,523  24.6  9,416  20.7  9,985  27.4  10,766  4.0 
Europe (non-EU/EEA countries)  31  16.1  29  13.8  26  7.7  29  10.3  27  0 
Africa  1,021  19.8  1,011  5.4  999  14.9  1,001  17.5  974  7.5 
Asia  908  30.0  904  5.4  889  29.6  889  33.2  887  17.5 
North and Central America  157  11.5  157  1.9  156  7.7  156  10.9  156  3.8 
South America  23  26.1  23  4.3  21  28.6  21  28.6  20  10.0 
Oceania  6  NA  6  NA  6  NA  6  NA  5  NA 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
NA = not applicable, if less than 10 isolates were tested resistance was not calculated. 
1. ECOFFs were used for interpretation in the Netherlands and Denmark. 
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3.4. Antimicrobial resistance in Salmonella isolates from animals and food 
Twenty MSs and one non-MS (Norway) reported quantitative MIC data on the antimicrobial resistance of 
Salmonella isolates recovered from animals and food in 2011. The MSs reporting either MIC or IZD data, for 
each  animal  or  food  category,  are  listed  in  Tables  SA1,  SA7  and  SA8.  The  results  of  97,602  MIC 
susceptibility tests performed on the Salmonella isolates were included in the analyses, as well as those of 
11,441 disc diffusion tests. As quantitative IZD data constitute a relatively small percentage (12 %) of the 
total data available, these data have therefore been analysed as qualitative data only. The susceptibility test 
results for Salmonella isolates reported as qualitative data are presented in Appendix 1. 
The antimicrobials selected by the different MSs and non-MSs for susceptibility testing of Salmonella are 
shown  in  Chapter  11,  Materials  and  Methods,  Table  MM4.  In  this  chapter,  resistance  to  ampicillin, 
cefotaxime,  ciprofloxacin,  chloramphenicol,  gentamicin,  nalidixic  acid,  streptomycin,  sulfonamides  and 
tetracyclines has been analysed in detail in line with the antimicrobials listed in the EFSA monitoring and 
reporting specifications for antimicrobial resistance in Salmonella (EFSA, 2007). 
In this report, antimicrobial resistance data for all reported Salmonella isolates were collated to generate a 
figure for Salmonella spp. (covering all reported serovars) for each country, year and animal/food category. 
In addition, the Salmonella serovars that are most prevalent and significant for public health, S. Enteritidis 
and  S. Typhimurium,  were  reported  separately  when  sufficient quantitative  data  were  available  from  the 
various animal/food categories.  
Table SA7.  Overview  of  countries  reporting  antimicrobial  resistance  data  using  MIC  and  disc 
inhibition zones on Salmonella Typhimurium from various animal and food categories in 2011 
Method  Origin  Total number of 
MSs reporting  Countries 
Diffusion 
Gallus gallus (fowl)  4  MSs: AT
1, PL
2, RO, SI
3 
Turkeys  1  MS: PL
2 
Pigs  2  MSs: AT
1, RO 
Meat from pig  1  MS: ES 
Cattle (bovine animals)  3  MSs: AT
1, IE
2, LU
1 
Meat from pig  5  MSs: AT
1, ES
2, LT
3, NL
3, PL
2 
Meat from bovine animals  5  MSs: AT
1, ES
2, HU
3, LU
2, PL
2 
Dilution 
Gallus gallus (fowl)  15 
MSs: AT, DE, DK, ES, FR, GR, HU, IT, 
LV, NL, PL, PT, SE, SK, UK 
Non-MS: NO 
Turkeys  9  MSs: DE, DK, ES, FI, FR, HU, IE, SK, 
UK 
Pigs  11 
MSs: DE, DK, EE, ES, FI, HU, IE, IT, NL, 
SE, SK 
Non-MS: NO 
Cattle (bovine animals)  9 
MSs: DE, EE, ES, FI, IE, IT, NL, SE, SK 
Non-MS: NO 
Meat from broilers (Gallus gallus)  6  MSs: BE, DE, GR, IE, LV, PT 
Meat from turkey  2  MSs: DE, FI 
Meat from pig  10  MSs: BE, DE, DK, EE, HU, IE, IT, PT, 
RO, SK 
Meat from bovine animals  5  MSs: DE, EE, FI, IE, RO 
1. These data were submitted with no test method specified but are believed to have been tested by disc diffusion based on information 
in the National Zoonoses Reports. 
2. These data were submitted with no test method specified and this information could not be obtained from the National Zoonoses 
Reports. 
3. These data were submitted with the test method listed as dilution but no MIC distribution data were supplied.   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Table SA8.  Overview  of  countries  reporting  antimicrobial  resistance  data  using  MIC  and  disc 
inhibition zones on Salmonella Enteritidis from various animal and food categories in 2011 
Method  Origin  Total number of 
MSs reporting  Countries 
Diffusion 
Gallus gallus (fowl)  5  MSs: AT
1, CY
2, PL
2, RO, SI
3 
Turkeys  2  MSs: AT
1, PL
2 
Pigs  1  MS: RO 
Cattle (bovine animals)  1  MS: IE
2 
Meat from pig  3 
MSs: HU
3, NL
3, PL
2 
Non-MS: IS
1 
Meat from bovine animals  1  MS: SI
3 
Dilution 
Gallus gallus (fowl)  16  MSs: AT, DE, DK, EE, ES, FI, FR, GR, 
HU, IT, LV, NL, PL, PT, SK, UK 
Turkeys  5  MSs: AT, DE, FR, HU, PT 
Pigs  6  MSs: DE, DK, EE, ES, HU, IT 
Cattle (bovine animals)  3  MSs: DE, IE, IT 
Meat from broilers (Gallus gallus)  4  MSs: BE, DE, LV, RO 
Meat from pig  2  MSs: IT, RO 
Meat from bovine animals  1  MS: DE 
1. These data were submitted with no test method specified but are believed to have been tested by disc diffusion based on information 
in the National Zoonoses Reports. 
2. These data were submitted with no test method specified and this information could not be obtained from the National Zoonoses 
Reports. 
3. These data were submitted with the test method listed as dilution but no MIC distribution data were supplied. 
Whenever a country subjected fewer than 10 isolates to susceptibility testing for a given animal or food 
category then these data were not included in any further analyses in this report. In addition, tables were 
generated and analysis performed only if four or more countries tested and reported quantitative data for a 
given Salmonella category and sampling origin. 
Where the minimum criteria for detailed analysis were met, temporal trend graphs were generated showing 
resistance  to  ampicillin,  cefotaxime,  chloramphenicol,  ciprofloxacin,  nalidixic  acid  and  tetracyclines  for 
Salmonella isolates from animals and food over the 2005–2011 period, by plotting the level of resistance 
against the year of sampling. Only countries which had reported data for four or more years in the 2005–
2011 period were included. Data from 2004 were excluded from the temporal trends graphs because of the 
relative  scarcity  of  data  compared  with  the  2005–2011  period.  Statistical  analysis  of  the  trend  within 
individual countries was performed using logistic regression when data were available for five or more years.  
The spatial distributions of ampicillin, nalidixic acid and tetracycline resistance rates in Salmonella spp. from 
Gallus gallus, turkeys, pigs and cattle are presented. For countries where resistance level figures for 2011 
were not available, 2010 figures were used.  
Where the minimum criteria for detailed analysis were met, multi-resistance was analysed in isolate-based 
data on Salmonella isolates tested for the full hamonised set of antimicrobials (nine substances) belonging to 
different  classes.  Multi-resistance  was  defined  as  the  non-susceptibility  to  at  least  three  different 
antimicrobial classes. The proportions of isolates susceptible to all and resistant (non-susceptible) to any one 
up to nine antimicrobials were presented. Co-resistance to cefotaxime and ciprofloxacin was estimated as 
these two antimicrobials are of particular interest in human medicine in the case of treatment of severe 
salmonellosis. Co-resistance was addressed using both ECOFFs (CTX >0.5 mg/L and CIP >0.06 mg/L) and 
clinical breakpoints (CTX >2 mg/L and CIP >1 mg/L). 
For  further  information  on  reported  MIC  distributions  and  number  of  resistant  isolates  for  apramycin, 
ceftazidime,  ceftiofur,  colistin,  florfenicol,  kanamycin,  neomycin,  spectinomycin,  streptomycin  and 
trimethoprim, refer to the Level 3 tables published on the EFSA website.   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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3.4.1. Antimicrobial resistance in Salmonella isolates from food 
This  section  describes  the  MIC  data  for  isolates  of  Salmonella  spp.  and  S. Enteritidis  from  meat  from 
broilers, and Salmonella spp. and S. Typhimurium from meat from pigs. Additionally, eight MSs reported data 
on  meat  from  bovine  animals  in  2011.  However,  as  only  three  MSs  tested  more  than  10  isolates,  the 
corresponding data have not been included in the report. 
3.4.1.1. Meat from broilers (Gallus gallus) 
Quantitative MIC susceptibility data for isolates of Salmonella spp. from broiler meat from eight MSs in 2011 
are included in the following analysis. Data for S. Typhimurium isolates are not presented separately for 
meat from broilers as only one MS tested more than 10 isolates. Details of the sampling scheme used for 
testing isolates from meat from broilers were submitted by some MSs. Belgium and Germany implement 
monitoring programmes at slaughterhouses, cutting plants, meat processing plants and at retail. Romania 
tests all Salmonella spp. strains isolated in foodstuffs derived from products of animal origin. The types of 
samples tested by MSs include neck skin, minced meat and meat preparations. 
Resistance levels in Salmonella spp. 
Table SA9 describes the occurrence of resistance to selected antimicrobials in Salmonella spp. isolated from 
broiler meat in MSs in 2011. 
Considering data from the eight reporting MSs, resistance levels to ampicillin, sulfonamides and tetracyclines 
were high at 20.6 %, 44.8 % and 43.7 % respectively. There was a substantial increase in the levels of 
resistance to sulfonamides and tetracyclines when compared with the levels reported by a similar group of 
MSs in 2010 (27 % and 20 % respectively). In 2011, resistance to these antimicrobials was highly variable 
across the reporting MSs, ranging from 5.0 % to 48.9 % for ampicillin, from 5.0 % to 77.3 % for sulfonamides 
and from 0 % to 81.2 % for tetracyclines. Resistance to chloramphenicol and gentamicin at the reporting MS 
group  level  was  5.4 %  and  1.6 %  respectively.  Resistance  levels  ranged  from  0 %  to  20.3 %  for 
chloramphenicol and from 0 % to 10.0 % for gentamicin, with a number of MSs observing no resistance to 
one or both of these antimicrobials. 
Resistance to ciprofloxacin and nalidixic acid among reporting MSs was 50.1 % and 48.8 % respectively, and 
was a considerable increase on the levels reported in 2010 (24 % for both antimicrobials). As in previous 
years,  the  occurrence  of  resistance  to  each  of  these  compounds  was  similar  within  MSs,  and  between 
countries levels ranged from 0 % to 98.8 %. The overall level of resistance to cefotaxime across the reporting 
MSs remained low in 2011 at 3.3 %. No resistance was observed in Greece, Hungary or Latvia, although 
Greece  and  Latvia  tested  only  a  limited  number  of  isolates.  The  Netherlands  reported  a  high  level  of 
resistance to cefotaxime of 31.9 %, which was an increase from the level of 11 % reported in 2010. 
Resistance levels in Salmonella Enteritidis 
Resistance among S. Enteritidis isolates from broiler meat in reporting MSs was generally lower than that 
reported in Salmonella spp. As low numbers of isolates of S. Enteritidis (fewer than 10) were recovered from 
meat from  broilers  in  Romania, this country  has  been excluded  from  the detailed analysis, leaving only 
Belgium,  Germany  and  Latvia  contributing  to  the analysis;  thus,  there  are  insufficient  data  to  present  a 
specific table. 
Belgium detected no resistance to gentamicin, chloramphenicol, nalidixic acid and cefotaxime. Resistance to 
ampicillin, sulfonamides, tetracyclines and ciprofloxacin (1.8 % for each compound) was observed in a single 
isolate of S. Enteritidis in meat from broilers. In both Germany and Latvia, no resistance was detected to 
ampicillin, cefotaxime, chloramphenicol, gentamicin, sulfonamides or tetracyclines. Resistance was detected 
against  ciprofloxacin  and  nalidixic  acid  in  both  countries.  Four  isolates  (25.0 %)  were  resistant  to  both 
antimicrobials in Germany, whilst three isolates (15.8 %) were resistant to both antimicrobials in Latvia. 
Multi-resistance among Salmonella isolates from meat from broilers 
As fewer than four MSs reported isolate-based resistance data on more than 10 isolates of Salmonella spp. 
in meat from broilers, multi-resistance analysis was not presented. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table SA9.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella spp. from meat from broilers in MSs reporting MIC data in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Belgium  253  28.1  256  1.6  256  0  254  11.0  256  0  256  10.9  256  33.6  256  15.2 
Germany  145  13.8  145  2.8  145  4.1  145  31.0  145  2.1  145  30.3  145  27.6  145  22.1 
Greece  10  10.0  10  0  10  0  10  0  10  10.0  10  0  10  10.0  10  0 
Hungary  170  9.4  170  0  170  1.2  170  98.2  170  1.8  170  98.8  37  75.7  170  81.2 
Ireland  47  17.0  47  8.5  47  0  47  12.8  47  0  47  12.8  47  23.4  47  23.4 
Latvia  20  5.0  20  0  20  5.0  20  20.0  20  0  20  20.0  20  5.0  20  5.0 
Netherlands  47  48.9  47  31.9  47  6.4  47  70.2  47  0  47  66.0  47  61.7  47  46.8 
Romania  172  22.1  172  1.2  172  20.3  172  87.2  172  4.1  172  82.6  172  77.3  172  79.1 
Total (8 MSs)  864  20.6  867  3.3  867  5.4  865  50.1  867  1.6  867  48.8  734  44.8  867  43.7 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
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3.4.1.2. Meat from pigs 
Ten MSs reported quantitative MIC data for Salmonella spp. from pig meat in 2011. Data for S. Enteritidis 
isolates are not presented separately for meat from pigs as none of the MSs reporting data tested more than 
10 isolates. Tables SA10 and SA11 present the level of resistance to selected antimicrobials for Salmonella 
spp. and S. Typhimurium isolates. Monitoring and surveillance programmes for Salmonella spp. in meat from 
pigs at slaughter are in place in Belgium, Denmark and Estonia, while passive surveillance of diagnostic 
submissions takes place in Germany and Italy. Sample types collected by MSs at slaughterhouses consisted 
of  carcass  swabs.  Belgium  and  Estonia  tested  minced  meat  and  other  meat  preparations  (e.g.  ham, 
sausages and paté) at meat processing plants and at retail. 
Resistance levels in Salmonella spp. 
Among the 10 reporting MSs, Salmonella spp. isolated from pig meat displayed very high levels of resistance 
to ampicillin, sulfonamides and tetracyclines (56.2 %, 54.5 % and 52.8 %, respectively). Within the reporting 
group,  the  occurrence  of  resistance  to  ampicillin  and  sulfonamides  ranged  from  high  to  extremely  high 
across the MSs, varying from 22.7 % to 82.4 % and from 25.0 % to 71.4 %, respectively. Six of the 10 
reporting MSs reported resistance to tetracyclines in at least 60.0 % of isolates. Chloramphenicol resistance 
remained moderate, at 13.7 %, for all reporting MSs, and ranged from 4.3 % to 26.7 % across the reporting 
MSs. Overall, gentamicin resistance was 1.4 % in the reporting group of MSs; it was not detected in five MSs 
and ranged between 1.1 % and 8.3 % in the other five reporting MSs. 
The proportion of Salmonella spp. isolates resistant to ciprofloxacin and nalidixic acid among the reporting 
MSs was similar to that reported in 2011–7.4 % and 6.1 % respectively compared with 5 % and 4 % in 2010. 
Once again, Denmark and Estonia reported no resistance to either ciprofloxacin or nalidixic acid. Hungary 
reported no resistance to nalidixic acid but a low level of resistance to ciprofloxacin. Among countries that did 
observe resistance to these two antimicrobials the level of resistance ranged from low to high, at 2.5 % to 
21.8 %. The occurrence of resistance to cefotaxime among all reporting MSs was very low, at 0.9 %. Four of 
the 10 reporting MSs reported resistance to cefotaxime in Salmonella spp. isolates from pig meat at levels 
ranging from 0.4 % to 8.3 %. 
Resistance levels in Salmonella Typhimurium 
Seven MSs reported quantitative MIC data for S. Typhimurium isolates from pig meat in 2011. For most 
antimicrobials, resistance levels were higher than the levels reported in Salmonella spp. isolates from pig 
meat. The level of resistance to ampicillin was extremely high across all reporting MSs, at 74.4 %, ranging 
from 58.3 % in Italy to 90.0 % in Germany. Resistance to sulfonamides, tetracyclines and chloramphenicol 
were  high,  at  62.4 %,  59.2 %  and  24.0 %,  respectively.  Fairly  wide  ranges  in  the  level  of  resistance  in 
individual reporting MSs were observed for sulfonamides and tetracyclines (from 53.4 % to 85.0 % and from 
41.7 % to 82.5 % respectively). Overall resistance to gentamicin was very low in the reporting MS group 
(0.8 %) and, as in 2010, reporting MSs did not detect resistance to cefotaxime. 
Similar levels of resistance to ciprofloxacin and nalidixic acid were observed among isolates within individual 
MSs. Among all reporting MSs, the occurrence of resistance to ciprofloxacin was 8.0 % and to nalidixic acid 
was 6.4 %. The levels of resistance to these compounds varied from 1.9 % to 33.3 % among reporting MSs. 
For the fifth consecutive year, Denmark reported no resistance to ciprofloxacin or nalidixic acid. Among 
Salmonella spp. isolates from pig meat, Hungary reported no resistance to nalidixic acid. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table SA10.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella spp. isolates from meat from pigs in MSs reporting MIC data in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Belgium  244  67.6  244  0.4  244  11.5  244  4.1  244  0  244  2.5  244  48.0  244  36.1 
Denmark  49  71.4  49  0  49  10.2  49  0  49  0  49  0  49  67.3  49  65.3 
Estonia  22  22.7  22  0  22  4.3  22  0  22  0  22  0  22  27.3  22  27.3 
Germany  115  56.5  115  2.6  115  12.2  115  6.1  115  2.6  115  5.2  115  63.5  115  59.1 
Hungary  17  82.4  17  0  17  23.5  17  5.9  17  0  17  0  14  71.4  17  64.7 
Ireland  139  48.9  139  0  139  18.7  139  4.3  139  1.4  139  2.9  139  64.0  139  64.7 
Italy  67  40.3  67  3.0  67  9.0  67  14.9  67  6.0  67  16.4  67  44.8  67  61.2 
Netherlands  15  53.3  15  0  15  26.7  15  20.0  15  0  15  20.0  15  53.3  15  60.0 
Portugal  12  50.0  12  8.3  12  25.0  12  8.3  12  8.3  12  8.3  12  25.0  12  66.7 
Romania  87  43.7  87  0  87  16.1  87  21.8  88  1.1  87  18.4  86  54.7  87  59.8 
Total (10 MSs)  767  56.2  767  0.9  767  13.7  767  7.4  768  1.4  767  6.1  763  54.5  767  52.8 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
Table SA11.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella Typhimurium isolates from meat from pigs in MSs reporting MIC data in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Belgium  103  78.6  103  0  103  13.6  103  3.9  103  0  103  1.9  103  53.4  103  41.7 
Denmark  28  60.7  28  0  28  17.9  28  0  28  0  28  0  28  60.7  28  50.0 
Germany  20  90.0  20  0  20  40.0  20  10.0  20  0  20  10.0  20  85.0  20  75.0 
Hungary  12  75.0  12  0  12  33.3  12  8.3  12  0  12  0  -  -  12  58.3 
Ireland  57  70.2  57  0  57  38.6  57  7.0  57  1.8  57  7.0  57  82.5  57  82.5 
Italy  12  58.3  12  0  12  16.7  12  25.0  12  8.3  12  33.3  12  58.3  12  75.0 
Romania  18  77.8  18  0  18  27.8  18  33.3  18  0  18  22.2  18  72.2  18  72.2 
Total (7 MSs)  250  74.4  250  0  250  24.0  250  8.0  250  0.8  250  6.4  250  62.4  250  59.2 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
– = no data reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Multi-resistance among Salmonella spp. isolates from meat from pigs 
In 2011, five MSs provided isolate-based data concerning resistance in Salmonella spp. in meat from pigs. 
Among the reporting MSs, isolates exhibiting complete susceptibility accounted for about 20 % to 25 % of the 
isolates  tested  and  this  figure  reached  above  70 %  in  Estonia,  although,  in  this  case,  the  complete 
susceptibility level was assessed on an isolate sample of small size. The multi-resistance levels ranged 
between 27.3 % in Estonia and 65.3 % in Denmark (Table SA12).The frequency distributions (Figure SA7) 
showed similarities among the multi-resistance recorded in three reporting MSs, with some isolates showing 
reduced  susceptibility  to  up  to  eight  different  substances,  while  Denmark  and  Estonia  recorded  multi-
resistance  to  five  classes  at  a  maximum.  Very  few  isolates  were  resistant  to  both  ciprofloxacin  and 
cefotaxime. 
Table SA12.  Complete susceptibility, multi-resistance and index of diversity in Salmonella spp. from 
meat from pigs in MSs reporting isolate-based data, 2011 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to                  
CIP and CTX 
n  %  n  %  n  % 
Denmark (N=49)  9  18.4  32  65.3  0.372  0  (0)  0  (0) 
Estonia (N=22)  16  72.7  6  27.3  0.259  0  (0)  0  (0) 
Germany (N=115)  29  25.2  71  61.7  0.451  0  (0)  0  (0) 
Ireland (N=139)  37  26.6  83  59.7  0.552  0  (0)  0  (0) 
Italy (N=67)  18  26.9  30  44.8  0.525  2  (0)  3.0  (0) 
N = total number of isolates tested for susceptibility against the whole EFSA antimicrobial set for Salmonella. 
n = number of isolates per category of complete susceptibility or multiple resistance. 
Susceptible to all = isolate susceptible to all antimicrobial substances of the EFSA common set for Salmonella. 
Multi-resistant = resistant to at least three different antimicrobial substances, belonging to any three classes from the common set. 
Index of diversity = see definition in Section 11.4.2.1 of Materials and Methods. 
Co-resistant to ciprofloxacin (CIP) and cefotaxime (CTX) = the frequencies and percentages of Salmonella isolates not susceptible to 
concentrations  greater  than  ECOFFs  (CTX: >0.5  mg/L  and  CIP: >0.06  mg/L).  Figures  in  parentheses  indicate  the  occurrence  of 
resistance determined using EUCAST clinical breakpoints (CTX: >2 mg/L and CIP: >1 mg/L). 
Figure SA7.  Frequency distribution of Salmonella spp. in meat from pigs completely susceptible or 
resistant to one to nine antimicrobials, in in MSs reporting isolate-based data, 2011 
 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
Susceptible = susceptible to all antimicrobial substances of the common set. 
res1/res9 = resistance to one antimicrobial substance/resistance to nine antimicrobial substances of the common set.   
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3.4.2. Antimicrobial resistance in Salmonella isolates from animals 
3.4.2.1. Fowl (Gallus gallus) 
A new feature of this section in 2011 is that data from broiler flocks and laying hens have been presented 
separately. As in previous years, an overview of all data including breeding, laying hen and broiler flocks, as 
well  as  unspecified  flocks  of  Gallus  gallus,  is  also  presented.  In  2011,  16  MSs  submitted  quantitative 
antimicrobial susceptibility data for Salmonella spp. from Gallus gallus. In the majority of MSs, isolates for 
antimicrobial resistance testing are obtained from national control programmes carried out according to EC 
regulations.  In  Greece  no  official  national  programme  is  in  force  and  isolates  are  obtained  from  faecal 
samples from broilers before slaughter and laying hens during rearing, and from eggshells from breeding 
flocks at the hatchery. In Latvia isolates were obtained from faecal samples from broilers before slaughter 
and from laying hens at farm. 
Resistance levels in Salmonella spp. 
Table  SA13  shows  the  level  of  resistance  to  antimicrobials  among  isolates  of  Salmonella  spp.  from 
Gallus gallus in 2011. There was moderate resistance to ampicillin and tetracyclines in the reporting MS 
group  (18.9 %  and  17.8 %,  respectively)  and  the  reported  levels  varied  between  2.6 %  and  39.5 %  for 
ampicillin and 2.4 % and 57.4 % for tetracyclines across the 16 reporting countries. Sulfonamide resistance 
was high at 25.3 % and ranged from 4.6 % to 55.8 % across the 16 reporting MSs. A low level of resistance 
to chloramphenicol was reported at MS group level (2.3 %) and reported levels ranged from 0 % to 6.6 % 
between countries. Considering the reporting MS group, the occurrence of resistance to ciprofloxacin was 
28.7 % and to nalidixic acid was 27.9 %. The level of resistance to both antimicrobials within individual MSs 
ranged widely, from 0 % to 63.5 %. As previously observed, there was considerable disparity in resistance to 
ciprofloxacin  and  nalidixic  acid  among  Salmonella  isolates  from  different  MSs,  which  may  reflect  the 
variability  of  serovars  of  Salmonella  spp.  included  in  the  analyses  of  the  different  MSs.  Gentamicin 
resistance was detected at a low level of 0.3 % to 4.5 % across the reporting MSs, and not detected at all by 
Denmark, France, Greece and Latvia. The overall occurrence of resistance considering all reporting MSs 
was 1.5 %. Cefotaxime resistance was reported by 9 of the 15 reporting MSs and varied from at 0.7 % to 
10.0 %, with an overall resistance at MS group level of 1.5 %. The highest level of resistance to cefotaxime 
was reported by the Netherlands (10.0 %), which saw a return to a similar level to that reported in 2009 
(12 %) following a decrease to 5 % in 2010. 
Resistance among isolates of Salmonella spp. from broiler flocks is presented in Table SA14. Thirteen MSs 
reported quantitative data from broilers in 2011, and in general the levels of resistance at this production 
level were slightly higher than those reported when all Gallus gallus were considered. There was moderate 
resistance to ampicillin at the MS group level (18.0 %) and the levels reported by individual MSs ranged from 
4.8 % to 42.7 %. Resistance to sulfonamides and tetracyclines was high at 38.0 % and 31.0 % respectively, 
and ranged from 4.8 % to 73.4 % for sulfonamides and from 3.2 % to 70.4 % for tetracyclines. Low levels of 
resistance were reported for chloramphenicol (2.7 %) and gentamicin (1.6 %) and these ranged from 0 % to 
7.4 %, and from 0 % to 10.0 % respectively. The occurrence of resistance to ciprofloxacin and nalidixic acid 
was high at the MS group level (35.1 % and 33.4 % respectively). Denmark observed no resistance to both 
compounds, while, in the remaining 12 MSs, resistance to both compounds ranged from 1.6 % to 82.8 %. 
Cefotaxime  resistance  was  observed  by  9  of  the  13  reporting  MSs  with  an  overall  level  of  2.8 %.  The 
Netherlands reported the highest level of resistance (16.5 %) with the remaining reported levels ranging from 
0.6 % to 5.6 %.  
Table SA15 describes the resistance among isolates of Salmonella spp. from laying hens. Twelve MSs 
reported quantitative data from laying hens in 2011, and in contrast to the data from broilers, the levels of 
resistance at this production level were lower than those reported when all Gallus gallus were considered. 
Low levels of resistance to ampicillin and sulfonamides were reported at the MS group level (7.1 % and 
9.1 % respectively) and the levels reported by individual MSs ranged from 0 % to 21.6 % for ampicillin, and 
from 0 % to 27.5 % for sulfonamides. Moderate resistance to tetracyclines was observed across all reporting 
MSs (11.6 %), and this ranged from 0 % to 29.4 %. Low levels of resistance to chloramphenicol (1.8 %) and 
gentamicin (1.1 %) were reported at the MS group level, and ranged from 0 % to 7.8 % and from 0 % to 
5.0 %, respectively. Moderate resistance to ciprofloxacin and nalidixic acid was reported at the MS group 
level  (12.7 %  and  12.4 %  respectively).  France,  Latvia,  Slovakia  and  the  United  Kingdom  observed  no 
resistance to both compounds, while in the remaining eight MSs resistance to both compounds ranged from 
3.9 %  to  26.5 %.  Cefotaxime  resistance  was  observed  only  by  Hungary,  Italy  and  the  United  Kingdom 
making the overall resistance at MS group level 0.4 %. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table SA13.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella spp. isolates from Gallus gallus in MSs reporting MIC data in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  176  10.8  176  1.1  176  0  176  26.7  176  0.6  176  26.1  176  21.6  176  28.4 
Belgium  755  39.5  -  -  756  3.2  755  33.4  756  2.0  755  33.4  722  36.8  756  15.5 
Denmark  48  14.6  48  0  48  0  48  0  48  0  48  0  48  12.5  48  12.5 
France  326  13.8  326  0  326  2.1  326  2.1  326  0  326  2.1  326  20.2  326  15.6 
Germany  291  12.0  291  0.7  291  2.4  291  7.9  291  0.7  291  8.2  291  17.2  291  8.9 
Greece  38  2.6  48  2.1  48  0  48  22.9  48  0  48  12.5  48  8.3  46  6.5 
Hungary  249  5.6  249  2.0  249  4.8  249  63.5  249  2.0  249  61.8  249  55.8  249  53.4 
Ireland  65  4.6  65  1.5  65  0  65  1.5  65  1.5  65  1.5  65  4.6  65  3.1 
Italy  198  26.3  199  3.5  198  6.6  199  24.1  198  4.5  198  23.7  198  16.7  198  23.2 
Latvia  12  8.3  12  0  12  0  12  0  12  0  12  0  12  16.7  12  8.3 
Netherlands  180  26.7  180  10.0  180  0.6  180  25.6  180  1.1  180  25.0  180  32.8  180  16.7 
Poland  340  10.9  340  0  333  0.3  340  51.2  340  0.3  339  49.3  340  8.2  340  2.4 
Portugal  170  13.5  170  1.2  170  1.2  170  46.5  170  1.2  170  43.5  170  11.8  170  8.8 
Slovakia  54  11.1  54  0  54  0  54  55.6  54  3.7  54  55.6  54  53.7  54  57.4 
Spain  220  10.0  220  0  220  0.9  220  35.0  220  2.7  220  33.2  220  9.1  220  10.9 
United Kingdom  221  9.0  221  0.9  221  3.6  221  4.5  221  1.4  221  4.1  221  35.3  221  24.9 
Total (16 MSs)  3,343  18.9  2,599  1.5  3,347  2.3  3,354  28.7  3,354  1.5  3,352  27.9  3,320  25.3  3,352  17.8 
N = number of isolates tested. 
% Res = percentage of resistant isolates.   
- = no data reported. 
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Table SA14.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella spp. isolates from broilers in MSs reporting MIC data in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  90  18.9  90  2.2  90  0  90  46.7  90  0  90  46.7  90  40.0  90  51.1 
Denmark  43  14.0  43  0  43  0  43  0  43  0  43  0  43  9.3  43  11.6 
France  160  21.3  160  0  160  2.5  160  4.4  160  0  160  4.4  160  33.8  160  18.8 
Germany  39  23.1  39  2.6  39  5.1  39  17.9  39  0  39  17.9  39  28.2  39  12.8 
Greece  15  6.7  25  4.0  25  0  25  24.0  25  0  25  12.0  25  8.0  24  4.2 
Hungary  169  7.1  169  1.8  169  6.5  169  82.8  169  0.6  169  79.9  169  73.4  169  70.4 
Ireland  63  4.8  63  1.6  63  0  63  1.6  63  1.6  63  1.6  63  4.8  63  3.2 
Italy  54  31.5  54  5.6  54  7.4  54  27.8  54  5.6  54  25.9  54  20.4  54  35.2 
Netherlands  103  42.7  103  16.5  103  1.0  103  37.9  103  1.9  103  36.9  103  51.5  103  25.2 
Portugal  100  23.0  100  2.0  100  2.0  100  62.0  100  2.0  100  57.0  100  18.0  100  11.0 
Slovakia  44  11.4  44  0  44  0  44  68.2  44  4.5  44  68.2  44  65.9  44  68.2 
Spain  40  32.5  40  0  40  5.0  40  67.5  40  10.0  40  60.0  40  22.5  40  17.5 
United Kingdom  170  7.1  170  0.6  170  2.4  170  5.9  170  1.8  170  5.3  170  37.6  170  23.5 
Total (13 MSs)  1,090  18.0  1,100  2.8  1,100  2.7  1,100  35.1  1,100  1.6  1,100  33.4  1,100  38.0  1,099  31.0 
N = number of isolates tested. 
% Res = percentage of resistant isolates.   
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Table SA15.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella spp. isolates from laying hens in MSs reporting MIC data in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  86  2.3  86  0  86  0  86  5.8  86  1.2  86  4.7  86  2.3  86  4.7 
France  166  6.6  166  0  166  1.8  166  0  166  0  166  0  166  7.2  166  12.7 
Germany  103  9.7  103  0  103  1.9  103  3.9  103  1.0  103  3.9  103  10.7  103  9.7 
Greece  18  0  18  0  18  0  18  22.2  18  0  18  16.7  18  11.1  17  11.8 
Hungary  80  2.5  80  2.5  80  1.3  80  22.5  80  5.0  80  23.8  80  18.8  80  17.5 
Italy  88  21.6  89  1.1  88  6.8  89  22.5  88  3.4  88  21.6  88  13.6  88  19.3 
Latvia  10  0  10  0  10  0  10  0  10  0  10  0  10  0  10  0 
Netherlands  67  4.5  67  0  67  0  67  7.5  67  0  67  7.5  67  6.0  67  4.5 
Portugal  64  0  64  0  64  0  64  23.4  64  0  64  23.4  64  3.1  64  6.3 
Slovakia  10  10.0  10  0  10  0  10  0  10  0  10  0  10  0  10  10.0 
Spain  170  5.3  170  0  170  0  170  26.5  170  0.6  170  25.9  170  5.3  170  8.8 
United Kingdom  51  15.7  51  2.0  51  7.8  51  0  51  0  51  0  51  27.5  51  29.4 
Total (12 MSs)  913  7.1  914  0.4  913  1.8  914  12.7  913  1.1  913  12.4  913  9.1  912  11.6 
N = number of isolates tested. 
% Res = percentage of resistant isolates.   
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Resistance levels in Salmonella Enteritidis 
Susceptibility  data  on  S. Enteritidis  isolates  from  Gallus  gallus  were  reported  by  11  MSs  in  2011 
(Table SA16).  The  levels  of  resistance  in  the  reporting  MS  group  to  ampicillin,  sulfonamides  and 
tetracyclines were low at 5.5 %, 4.8 % and 2.5 % respectively. The occurrence of resistance to ampicillin 
ranged from 3.1 % to 20.0 % among reporting MS, and no resistance to this antimicrobial was observed by 
France,  Germany,  the  Netherlands  and  Slovakia.  A  similar  observation  was  made  for  sulfonamides, 
resistance to which ranged from 0 % to 26.8 % across the reporting countries. Six countries did not detect 
resistance to tetracyclines and among those that did, reported resistance ranged from 0.4 % to 26.8 %. As in 
2010, resistance to chloramphenicol in 2011 was relatively rare among S. Enteritidis isolates in the reporting 
MS  group  (0.3 %)  and  was  detected  only  in  isolates  from  Hungary  and  Poland.  Hungary  was  the  only 
country to report gentamicin resistance, at a low level (3.1 %). In contrast to the other antimicrobials tested, 
the occurrence of ciprofloxacin and nalidixic acid resistance in the reporting MSs was high at 30.8 % for both 
compounds.  This  continues  the  overall  increasing  trend  in  resistance  to  these  compounds  observed  in 
recent years among isolates of S. Enteritidis from Gallus gallus. Once again, the levels of ciprofloxacin and 
nalidixic acid resistance within each MS were generally very similar, as would be expected. The levels of 
resistance to both antimicrobials varied from 0 % to 90.2 % among reporting MSs. In a similar pattern to the 
data reported in 2010, the highest occurrence of ciprofloxacin and nalidixic acid resistance was reported by 
Portugal (90.2 %), followed by Spain (65.7 %) and then Poland (47.4 % for ciprofloxacin and 46.9 % for 
nalidixic acid). Resistance to cefotaxime in S. Enteritidis was reported only by Austria and Hungary in 2011, 
making the overall resistance at MS group level very low at 0.6 %. Hungary was also the only country to 
report resistance to gentamicin at a low level of 3.1 %. Germany and Slovakia did not observe resistance to 
any of the antimicrobials tested. 
Four MSs reported quantitative data on isolates of S. Enteritidis from broiler flocks in 2011 (Table SA16). In 
the  case  of  almost  all  antimicrobials  tested,  the  levels  of  resistance  among  isolates  were  higher  when 
considering only broiler flocks than considering all Gallus gallus, although the overall number of isolates 
tested  was  considerably  lower.  Germany  and  Slovakia  did  not  observe  resistance  to  any  of  the 
antimicrobials tested, however they each tested only 10 isolates from broiler flocks. Among the four reporting 
MSs, the overall resistance to ampicillin was low, at 9.4 %, and was only reported by Austria (26.7 %) and 
Portugal (6.9 %). Within these two countries the level of resistance to sulfonamides and tetracyclines was 
the same, with the overall level of resistance to each compound being 15.6 %. Portugal was the only country 
to report resistance to ciprofloxacin and nalidixic acid among isolates of S. Enteritidis from broiler flocks. In 
both cases, it observed an extremely high level of resistance (93.1 %). Austria was the only country to 
observe resistance to cefotaxime, at the moderate level of 13.3 %. None of the reporting MSs observed 
resistance to chloramphenicol or gentamicin. 
Quantitative  data  on  isolates  of  S. Enteritidis  from  laying  hens  were  reported  by  seven  MSs  in  2011 
(Table SA16).  As  for  Salmonella spp.,  the  levels  of  resistance  among  isolates  from  laying  hens  were 
generally lower than those observed in broiler flocks, or when all Gallus gallus were considered together. 
France and Germany did not observe resistance to any of the antimicrobials tested. The occurrence of 
resistance to ampicillin, sulfonamides and tetracyclines was low across the reporting MSs (2.2 %, 1.9 % and 
1.9 % respectively). Only three MSs observed resistance to ampicillin and sulfonamides with values varying 
from  3.3 %  to  21.4 %,  and  from  3.3 %  to  14.3 %  respectively.  Tetracycline  resistance  was  observed  in 
isolates  from  laying  hens  only  in  Italy  (21.4 %)  and  Spain  (3.4 %).  Moderate  levels  of  resistance  to 
ciprofloxacin and nalidixic acid were observed at the MSs group level (16.2 % and 16.7 % respectively). As 
usually observed, the levels of resistance within each MS were generally very similar for the two compounds. 
For both antimicrobials, reported resistance levels reported ranged from 0 % to 61.0 %. Hungary was the 
only country to observe resistance to chloramphenicol (3.3 %), gentamicin (3.3 %) and cefotaxime (6.7 %). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table SA16.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella Enteritidis isolates from Gallus gallus in MSs reporting MIC data in 2011, using harmonised epidemiological cut-off values 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
Note: Data reported under 'All Gallus gallus' include that data which have been reported by production level.   
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
All Gallus gallus   
Austria  53  7.5  53  3.8  53  0  53  5.7  53  0  53  5.7  53  1.9  53  1.9 
France  41  0  41  0  41  0  41  2.4  41  0  41  2.4  41  0  41  0 
Germany  133  0  133  0  133  0  133  0  133  0  133  0  133  0  133  0 
Greece  -  -  17  0  17  0  17  11.8  17  0  17  11.8  17  0  17  0 
Hungary  32  3.1  32  6.3  32  3.1  32  9.4  32  3.1  32  12.5  32  3.1  32  0 
Italy  15  20.0  16  0  15  0  16  6.3  15  0  15  6.7  15  13.3  15  20.0 
Netherlands  31  0  31  0  31  0  31  6.5  31  0  31  6.5  31  3.2  31  0 
Poland  274  9.5  274  0  274  0.4  274  47.4  274  0  273  46.9  274  6.2  274  0.4 
Portugal  41  4.9  41  0  41  0  41  90.2  41  0  41  90.2  41  26.8  41  26.8 
Slovakia  18  0  18  0  18  0  18  0  18  0  18  0  18  0  18  0 
Spain  67  4.5  67  0  67  0  67  65.7  67  0  67  65.7  67  3.0  67  3.0 
Total (11 MSs)  705  5.5  723  0.6  722  0.3  723  30.8  722  0.1  721  30.8  722  4.8  722  2.5 
Broiler flocks 
Austria  15  26.7  15  13.3  15  0  15  0  15  0  15  0  15  6.7  15  6.7 
Germany  10  0  10  0  10  0  10  0  10  0  10  0  10  0  10  0 
Portugal  29  6.9  29  0  29  0  29  93.1  29  0  29  93.1  29  31.0  29  31.0 
Slovakia  10  0  10  0  10  0  10  0  10  0  10  0  10  0  10  0 
Total (4 MSs)  64  9.4  64  3.1  64  0  64  42.2  64  0  64  42.2  64  15.6  64  15.6 
Laying hens 
Austria  38  0  38  0  38  0  38  7.9  38  0  38  7.9  38  0  38  0 
France  39  0  39  0  39  0  39  0  39  0  39  0  39  0  39  0 
Germany  64  0  64  0  64  0  64  0  64  0  64  0  64  0  64  0 
Hungary  30  3.3  30  6.7  30  3.3  30  10.0  30  3.3  30  13.3  30  3.3  30  0 
Italy  14  21.4  15  0  14  0  15  6.7  14  0  14  7.1  14  14.3  14  21.4 
Netherlands  26  0  26  0  26  0  26  3.8  26  0  26  3.8  26  0  26  0 
Spain  59  3.4  59  0  59  0  59  61.0  59  0  59  61.0  59  3.4  59  3.4 
Total (7 MSs)  270  2.2  271  0.7  270  0.4  271  16.2  270  0.4  270  16.7  270  1.9  270  1.9 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Resistance levels in Salmonella Typhimurium 
Six  MSs  reported  quantitative  MIC  antimicrobial  susceptibility  data  for  S. Typhimurium  isolates  from 
Gallus gallus in 2011 (Table SA17). Only two MSs provided production level information with these data and 
this has been indicated in the table footnotes. The overall level of resistance to ampicillin, sulfonamides and 
tetracyclines  in  the  reporting  MS  group  was  higher  among  S. Typhimurium  isolates  from  Gallus  gallus 
(26.8 %, 33.9 % and 27.7 %, respectively), than in S. Enteritidis isolates and all Salmonella spp. isolates as 
a whole. All MSs except Hungary reported resistance to ampicillin, and the prevalence ranged from 13.3 % 
to 53.3 %. Overall resistance to sulfonamides and tetracyclines ranged from 10.0 % to 53.3 % and from 
13.3 % to 46.7 %, respectively. At the reporting MS group level, the occurrence of resistance to ciprofloxacin 
and nalidixic acid was 10.7 % and 9.8 %, respectively. Among individual MSs, the level of ciprofloxacin 
resistance varied from 0 % in France, Germany, the Netherlands and the United Kingdom, to 73.3 % in 
Poland. Similarly, the level of resistance to nalidixic acid among individual MSs varied from 0 % in France, 
the Netherlands and the United Kingdom, to 53.3 % in Poland. Neither cefotaxime nor gentamicin resistance 
was detected in S. Typhimurium isolates from any reporting MSs. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table SA17.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella Typhimurium isolates from Gallus gallus in MSs reporting MIC data in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
France
1  33  36.4  33  0  33  15.2  33  0  33  0  33  0  33  39.4  33  36.4 
Germany  29  17.2  29  0  29  13.8  29  0  29  0  29  6.9  29  34.5  29  13.8 
Hungary  10  0  10  0  10  0  10  10.0  10  0  10  10.0  10  10.0  10  30.0 
Netherlands
2  15  13.3  15  0  15  6.7  15  0  15  0  15  0  15  20.0  15  13.3 
Poland  15  53.3  15  0  0  0  15  73.3  15  0  15  53.3  15  53.3  15  46.7 
United Kingdom  10  30.0  10  0  10  10.0  10  0  10  0  10  0  10  30.0  10  30.0 
Total (6 MSs)  112  26.8  112  0  97  11.3  112  10.7  112  0  112  9.8  112  33.9  112  27.7 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
1. Twenty-eight of the isolates tested by France were from laying hens. 
2. Eleven of the isolates tested by the Netherlands were from broiler chickens. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Temporal trends in resistance among Salmonella spp. isolates from Gallus gallus 
Figures SA8–SA11 indicate how the level of resistance to selected antimicrobials in Salmonella spp. isolates 
from Gallus gallus has changed over the period 2005–2011 in the MSs and non-MSs. It is important to note 
that because some antimicrobial resistance is associated with particular serovars or clones within serovars, 
fluctuations in the occurrence of resistance in Salmonella spp. isolates within a country may result from 
changes  in  the  proportions  of  different  Salmonella  serovars  which  contribute  to  the  total  numbers  of 
Salmonella spp. isolates tested.  
For  the  majority  of  MSs,  resistance  to  ampicillin  increased  slightly  between  2010  and  2011,  although 
decreases were observed in the Netherlands, Poland and the United Kingdom. Across the seven years of 
data,  statistically  significant  increasing  trends  were  observed  in  Austria,  Germany  and  Poland,  while 
decreasing trends were observed in Italy and the Netherlands. Regarding tetracyclines, increasing trends 
were observed in Austria and Germany for five or more years, and decreasing trends were observed in Italy, 
the Netherlands and Spain.  
The level of resistance to cefotaxime in Salmonella spp. was generally low, very low or absent in reporting 
MSs between 2005 and 2011. A statistically significant decreasing trend for five or more years was observed 
in Italy and Spain. Statistically significant increasing trends in resistance to ciprofloxacin and nalidixic acid 
were  registered  in  three  MSs  for  five  or  more  years  over  the  2005–2011  period.  Spain  observed  a 
statistically significant decreasing trend in resistance to both antimicrobials, while Italy and the Netherlands 
observed a significant decrease in resistance to ciprofloxacin only.  
All reporting MSs observed a similarity in their trends in resistance to ciprofloxacin and nalidixic acid among 
isolates of S. Enteritidis from Gallus gallus. In most MSs there was little change in the trends reported in the 
2005-2011 period. Statistically significant decreasing trends were observed in Germany and the Netherlands 
for both substances, while a significant increasing trend was observed in Poland, also for both substances. 
Figure SA8.  Trends in ampicillin resistance in tested Salmonella spp. isolates from Gallus gallus in 
reporting MSs, 2005-2011, quantitative data 
 
Note: Statistically significant increasing or decreasing trends for five or more years, as tested by a logistic regression model (p ≤0.05), 
were observed in Austria (↑), Germany (↑), Italy (↓), the Netherlands (↓) and Poland (↑). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure SA9.  Trends in cefotaxime resistance in tested Salmonella spp. isolates from Gallus gallus in 
reporting MSs, 2005-2011, quantitative data 
 
Note: A statistically significant decreasing trend for five or more years, as tested by logistic regression model (p  ≤0.05), was observed 
for Italy (↓) and Spain (↓). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure SA10.  Trends in ciprofloxacin and nalidixic acid resistance in tested Salmonella spp. isolates 
from Gallus gallus in reporting MSs, 2005-2011, quantitative data 
 
Note: A statistically significant increasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in Austria (↑), Poland (↑) and Slovakia (↑) for both ciprofloxacin and nalidixic acid. A statistically significant decreasing trend was 
observed for ciprofloxacin in Italy (↓) and the Netherlands (↓), and for both ciprofloxacin and nalidixic acid in Spain (↓). 
 
    EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure SA11.  Trends in tetracycline resistance in tested Salmonella spp. isolates from Gallus gallus 
in reporting MSs, 2005-2011, quantitative data 
 
Note: Statistically significant increasing or decreasing trends for five or more years, as tested by a logistic regression model (p ≤0.05), 
were observed in Austria (↑), Germany (↑), Italy (↓), the Netherlands (↓) and Spain (↓).  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Temporal trends in resistance among S. Enteritidis isolates from Gallus gallus 
Figure SA12.  Trends in ciprofloxacin and nalidixic acid resistance in tested Salmonella Enteritidis 
isolates from Gallus gallus in reporting MSs, 2005-2011, quantitative data 
 
Note: A statistically significant decreasing trend for five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in Germany (↓) and the Netherlands (↓) for both ciprofloxacin and nalidixic acid. A statistically significant increasing trend was 
observed in Poland (↑) for both ciprofloxacin and nalidixic acid. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Spatial distribution of resistance among Salmonella 
Figures SA13-SA15 show the spatial distributions of ampicillin, nalidixic acid and tetracycline resistance in 
Salmonella spp. isolated from Gallus gallus in 2011. Figures SA13 and SA15 illustrate the variability in levels 
of ampicillin and tetracycline resistance in Salmonella spp. across the EU and the absence of a clear spatial 
distribution. Figure SA14 illustrates the continued absence, or low prevalence, of resistance to nalidixic acid 
in Salmonella spp. in northern Europe, but high levels of resistance in southern and Eastern Europe. 
Figure SA13.  Spatial distribution of ampicillin resistance among Salmonella spp. from Gallus gallus 
in countries reporting MIC data in 2011
1 
 
Note:  Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative  2011  data  were  not  available,  2010  data  have  been  used  instead.  The  countries  labelled  as  ‘qualitative  data’ 
therefore include those reporting either IZD data, MIC data for fewer than 10 isolates, or purely qualitative data (as proportion of 
resistant isolates). 
1.  For the Czech Republic, Slovenia and Sweden, 2010 data were used. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure SA14.  Spatial  distribution  of  nalidixic  acid  resistance  among  Salmonella  spp.  from 
Gallus gallus in countries reporting MIC data in 2011
1 
 
Note:  Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative  2011  data  were  not  available,  2010  data  have  been  used  instead.  The  countries  labelled  as  ‘qualitative  data’ 
therefore include those reporting either IZD data, MIC data for fewer than 10 isolates, or purely qualitative data (as proportion of 
resistant isolates). 
1.  For the Czech Republic, Slovenia and Sweden, 2010 data were used. 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure SA15.  Spatial  distribution  of  tetracycline  resistance  among  Salmonella spp.  from 
Gallus gallus in countries reporting MIC data in 2011
1 
 
Note:  Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data have been used instead.  
1.  For the Czech Republic, Slovenia and Sweden, 2010 data were used. 
Multi-resistance among Salmonella spp. isolates from broilers of Gallus gallus 
In 2011, eight MSs reported isolate-based data on resistance in Salmonella spp. from broiler flocks. Among 
the  reporting  MSs,  more  than  40 %  of  the  isolates  tested  were  susceptible  to  all  nine  antimicrobials; 
complete susceptibility varied from 43.3 % in Austria to 90.5 % in Ireland. The only exception was Spain, 
which reported a level of complete susceptibility of 20 %. Multi-resistance levels were low in Ireland (3.2 %) 
and Denmark (7.0 %), while in the remaining reporting MSs they were high reaching 37 % in Italy and 50 % 
in Austria (Table SA18). Similarities among the multi-resistance distributions (Figure SA16) were observed in 
France and Germany with some isolates showing reduced susceptibility to up to six and seven different 
substances, respectively. Although Austria and Italy reported similar levels of complete-susceptibility, Austria 
recorded higher proportions of isolates exhibiting reduced susceptibility to one or two classes, while Italy 
detected  isolates  showing  reduced  susceptibility  to  eight  different  substances.  These  differences  in 
frequency distributions results in values of the index of diversity (weighted entropy) of 0.319 and 0.487 in 
Austria  and  Italy,  respectively  (Table  SA18).  Diversity  in  the  structure  of  the  frequency  distributions  of 
resistant isolates is also summarised in Table SA18. Very few isolates were resistant to both ciprofloxacin 
and cefotaxime. 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table SA18.  Complete susceptibility, multi-resistance and index of diversity in Salmonella spp. from 
broilers in MSs reporting isolate-based data, 2011 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to 
CIP and CTX 
n  %  n  %  n  % 
Austria (N=90)  39  43.3  45  50.0  0.319  0  (0)  0  (0) 
Denmark (N=43)  34  79.1  3  7.0  0.280  0  (0)  0  (0) 
France (N=156)  94  60.3  35  22.4  0.328  0  (0)  0  (0) 
Germany (N=39)  24  61.5  10  25.6  0.440  1  (0)  2.6  (0) 
Ireland (N=63)  57  90.5  2  3.2  0.351  0  (0)  0  (0) 
Italy (N=54)  24  44.4  20  37.0  0.487  2  (0)  3.7  (0) 
Spain (N=40)  8  20.0  11  27.5  0.322  0  (0)  0  (0) 
United Kingdom (N=23)  12  52.2  3  13.0  0.318  NA  NA 
N = total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella spp. 
n = number of isolates per category of complete susceptibility or multiple resistance. 
NA = Not available. 
Susceptible to all = isolate susceptible to all antimicrobial substances of the EFSA common set for Salmonella spp. 
Multi-resistant = resistant to at least three different antimicrobial substances, belonging to any three antimicrobial families from the 
common antimicrobial set. 
Index of diversity = see definition in Section 11.4.2.1 of Materials and Methods. 
Co-resistant to ciprofloxacin (CIP) and cefotaxime (CTX) = the frequencies and percentages of Salmonella isolates not susceptible to 
concentrations  greater  than  ECOFFs  (CTX: >0.5  mg/L  and  CIP: >0.06  mg/L).  Figures  in  parentheses  indicate  the  occurrence  of 
resistance determined using EUCAST clinical breakpoints (CTX: >2 mg/L and CIP: >1 mg/L). 
Figure SA16.  Frequency  distribution  of  Salmonella  spp.  isolates  from  broilers  completely 
susceptible or resistant to one to nine antimicrobials in MSs reporting isolate based data, 2011 
 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
sus = susceptible to all antimicrobial substances of the common set. 
res1/res9 = resistance to one antimicrobial substance/resistance to nine antimicrobial substances of the common set. 
Multi-resistance among Salmonella spp. isolates from laying hens of Gallus gallus 
In 2011, six MSs provided isolate-based data concerning resistance in Salmonella spp. from laying hen 
flocks.  Analysis  of  multi-resistance  showed  that,  among  the  reporting  MSs,  isolates  exhibiting  complete 
susceptibility accounted for a very high level of more than 85 % in Austria, France and Germany, 65.9 % in 
Spain, 58.3 % in the United Kingdom and 53.4 % in Italy. Multi-resistance levels were low in most reporting 
MSs, ranging between 2.3 % in Austria and 9.7 % in Germany (Table SA19), while Italy and the United 
Kingdom recorded multi-resistance levels of 20.5 % and 33.3 %, respectively. The frequency distributions 
(Figure SA17) showed low frequencies of isolates showing reduced susceptibility to important numbers of 
different substances with Germany, for example, recording isolates with reduced susceptibility to up to eight 
different substances. The corresponding values of the indices of diversity are presented in Table SA19. Very 
few isolates were resistant to both ciprofloxacin and cefotaxime. 
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Table SA19.  Complete susceptibility, multi-resistance and index of diversity in Salmonella spp. from 
laying hens in MSs reporting isolate-based data, 2011 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to                  
CIP and CTX 
n  %  n  %  n  % 
Austria (N=86)  77  89.5  2  2.3  0.199  0  (0)  0  (0) 
France (N=165)  141  85.5  11  6.7  0.339  0  (0)  0  (0) 
Germany (N=103)  89  86.4  10  9.7  0.425  0  (0)  0  (0) 
Italy (N=88)  47  53.4  18  20.5  0.402  1  (0)  1.1  (0) 
Spain (N=170)  112  65.9  9  5.3  0.210  0  (0)  0  (0) 
United Kingdom (N=12)  7  58.3  4  33.3  0.240  NA  NA 
N = total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella spp. 
n = number of isolates per category of complete susceptibility or multiple resistance. 
NA = Not available. 
Susceptible to all = isolate susceptible to all antimicrobial substances of the EFSA common set for Salmonella spp. 
Multi-resistant = resistant to at least three different antimicrobial substances, belonging to any three antimicrobial families from the 
common antimicrobial set. 
Index of diversity = see definition in section 11.4.2.1 of Materials and Methods. 
Co-resistant to ciprofloxacin (CIP) and cefotaxime (CTX) = the frequencies and percentages of Salmonella isolates not susceptible to 
concentrations  greater  than  ECOFFs  (CTX: >0.5  mg/L  and  CIP: >0.06  mg/L).  Figures  in  parentheses  indicate  the  occurrence  of 
resistance determined using EUCAST clinical breakpoints (CTX: >2 mg/L and CIP: >1 mg/L). 
Figure SA17.  Frequency  distribution  of  Salmonella  spp.  isolates  from  laying  hens  completely 
susceptible or resistant to one to nine antimicrobials in MSs reporting isolate-based data, 2011 
 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
sus =  susceptible to all antimicrobial substances of the common set. 
res1/res9 = resistance to one antimicrobial substance/resistance to nine antimicrobial substances of the common set. 
Multi-resistance among S. Enteritidis and S. Typhimurium isolates from Gallus gallus 
Multi-resistance data on S. Typhimurium isolates from either broilers or laying hens and on S. Enteritidis 
from  broilers  are  not  presented  in  this  report  because  the  inclusion  criteria  (more  than  four  reporting 
countries providing data on more than 10 isolates per production type) were not met. Generally, the isolates 
of S. Enteritidis and S. Typhimurium in these production types were very rare in the isolate-based dataset of 
the  reporting  countries.  The  same  observation  is  true  with  respect  to  monophasic  S. Typhimurium  from 
broilers and laying hens.  
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3.4.2.2. Turkeys 
In 2011, 10 MSs submitted quantitative antimicrobial susceptibility data for Salmonella spp. from turkeys, in 
accordance with the EU legislation. This section includes data from meat production flocks and mixed flocks 
of turkeys. Nine MSs reported data on S. Typhimurium in turkeys; however, no countries submitted sufficient 
data to warrant inclusion. Austria, Germany, Italy, Spain and the United Kingdom tested isolates obtained as 
part of their national control programmes in accordance to EU regulations. No information on the sampling 
scheme used was provided by France, Hungary, Ireland, Poland and Portugal. 
Resistance levels in Salmonella spp. 
Data  on  antimicrobial  resistance  among  Salmonella  spp.  in  turkeys  were  reported  by  10  MSs  in  2011 
(Table SA20). The occurrence of resistance to ampicillin in the reporting MS group was high at 43.6 % and 
ranged  widely  from  14.3 %  to  90.9 %  across  the  reporting  countries.  Resistance  to  sulfonamides  and 
tetracyclines in the reporting MS group was very high at 51.0 % and 52.2 %, respectively, and ranged from 
20.0 % to 91.6 % and from 0 % to 77.9 %, respectively, across the reporting MSs. For chloramphenicol, the 
level of resistance in the reporting MS group increased from 7 % in 2010 to 13.0 % in 2011, and ranged from 
0 % to 61.7 % between countries. Reported levels of resistance to gentamicin varied among MSs, ranging 
from 0 % to 33.3 % across the group; the occurrence of resistance considering all reporting MSs was 9.4 %. 
At the reporting MS group level, resistance to ciprofloxacin was 50.4 % and to nalidixic acid was 36.9 %, and 
for both antimicrobials the resistance levels ranged from 4.8 % to 80.0 %. Cefotaxime resistance was very 
low  in  the  reporting  group  of  10  MSs  at  0.4 %,  with  only  France,  Hungary  and  Spain  reporting  any 
cefotaxime-resistant isolates, at low proportions of 0.6 %, 0.4 % and 1.3 %, respectively. 
Ten MSs reported resistance among Salmonella spp. isolates from both fowl (Gallus gallus) and turkeys, 
and as was also observed in 2010, the levels of resistance recorded were generally much higher in turkeys 
than  in  Gallus  gallus,  in  particular  for  ampicillin,  chloramphenicol,  gentamicin,  sulfonamides  and 
tetracyclines. Resistance levels to ciprofloxacin and nalidixic acid were also considerably higher in turkeys 
than in Gallus gallus. Once again, more reporting MSs detected no resistance to cefotaxime in isolates from 
turkeys than in isolates from Gallus gallus and, among the nine MSs overall, resistance was lower (0.4 %) in 
turkeys than in Gallus gallus (1.5 %). However, the difference in resistance levels between the two species 
needs to be interpreted with caution because, other than in Hungary, estimated resistance levels among 
Salmonella spp. isolates from turkeys are based on low numbers of isolates compared with Gallus gallus. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table SA20.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella spp. isolates from turkeys in MSs reporting MIC data in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  22  18.2  22  0  22  0  22  68.2  22  0  22  63.6  22  36.4  22  40.9 
France  176  29.5  176  0.6  174  7.5  174  24.1  174  5.7  174  21.8  174  39.7  174  41.4 
Germany  78  41.0  78  0  78  7.7  78  52.6  78  10.3  78  34.6  78  51.3  78  53.8 
Hungary  258  38.8  258  0.4  258  1.2  258  77.1  258  17.8  258  74.8  258  29.8  258  46.9 
Ireland  14  14.3  14  0  14  14.3  14  14.3  14  0  14  7.1  14  28.6  14  28.6 
Italy  27  59.3  27  0  27  0  27  25.9  27  33.3  27  25.9  27  51.9  27  77.8 
Poland  41  61.0  41  0  41  0  41  61.0  41  31.7  41  51.2  41  34.1  41  0 
Portugal  10  20.0  10  0  10  0  10  80.0  10  0  10  80.0  10  20.0  10  20.0 
Spain  154  90.9  154  1.3  154  61.7  154  77.3  154  0.6  154  16.2  154  91.6  154  77.9 
United Kingdom  145  20.7  145  0  145  0.7  145  4.8  145  0  145  4.8  145  70.3  145  62.8 
Total (10 MSs)  925  43.6  925  0.4  923  13.0  923  50.4  923  9.4  923  36.9  923  51.0  923  52.2 
N = number of isolates tested. 
% Res = percentage of resistant isolates.   
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Spatial distribution of resistance among Salmonella 
Figures SA18-SA20 show the spatial distributions of ampicillin, nalidixic acid and tetracycline, resistance in 
Salmonella spp. isolated from turkeys in 2011. They illustrate the variability in levels of tetracycline and 
ampicillin resistance in Salmonella spp. across the EU and the absence of a clear spatial distribution. 
 
Figure SA18.  Spatial  distribution  of  ampicillin  resistance  among  Salmonella  spp.  from  turkeys  in 
countries reporting MIC data in 2011
1 
 
Note:  Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative  2011  data  were  not  available,  2010  data  have  been  used  instead.  The  countries  labelled  as  ‘qualitative  data’ 
therefore include those reporting either IZD data, MIC data for fewer than 10 isolates, or purely qualitative data (as proportion of 
resistant isolates). 
1.  For the Czech Republic and Slovakia, 2010 data were used. 
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Figure SA19.  Spatial distribution of nalidixic acid resistance among Salmonella spp. from turkeys in 
countries reporting MIC data in 2011
1 
 
Note:  Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative  2011  data  were  not  available,  2010  data  have  been  used  instead.  The  countries  labelled  as  ‘qualitative  data’ 
therefore include those reporting either IZD data, MIC data for fewer than 10 isolates, or purely qualitative data (as proportion of 
resistant isolates). 
1.  For the Czech Republic and Slovakia, 2010 data were used. 
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Figure SA20.  Spatial distribution of tetracycline resistance among Salmonella spp. from turkeys in 
countries reporting MIC data in 2011
1 
 
Note:  Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data have been used instead.  
1.  For the Czech Republic and Slovakia, 2010 data were used. 
Multi-resistance among Salmonella spp. isolates from turkeys 
In  2011,  six  MSs  provided  isolate-based  data  concerning  resistance  in  Salmonella  spp.  from  turkeys. 
Analysis of multi-resistance showed that, among the reporting MSs, complete susceptibility was exhibited by 
about fewer than one-third of the isolates tested, with the exception of Ireland, which reported a level of 
complete  susceptibility  of  57.1 %.  Multi-resistance  levels  were  high  in  all  reporting  MSs  and  varied 
importantly  between  28.6 %  in  Ireland  and  94.8 %  in  Spain  (Table  SA21).  The  frequency  distributions 
(Figure SA21) showed similarities among the multi-resistance recorded in Austria, France and Germany with 
some isolates showing reduced susceptibility to as many as six different substances, while Italy and Spain 
reported fewer completely susceptible isolates and isolates showing reduced susceptibility to seven or eight 
different substances. Ireland recorded multi-resistance to five classes of antimicrobials at a maximum. The 
difference in the structure of the frequency distributions of resistant isolates is summarised in Table SA21. 
Very few isolates were resistant to both ciprofloxacin and cefotaxime. 
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Table SA21.  Complete susceptibility, multi-resistance and index of diversity in Salmonella spp. from 
turkeys in MSs reporting isolate-based data, 2011 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to                          
CIP and CTX 
n  %  n  %  n  % 
Austria (N=22)  6  27.3  8  36.4  0.438  0  (0)  0  (0) 
France (N=174)  64  36.8  66  37.9  0.434  0  (0)  0  (0) 
Germany (N=78)  24  30.8  46  59.0  0.469  0  (0)  0  (0) 
Ireland (N=14)  8  57.1  4  28.6  0.274  0  (0)  0  (0) 
Italy (N=27)  5  18.5  18  66.7  0.595  0  (0)  0  (0) 
Spain (N=154)  4  2.6  146  94.8  0.593  2  (0)  1.3  (0) 
N = total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella spp. 
n = number of isolates per category of complete susceptibility or multiple resistance. 
Susceptible to all = isolate susceptible to all antimicrobial substances of the EFSA common set for Salmonella spp. 
Multi-resistant = resistant to at least three different antimicrobial substances, belonging to any three antimicrobial families from the 
common antimicrobial set. 
Index of diversity = see definition in section 11.4.2.1 of Materials and Methods. 
Co-resistant to ciprofloxacin (CIP) and cefotaxime (CTX) = the frequencies and percentages of Salmonella isolates not susceptible to 
concentrations  greater  than  ECOFFs  (CTX: >0.5  mg/L  and  CIP: >0.06  mg/L).  Figures  in  parentheses  indicate  the  occurrence  of 
resistance determined using EUCAST clinical breakpoints (CTX: >2 mg/L and CIP: >1 mg/L). 
Figure SA21.  Frequency  distribution  of  Salmonella  spp.  isolates  from  turkeys  completely 
susceptible or resistant to one to nine antimicrobials in MSs reporting isolate based data, 2011 
 
N = Total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
sus = susceptible to all antimicrobial substances of the common set. 
res1/res9 = resistance to one antimicrobial substance/resistance to nine antimicrobial substances of the common set. 
Multi-resistance among S. Enteritidis and S. Typhimurium isolates from turkeys 
Generally, the S. Enteritidis and S. Typhimurium isolates from turkey flocks were very rare in the isolate-
based  dataset  of  the  reporting  countries.  Data  in  multi-resistance  in  these  serovars  from  turkeys  are 
therefore not presented in this report, as the inclusion criteria (more than four reporting countries providing 
data on more than 10 isolates per production type) were not met. The same observation is true with respect 
to monophasic S. Typhimurium from broilers and laying hens. 
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3.4.2.3. Pigs 
Quantitative MIC data for Salmonella spp. isolated from pigs from eight MSs in 2011 are included in the 
following analyses. Isolates from Estonia and Spain were collected as part of monitoring plans, whereas 
Germany  and  Italy  tested  isolates  obtained  through  passive  surveillance  via  diagnostic  submissions. 
Denmark collected isolates from sub-clinical infections detected via the serological surveillance programme, 
from healthy pigs at slaughter and from herds with clinical salmonellosis. Sample types collected by MSs 
were generally faecal, while Estonia and Spain also tested ileocaecal lymph nodes at slaughter. 
Resistance levels in Salmonella spp. 
Data describing the occurrence of resistance to selected antimicrobials in isolates of Salmonella spp. from 
pigs are presented in Table SA22. Isolates tested by Denmark and Germany made up over 78 % of the total 
isolates tested in 2011 so the results from these two countries will have influenced the overall levels reported 
at MS group level. A similar level of resistance to ampicillin at MS group level was reported in 2011 (54.2 %) 
compared with 2010 (55 %). The levels of resistance among MSs ranged from 11.8 % to 73.6 % in 2011. 
Overall resistance  to  sulfonamides  and  tetracyclines  was  very  high  at  60.5 %,  among  the  reporting  MS 
group. The level of resistance to sulfonamides in Salmonella spp. from pigs ranged from 0.3 % to 88.6 % 
among the reporting MSs. A similar range was observed in the occurrence of resistance to tetracyclines 
(0.4–76.8 %). There was moderate resistance to chloramphenicol at MS group level (15.6 %), and among 
the MSs the levels ranged from 0 % to 33.3 %. Resistance to gentamicin in the reporting MS group was low, 
at 3.7 %, and ranged from 0 % to 10.3 %. 
The levels of resistance for ciprofloxacin and nalidixic acid in the reporting MS group were similar to those 
reported in 2010 (4.0 % and 3.4 % respectively in 2011 compared with 3 % and 2 % in 2010). Three MSs 
detected no resistance to either compound in Salmonella spp. isolates from pigs. Among the MSs that did 
detect resistance, the occurrence of ciprofloxacin and nalidixic acid resistance was low to moderate (range 
2.8–17.1 %). The overall level of resistance to cefotaxime was 1.0 %, with three MSs not detecting any 
cefotaxime resistance in Salmonella spp. isolates from pigs. Among those MSs reporting resistance, levels 
ranged from 0.3 % to 2.9 %. 
Resistance levels in Salmonella Typhimurium 
Quantitative  MIC  antimicrobial  susceptibility  results  for  Salmonella  Typhimurium  isolates  from  pigs  were 
reported by four MSs in 2011 (Table SA23). As for Salmonella spp., the majority of isolates tested were from 
Denmark and Germany so the results from these two countries will have more bearing on the overall levels. 
The  occurrence  of  resistance  to  ampicillin,  chloramphenicol  and  sulfonamides  among  S. Typhimurium 
isolates from pigs was higher than that reported in Salmonella spp., with the overall level of resistance in the 
reporting MS group being 71.5 % for ampicillin, 30.0 % for chloramphenicol and 74.5 % for sulfonamides. 
Among the individual reporting MSs, resistance to ampicillin ranged from 36.6 % to 89.5 %, resistance to 
chloramphenicol  ranged  from  7.6 %  to  76.5 %  and  resistance  to  sulfonamides  ranged  from  41.2 %  to 
90.7 %. Resistance to tetracyclines was fairly similar in S. Typhimurium and Salmonella spp. (69.1 % vs. 
60.5 %) and among MSs the reported levels ranged from 37.4 % to 94.1 %. A low level of resistance to 
gentamicin (5.9 %) was reported by the MS group. In a similar pattern to that observed in 2010, Denmark, 
Germany and Spain reported low levels of resistance (range 1.5 %–7.2 %), while in Ireland the figure was 
higher, at 23.5 %. 
Low levels of resistance to ciprofloxacin and nalidixic acid were reported at MS group level (4.5 % and 
3.7 %, respectively). Denmark reported no resistance to either compound, and Germany reported low levels 
of resistance to both. Moderate to high levels of resistance were reported by Ireland and Spain, ranging from 
17.6 % to 26.3 %. In the reporting MS group, cefotaxime resistance was detected only in S. Typhimurium 
isolates from Spain, and at a low level (5.3 %). 
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Table SA22.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella spp. isolates from pigs in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Denmark
1  371  30.2  371  0.3  371  5.7  371  0  371  1.6  371  0  371  36.6  371  43.6 
Denmark
2  23  0.3  23  0  23  0.1  23  0  23  0  23  0  23  0.3  23  0.4 
Estonia  17  11.8  17  0  17  0  17  0  17  0  17  0  17  23.5  17  23.5 
Germany  614  73.6  614  1.3  614  19.5  614  3.7  614  4.4  614  2.8  614  77.9  614  73.6 
Hungary  35  34.3  35  2.9  35  31.4  35  11.4  35  5.7  35  14.3  35  88.6  35  60.0 
Ireland  39  56.4  39  0  39  33.3  39  12.8  39  10.3  39  10.3  39  56.4  39  61.5 
Italy  86  55.8  86  1.2  86  24.4  86  7.0  86  5.8  86  8.1  86  55.8  86  50.0 
Netherlands  19  47.4  19  0  19  5.3  19  0  19  0  19  0  19  52.6  19  47.4 
Spain  82  48.8  82  2.4  82  17.1  82  17.1  82  3.7  82  13.4  81  59.3  82  76.8 
Total (8 MSs)  1,286  54.2  1,286  1.0  1,286  15.6  1,286  4.0  1,286  3.7  1,286  3.4  1,286  60.5  1,286  60.5 
N = number of isolates tested.  
% Res = percentage of resistant isolates.   
1. Fattening pigs, pigs unspecified and mixed herds. 
2. Breeding pigs. 
Table SA23.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella Typhimurium isolates from pigs in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Denmark  131  36.6  131  0  131  7.6  131  0  131  1.5  131  0  131  41.2  131  37.4 
Germany  237  88.2  237  0  237  39.2  237  3.8  237  7.2  237  3.4  237  90.7  237  83.1 
Ireland  17  88.2  17  0  17  76.5  17  23.5  17  23.5  17  17.6  17  88.2  17  94.1 
Spain  19  89.5  19  5.3  19  26.3  19  26.3  19  5.3  19  21.1  19  89.5  19  89.5 
Total (4 MSs)  404  71.5  404  0.2  404  30.0  404  4.5  404  5.9  404  3.7  404  74.5  404  69.1 
N = number of isolates tested.  
% Res = percentage of resistant isolates.   
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Temporal trends in resistance among Salmonella isolates from pigs 
The temporal variation in the level of resistance to selected antimicrobials in Salmonella spp. isolated from 
pigs between 2005 and 2011 is presented in Figures SA22-SA26. The figures demonstrate that, in some 
MSs,  resistance  levels  have  continued  to  fluctuate;  however,  in  other  countries,  such  as  Germany  and 
Sweden the occurrence of resistance has remained fairly stable in recent years. 
Over the seven reporting years, reported significantly decreasing trends in resistance were reported by the 
Netherlands  for  ampicillin,  chloramphenicol  and  tetracyclines  ,  by  Germany  for  chloramphenicol  and 
tetracyclines, by Spain for tetracyclines and by Denmark for chloramphenicol, while Italy reported statistically 
significant increasing trends in resistance to ampicillin and chloramphenicol. Increasing trends in resistance 
to  ampicillin  have  also  been  reported  by  Denmark,  Ireland  and  Spain.  Considering  resistance  to 
(fluoro)quinolones,  ciprofloxacin  and  nalidixic  acid,  both  Estonia  and  Germany  reported  statistically 
decreasing trends in resistance to both compounds over the 2005–2011 period. In contrast, Spain showed 
increasing trends in resistance to these two substances. Additionally, Denmark registered decreasing trends 
in resistance to nalidixic acid and Ireland an increasing trend in resistance to ciprofloxacin. 
Cefotaxime resistance among Salmonella spp. isolates from pigs remained either low, very low or absent in 
the reporting MSs between 2005 and 2011; and no significant trends were detected for MSs reporting five or 
more years of data. 
Figure SA22.  Trends in ampicillin resistance in Salmonella spp. from pigs in reporting MSs, 2005-
2011, quantitative data 
 
Note: Statistically significant increasing or decreasing trends for five or more years, as tested by a logistic regression model (p ≤0.05), 
were observed in Denmark (↑), Ireland (↑), Italy (↑), the Netherlands (↓) and Spain (↑). 
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Figure SA23.  Trends in cefotaxime resistance in Salmonella spp. from pigs in reporting MSs, 2005-
2011, quantitative data 
 
Note: No statistically significant trend for five or more years, as tested by a logistic regression model (p ≤0.05), was observed in any of 
the reporting countries. 
Figure SA24.  Trends in chloramphenicol resistance in Salmonella spp. from pigs in reporting MSs, 
2005-2011, quantitative data 
 
Note: A statistically significant increasing or decreasing trend for five or more years, as tested by a logistic regression model (p ≤0.05), 
was observed in Denmark (↓), Germany (↓), Italy (↑) and the Netherlands (↓). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure SA25.  Trends in ciprofloxacin and nalidixic acid resistance in Salmonella spp. from pigs in 
reporting MSs, 2005-2011, quantitative data 
 
Note: A statistically significant decreasing trend for five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in Estonia (↓) and Germany (↓), for both ciprofloxacin and nalidixic acid, and in Denmark (↓) for nalidixic acid. A statistically 
significant increasing trend was observed in Spain (↑) for both ciprofloxacin and nalidixic acid, and in Ireland (↑) for ciprofloxacin. 
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Figure SA26.  Trends in tetracycline resistance in Salmonella spp. from pigs in reporting MSs, 2005-
2011, quantitative data 
 
Note: A statistically significant decreasing trend for five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in Germany (↓), the Netherlands (↓) and Spain (↓). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Spatial distribution of resistance among Salmonella 
The spatial distribution of ampicillin, nalidixic acid and tetracycline resistance in Salmonella spp. from pigs in 
2011 is shown in Figures SA27–SA29. Figures SA27 and SA29 emphasise the large differences in ampicillin 
and tetracycline resistance rates in different MSs, although no clear spatial distributions were observed. In 
most countries, nalidixic acid resistance in Salmonella spp. isolated from pigs was reported to be low, with 
no clear spatial distribution apparent (Figure SA27). 
Figure SA27.  Spatial  distribution  of  ampicillin  resistance  among  Salmonella  spp.  from  pigs  in 
countries reporting MIC data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data have been used instead. The countries labelled as ‘qualitative data’ therefore 
include those reporting either IZD data, MIC data for fewer than 10 isolates, or purely qualitative data (as proportion of resistant 
isolates). 
1.  For the Czech Republic, Slovenia and Sweden, 2010 data were used. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure SA28.  Spatial distribution of nalidixic acid resistance among Salmonella spp. from pigs in 
countries reporting MIC data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data have been used instead. The countries labelled as ‘qualitative data’ therefore 
include those reporting either IZD data, MIC data for fewer than 10 isolates, or purely qualitative data (as proportion of resistant 
isolates). 
1.  For the Czech Republic, Slovenia and Sweden, 2010 data were used. 
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Figure SA29.  Spatial  distribution  of  tetracycline  resistance  among  Salmonella  spp.  from  pigs  in 
countries reporting MIC data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data have been used instead. The countries labelled as ‘qualitative data’ therefore 
include those reporting either IZD data, MIC data for fewer than 10 isolates, or purely qualitative data (as proportion of resistant 
isolates). 
1.  For the Czech Republic, Slovenia and Sweden, 2010 data were used. 
Multi-resistance among Salmonella spp. isolates from pigs 
In 2011, six MSs provided isolate-based data concerning resistance in Salmonella spp. from pigs. The levels 
of complete susceptibility varied importantly between the reporting MSs, from 14.7 % in Germany to 70.6 % 
in Estonia, although, in the latter case, the complete susceptibility level was assessed on a sample of 17 
isolates only. Multi-resistance levels were high in all reporting MSs, ranging between 23.5 % in Estonia and 
74.8 % in Germany (Table SA24). The frequency distributions (Figure SA30) showed discrepancies among 
the multi-resistance recorded in the reporting MSs with some isolates showing reduced susceptibility to up to 
eight different substances in Ireland, Italy and Spain, while Estonia recorded multi-resistance to four classes 
at a maximum. The values of the indices of diversity summarising the frequency distributions of resistant 
isolates are presented in Table SA12. Very few isolates were resistant to both ciprofloxacin and cefotaxime. 
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Table SA24.  Complete susceptibility, multi-resistance and index of diversity in Salmonella spp. from 
pigs in MSs reporting isolate-based data, 2011 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to                          
CIP and CTX 
n  %  n  %  n  % 
Denmark (N=371)  183  49.3  118  31.8  0.408  0  (0)  0  (0) 
Estonia (N=17)  12  70.6  4  23.5  0.086  0  (0)  0  (0) 
Germany (N=614)  90  14.7  459  74.8  0.505  0  (0)  0  (0) 
Ireland (N=39)  15  38.5  22  56.4  0.665  0  (0)  0  (0) 
Italy (N=86)  27  31.4  49  57.0  0.497  1  (1)  1.2  (1.2) 
Spain (N=81)  18  22.2  51  63.0  0.609  1  (0)  1.2  (0) 
N = Total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella spp. 
n = number of isolates per category of complete susceptibility or multiple resistance. 
Susceptible to all =isolate susceptible to all antimicrobial substances of the EFSA common set for Salmonella spp. 
Multi-resistant = resistant to at least 3 different antimicrobial substances, belonging to any three antimicrobial families from the common 
antimicrobial set. 
Index of diversity = see definition in section 11.4.2.1 of Materials and Methods. 
Co-resistant to ciprofloxacin (CIP) and cefotaxime (CTX) = the frequencies and percentages of Salmonella isolates not susceptible to 
concentrations  greater  than  ECOFFs  (CTX: >0.5  mg/L  and  CIP: >0.06  mg/L).  Figures  in  parentheses  indicate  the  occurrence  of 
resistance determined using EUCAST clinical breakpoints (CTX: >2 mg/L and CIP: >1 mg/L). 
Figure SA30.  Frequency distribution of Salmonella spp. from pigs isolates completely susceptible or 
resistant to one to nine antimicrobials in MSs reporting isolate-based data, 2011 
 
N = Total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
sus = susceptible to all antimicrobial substances of the common set. 
res1/res9 = resistance to one antimicrobial substance/resistance to nine antimicrobial substances of the common set. 
Multi-resistance among S. Typhimurium isolates from pigs 
As  fewer  than  four  MSs  reported  multi-resistance  isolate-based  data  on  more  than  10  isolates  of 
S. Typhimurium isolates in pigs, tables and graphs on multi-resistance are not presented in this report. 
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3.4.2.4. Cattle (bovine animals) 
In this report, calves, dairy cattle, beef cows and heifers are included under the term ‘cattle’. Where data on 
the  production  level  of  animals  have  been  provided,  these  have  been  included  in  the  table  footnotes. 
Quantitative MIC data for Salmonella spp. isolated from cattle in eight MSs in 2011 are included in the 
following analysis of antimicrobial resistance levels. Isolates tested by Estonia, Finland, Spain, Sweden and 
Norway were obtained through national monitoring programmes and generally consisted of faecal samples. 
Finland also tested lymph nodes at slaughter. Italy obtained isolates through passive surveillance. 
Resistance levels in Salmonella spp. 
The levels of resistance to selected antimicrobials in isolates of Salmonella spp. from cattle reported by MSs 
in 2011 are presented in Table SA25. High levels of resistance to ampicillin, sulfonamides and tetracyclines 
were commonly reported in Salmonella spp. from cattle in 2011; considering all reporting MSs, the levels of 
resistance were 29.1 %, 33.4 % and 31.1 %, respectively. Ampicillin resistance ranged from 0 % to 50.0 % 
across reporting MSs, while the range for both sulfonamides and tetracyclines was 0 % to 59.1 %. Only 
Germany and Italy reported resistance to gentamicin at low or very low levels. 
At MS group level, the overall occurrence of resistance to ciprofloxacin and nalidixic acid was 1.7 % and 
1.4 % respectively. Germany, Ireland and Italy were the only MSs to report resistance to ciprofloxacin or 
nalidixic acid in Salmonella spp. isolates from cattle and, in general, for these countries the levels reported 
were low. However, Italy reported moderate resistance to ciprofloxacin (10.7 %). Cefotaxime resistance was 
not reported by any of the MSs. 
Resistance levels in Salmonella Typhimurium 
Table SA26 shows the level of resistance reported among S. Typhimurium isolates from cattle in 2011. 
Across the five reporting MSs, the level of resistance to sulfonamides and tetracyclines was very high, at 
57.9 % and 52.3 %, respectively. The resistance levels reported by individual MSs varied from 0 % to 76.0 % 
for tetracyclines and from 9.1 % to 76.0 % for sulfonamides. There were also high levels of resistance to 
ampicillin (45.8 %) and chloramphenicol (23.4 %) at MS group level, which ranged from 9.1 % to 62.2 % and 
from 0 % to 52.0 % respectively. Resistance to gentamicin in S. Typhimurium from cattle was detected only 
in Germany at the low level of 2.7 %. 
The occurrence of resistance to both ciprofloxacin and nalidixic acid in the reporting MS group as a whole 
was very low (0.9 % for both antimicrobials) as Germany was the only country to report resistance (2.7 %). 
Cefotaxime resistance in S. Typhimurium isolates from cattle in 2011 was not reported by any MS. 
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Table SA25.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella spp. isolates from cattle in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Estonia  15  0  15  0  15  0  15  0  15  0  15  0  15  0  15  0 
Finland
1  11  9.1  11  0  11  0  11  0  11  0  11  0  11  9.1  11  0 
Germany  146  33.6  146  0  146  7.5  146  1.4  146  0.7  146  1.4  146  32.9  146  28.8 
Ireland  44  50.0  44  0  44  29.5  44  2.3  44  0  44  2.3  44  59.1  44  59.1 
Italy  28  39.3  28  0  28  17.9  28  10.7  28  3.6  28  7.1  28  46.4  28  42.9 
Netherlands
2  69  23.2  69  0  69  7.2  69  0  69  0  69  0  69  34.8  69  34.8 
Spain
3  13  7.7  13  0  13  0  13  0  13  0  13  0  13  0  13  15.4 
Sweden  24  8.3  24  0  24  0  24  0  24  0  24  0  24  20.8  24  12.5 
Total (8 MSs)  350  29.1  350  0  350  9.7  350  1.7  350  0.6  350  1.4  350  33.4  350  31.1 
Norway  12  25.0  12  0  12  0  12  8.3  12  0  12  8.3  12  25.0  12  33.3 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
1. All isolates from adult cattle over two years old. 
2. Twenty-nine of the isolates tested by the Netherlands were from dairy cows and 23 were from veal calves under one year old. 
3. All isolates from beef cattle (one to two years old). 
 
Table SA26.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella Typhimurium from cattle in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Finland  11  9.1  11  0  11  0  11  0  11  0  11  0  11  9.1  11  0 
Germany  37  62.2  37  0  37  18.9  37  2.7  37  2.7  37  2.7  37  56.8  37  51.4 
Ireland  25  60.0  25  0  25  52.0  25  0  25  0  25  0  25  76.0  25  76.0 
Netherlands  24  37.5  24  0  24  20.8  24  0  24  0  24  0  24  70.8  24  70.8 
Sweden  10  10.0  10  0  10  0  10  0  10  0  10  0  10  40.0  10  10.0 
Total (5 MSs)  107  45.8  107  0  107  23.4  107  0.9  107  0.9  107  0.9  107  57.9  107  52.3 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Temporal trends in resistance among Salmonella isolates from cattle 
It is evident from figures SA31–SA34 that large variations exist between MSs in the level of resistance to 
some antimicrobials, particularly ampicillin and tetracyclines. The figures illustrate the trends in resistance to 
ampicillin, chloramphenicol, ciprofloxacin, nalidixic acid and tetracyclines among Salmonella isolates from 
cattle from 2005 to 2011. 
As  in  2010,  trends  in  resistance  over  time  were  mainly decreasing  among  Salmonella  spp.  from  cattle. 
Germany and Sweden experienced statistically significant decreasing trends in resistance to ampicillin and 
chloramphenicol,  and  Germany  also  reported  statistically  significant  decreasing  trends  in  resistance  to 
tetracyclines. No significant trends were observed in the reported resistance to ciprofloxacin and nalidixic 
acid between 2005 and 2011. 
Figure SA31.  Trends in ampicillin resistance in Salmonella spp. from cattle in reporting MSs, 2005-
2011, quantitative data 
 
Note: A statistically significant decreasing trend for five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in Germany (↓) and Sweden (↓). 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Figure SA32.  Trends in chloramphenicol resistance in Salmonella spp. from cattle in reporting MSs, 
2005-2011, quantitative data 
 
Note: A statistically significant decreasing trend for five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in Germany (↓) and Sweden (↓). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure SA33.  Trends in ciprofloxacin and nalidixic acid resistance in Salmonella spp. from cattle in 
reporting MSs, 2005-2011, quantitative data 
 
Note: For both ciprofloxacin and nalidixic acid, no statistically significant trend for five or more years, as tested by a logistic regression 
model (p ≤0.05), was observed in any of the reporting countries. 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Figure SA34.  Trends in tetracycline resistance in Salmonella spp. from cattle in reporting MSs, 2005-
2011, quantitative data 
 
Note: A statistically significant decreasing trend for five or more years, as tested by a logistic regression model (p  ≤0.05), was observed 
in Germany (↓). 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Spatial distribution of resistance among Salmonella 
Figures SA35-SA37 show the spatial distributions of ampicillin, nalidixic acid and tetracycline resistance in 
Salmonella spp. isolated from cattle in 2011. Figures SA35 and SA37 illustrate the similarity in levels of 
ampicillin and tetracycline resistance in Salmonella spp. across the EU and the absence of a clear spatial 
distribution. Figure SA36 illustrates the continued absence, or low prevalence, of resistance to nalidixic acid 
in Salmonella spp. isolated from cattle in Europe. 
Figure SA35.  Spatial  distribution  of  ampicillin  resistance  among  Salmonella  spp.  from  cattle  in 
countries reporting MIC data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data have been used instead. The countries labelled as ‘qualitative data’ therefore 
include those reporting either IZD data, MIC data for less than 10 isolates, or purely qualitative data (as proportion of resistant 
isolates). 
1.  For Denmark and Switzerland, 2010 data were used. 
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Figure SA36.  Spatial distribution of nalidixic acid resistance among Salmonella spp. from cattle in 
countries reporting MIC data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data have been used instead. The countries labelled as ‘qualitative data’ therefore 
include those reporting either IZD data, MIC data for fewer than 10 isolates, or purely qualitative data (as proportion of resistant 
isolates). 
1.  For Denmark and Switzerland 2010, data were used. 
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Figure SA37.  Spatial  distribution  of  tetracycline  resistance  among  Salmonella  spp.  from  cattle  in 
countries reporting MIC data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data have been used instead. The countries labelled as ‘qualitative data’ therefore 
include those reporting either IZD data, MIC data for fewer than 10 isolates, or purely qualitative data (as proportion of resistant 
isolates). 
1.  For Denmark and Switzerland, 2010 data were used. 
Multi-resistance among Salmonella spp. isolates from cattle 
In 2011, eight MSs reported isolate-based data concerning resistance in Salmonella spp. from cattle. The 
proportions of completely susceptible isolates were high and varied importantly between the reporting MSs, 
from 38.6 % in Ireland to 100 % in Estonia. Three reporting MSs (Estonia, Finland and Spain) did not detect 
any multi-resistant isolates among those tested from cattle, while Sweden recorded a multi-resistance level 
of 12.5 % and the remaining MSs high levels of multi-resistance ranging between 32.2 % and 59.1 % (Table 
SA27).  The  frequency  distributions (Figure  SA38) showed  that isolates  from  Germany, Ireland and  Italy 
exhibited reduced susceptibility to more different substances than isolates from the other MSs. No isolates 
were resistant to both ciprofloxacin and cefotaxime. 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Table SA27.  Complete susceptibility, multi-resistance and index of diversity in Salmonella spp. from 
cattle in MSs and one non-MS reporting isolate-based data, 2011 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to                          
CIP and CTX 
n  %  n  %  n  % 
Estonia (N=15)  15  100  0  0  NA  NA  NA 
Finland (N=11)  10  90.9  0  0  0  NA  NA 
Germany (N=146)  91  62.3  47  32.2  0.355  0  (0)  0  (0) 
Ireland (N=44)  17  38.6  26  59.1  0.407  0  (0)  0  (0) 
Italy (N=28)  14  50.0  12  42.9  0.636  0  (0)  0  (0) 
Spain (N=13)  11  84.6  0  0  0.086  NA  NA 
Sweden (N=24)  18  75.0  3  12.5  0.276  0  (0)  0  (0) 
Norway (N=12)  8  66.7  4  33.3  0.158  0  (0)  0  (0) 
N = total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella. 
n = number of isolates per category of complete susceptibility or multiple resistance. 
NA = not applicable. 
Susceptible to all = isolate susceptible to all antimicrobial substances of the EFSA common set for Salmonella. 
Multi-resistant = resistant to at least three different antimicrobial substances, belonging to any three antimicrobial families from the 
common antimicrobial set. 
Index of diversity = see definition in section 11.4.2.1 of Materials and Methods. 
Co-resistant to ciprofloxacin (CIP) and cefotaxime (CTX) = the frequencies and percentages of Salmonella isolates not susceptible to 
concentrations  greater  than  ECOFFs  (CTX: >0.5  mg/L  and  CIP: >0.06  mg/L).  Figures  in  parentheses  indicate  the  occurrence  of 
resistance determined using EUCAST clinical breakpoints (CTX: >2 mg/L and CIP: >1 mg/L). 
Figure SA38.  Frequency  distribution  of  Salmonella  spp.  from  cattle  completely  susceptible  or 
resistant to one to nine antimicrobials in MSs and one non-MS reporting isolate-based data, 2011 
 
N = Total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
sus = susceptible to all antimicrobial substances of the common set. 
res1/res9 =  resistance to one antimicrobial substance/resistance to nine antimicrobial substances of the common set. 
Multi-resistance among S. Typhimurium isolates from cattle 
Since fewer than four MSs reported multi-resistance isolate-based data on more than 10 isolates of 
S. Typhimurium isolates in cattle, tables and graphs on multi-resistance are not presented in this report.    
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3.4.3. Comparison of ‘clinical’ and ‘microbiological’ resistance to ciprofloxacin 
Fluoroquinolones, including ciprofloxacin, are recognised to be critically important in human medicine and 
often  constitute  the  first-line  treatment  for  invasive  salmonellosis.  Therefore,  the  high  levels  of 
ciprofloxacin resistance observed among Salmonella spp. from some animal species that were discussed 
earlier in this chapter are of concern. Resistance levels were particularly high among  Gallus gallus and 
turkeys when interpreted using the EUCAST ECOFFs. 
When the data were re-analysed using the CLSI breakpoints, the resistance levels were considerably lower 
(Table SA28). Several countries reported very high or extremely high resistance  to ciprofloxacin among 
Salmonella spp. from turkeys when using the EUCAST ECOFFS, none of the 10 countries reporting more 
than 10 isolates detected no resistance. However, when the CLSI breakpoints were applied to analyse these 
data, resistance was detected only in Poland (31.7 %) and Hungary (12.4 %). Among Salmonella spp. from 
Gallus gallus, resistance levels reached up to 63.5 % using the EUCAST ECOFFs and only two of the 16 
countries reporting more than 10 isolates detected no resistance. However, using the CLSI breakpoints, 
resistance was only found in four countries, at low levels in Belgium (2.0 %), Slovakia (1.9 %) and Spain 
(1.4 %) and at a very low level in Hungary (0.4 %). Similarly, whereas several countries expressed low or 
moderate resistance among Salmonella spp. from pigs and cattle when EUCAST ECOFFS were used, none 
of these countries were found to have any resistant isolates when using the CLSI breakpoints. 
The geographical distribution of the occurrence of resistance to ciprofloxacin in turkeys and the fact that it is 
high parallels the occurrence of S. Kentucky in that farm animal species and indicates how the clonal spread 
of one serovar can influence the overall picture. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table SA28.  Resistance  (%)  to  ciprofloxacin  among  Salmonella  spp.  from  Gallus  gallus,  turkeys,  pigs  and  cattle  in  2011,  using  harmonised 
epidemiological cut-off values or CLSI breakpoints 
Country 
Gallus gallus
1  Turkeys
2  Pigs
3  Cattle 
EUCAST % Res  CLSI % Res  EUCAST % Res  CLSI % Res  EUCAST % Res  CLSI % Res  EUCAST % Res  CLSI % Res 
Austria  26.7  0  68.2  0  -  -  -  - 
Belgium  33.4  2.0  -  -  -  -  -  - 
Denmark  0  0  -  -  0  0  -  - 
Estonia  -  -  -  -  0  0  0  0 
Finland  -  -  -  -  -  -  0  0 
France  2.1  0  24.1  0  -  -  -  - 
Germany  7.9  0  52.6  0  3.7  0  1.4  0 
Greece  22.9  0  -  -  -  -  -  - 
Hungary  63.5  0.4  77.1  12.4  11.4  0  -  - 
Ireland  1.5  0  14.3  0  12.8  0  2.3  0 
Italy  24.1  0  25.9  0  7.0  0  10.7  0 
Latvia  0  0  -  -  -  -  -  - 
Netherlands  25.6  0  -  -  0  0  0  0 
Poland  51.2  0  61.0  31.7  -  -  -  - 
Portugal  46.5  0  80.0  0  -  -  -  - 
Slovakia  55.6  1.9  -  -  -  -  -  - 
Spain  35.0  1.4  77.3  0  17.1  0  0  0 
Sweden  -  -  -  -  -  -  0  0 
United Kingdom  4.5  0  4.8  0  -  -  -  - 
Norway  -  -  -  -  -  -  8.3  0 
- = no data reported. 
1. Gallus gallus: in Estonia, two isolates (N=4) displayed reduced susceptibility to ciprofloxacin (MIC above the EUCAST ECOFF), whereas, in Finland, Sweden and Norway one, four and two isolates were 
respectively sensitive to ciprofloxacin (MIC below the ECOFF). 
2. Turkeys: in Slovakia, one isolate (N=4) displayed reduced susceptibility to ciprofloxacin (MIC above both the EUCAST and CLSI thresholds),  while,  in  Denmark,  Finland  and  Norway  one,  two  and  one 
isolates were respectively sensitive to ciprofloxacin (MIC below the EUCAST ECOFF). 
3. Pigs: in Sweden one isolate (N=9) displayed reduced susceptibility to ciprofloxacin (MIC above the EUCAST ECOFF), whereas, in Finland and Norway four and five isolate were respectively sensitive to 
ciprofloxacin (MIC below the EUCAST ECOFF).  
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3.4.4. Overview of the findings of antimicrobial resistance in  Salmonella at MS reporting 
group level, 2011 
Figures SA39 and SA40 illustrate the resistance levels for the groups of MSs reporting quantitative MIC data 
in 2011. These data were not all derived from the same group of MSs, which needs to be considered when 
interpreting these figures. Resistance levels to ampicillin, chloramphenicol, sulfonamides and tetracyclines in 
S. Typhimurium from Gallus gallus were higher than in S. Enteritidis from Gallus gallus. However, resistance 
to  ciprofloxacin  and  nalidixic  acid  was  higher  in  S. Enteritidis  than  in  S. Typhimurium.  In  terms  of  all 
Salmonella  spp., resistance  levels  in  isolates  from broiler  meat were  higher than  those  in  isolates  from 
Gallus gallus. This represents a return to the pattern observed in 2009 with an increase in resistance in 
isolates from broiler meat compared with the levels reported in 2010. 
In  a  very  similar  pattern  to  that  observed  in  2010,  resistance  levels  to  tetracyclines,  sulfonamides  and 
ampicillin were higher in Salmonella isolated from turkeys, pigs and cattle than in isolates from Gallus gallus, 
whereas, for ciprofloxacin and nalidixic acid, the highest resistance was observed in turkeys and in Gallus 
gallus. The levels of resistance to sulfonamides and tetracyclines in isolates from turkeys decreased in 2011, 
whereas the levels of resistance to these antimicrobials in isolates from pigs increased compared with 2010. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Figure SA39.  Resistance  to  ampicillin,  cefotaxime,  chloramphenicol,  ciprofloxacin,  gentamicin,  nalidixic  acid,  sulfonamides  and  tetracyclines  in 
Salmonella spp., S. Enteritidis and S. Typhimurium from Gallus gallus and Salmonella spp. from meat from broilers at reporting MS group level in 2011 
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Figure SA40.  Resistance  to  ampicillin,  cefotaxime,  chloramphenicol,  ciprofloxacin,  gentamicin,  nalidixic  acid,  sulfonamides  and  tetracyclines  in 
Salmonella spp. from Gallus gallus, turkey, pigs and cattle at reporting MS group level in 2011 
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3.5. Discussion 
Salmonellosis continues to be the second most commonly reported zoonotic disease in humans in the EU, 
after  campylobacteriosis, although  there  has  been a  significant decline  in  human  cases  over  the period 
2007–2011. This decrease is assumed to be mainly due to the reduction in Salmonella prevalence in flocks 
of laying hens, broilers and turkeys, most likely as beneficial results of the national control and monitoring 
programmes implemented by the MSs in the corresponding production sectors (EFSA and ECDC, 2013).  
In 2011, information on antimicrobial resistance in Salmonella isolates from human salmonellosis cases was 
reported  by  19  MSs  and  one  non-MS  (Iceland).  The  number  of  isolates  submitted  by  these  countries 
corresponded to a quarter of the salmonellosis cases reported within the EU in 2011, which is considered a 
representative sample. MSs not reporting antimicrobial resistance data are, however, still encouraged to do 
so to achieve the best possible assessment of the levels of antimicrobial resistance in human Salmonella 
isolates in the EU.  
Resistance  in  human  Salmonella  isolates  was  high  for  ampicillin,  tetracyclines  and  sulfonamides  and 
moderate for streptomycin and nalidixic acid. These are antimicrobials that are or have commonly been used 
for treatment in humans and animals. For these first four antimicrobials, the important resistance observed 
was  largely  due  to  the  high  to  extremely  high  resistance  levels  observed  among  S. Typhimurium  and 
particularly monophasic S. Typhimurium isolates. This corresponding resistance pattern (ASSuT) is the most 
commonly  observed  among  the  emerging  monophasic  S. Typhimurium  definitive  type  193/120  strains 
(EFSA, 2010d). In contrast, resistance to the clinically-important antimicrobials, ciprofloxacin and cefotaxime, 
was relatively low among the isolates tested. However, levels of resistance to ciprofloxacin were significantly 
higher  in  countries  using  epidemiological  cut-off  values  or  similar  values  for  the  interpretation  of  the 
resistance  than  in  those  using  clinical  breakpoints  (with  the  notable  exception  of  Italy).  Resistance  to 
quinolones  (ciprofloxacin  and  nalidixic  acid)  was  also  generally  higher  in  S. Enteritidis  isolates  than  in 
S. Typhimurium isolates of human origin.  
On  average,  a  quarter  of  human  Salmonella  spp.  isolates  in  the  12  MSs  testing  for  all  antimicrobials 
collected at EU level exhibited multi-drug resistance, meaning that they were clinically resistant to at least 
three different antimicrobial classes. Two MSs recorded multi-resistance levels greater than 50 %. More than 
half  of  all  isolates  tested  were  susceptible  to  the  complete  range  of  antimicrobials  in  the  human  data 
collection. Co-resistance to the critically important antimicrobials ciprofloxacin and cefotaxime was low and 
observed in a total of 65 isolates in 5 of the 12 reporting MSs.  
The multi-resistance levels observed in human isolates were generally lower than those observed in turkeys, 
pigs and pig meat. Compared with broilers and laying hens, however, multi-resistance levels observed in 
humans were generally higher. Although clinical breakpoints were mainly used to estimate multi-resistance in 
the  human  isolates,  because  both  resistant  and  intermediate  results  were  combined  to  estimate  multi-
resistance in human isolates, the clinical breakpoints for only 4 out of 10 antimicrobials had less sensitive 
MIC values than the ECOFFs. This resulted in lower than expected difference in multi-resistance estimates 
between  human  and  animal/food  isolates.  A  striking  observation  was  that  many  human  isolates  were 
resistant to a large number of antimicrobials, some even to all 10, something which was not observed in any 
animal or food isolates included in the analysis. This could reflect the impact of use of antimicrobials in 
humans, in addition to that in food-producing animals. 
In order to assess the importance of travel-associated infections, antimicrobial resistance was also analysed 
based  on  the  most  likely  country  of  infection  and  aggregated  by  geographical  region.  Overall,  human 
Salmonella spp. isolates acquired within the EU/EEA countries exhibited greater resistance to ampicillin and 
streptomycin  than  isolates  from  other  regions,  while  the  highest  levels  of  resistance  to  six  of  the 
antimicrobials tested, including ciprofloxacin, were observed in isolates acquired from Asia. 
In  Salmonella  isolates  from  animals  and  meat,  information  on  antimicrobial  resistance  was  reported  by 
20 MSs and one non-MS (Norway) in accordance with EFSA’s recommendations (EFSA, 2007) in 2011. The 
(quantitative)  MIC  results  obtained  using  the  methods  recommended  by  EFSA  provided  the  most 
harmonised and comparable set of data for reporting MSs, and these datasets have therefore been analysed 
in detail. 
For the first time, this EUSR has examined the levels of resistance in isolates within different production 
types of animal species. Differences in animal husbandry and physiological differences between animals EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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involved in different production types (e.g. fattening veal calves and dairy cattle) make evaluation of the 
antimicrobial resistance results at the animal species level difficult, where the production types of the species 
in question are not comparable. Sub-division of resistance data allows for more accurate analysis; however, 
this is possible only where sufficient information on production type has been submitted. In 2011, the large 
number of MSs providing data on isolates from Gallus gallus by production type allowed for more accurate 
analysis. However, more information is required at production level for other  animal species, particularly 
cattle, to improve these sections of the report in future years. Moreover, the analysis of the results may be 
hampered where there are few reporting MSs, as sub-division into production types reduces the size of 
isolate samples available, unless sampling plans have been previously designed at the level of production 
types. 
Antimicrobials such as ampicillin, sulfonamides and tetracyclines have been widely used for many years 
in veterinary medicine to treat bacterial diseases.Thus, levels of resistance to these antimicrobials observed 
within this reporting process are generally moderate to high among isolates from food-producing animals and 
meat  products  thereof.  The  data  submitted  by  MSs  in  2011  are  evidence  of  this.  For  ampicillin, 
chloramphenicol,  sulfonamides  and  tetracyclines,  resistance  levels  were  highest  in  isolates  from  pigs, 
followed closely by isolates from turkeys, and then cattle. Isolates from Gallus gallus displayed the least 
resistance to these antimicrobials within the reported data, but still at moderate to high levels. Considering 
the production level data for Salmonella spp. and S. Enteritidis from Gallus gallus, higher levels of resistance 
were  observed  among  isolates  from  broiler  flocks  than  in  isolates  from  laying  hen  flocks.  This  was 
particularly evident for tetracyclines and sulfonamides. This may reflect the relative infrequency with which 
laying  hens  are  treated  with  antimicrobials  compared  with  broilers,  as  well  as  the  limited  numbers  of 
antimicrobial compounds which are authorised for the treatment of laying hens in many EU MSs. 
Among  food  and  animal  isolates,  the  highest  occurrence  of  resistance  to  ciprofloxacin  was  noted  in 
Salmonella from turkeys, fowl (Gallus gallus) and broiler meat, with 50.4 %, 28.7 % and 50.1 %, respectively, 
of the isolates found resistant in the reporting MS group. The ciprofloxacin resistance level of 28.7 % for the 
Gallus gallus species can be further sub-divided into production types and reveals a difference between 
Salmonella isolates from laying hens, among which resistance to ciprofloxacin was 12.7 % and broilers, in 
which resistance to ciprofloxacin in the reporting MS group was 35.1 %. A number of reporting MSs showed 
increasing trends in ciprofloxacin and nalidixic acid resistance in Salmonella spp. isolates from Gallus gallus 
over the 2005-2011 period, whereas decreasing trends were observed in other MSs. These observations 
relating to Salmonella spp. may reflect the occurrence of S. Enteritidis definitive phage type 1 in Gallus gallus 
within these MSs, since this phage type commonly displays resistance to nalidixic acid and ciprofloxacin. 
Similarly, in turkeys, the dissemination of certain serovars (such as S. Newport in some MSs), which, again, 
are commonly resistant to nalidixic acid and ciprofloxacin, may affect the overall levels of resistance among 
all  Salmonella spp.  In addition,  the  reporting of resistance results  for  an expanded  number  of individual 
serovars in this report enables some of the resistances which are associated with particular serovars to be 
clearly seen.  
Resistance to third-generation cephalosporins (such as cefotaxime) was detected in Salmonella isolates 
from turkeys, fowl (Gallus gallus), pigs, cattle and the meat derived from broilers and pigs, but at low or very 
low levels when all reporting MSs were considered. However, there was some variability in third-generation 
cephalosporin resistance observed between the different animal or meat origins in the reporting MSs. Some 
MSs recorded a decline in resistance to cefotaxime in Salmonella spp. from Gallus gallus. However, Austria 
and Hungary detected cefotaxime resistance in S. Enteritidis from Gallus gallus in 2011, whereas, in 2010, 
cefotaxime  resistance  in  S. Enteritidis  from  Gallus  gallus  was  reported  only  by  the  Czech  Republic.  As 
S. Enteritidis is one of the main serovars affecting humans, the emergence of resistance to third-generation 
cephalosporins is extremely undesirable. A further trend is that the number of MSs reporting cefotaxime 
resistance in Salmonella spp. from pigs has increased.  
Antimicrobial resistance in certain Salmonella serovars and phage types may be related not only to the 
selective pressure exerted by the use of antimicrobials, but also to the clonal diffusion of these Salmonella 
serovars and phage types, and may also be influenced by factors such as on-farm hygienic management 
and  animal  movements  and  trade.  It  was  evident  in  both  humans  and  animals  that  isolates  of 
S. Typhimurium  displayed  higher  levels  of  resistance  than  isolates  of  S. Enteritidis  to  ampicillin, 
chloramphenicol, streptomycin, sulfonamides and tetracyclines. This is usually observed among the data 
reported by MSs and is not surprising since certain phage types of S. Typhimurium have an associated 
pattern of pentavalent resistance to these antimicrobials. 
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The MS specific temporal trends in the resistant Salmonella isolates from animals over the years 2005-
2011  were  analysed  statistically.  Some  statistically  significant  increasing  and  decreasing  trends  were 
observed at MS specific level. In contrast to 2010, more decreasing trends than increasing trends were 
detected in isolates from Gallus gallus, and the same was observed for isolates from pigs. Once again in 
cattle isolates, all the significant trends observed were also decreasing. In 2011, an equal number of MSs 
had significant increasing and decreasing national trends for ciprofloxacin and/or nalidixic acid resistance in 
isolates from Gallus gallus, whereas in 2010 the majority of significant trends were increasing. Ultimately, it 
would be most useful to correlate trends and the occurrence of antimicrobial resistance, with the usage of 
antimicrobial compounds in each animal production type that is monitored. 
The  multi-resistance  levels  (proportions  of  isolates  showing  reduced  susceptibility  to  more  than  three 
antimicrobial classes according to ECOFFs) in Salmonella spp. isolates were generally high in the animal 
populations investigated, with notable variations between reporting countries. A striking exception to this is 
the multi-resistance levels recorded in isolates from laying hens which are generally low to moderate, in 
particular  compared  with  those  observed  in  isolates  from  broilers.  Generally,  the  proportions  of 
Salmonella spp.  isolates  susceptible  to  all  or  resistant  (or  non-susceptible)  to  any  one  up  to  nine 
antimicrobials differed substantially among the reporting countries, and the relative contribution of different 
serovars, which may exhibit particular multi-resistance patterns, should be kept in mind, when comparing the 
situation between the reporting countries. Co-resistance to cefotaxime and ciprofloxacin was recorded, using 
ECOFFs, at low levels in very rare cases and when using clinical breakpoints, not detected, in Salmonella 
spp. isolates from meat and animal populations studied in this report (meat from pigs, broilers, laying hens, 
turkeys, pigs and cattle) in the reporting countries.  
Salmonella spp. comprises the amalgamated results for all Salmonella serovars reported by a reporting MS 
for a different animal or food category. The relative contribution of different serovars possessing a particular 
resistance should ideally be considered when interpreting the results, in order to evaluate the influence of 
clonal  dissemination  of  serovars.  The  recent  proposed  changes  to  and  implementation  of  isolate-based 
reporting (EFSA, 2012a) will facilitate the evaluation of the results in this way in future. The next chapter 
makes an attempt to present information on antimicrobial resistance at serovar level for the serovars of most 
relevance for public health in 2011. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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4. RESISTANCE  AMONG  OTHER  SALMONELLA  SEROVARS  OF  PUBLIC  HEALTH 
SIGNIFICANCE 
4.1. Introduction 
In 2011, a substantial number of data was submitted by MSs regarding antimicrobial resistance among 
specific serovars of Salmonella of public health significance from humans, food and animal sources. The 
data reported for serovars of public health significance have been specifically analysed in this chapter. This 
section describes the data reported for a total of 15 serovars: the top 10 serovars in humans and some 
additional serovars displaying particular patterns of resistance. In particular, S. Enteritidis, S. Typhimurium, 
S. Hadar, S. Infantis and S. Virchow are specifically targeted by national control and monitoring programmes 
of Salmonella in poultry in the EU (see box below). Comparisons should be made with caution as interpretive 
criteria differ between human and animal data.  
NATIONAL CONTROL PROGRAMMES FOR SALMONELLA IN GALLUS GALLUS 
Under  EU  Regulation  (EC)  No.  2160/2003,
13  EU MSs  are  required  to  implement  National Control 
Programmes  (NCPs)  for  Salmonella  serovars  that  are  deemed  to  be  of  particular  public  health 
significance  in  animal  species  that  present  a  high  potential  risk  of  transmitting  those  Salmonella  to 
humans.  The  NCPs  are  implemented  in  order  to  achieve  agreed  targets  for  the  reduction  in  the 
prevalence of particular regulated Salmonella serovars in animal populations at the primary production 
level over specified time periods. The initial focus of the NCPs was Gallus gallus, with the NCPs for 
breeding flocks, laying hens, and broilers coming into place in 2007, 2008 and 2009, respectively. The 
targets were set by the EC in consultation with MSs. For laying and broiler flocks, the targets were set 
following standardised EU-wide baseline prevalence surveys. The NCPs may vary between MSs owing to 
different circumstances but they generally set minimum Salmonella monitoring requirements and control 
methods to be used upon finding regulated serovars. NCPs must be approved by the EC. 
S. Enteritidis,  S. Typhimurium  and  monophasic  strains  of  Salmonella  with  the  antigenic  formula 
S. 1,4,[5],12:i:- are regulated serovars within NCPs for breeding flocks, laying hens and broiler flocks. 
However, the NCPs for breeding flocks also include  S. Infantis, S. Virchow and  S. Hadar. In 2011, a 
number of MSs provided quantitative data on antimicrobial resistance for these three serovars in isolates 
from Gallus gallus. Although antimicrobial resistance data were not specifically provided on isolates from 
breeding  flocks  in  2011,  it  is  interesting  to  present  separately  some  information  on  the  degree  of 
resistance observed among these important serovars isolated from broilers and laying hens. 
   
                                                       
13 Commission Regulation (EC) No 2160/2003 of the European Parliament and of the Council and Regulation of 17 November 2003 on 
the control of Salmonella and other specified food-borne zoonotic agents. OJ L 325, 12.12.2003, pp. 1–15. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Information  on  Salmonella  serovars  in  humans  was  available  from  25  MSs  in  2011.  Monophasic 
S. Typhimurium was the third most commonly reported serovar in human confirmed cases in the EU after 
S. Enteritidis and S. Typhimurium, which represented 4.7 %, 44.4 % and 24.9 %, respectively, of confirmed 
cases of all reported serovars, as more MSs reported monophasic S. Typhimurium cases according to the 
new  agreed  serotype  code.  The  next  most  frequent  serovar  in  the  list  was  S.  Infantis,  followed  by  S. 
Newport, S. Derby, S. Kentucky, S. Poona, S. Virchow and S. Agona (see Figure SAS1). New on the top 10 
serovar list was S. Poona. 
Figure SAS1.   Distribution of the 10 most common Salmonella serovars in humans, TESSy data from 
25 MSs, 2011 
 
Source: The European Union Summary Report on Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks in 
2011. Available on line: http://www.efsa.europa.eu/en/efsajournal/pub/3129.htm 
Data  originating  from  food-producing  animals  and  food  have  been  included  in  the  report  even  if  there 
originated from fewer than four reporting MSs and fewer than 10 tested isolates. This is indicated in the 
footnotes of the relevant tables. 
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4.2. Resistance in monophasic S. Typhimurium 
Monophasic  S. Typhimurium  has  been  considered  a  new  pandemic  strain  of  Salmonella  in  Europe, 
typically  showing  resistance  to  four  antimicrobials  (ampicillin,  streptomycin,  sulfonamides  and 
tetracyclines) (Mossong et al., 2007; Hopkins et al., 2010). Many isolates are genetically related and, of 
definitive phage-types, DT120 or DT193, have been detected in several European countries, with pigs 
considered the likely reservoir of infection. However, monophasic S. Typhimurium isolates belonging to 
phage type U302 have also been previously detected in Spain; these isolates have commonly been found 
to  express  additional  resistance  to  gentamicin  and  trimethoprim/sulfonamides  and/or  chloramphenicol 
(Echeita et al., 1999). In monophasic S. Typhimurium of phage types DT120 and DT193, the resistance 
genes appear to be located on a new resistance island and it seems that deletions of parts of this island 
in  related  strains  of  the  organism  account  for  differences  in  the  observed  ampicillin,  streptomycin, 
sulfonamides and tetracycline pattern of resistance (Hopkins et al., 2010). This serovar has been included 
in  the  list  of  serovar  targets  for  the  NCPs  in  poultry  since  2010  (Commission  Regulation  (EU)  No. 
517/2011
14). 
Monophasic S. Typhimurium was the fourth most commonly reported serovar in 2010, with a total of 
1,407 human cases (1.5 % of all Salmonella cases), compared with 360 in 2007 (EFSA and ECDC, 
2012). There were also three outbreaks in Germany caused by pig meat or pork buffet meals, involving 
45 cases, 10 hospitalisations and one death, which follows other outbreaks associated with pork meat or 
products in Luxembourg and France in recent years (EFSA, 2010d). Monophasic S. Typhimurium was 
also the second most common serovar in pigs (9.3 %) in 2010 and the third most common serovar in pig 
meat (7.4 %), cattle (4.7 %) and bovine meat (10.0 %), with several countries also reporting isolations 
from turkey meat and Gallus gallus (EFSA and ECDC, 2012). Multidrug-resistant Salmonella 4,[5],12:i:- 
DT 193 has been associated with large diffuse human outbreaks in Germany since 2006 (EFSA, 2010d). 
4.2.1. In humans 
In 2011, eight MSs submitted AMR data for this serovar, which was the third most common isolated with 
3,666 cases (EFSA and ECDC, 2013). The highest resistance in monophasic Salmonella Typhimurium was 
observed for tetracyclines (90.9 %; N=914), ampicillin (90.4 %; N=914) and streptomycin (85.1 %; N=914). 
This was in accordance with the highest resistance observed for generic S. Typhimurium isolates described 
in the previous chapter. The occurrence of resistance to these antimicrobials was generally high to extremely 
high in the majority of reporting MSs, although the number of isolates tested was low (N=914). Resistance in 
sulfonamides decreased markedly from 86.5 % (N=252) in 2010 to 57.5 % (N=914) in 2011 which was due 
to a very low resistance to sulfonamides reported for this serovar from Spain (1.5 %; N=342), Spain did not 
submit data on sulfonamide resistance in this serovar in 2010 (Table SAS1). The resistance observed in 
monophasic S. Typhimurium isolates to the two most important antimicrobials for treatment of clinical human 
cases was low, at 1.6 % (N=914) for ciprofloxacin and 1.8 % (N=914) for cefotaxime (Table SAS1).  
                                                       
14 Commission Regulation (EU) No. 517/2011 of 25 May 2011 implementing Regulation (EC) No 2160/2003 of the European Parliament 
and of the Council as regards a Union target for the reduction of the prevalence of certain Salmonella serotypes in laying hens of 
Gallus gallus and amending Regulation (EC) No 2160/2003 and Commission Regulation (EU) No 200/2010. OJ L 138, 26.05.2011, 
pp. 45–51. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Table SAS1.  Antimicrobial resistance in monophasic Salmonella Typhimurium 1,4,[5],12:i:- from humans per country in 2011, using clinical breakpoints, 
with some exceptions
1 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  73  94.5  73  4.1  73  8.2  73  0  73  4.1  73  4.1 
Denmark
1  140  90.7  140  7.1  140  10.7  140  7.1  140  9.3  140  1.4 
Estonia  2  NA  2  NA  2  NA  2  NA  2  NA  2  NA 
Hungary  86  88.4  86  0  86  2.3  86  0  86  0  86  0 
Ireland  28  82.1  28  0  28  7.1  28  0  28  3.6  28  3.6 
Luxembourg  29  89.7  29  0  29  3.4  29  3.4  29  0  29  0 
Netherlands
1  214  93.9  214  0  214  3.7  214  1.4  214  0.5  -  - 
Spain  342  88.9  342  0.9  342  5.6  342  0.3  342  3.2  342  0.9 
Total (8 MSs)  914  90.4  914  1.8  914  5.8  914  1.6  914  3.2  700  1.3 
 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  73  1.4  73  94.5  73  94.5  73  97.3  73  5.5 
Denmark
1  140  1.4  140  92.9  140  94.3  140  90.7  140  5.0 
Estonia  2  NA  2  NA  2  NA  2  NA  2  NA 
Hungary  86  2.3  86  84.9  86  86.0  86  74.4  86  0 
Ireland  28  3.6  28  82.1  28  82.1  28  92.9  28  7.1 
Luxembourg  29  3.4  29  86.2  29  86.2  29  86.2  29  10.3 
Netherlands
1  214  0.9  214  93.0  214  92.1  214  92.5  -  - 
Spain  342  2.3  342  75.4  342  1.5  342  93.3  342  0.3 
Total (8 MSs)  914  1.9  914  85.1  914  57.5  914  90.9  700  2.4 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
– = no data reported. 
NA = not applicable; if fewer than 10 isolates were tested, resistance was not calculated. 
1. ECOFFs were used for interpretation. 
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4.2.2. In pigs and pig meat 
In  the  analysis  below,  the  Salmonella  serovars  considered  as  monophasic  S.  Typhimurium  are 
S. 1,4,[5],12:i:-,  S. 4,12:i:-,  S. 4,5,12:i:-  and  those  reported  as  ‘S. Typhimurium,  monophasic’.  However, 
where MSs have incorporated monophasic S. Typhimurium in their results for S. Typhimurium, the results 
could not be included in this analysis. Over 90 % of the isolates tested were reported by Germany and 
Denmark, and over 70 % from Germany alone, so the levels of resistance reported as total proportions will 
be heavily influenced by these results. A complete overview of the animal populations and food categories in 
which resistance data on monophasic S. Typhimurium have been reported is presented in Table SAS2. 
Five  MSs  reported  data  on  monophasic  S. Typhimurium  in  pigs  and  pig  meat  in  2011.  Italy  and  Spain 
reported data only for isolates from pigs and Ireland reported data only for isolates from pig meat. Both 
Denmark and Germany reported resistance levels among isolates from both sources and in the case of pigs, 
data from these countries made up a significant proportion of the total data. 
All  MSs  reported  extremely  high  levels  of  resistance  to  ampicillin  (95.8 %),  sulfonamides  (89.4 %)  and 
tetracyclines  (95.8 %).  Almost  every  isolate  tested  by  Italy  and  Spain  was  resistant  to  these  three 
compounds. The occurrence of resistance to chloramphenicol and gentamicin was low overall among the 
reporting  MSs  (8.4 %  and  3.2 %,  respectively),  although  Spain  reported  a  high  level  of  resistance  to 
chloramphenicol  (23.1 %)  and  a  moderate  level  to  gentamicin  (15.4 %)  among  isolates  of  monophasic 
S. Typhimurium from pigs. 
No resistance to ciprofloxacin and nalidixic acid was detected among isolates from pigs tested by Denmark 
and Italy in 2011. Germany detected low levels of resistance to both antimicrobials (2.7 % for ciprofloxacin 
and  1.4 %  for  nalidixic  acid),  and  Spain  reported  moderate  resistance  to  ciprofloxacin  (15.4 %)  but  no 
resistance to nalidixic acid. Germany was the only country to report resistance to cefotaxime in monophasic 
S. Typhimurium from pigs and only at a very low level (0.9 %). 
Three MSs reported data on monophasic S. Typhimurium in pig meat and overall the levels of resistance 
were  similar  to  those  reported  for  isolates  from  pigs.  Extremely  high  levels  of  resistance  to  ampicillin 
(78.3 %), sulfonamides (91.3 %) and tetracyclines (93.5 %) were reported at the MS group level. Denmark 
did  not  detect  resistance  to  chloramphenicol  or  gentamicin,  while  for  Germany  and  Ireland,  the  overall 
resistance levels for these antimicrobials were 3.3 % and 2.2 % respectively. Germany was the only MS to 
report resistance to ciprofloxacin (5.3 %) and nalidixic acid (2.6 %) and none of the reporting MSs detected 
resistance to cefotaxime among monophasic S. Typhimurium from pig meat. 
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Table SAS2.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
monophasic Salmonella Typhimurium from pigs and meat from pigs in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Pigs                                                 
Denmark  59  78.0  59  0  59  5.1  59  0  59  3.4  59  0  59  79.7  59  89.8 
Germany  222  92.8  222  0.9  222  8.6  222  2.7  222  2.3  222  1.4  222  91.0  222  96.8 
Italy  17  100  17  0  17  5.9  17  0  17  5.9  17  0  17  100  17  100 
Spain  13  100  13  0  13  23.1  13  15.4  13  15.4  13  0  13  92.3  13  100 
Total (4 MSs)  311  95.8  311  0.6  311  8.4  311  2.6  311  3.2  311  1.0  311  89.4  311  95.8 
Meat from pigs                                                 
Denmark  21  85.7  21  0  21  0  21  0  21  0  21  0  21  76.2  21  85.7 
Germany  38  84.2  38  0  38  5.3  38  5.3  38  2.6  38  2.6  38  94.7  38  94.7 
Ireland  33  66.7  33  0  33  3.0  33  0  33  3.0  33  0  33  97.0  33  97.0 
Total (3 MSs)  92  78.3  92  0  92  3.3  92  2.2  92  2.2  92  1.1  92  91.3  92  93.5 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
Note: Includes data where fewer than four countries have reported.   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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4.3. Resistance in S. Infantis 
4.3.1. In humans 
There were 1,676 S. Infantis infections reported at the EU level in 2011, making it the fourth most common 
serovar (EFSA and ECDC, 2013). Data on the antimicrobial resistance of S. Infantis isolates were submitted 
by 16 MSs and Iceland for 2011. Overall resistance to ciprofloxacin in this serovar was 16.1 % (N=683) 
notably higher than for all non-typhoidal Salmonella isolates (9.1 %; N=24,126). This was due to high levels 
of resistance in Denmark (57.1 %; N=21) and in the United Kingdom (53.6 %; N=166), where more sensitive 
interpretative criteria for resistance (ECOFFs) were used. High overall levels of resistance to nalidixic acid 
(56.0 %; N=627), sulfonamides (53.7 %; N=562) and tetracyclines (51.3 %;  N=573) were also observed. 
These results were attributable to the United Kingdom and Hungary, which together accounted for at least 
60 % of the isolates of S. Infantis tested for susceptibility to these three antimicrobials (Table SAS3).  
4.3.2. In Gallus gallus 
Twelve MSs reported antimicrobial resistance data for isolates of S. Infantis from Gallus gallus in 2011, and 
eight also reported the production type of animals from which isolates were obtained (Table SAS4). The 
majority of isolates were from broilers and so the proportions presented under ‘All Gallus gallus’ are heavily 
weighted by the results from this production type. For this reason, the levels of resistance observed within 
these two sets of data were very similar. 
Extremely high levels of resistance to sulfonamides and tetracyclines were observed among isolates from all 
Gallus gallus and from broilers specifically. In Gallus gallus, the level of resistance to sulfonamides reported 
at MS group level was 73.6 % and the level of resistance to tetracyclines was 70.9 %. For broilers, the eight 
MSs reported resistance levels of 87.9 % for sulfonamides and 86.4 % for tetracyclines. Similar results were 
observed for ciprofloxacin and nalidixic acid. For isolates of S. Infantis from all Gallus gallus, the levels of 
resistance to ciprofloxacin and nalidixic acid were 79.5 % and 79.1 %, respectively. For broilers the levels of 
resistance to these two compounds were 96.5 % for ciprofloxacin and 96.0 % for nalidixic acid. Low levels of 
resistance to ampicillin, cefotaxime, chloramphenicol and gentamicin were reported at the MS group level for 
all Gallus gallus and broilers specifically.  
As observed with Salmonella spp., the levels of resistance among S. Infantis isolated from laying hens were 
lower than among isolates from broilers. At the MS group level, high levels of resistance to tetracyclines 
(25.0 %), sulfonamides (27.5 %), ciprofloxacin and nalidixic acid (both 27.5 %) were observed in isolates 
from laying hens. Hungary reported moderate resistance to gentamicin (10.5 %), while no resistance to this 
antimicrobial  was  observed  among  isolates  tested  by  France,  Italy,  Latvia  or  Spain.  No  MS  reported 
resistance to ampicillin, chloramphenicol or cefotaxime. 
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Table SAS3.  Antimicrobial resistance in Salmonella Infantis from humans per country in 2011, using clinical breakpoints, with some exceptions
1 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  69  8.7  69  5.8  69  0  69  0  69  1.4  69  0 
Denmark
1  21  4.8  21  0  21  4.8  21  57.1  21  9.5  21  14.3 
Estonia  21  9.5  21  0  21  0  22  0  21  0  21  0 
Germany  62  6.5  62  1.6  -  -  62  0  62  0  62  0 
Hungary  222  15.3  222  0.5  222  0.9  222  0.5  222  0.5  222  0.5 
Ireland  6  NA  6  NA  6  NA  6  NA  6  NA  6  NA 
Italy  25  24.0  24  4.2  6  NA  27  11.1  24  25.0  5  NA 
Lithuania  34  2.9  25  0  12  0  29  0  12  0  11  0 
Luxembourg  2  NA  2  NA  2  NA  2  NA  2  NA  2  NA 
Malta  7  NA  -  -  -  -  7  NA  7  NA  -  - 
Netherlands
1  12  8.3  12  0  12  8.3  12  25.0  12  0  -  - 
Romania  6  NA  6  NA  6  NA  6  NA  6  NA  6  NA 
Slovakia  14  14.3  9  NA  2  NA  10  0  7  NA  -  - 
Slovenia  10  10.0  10  0  10  0  10  0  10  0  10  0 
Spain  12  0  12  0  12  0  12  0  12  0  12  0 
United Kingdom  165  14.5  164  0.6  165  11.5  166  53.6  165  10.9  164  35.4 
Total (16 MSs)  688  13.2  665  1.4  566  4.2  683  16.1  658  6.2  611  10.3 
Iceland  1  NA  -  -  1  NA  1  NA  -  -  -  - 
Table continued overleaf. 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
– = no data reported. 
NA = not applicable; if fewer than 10 isolates were tested, resistance was not calculated. 
1. ECOFFs were used for interpretation. 
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Table  SAS3  (continued).  Antimicrobial  resistance  in  Salmonella  Infantis  from  humans  per  country  in  2011,  using  clinical  breakpoints,  with  some 
exceptions
1 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  69  53.6  69  42.0  69  40.6  69  49.3  69  4.3 
Denmark
1  21  57.1  21  47.6  21  47.6  21  42.9  21  33.3 
Estonia  19  5.3  21  14.3  21  9.5  21  9.5  21  9.5 
Germany  62  9.7  62  16.1  -  -  -  -  62  4.8 
Hungary  222  79.3  222  35.1  222  70.3  222  59.5  222  1.4 
Ireland  6  NA  6  NA  6  NA  6  NA  6  NA 
Italy  8  NA  5  NA  5  NA  10  20.0  23  8.7 
Lithuania  12  0  12  8.3  12  0  11  9.1  34  2.9 
Luxembourg  2  NA  2  NA  2  NA  2  NA  2  NA 
Malta  -  -  -  -  -  -  -  -  7  NA 
Netherlands
1  12  25.0  12  41.7  12  33.3  12  33.3  -  - 
Romania  6  NA  6  NA  6  NA  6  NA  6  NA 
Slovakia  -  -  -  -  -  -  7  NA  -  - 
Slovenia  10  70.0  10  40.0  10  50.0  10  50.0  10  0 
Spain  12  8.3  12  0  12  0  12  0  12  0 
United Kingdom  166  59.0  165  1.2  164  54.3  164  56.1  166  39.2 
Total (16 MSs)  627  56.0  625  23.4  562  53.7  573  51.3  661  14.2 
Iceland  1  NA  -  -  -  -  -  -  1  NA 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
– = no data reported. 
NA = not applicable; if fewer than 10 isolates were tested, resistance was not calculated. 
1. ECOFFs were used for interpretation. 
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Table SAS4.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella Infantis from Gallus gallus in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
All Gallus gallus 
Austria  32  0  32  0  32  0  32  100  32  0  32  100  32  100  32  100 
Denmark  2  0  2  0  2  0  2  0  2  0  2  0  2  0  2  0 
France  2  0  2  0  2  0  2  0  2  0  2  0  2  0  2  0 
Germany  9  33.3  9  0  9  11.1  9  22.2  9  0  9  22.2  9  55.6  9  22.2 
Greece  2  0  2  0  2  0  2  0  2  0  2  0  2  0  2  0 
Hungary  154  5.2  154  1.9  154  5.2  154  93.5  154  1.9  154  92.9  154  83.1  154  80.5 
Italy  5  0  5  0  5  0  5  0  5  0  5  0  5  0  5  0 
Latvia  2  0  2  0  2  0  2  0  2  0  2  0  2  0  2  0 
Netherlands  10  10.0  10  10.0  10  0  10  20  10  0  10  20  10  20  10  10.0 
Slovakia  24  4.2  24  0  24  0  24  100  24  4.2  24  100  24  95.8  24  100 
Spain  15  0  15  0  15  0  15  6.7  15  0  15  6.7  15  0  15  0 
United Kingdom  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
Total (12 MSs)  258  5.0  258  1.6  258  3.5  258  79.5  258  1.6  258  79.1  258  73.6  258  70.9 
Broilers 
Austria  32  0  32  0  32  0  32  100  32  0  32  100  32  100  32  100 
Denmark  2  0  2  0  2  0  2  0  2  0  2  0  2  0  2  0 
Germany  3  33.3  3  0  3  33.3  3  66.7  3  0  3  66.7  3  100  3  66.7 
Hungary  135  5.9  135  2.2  135  5.9  135  99.3  135  0.7  135  98.5  135  86.7  135  84.4 
Italy  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
Slovakia  24  4.2  24  0  24  0  24  100  24  4.2  24  100  24  95.8  24  100 
Spain  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
United Kingdom  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
Total (8 MSs)  199  5.0  199  1.5  199  4.5  199  96.5  199  1.0  199  96.0  199  87.9  199  86.4 
Laying hens 
France  2  0  2  0  2  0  2  0  2  0  2  0  2  0  2  0 
Hungary  19  0  19  0  19  0  19  52.6  19  10.5  19  52.6  19  57.9  19  52.6 
Italy  3  0  3  0  3  0  3  0  3  0  3  0  3  0  3  0 
Latvia  2  0  2  0  2  0  2  0  2  0  2  0  2  0  2  0 
Spain  14  0  14  0  14  0  14  7.1  14  0  14  7.1  14  0  14  0 
Total (5 MSs)  40  0  40  0  40  0  40  27.5  40  5.0  40  27.5  40  27.5  40  25.0 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
Note: Includes data where fewer than 10 isolates have been tested.  
Note: Data reported under 'All Gallus gallus' include data which have been reported by production level.   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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4.4. Resistance in S. Virchow 
4.4.1. In humans 
S. Virchow was the ninth most commonly isolated Salmonella serovar in Europe in 2011 with 467 cases 
(EFSA  and  ECDC,  2013).  S. Virchow  resistance  data  was  submitted  by  16  MSs  and  Iceland  for  2011, 
however Denmark and the United Kingdom accounted for over 80 % of the data for all antimicrobials. There 
were high levels of resistance to ciprofloxacin (45.6 %; N=204) and trimethoprim (35.0 %; N=203), and very 
high resistance to nalidixic acid (54.8 %; N=199), when compared to all non-typhoidal Salmonella isolates 
(Table SAS5). 
4.4.2. In Gallus gallus 
Seven MSs reported antimicrobial resistance data on isolates of S. Virchow from Gallus gallus in 2011, and 
six  of  these  provided  information  on  the  production  type  from  which  the  isolates  were  obtained  (Table 
SAS6). Overall the number of isolates tested was low with only two MSs testing more than 10 isolates. 
Considering overall levels of resistance at MS group level among isolates from all Gallus gallus, low levels of 
resistance were reported for ampicillin (8.3 %) and tetracyclines (4.2 %), and moderate levels of resistance 
were reported for sulfonamides (10.4 %) and gentamicin (12.5 %). Resistance to ciprofloxacin and nalidixic 
acid among isolates from Gallus gallus was detected only by three MSs, where it ranged from 83.3 % to 
100 %. Overall levels within the reporting MSs group were 79.2 % for ciprofloxacin and 77.1 % for nalidixic 
acid. No resistance to either cefotaxime or chloramphenicol was observed among isolates of S. Virchow in 
2011. 
Four MSs reported antimicrobial data on isolates of S. Virchow from broilers in 2011. Only 11 isolates were 
tested overall, so the resistance levels presented should be interpreted with caution. Only Ireland and Spain 
detected any resistance to selected antimicrobials among the isolates tested. A low level of resistance to 
tetracyclines  was  reported  across  the  MS  group  (9.1 %),  and  this  was  due  to  a  single  resistant  isolate 
reported  by  Ireland.  A  moderate  level  of  resistance  was  reported  for  ampicillin  at  the  MS  group  level 
(18.2 %),  whereas  high  levels  of  resistance  to  sulfonamides  (36.4 %)  and  gentamicin  (45.5 %)  were 
reported. All isolates of S. Virchow tested by Ireland and Spain (one and eight, respectively) were resistant 
to ciprofloxacin and nalidixic acid. No MSs reported resistance to chloramphenicol or cefotaxime. 
Four MSs reported antimicrobial data on isolates of S. Virchow from laying hens in 2011 and, as for broilers, 
only 11 isolates were tested overall. Resistance to tetracyclines was low overall, with only France reporting 
any resistance, in one of the five isolates tested. A moderate level of resistance to ampicillin was observed at 
MS group level (18.2 %), while no resistance was reported for sulfonamides, gentamicin, chloramphenicol or 
cefotaxime. Only Spain reported resistance to ciprofloxacin and nalidixic acid, with three out of four and two 
out of four isolates, respectively, testing positive.  
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Table SAS5.  Antimicrobial resistance in Salmonella Virchow from humans per country in 2011, using clinical breakpoints, with some exceptions
1 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  13  15.4  13  0  13  0  13  0  13  7.7  13  0 
Denmark
1  17  29.4  17  5.9  17  5.9  17  70.6  17  23.5  17  5.9 
Estonia  1  NA  1  NA  1  NA  1  NA  1  NA  1  NA 
Germany  7  NA  7  NA  -  -  7  NA  7  NA  7  NA 
Greece  1  NA  -  -  1  NA  1  NA  -  -  1  NA 
Ireland  2  NA  2  NA  2  NA  2  NA  2  NA  2  NA 
Italy  2  NA  -  -  -  -  -  -  1  NA  -  - 
Latvia  2  NA  2  NA  2  NA  -  -  -  -  -  - 
Luxembourg  1  NA  1  NA  1  NA  1  NA  1  NA  1  NA 
Malta  4  NA  -  -  -  -  4  NA  4  NA  -  - 
Netherlands
1  1  NA  1  NA  1  NA  1  NA  1  NA  -  - 
Romania  4  NA  4  NA  4  NA  4  NA  4  NA  4  NA 
Slovakia  1  NA  -  -  1  NA  -  -  1  NA  -  - 
Slovenia  3  NA  3  NA  3  NA  3  NA  3  NA  3  NA 
Spain  4  NA  4  NA  4  NA  4  NA  4  NA  4  NA 
United Kingdom  146  17.1  145  0  145  0  146  52.1  146  23.3  145  2.1 
Total (16 MSs)  209  20.6  200  0.5  195  0.5  204  45.6  205  22.4  198  2.5 
Iceland  1  NA  -  -  1  NA  1  NA  -  -  -  - 
Table continued overleaf. 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
– = no data reported. 
NA = not applicable; if fewer than 10 isolates were tested, resistance was not calculated. 
1. ECOFFs were used for interpretation.  
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Table  SAS5  (continued).  Antimicrobial  resistance  in  Salmonella  Virchow  from  humans  per  country  in  2011,  using  clinical  breakpoints,  with  some 
exceptions
1 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  13  38.5  13  7.7  13  7.7  13  7.7  13  7.7 
Denmark
1  17  70.6  17  29.4  17  41.2  17  41.2  17  41.2 
Estonia  1  NA  1  NA  1  NA  1  NA  1  NA 
Germany  7  NA  7  NA  -  -  -  -  7  NA 
Greece  1  NA  1  NA  -  -  1  NA  -  - 
Ireland  2  NA  2  NA  2  NA  2  NA  2  NA 
Italy  -  -  -  -  -  -  -  -  2  NA 
Latvia  -  -  -  -  -  -  -  -  -  - 
Luxembourg  1  NA  1  NA  1  NA  1  NA  1  NA 
Malta  -  -  -  -  -  -  -  -  4  NA 
Netherlands
1  1  NA  1  NA  1  NA  1  NA  -  - 
Romania  4  NA  4  NA  4  NA  4  NA  4  NA 
Slovakia  -  -  -  -  -  -  -  -  -  - 
Slovenia  3  NA  3  NA  3  NA  3  NA  3  NA 
Spain  4  NA  4  NA  4  NA  4  NA  4  NA 
United Kingdom  145  53.1  145  13.1  145  36.6  145  34.5  145  35.9 
Total (16 MSs)  199  54.8  199  15.1  191  34.0  192  32.3  203  35.0 
Iceland  1  NA  -  -  -  -  -  -  1  NA 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
– = no data reported. 
NA = not applicable, if fewer than 10 isolates were tested, resistance was not calculated. 
1. ECOFFs were used for interpretation.  
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Table SAS6.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella Virchow from Gallus gallus in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
All Gallus gallus 
France  5  20.0  5  0  5  0  5  0  5  0  5  0  5  0  5  20.0 
Germany  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
Ireland  1  100  1  0  1  0  1  100  1  100  1  100  1  100  1  100 
Italy  2  0  2  0  2  0  2  0  2  0  2  0  2  0  2  0 
Poland  26  0  26  0  26  0  26  100  26  3.8  26  100  26  3.8  26  0 
Spain  12  16.7  12  0  12  0  12  91.7  12  33.3  12  83.3  12  25.0  12  0 
United Kingdom  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
Total (7 MSs)  48  8.3  48  0  48  0  48  79.2  48  12.5  48  77.1  48  10.4  48  4.2 
Broilers 
Germany  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
Ireland  1  100  1  0  1  0  1  100  1  100  1  100  1  100  1  100 
Italy  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
Spain  8  12.5  8  0  8  0  8  100  8  50.0  8  100  8  37.5  8  0 
Total (4 MSs)  11  18.2  11  0  11  0  11  81.8  11  45.5  11  81.8  11  36.4  11  9.1 
Laying hens 
France  5  20.0  5  0  5  0  5  0  5  0  5  0  5  0  5  20.0 
Italy  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
Spain  4  25.0  4  0  4  0  4  75.0  4  0  4  50.0  4  0  4  0 
United Kingdom  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
Total (4 MSs)  11  18.2  11  0  11  0  11  27.3  11  0  11  18.2  11  0  11  9.1 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
Note: Includes data where fewer than 10 isolates have been tested and fewer than four countries have reported. 
Note: Data reported under 'All Gallus gallus' include data which have been reported by production level.   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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4.5. Resistance in S. Hadar in Gallus gallus 
Only  three  MSs  reported  quantitative  MIC  data  on  antimicrobial  resistance  among  S. Hadar  from 
Gallus gallus in 2011 (Table SAS7). All three countries provided information on the production type of the 
birds;  Austria  only  tested  only  broilers  while  Italy  and  Spain  tested  broilers  as  well  as  laying  hens  and 
breeding flocks. Only 23 isolates of S. Hadar were tested in total, with fewer than 10 tested in each country. 
Roughly three-quarters of the isolates were from broilers. 
All 23 S. Hadar isolates from Gallus gallus were resistant to ciprofloxacin and nalidixic acid. However, no 
resistance  was  detected  against  cefotaxime,  chloramphenicol  or  sulfonamides.  All  of  the  isolates  from 
Austria and Italy were resistant to ampicillin and tetracyclines. In contrast, only one and four, respectively, of 
the six isolates from Spain were resistant to these antimicrobials, respectively. Thus, the overall occurrence 
of resistance at the reporting MS group level was extremely high, at 78.3 % for ampicillin and 91.3 % for 
tetracyclines. Austria and Spain reported full sensitivity to gentamicin whereas Italy reported resistance in 
one of the eight isolates tested, resulting in a low overall level of resistance at the reporting MS group level 
of 4.3 %.   
As most of the isolates from Gallus gallus were from broilers, the results for this production type are very 
similar to those for Gallus gallus as a whole. None of the isolates from broilers in Spain was resistant to 
ampicillin, and only one out of three isolates was resistant to tetracyclines. However, broilers accounted for a 
smaller  proportion  of  the  Gallus  gallus  isolates  in  Spain  than  in  the  other  two  countries,  both  of  which 
showed full resistance to these antimicrobials. Therefore, the overall occurrence of resistance to ampicillin at 
the reporting MS group level was actually slightly higher in broilers than in Gallus gallus, at 83.3 %; however, 
for tetracyclines, it was slightly lower at 88.9 %. With respect to gentamicin, one of the six S. Hadar isolates 
from broilers in Italy was resistant, resulting in an overall reporting MS group level resistance of 5.6 %. 
Italy and Spain each tested a single isolate of S. Hadar from laying hens. Both of these isolates expressed 
resistance to ampicillin, ciprofloxacin, nalidixic acid and tetracyclines, but none of the other antimicrobials. 
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Table SAS7.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella Hadar from Gallus gallus in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
All Gallus gallus 
Austria  9  100  9  0  9  0  9  100  9  0  9  100  9  0  9  100 
Italy  8  100  8  0  8  0  8  100  8  12.5  8  100  8  0  8  100 
Spain  6  16.7  6  0  6  0  6  100  6  0  6  100  6  0  6  66.7 
Total (3 MSs)  23  78.3  23  0  23  0  23  100  23  4.3  23  100  23  0  23  91.3 
Broilers 
Austria  9  100  9  0  9  0  9  100  9  0  9  100  9  0  9  100 
Italy  6  100  6  0  6  0  6  100  6  16.7  6  100  6  0  6  100 
Spain  3  0  3  0  3  0  3  100  3  0  3  100  3  0  3  33.3 
Total (3 MSs)  18  83.3  18  0  18  0  18  100  18  5.6  18  100  18  0  18  88.9 
Laying hens 
Italy  1  100  1  0  1  0  1  100  1  0  1  100  1  0  1  100 
Spain  1  100  1  0  1  0  1  100  1  0  1  100  1  0  1  100 
Total (2 MSs)  2  100  2  0  2  0  2  100  2  0  2  100  2  0  2  100 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
Note: Includes data where fewer than 10 isolates have been tested and fewer than four countries have reported. 
Note: Data reported under 'All Gallus gallus' include data which have been reported by production level. 
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4.6. Resistance in S. Newport  
 
4.6.1. In humans 
A total of 771 S. Newport cases were reported at the EU level in 2011, making this the fifth most commonly 
isolated  serovar  in  2011  (EFSA  and  ECDC,  2013).  Data  on  the  antimicrobial  resistance  of  S. Newport 
isolates were submitted by 14 MSs for 2011. Overall resistance to all antimicrobials was lower than for non-
typhoidal Salmonella isolates, most notably ampicillin (7.5 %; N=358), nalidixic acid (1.7 %; N=348) and 
tetracyclines (8.1 %; N=283). At least 50 % of all S. Newport data were submitted by the United Kingdom for 
all antimicrobials (Table SAS8). 
There were 831 cases of S. Newport infection in humans in the EU in 2010, rendering it the fifth most 
common cause of salmonellosis, responsible for 0.9 % of cases (EFSA and ECDC, 2012). In addition, 
there were two strong evidence outbreaks involving 16 cases. In 2010, S. Newport was the second most 
commonly reported  (13.6 %)  serovar  isolated  from  turkey  meat  and  the  third  most common  serovar 
(3.7 %) in turkeys. S. Newport was one of the most common serovars to express multi-drug resistance 
among all Salmonella isolates collected via routine surveillance of British turkeys between 1995 and 
2006 (Papadopoulou et al., 2009). S. Newport is one of the serovars which can acquire pentavalent 
resistance  (to  ampicillin,  chloramphenicol,  streptomycin,  sulfonamides,  tetracyclines)  (Velge  et  al., 
2005), although isolates reported from turkeys in 2011 were susceptible to chloramphenicol. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Table SAS8.  Antimicrobial resistance in Salmonella Newport from humans per country in 2011, using clinical breakpoints, with some exceptions
1 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  16  25.0  16  12.5  16  18.8  16  0  16  0  16  6.3 
Denmark
1  16  0  16  0  16  0  16  0  16  0  16  0 
Germany  64  4.7  64  1.6  -  -  64  0  64  0  64  0 
Greece  6  NA  -  -  6  NA  6  NA  -  -  6  NA 
Ireland  10  0  10  0  10  0  10  0  10  0  10  0 
Italy  9  NA  4  NA  3  NA  9  NA  7  NA  1  NA 
Lithuania  1  NA  1  NA  -  -  1  NA  -  -  -  - 
Malta  2  NA  -  -  -  -  2  NA  2  NA  -  - 
Netherlands
1  27  7.4  27  0  27  0  27  0  27  0  -  - 
Romania  1  NA  1  NA  1  NA  1  NA  1  NA  1  NA 
Slovakia  1  NA  -  -  -  -  -  -  -  -  -  - 
Slovenia  1  NA  1  NA  1  NA  1  NA  1  NA  1  NA 
Spain  24  8.3  24  0  24  0  24  0  24  0  24  0 
United Kingdom  180  3.9  179  0.6  180  1.7  181  1.7  180  1.7  179  2.2 
Total (14 MSs)  358  7.5  343  1.2  284  2.1  358  0.8  348  2.3  318  1.6 
Table continued overleaf. 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
– = no data reported. 
NA = not applicable; if fewer than 10 isolates were tested, resistance was not calculated. 
1. ECOFFs were used for interpretation.  
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Table  SAS8  (continued).  Antimicrobial  resistance  in  Salmonella  Newport  from  humans  per  country  in  2011,  using  clinical  breakpoints,  with  some 
exceptions
1 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  16  6.3  16  18.8  16  37.5  16  43.8  16  25.0 
Denmark
1  16  0  16  6.3  16  6.3  16  6.3  16  6.3 
Germany  64  3.1  64  1.6  -  -  -  -  64  0 
Greece  6  NA  6  NA  -  -  6  NA  -  - 
Ireland  10  10.0  10  0  10  0  10  0  10  0 
Italy  3  NA  1  NA  1  NA  3  NA  8  NA 
Lithuania  -  -  -  -  -  -  -  -  1  NA 
Malta  -  -  -  -  -  -  -  -  2  NA 
Netherlands
1  27  0  27  14.8  27  3.7  27  3.7  -  - 
Romania  1  NA  1  NA  1  NA  1  NA  1  NA 
Slovakia  -  -  -  -  -  -  -  -  -  - 
Slovenia  1  NA  1  NA  1  NA  1  NA  1  NA 
Spain  24  0  24  4.2  24  0  24  4.2  24  0 
United Kingdom  180  1.7  180  1.7  179  4.5  179  5.6  181  3.3 
Total (14 MSs)  348  2.0  346  3.8  275  6.5  283  8.1  324  5.2 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
– = no data reported. 
NA = not applicable; if fewer than 10 isolates were tested, resistance was not calculated. 
1. ECOFFs were used for interpretation. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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4.6.2. In turkeys 
Five  MSs  reported  antimicrobial  resistance  data  for  isolates  of  S. Newport  from  turkeys  in  2011  (Table 
SAS9). It should be noted when interpreting the data that all five MSs tested a relatively low number of 
isolates. Across the reporting MSs, a high level of resistance to ampicillin was reported (54.7 %). The level of 
resistance differed substantially between the MSs with France reporting no resistance and Hungary reporting 
ampicillin resistance in all of the seven isolates tested. The United Kingdom was the only country to report 
resistance to tetracyclines out of those testing more than 10 isolates, and this was observed at a high level 
(29.4 %).  Poland  reported  a  low  level of  resistance  to  sulfonamides  among  isolates  of  S. Newport  from 
turkeys (6.3 %) while an extremely high level of resistance to  sulfonamides was reported by the United 
Kingdom (88.2 %). All MSs excluding Italy detected resistance to ciprofloxacin and nalidixic acid and the 
overall  levels  of  resistance  for  the  reporting  MS  group  were  high  for  both  antimicrobials  (37.5 %  for 
ciprofloxacin and 25.0 % for nalidixic acid). None of the reporting MSs detected resistance to cefotaxime, 
chloramphenicol or gentamicin among isolates of S. Newport from turkeys. 
Table SAS9.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, 
nalidixic  acid,  sulfonamides  and  tetracyclines  among  Salmonella  Newport  from  turkeys  in  2011, 
using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin 
N  % Res  N  % Res  N  % Res  N  % Res 
Belgium  103  78.6  103  0  103  13.6  103  3.9 
Denmark  28  60.7  28  0  28  17.9  28  0 
Germany  20  90.0  20  0  20  40.0  20  10.0 
Hungary  12  75.0  12  0  12  33.3  12  8.3 
Ireland  57  70.2  57  0  57  38.6  57  7.0 
Italy  12  58.3  12  0  12  16.7  12  25.0 
Romania  18  77.8  18  0  18  27.8  18  33.3 
Total (7 MSs)  250  74.4  250  0  250  24.0  250  8.0 
 
Country 
Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res 
Belgium  103  0  103  1.9  103  53.4  103  41.7 
Denmark  28  0  28  0  28  60.7  28  50.0 
Germany  20  0  20  10.0  20  85.0  20  75.0 
Hungary  12  0  12  0  -  -  12  58.3 
Ireland  57  1.8  57  7.0  57  82.5  57  82.5 
Italy  12  8.3  12  33.3  12  58.3  12  75.0 
Romania  18  0  18  22.2  18  72.2  18  72.2 
Total (7 MSs)  250  0.8  250  6.4  250  62.4  250  59.2 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
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4.7. Resistance in S. Kentucky  
 
4.7.1. In humans 
In 2011, a total of 559 S. Kentucky cases were reported to the EU level, making this serotype the seventh 
most commonly isolated serovar in 2011 (EFSA and ECDC, 2013). Fourteen MSs and Iceland submitted 
data on S. Kentucky. Overall, resistance levels to all antimicrobials, except cefotaxime, were very high to 
extremely  high  when  compared  with  all  non-typhoidal  Salmonella  isolates.  This  was  most  notable  for 
ampicillin (66.2%; N=222), ciprofloxacin (81.5 %; N=222), gentamicin (59.7 %; N=221) and nalidixic acid 
(84.3 %; N=216). For all antimicrobials, over 57 % of all S. Kentucky data were submitted from the United 
Kingdom (Table SAS10).  
In 2010, there were 780 reported cases of human salmonellosis due to S. Kentucky within the EU, which 
was an increase of 69.6 % relative to the number in 2009, and this serovar accounted for 0.8 % of all 
human cases of salmonellosis (EFSA and ECDC, 2012). S. Kentucky was the second most frequently 
reported serovar isolated from broiler meat in 2010 (5.7 % of Salmonella isolates) and this was largely 
due to the high prevalence reported by Ireland (EFSA and ECDC, 2012). Isolates of S. Kentucky which 
possess  either  an  ESBL  (SHV-12)  or  an  AmpC  (CMY2)  enzyme  have  recently  been  reported  from 
broilers in Ireland (Boyle et al., 2010) and these were found to be related at the molecular level to pan-
susceptible  S. Kentucky  isolates  from  human,  poultry  and  environmental  sources.  The  cephalosporin 
resistant S. Kentucky isolates detected in Irish poultry possessed either an ESBL (SHV-12) or an AmpC 
(CMY2) enzyme. These  isolates differ from  those causing  travel-associated S. Kentucky  infections  in 
humans, which generally show ESBL resistance through possession of CTX-M-1, as well as resistance to 
ciprofloxacin and trimethoprim/ sulfonamides (Collard et al., 2007).  
S. Kentucky also made up 7.5 % of Salmonella isolates from turkey meat in the EU in 2010 (EFSA and 
ECDC, 2012), with Ireland reporting a high proportion of these isolates. However, isolates of S. Kentucky 
have also recently been described in turkeys, turkey neck skin and turkey products in Poland (Wasyl and 
Hoszowski,  2012).  In  these  Polish  isolates,  the  most  commonly  observed  resistance  profile  was 
ampicillin,  streptomycin,  sulfonamides,  tetracyclines,  gentamicin,  nalidixic  acid  and  ciprofloxacin, 
occurring in 68 % (49/72) of isolates. It was found that 89 % of the 72 isolates examined were resistant to 
both nalidixic acid and ciprofloxacin, with the unusual feature that the ciprofloxacin MIC was high at 
≥8 mg/L in almost all resistant isolates. The most frequently observed pulsed-field gel electrophoresis 
(PFGE) pattern exhibited by the Polish S. Kentucky isolates was indistinguishable from that observed in 
S. Kentucky ST198 by Le Hello et al. (2011), who described the international spread of  S. Kentucky 
ST198  resistant  to  ciprofloxacin  in  humans.  Between  2002  and  2008,  there  were  about  500  human 
infections in France, England, Wales, Denmark and the USA caused by multidrug-resistant S. Kentucky 
isolates displaying high-level resistance to ciprofloxacin (Le Hello et al., 2011). These isolates belonged 
to a single clone referred to as ST198-X1. Since 2010, this clone has also been recorded in turkey meat 
products in Germany (Beutlich et al., 2012). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table SAS10.  Antimicrobial resistance in Salmonella Kentucky from humans per country in 2011, using clinical breakpoints, with some exceptions
1 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  14  100  14  0  14  0  14  92.9  14  78.6  14  7.1 
Denmark
1  16  50.0  16  0  16  18.8  16  93.8  16  81.3  16  6.3 
Estonia  1  NA  1  NA  1  NA  1  NA  1  NA  1  NA 
Germany  20  90.0  20  0  -  -  20  95.0  20  75.0  20  5.0 
Ireland  4  NA  4  NA  4  NA  4  NA  4  NA  4  NA 
Italy  2  NA  2  NA  1  NA  2  NA  1  NA  1  NA 
Lithuania  1  NA  1  NA  1  NA  1  NA  1  NA  1  NA 
Luxembourg  1  NA  1  NA  1  NA  1  NA  1  NA  1  NA 
Malta  5  NA  -  -  -  -  5  NA  5  NA  -  - 
Netherlands
1  14  71.4  14  0  14  0  14  85.7  14  71.4  -  - 
Romania  1  NA  1  NA  1  NA  1  NA  1  NA  1  NA 
Slovenia  1  NA  1  NA  1  NA  1  NA  1  NA  1  NA 
Spain  14  64.3  14  0  14  0  14  85.7  14  57.1  14  0 
United Kingdom  128  63.3  128  0.8  128  11.7  128  79.7  128  50.8  128  10.9 
Total (14 MSs)  222  66.2  217  0.5  196  9.2  222  81.5  221  59.7  202  8.9 
Iceland  2  NA  -  -  2  NA  2  NA  -  -  -  - 
Table continued overleaf. 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
- = no data reported. 
NA = not applicable; if fewer than 10 isolates were tested, resistance was not calculated. 
1. ECOFFs were used for interpretation.  
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Table SAS10 (continued). Antimicrobial resistance in Salmonella Kentucky from humans per country in 2011, using clinical breakpoints, with some 
exceptions
1 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  14  100  14  78.6  14  85.7  14  85.7  14  14.3 
Denmark
1  16  93.8  16  75.0  16  87.5  16  93.8  16  31.3 
Estonia  1  NA  1  NA  1  NA  1  NA  1  NA 
Germany  20  100  20  85.0  -  -  -  -  20  10.0 
Ireland  4  NA  4  NA  4  NA  4  NA  4  NA 
Italy  1  NA  1  NA  1  NA  1  NA  2  NA 
Lithuania  1  NA  1  NA  1  NA  1  NA  1  NA 
Luxembourg  1  NA  1  NA  1  NA  1  NA  1  NA 
Malta  -  -  -  -  -  -  -  -  5  NA 
Netherlands
1  14  85.7  14  71.4  14  85.7  14  85.7  -  - 
Romania  1  NA  1  NA  1  NA  1  NA  1  NA 
Slovenia  1  NA  1  NA  1  NA  1  NA  1  NA 
Spain  14  85.7  14  57.1  14  7.1  14  71.4  14  0 
United Kingdom  128  78.9  128  14.1  128  68.8  128  71.9  128  14.8 
Total (14 MSs)  216  84.3  216  38.0  196  68.9  196  76.0  208  13.9 
Iceland  2  NA  -  -  -  -  -  -  2  NA 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
- = no data reported. 
NA = not applicable;, if fewer than 10 isolates were tested, resistance was not calculated. 
1. ECOFFs were used for interpretation.  
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4.7.2. In poultry 
Eight  MSs  reported  antimicrobial  resistance  data  for  S. Kentucky  isolates  in  2011  (Table  SAS11).  Only 
Ireland and Italy reported data for more than 10 isolates from Gallus gallus, while Hungary and Poland 
reported data for mor than 10 isolates from turkeys. 
For Gallus gallus, moderate to high levels of resistance to sulfonamides (16.7 %), tetracyclines (20.8 %) and 
ampicillin  (41.7 %)  were  reported  by  Italy,  while  Ireland  reported  low  levels  of  resistance  to  all  three 
compounds  (3.6 %,  1.8 %  and  3.6 %,  respectively).  Low  levels  of  resistance  were  reported  for  both 
chloramphenicol  and  gentamicin  at  the  reporting  MS  group  level  (6.5 %  for  gentamicin  and  3.3 %  for 
chloramphenicol). A high level of resistance to ciprofloxacin or nalidixic acid was reported among isolates of 
S. Kentucky from Gallus gallus at the reporting MS group level (28.3 % for both compounds). Both Ireland 
and  Italy  detected  a  low  level  of  resistance  to  cefotaxime  (1.8 %  and  8.3 %,  respectively);  whilst  no 
resistance was reported by the remaining MSs. 
For isolates of S. Kentucky from turkeys, extremely high levels of resistance were observed for ampicillin 
(94.1 %) and sulfonamides (90.2 %) across the reporting MS group. Hungary also reported an extremely 
high  level  of  resistance  to  tetracyclines  (94.1 %)  while  one  of  the  two  isolates  tested  by  Slovakia  was 
resistant and no resistance was observed among isolates from Poland. None of the reporting MSs detected 
resistance to cefotaxime or chloramphenicol, but all three reported extremely high levels of resistance to 
gentamicin (90.2 % overall). Extremely high levels of resistance were also reported for ciprofloxacin and 
nalidixic  acid  at  the  MS  group  level  (94.1 %  for  both  compounds  overall).  All  of  the  isolates  tested  by 
Hungary were resistant to the (fluoro-)quinolones. 
Table SAS11.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, 
nalidixic  acid,  sulfonamides  and  tetracyclines  among  Salmonella  Kentucky  from  poultry  in  2011, 
using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin 
N  % Res  N  % Res  N  % Res  N  % Res 
Gallus gallus                         
Denmark  3  0  3  0  3  0  3  0 
France  1  0  1  0  1  0  1  0 
Hungary  3  33.3  3  0  3  0  3  33.3 
Ireland  55  3.6  55  1.8  55  0  55  0 
Italy  24  41.7  24  8.3  24  12.5  24  87.5 
Slovakia  1  100  1  0  1  0  1  100 
Spain  5  20.0  5  0  5  0  5  60.0 
Total (7 MSs)  92  16.3  92  3.3  92  3.3  92  28.3 
Turkeys                         
Hungary  34  97.1  34  0  34  0  34  100 
Poland  15  86.7  15  0  15  0  15  86.7 
Slovakia  2  100  2  0  2  0  2  50.0 
Total (3 MSs)  51  94.1  51  0  51  0  51  94.1 
Table continued overleaf. 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
Note: Includes data where fewer than 10 isolates have been tested and fewer than four countries have reported. 
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Table SAS11 (continued). Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, 
gentamicin, nalidixic acid, sulfonamides and tetracyclines among Salmonella Kentucky from poultry 
in 2011, using harmonised epidemiological cut-off values 
Country 
Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res 
Gallus gallus                         
Denmark  3  0  3  0  3  0  3  0 
France  1  0  1  0  1  0  1  0 
Hungary  3  33.3  3  33.3  3  66.7  3  100 
Ireland  55  0  55  0  55  3.6  55  1.8 
Italy  24  8.3  24  87.5  24  16.7  24  20.8 
Slovakia  1  100  1  100  1  100  1  100 
Spain  5  40.0  5  60.0  5  60.0  5  40.0 
Total (7 MSs)  92  6.5  92  28.3  92  13.0  92  13.0 
Turkeys                         
Hungary  34  94.1  34  100  34  94.1  34  94.1 
Poland  15  86.7  15  86.7  15  86.7  15  0 
Slovakia  2  50.0  2  50.0  2  50.0  2  50.0 
Total (3 MSs)  51  90.2  51  94.1  51  90.2  51  64.7 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
Note: Includes data where fewer than 10 isolates have been tested and fewer than four countries have reported. 
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4.8. Resistance in S. Derby 
 
4.8.1. In humans 
S. Derby was the sixth most commonly reported Salmonella serovar at the EU level in 2011, accounting for 
704 cases of salmonellosis (EFSA and ECDC, 2013). S. Derby resistance data were submitted by 14 MSs 
for  2011.  High  overall  resistance  to  tetracyclines  was  observed  (43.4 %;  N=122),  particularly  in  Spain 
(64.3 %; N=14) and Italy (47.1 %; N=34). There was low overall resistance to ampicillin (9.9 %; N=232), 
ciprofloxacin (1.3 %; N=237) and nalidixic acid (3.1 %; N=193) compared with all non-typhoidal Salmonella 
isolates (Table SAS12).  
4.8.2. In pigs 
In 2011, eight MSs reported antimicrobial resistance data for S. Derby from pigs, but three MSs tested fewer 
than 10 isolates each (Table SAS13). More than half of the isolates were tested by Denmark, so its results 
will have a large influence on those for the reporting MS group as a whole.  
Overall,  there  was  a  high  level  of  resistance  to  tetracyclines  (39.4 %)  and  sulfonamides  (31.8 %),  with 
resistance levels in the individual countries ranging between 32.3 % and 92.3 % for the former and between 
15.5 % and 75.0 % for the latter. For ampicillin, there was a moderate level of resistance of 14.7 % at the 
reporting MS group level. Estonia (three isolates), Spain (13 isolates) and Sweden (one isolate) reported full 
sensitivity  to  this  antimicrobial,  but  the  other  countries  reported  between  9.5 %  and  37.5 %  resistance. 
Similarly, Estonia, Spain and Sweden, each with the same number of isolates reported for ampicillin, and the 
Netherlands  (reporting  three  isolates)  reported  no  resistance  to  chloramphenicol.  The  other  countries 
reported levels between 4.1 % and 43.8 %, resulting in an overall level of 8.1 %. Concerning ciprofloxacin 
and nalidixic acid, Germany reported 8.1 % resistance to both and Italy reported 7.7 % resistance to both, 
resulting in a low overall level of 2.3 % for both antimicrobials. Resistance to gentamicin was low (1.5 %) at 
the  reporting  MS  group  level,  with  most  MSs  reporting  full  sensitivity  and  Denmark,  Hungary  and  Italy 
reporting low levels of resistance. Germany was the only country to report resistance to cefotaxime (4.8 %), 
so overall resistance at the reporting MS group level was low at 1.2 %. 
 
There were 665 cases of salmonellosis attributable to S. Derby in 2010, which is comparable to the 
number reported in 2009, and rendered S. Derby the eighth most commonly reported serovar. In the EU-
wide baseline survey of holdings with breeding pigs conducted in 2008 (EFSA, 2008c), S. Derby was the 
most frequently isolated serovar from both breeding and production holdings, detected in 29.6 % and 
28.5 %  of  the  Salmonella-positive  holdings,  respectively.  The  resulting  estimated  EU  prevalence  of 
positive breeding and production holdings was 8.9 % and 9.0 %, respectively. This serovar was also the 
second most commonly isolated serovar from pig meat in the EU in 2010, accounting for 16.2 % of 
Salmonella isolates from this source. 
A recent study in Germany (Hauser et al., 2011) examined 82 epidemiologically unrelated isolates of 
S. Derby recovered from pigs, pork and humans over 2006–2008 and found 72 % of isolates to be fully-
susceptible, while the remaining isolates were resistant only to tetracyclines or multiply-resistant with 
different resistance profiles. S. Derby has also been detected with Salmonella genomic island 1, which 
can  confer  resistance  to  ampicillin,  chloramphenicol,  streptomycin,  sulfonamides  and  tetracyclines 
(Beutlich et al., 2011). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table SAS12.  Antimicrobial resistance in Salmonella Derby from humans per country in 2011, using clinical breakpoints, with some exceptions
1 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  5  NA  5  NA  5  NA  5  NA  5  NA  5  NA 
Denmark
1  12  16.7  12  0  12  0  12  0  12  0  12  0 
Estonia  3  NA  3  NA  3  NA  3  NA  3  NA  3  NA 
Germany  72  4.2  72  1.4  -  -  72  0  72  1.4  72  2.8 
Greece  2  NA  -  -  2  NA  2  NA  -  -  2  NA 
Ireland  2  NA  2  NA  2  NA  2  NA  2  NA  2  NA 
Italy  69  18.8  66  1.5  33  6.1  74  4.1  54  25.9  23  0 
Lithuania  5  NA  5  NA  3  NA  5  NA  3  NA  3  NA 
Netherlands
1  10  0  10  0  10  0  10  0  10  0  -  - 
Romania  7  NA  7  NA  7  NA  7  NA  7  NA  7  NA 
Slovakia  2  NA  1  NA  2  NA  1  NA  1  NA  -  - 
Slovenia  1  NA  1  NA  1  NA  1  NA  1  NA  1  NA 
Spain  14  0  14  0  14  7.1  14  0  14  7.1  14  0 
United Kingdom  28  7.1  28  0  29  0  29  0  29  0  28  0 
Total (14 MSs)  232  9.9  226  0.9  123  3.3  237  1.3  213  8.0  -  - 
Table continued overleaf. 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
– = no data reported. 
NA = not applicable; if fewer than 10 isolates were tested, resistance was not calculated. 
1. ECOFFs were used for interpretation. 
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Table  SAS12  (continued).  Antimicrobial  resistance  in  Salmonella  Derby  from  humans  per  country  in  2011,  using  clinical  breakpoints,  with  some 
exceptions
1 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  5  NA  5  NA  5  NA  5  NA  5  NA 
Denmark
1  12  0  12  25.0  12  25.0  12  33.3  12  16.7 
Estonia  3  NA  3  NA  3  NA  3  NA  3  NA 
Germany  72  2.8  72  13.9  -  -  -  -  72  1.4 
Greece  2  NA  2  NA  -  -  2  NA  -  - 
Ireland  2  NA  2  NA  2  NA  2  NA  2  NA 
Italy  33  9.1  24  41.7  21  38.1  34  47.1  64  10.9 
Lithuania  3  NA  3  NA  3  NA  3  NA  5  NA 
Netherlands
1  10  0  10  20.0  10  10.0  10  30.0  -  - 
Romania  7  NA  7  NA  7  NA  7  NA  7  NA 
Slovakia  -  -  -  -  -  -  1  NA  -  - 
Slovenia  1  NA  1  NA  1  NA  1  NA  1  NA 
Spain  14  7.1  14  35.7  14  0  14  64.3  14  0 
United Kingdom  29  0  29  3.4  28  25.0  28  35.7  29  0 
Total (14 MSs)  193  3.1  184  21.7  106  25.5  122  43.4  214  4.7 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
– = no data reported. 
NA = not applicable; if fewer than 10 isolates were tested, resistance was not calculated. 
1. ECOFFs were used for interpretation. 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Table SAS13.  Resistance  (%)  to  ampicillin,  cefotaxime,  chloramphenicol,  ciprofloxacin,  gentamicin,  nalidixic  acid,  sulfonamides  and  tetracyclines 
among Salmonella Derby from pigs in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Denmark  148  9.5  148  0  148  4.1  148  0  148  1.4  148  0  148  15.5  148  34.5 
Estonia  3  0  3  0  3  0  3  0  3  0  3  0  3  0  3  0 
Germany  62  21.0  62  4.8  62  8.1  62  8.1  62  0  62  8.1  62  50.0  62  32.3 
Hungary  16  37.5  16  0  16  43.8  16  0  16  6.3  16  0  16  75.0  16  62.5 
Italy  13  30.8  13  0  13  23.1  13  7.7  13  7.7  13  7.7  13  46.2  13  61.5 
Netherlands  3  33.3  3  0  3  0  3  0  3  0  3  0  3  33.3  3  33.3 
Spain  13  0  13  0  13  0  13  0  13  0  13  0  12  75.0  13  92.3 
Sweden  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
Total (8 MSs)  259  14.7  259  1.2  259  8.1  259  2.3  259  1.5  259  2.3  258  31.8  259  39.4 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
Note: Includes data where fewer than 10 isolates have been tested.  
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4.9. Resistance in S. Mbandaka 
 
4.9.1. In humans 
In 2011, a total of 218 S. Mbandaka cases were reported at the EU level. This serovar was the eighth most 
common serovar isolated in 2010 (EFSA and ECDC, 2013) and in the top 25 in 2011. Data on antimicrobial 
resistance of S. Mbandaka isolates were submitted by nine MSs for 2011, but over 50 % of all data was 
reported by the United Kingdom. Overall resistance levels to all antimicrobials were low or very low and a 
maximum of only 137 isolates were tested for each antimicrobial (Table SAS14). 
4.9.2. In Gallus gallus, turkeys, pigs, cattle and meat products thereof 
In  2011,  nine  MSs  submitted  antimicrobial  resistance  data  concerning  S. Mbandaka  from  Gallus  gallus 
(Table SAS15). A total of 114 isolates were tested, but five countries tested fewer than 10 isolates each. At 
the  reporting  MS  group  level,  there  was  a  high  overall  occurrence  of  resistance  to  ampicillin  (21.9 %), 
sulfonamides  (23.7 %)  and  tetracyclines (32.5 %). Resistance levels  varied markedly between countries, 
with four or five countries reporting no resistance to each of these antimicrobials, but others reporting up to 
83.3 % resistance. Overall, a low level of resistance was reported for chloramphenicol (1.8 %), ciprofloxacin 
(7.9 %)  and  nalidixic  acid  (5.3 %).  The  United  Kingdom  reported  4.3 %  resistance  to  all  three  of  these 
antimicrobials, and Italy and Poland reported resistance  to two of them; all other countries reported full 
sensitivity. No resistance to cefotaxime or gentamicin was recorded in any of the reporting countries.  
Six MSs reported data concerning isolates of S. Mbandaka from broilers in 2011. Data were submitted for a 
total of 53 isolates although most of these were tested by either France or the United Kingdom. At the 
reporting MS group level, high levels of resistance against ampicillin (39.6 %), sulfonamides (45.3 %) and 
tetracyclines  (43.4 %)  were  observed.  Italy  reported  resistance  to  chloramphenicol  in  one  of  the  seven 
isolates tested and the United Kingdom reported a low level of resistance (4.8 %), but all other countries 
reported full sensitivity, resulting in an overall resistanct of 3.8 % at the reporting MS group level. The United 
Kingdom was the only country to report resistance to ciprofloxacin or nalidixic acid (4.8 % in both cases), 
resulting in a low overall level of 1.9 % resistance in each case. No resistance to cefotaxime or gentamicin 
was observed. 
Seven  MSs  reported  antimicrobial  data  on  isolates  of  S. Mbandaka  from  laying  hens  in  2011,  with  33 
isolates tested overall. France was responsible for nearly half of the isolates and was the only country to test 
more than 10 isolates. Resistance to tetracyclines was high at the reporting MS group level (42.4 %) with 
resistance levels in individual countries ranging from 0 % to 80.0 %. One isolate from Italy tested resistant to 
ampicillin, ciprofloxacin and sulfonamides, resulting in a low overall occurrence of resistance at the reporting 
MS group level of 3.0 %. No resistance to cefotaxime, chloramphenicol, gentamicin or nalidixic acid was 
reported. 
Only two MSs submitted data concerning isolates of S. Mbandaka from turkeys in 2011: France tested eight 
isolates and the United Kingdom tested one. France reported resistance to sulfonamides in three isolates 
and resistance to ampicillin and tetracyclines in one isolate each. No resistance to the other antimicrobials in 
the single isolate from the United Kingdom was reported. 
Estonia was the only MS to report data for S. Mbandaka collected from pigs. A single isolate was tested and 
was found to be fully sensitive to all of the antimicrobials tested. In addition, Ireland was the only MS to 
report data for S. Mbandaka collected from meat from pigs. Similarly, no resistance was reported for the 
single isolate tested. 
In  2010,  S. Mbandaka  was  the  ninth  most  common  serovar  isolated  in  human  salmonellosis  cases 
(EFSA and ECDC, 2012). It was isolated from 0.5 % of cases, and there were also two strong evidence 
outbreaks involving 161 cases, of whom 33 were hospitalised. Similarly to S. Agona, isolations of this 
serovar from livestock are commonly feed-related. S. Mbandaka was the fifth most frequently reported 
serovar  from  both  Gallus  gallus  and  cattle  in  2010,  responsible  for  6.2 %  and  2.6 %  of  Salmonella 
isolations from these species, respectively. Also like S. Agona, this serovar was responsible for a greater 
proportion of cases in humans, animal and food than in the preceding year.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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In 2011, Ireland and Spain submitted antimicrobial resistance data for three S. Mbandaka isolates collected 
from cattle. No resistance was detected to any of the antimicrobials.   
Ireland and Italy submitted data for three isolates from bovine meat. The isolate from Ireland was resistant to 
sulfonamides  and  one  of  the  isolates  from  Italy  was  resistant  to  tetracyclines.  The  isolates  were  fully 
susceptible to all other antimicrobials. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table SAS14.  Antimicrobial resistance in Salmonella Mbandaka from humans per country in 2011, using clinical breakpoints, with some exceptions
1 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  25  0  25  0  25  0  25  0  25  0  25  0 
Denmark
1  10  0  10  0  10  0  10  0  10  0  10  0 
Germany  8  NA  8  NA  -  -  8  NA  8  NA  8  NA 
Ireland  5  NA  5  NA  5  NA  5  NA  5  NA  5  NA 
Luxembourg  1  NA  1  NA  1  NA  1  NA  1  NA  1  NA 
Netherlands
1  1  NA  1  NA  1  NA  1  NA  1  NA  -  - 
Slovenia  6  NA  6  NA  6  NA  6  NA  6  NA  6  NA 
Spain  12  8.3  12  0  12  0  12  0  12  8.3  12  0 
United Kingdom  69  5.8  69  1.4  69  0  69  8.7  69  0  69  0 
Total (9 MSs)  137  4.4  137  0.7  129  0  137  5.1  137  0.7  136  0 
 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  25  0  25  0  25  4.0  25  0  25  4.0 
Denmark
1  10  0  10  0  10  0  10  0  10  0 
Germany  8  NA  8  NA  -  -  -  -  8  NA 
Ireland  5  NA  5  NA  5  NA  5  NA  5  NA 
Luxembourg  1  NA  1  NA  1  NA  1  NA  1  NA 
Netherlands
1  1  NA  1  NA  1  NA  1  NA  -  - 
Slovenia  6  NA  6  NA  6  NA  6  NA  6  NA 
Spain  12  0  12  0  12  0  12  0  12  0 
United Kingdom  69  1.4  69  0  69  2.9  69  4.3  69  4.3 
Total (9 MSs)  137  0.7  137  0  129  3.1  129  2.3  136  4.4 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
– = no data reported. 
NA = not applicable, if fewer than 10 isolates were tested resistance was not calculated. 
1. ECOFFs were used for interpretation. 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Table SAS15.  Resistance  (%)  to  ampicillin,  cefotaxime,  chloramphenicol,  ciprofloxacin,  gentamicin,  nalidixic  acid,  sulfonamides  and  tetracyclines 
among Salmonella Mbandaka from Gallus gallus, turkeys, pigs, cattle and meat products thereof in 2011, using harmonised epidemiological cut-off 
values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
All Gallus gallus 
Austria  6  0  6  0  6  0  6  0  6  0  6  0  6  0  6  83.3 
Denmark  2  50.0  2  0  2  0  2  0  2  0  2  0  2  0  2  0 
France  36  50.0  36  0  36  0  36  0  36  0  36  0  36  50.0  36  69.4 
Ireland  2  0  2  0  2  0  2  0  2  0  2  0  2  0  2  0 
Italy  12  16.7  12  0  12  8.3  12  8.3  12  0  12  0  12  25.0  12  25.0 
Poland  25  12.0  25  0  25  0  25  28.0  25  0  25  20.0  25  8.0  25  0 
Spain  7  0  7  0  7  0  7  0  7  0  7  0  7  0  7  28.6 
Sweden  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
United Kingdom  23  4.3  23  0  23  4.3  23  4.3  23  0  23  4.3  23  17.4  23  8.7 
Total (9 MSs)  114  21.9  114  0  114  1.8  114  7.9  114  0  114  5.3  114  23.7  114  32.5 
Broilers 
Austria  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  100 
Denmark  1  100  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
France  21  85.7  21  0  21  0  21  0  21  0  21  0  21  85.7  21  85.7 
Ireland  2  0  2  0  2  0  2  0  2  0  2  0  2  0  2  0 
Italy  7  14.3  7  0  7  14.3  7  0  7  0  7  0  7  28.6  7  28.6 
United Kingdom  21  4.8  21  0  21  4.8  21  4.8  21  0  21  4.8  21  19.0  21  9.5 
Total (6 MSs)  53  39.6  53  0  53  3.8  53  1.9  53  0  53  1.9  53  45.3  53  43.4 
Table continued overleaf. 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
Note: Includes data where fewer than 10 isolates have been tested and fewer than four countries have reported. 
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Table  SAS15  (continued).  Resistance  (%)  to  ampicillin,  cefotaxime,  chloramphenicol,  ciprofloxacin,  gentamicin,  nalidixic  acid,  sulfonamides  and 
tetracyclines  among  Salmonella  Mbandaka  from  Gallus  gallus,  turkeys,  pigs,  cattle  and  meat  products  thereof  in  2011,  using  harmonised 
epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Laying hens 
Austria  5  0  5  0  5  0  5  0  5  0  5  0  5  0  5  80.0 
Denmark  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
France  15  0  15  0  15  0  15  0  15  0  15  0  15  0  15  46.7 
Italy  3  33.3  3  0  3  0  3  33.3  3  0  3  0  3  33.3  3  33.3 
Spain  6  0  6  0  6  0  6  0  6  0  6  0  6  0  6  33.3 
Sweden  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
United Kingdom  2  0  2  0  2  0  2  0  2  0  2  0  2  0  2  0 
Total (7 MSs)  33  3.0  33  0  33  0  33  3.0  33  0  33  0  33  3.0  33  42.4 
Turkeys 
France  8  12.5  8  0  8  0  8  0  8  0  8  0  8  37.5  8  12.5 
United Kingdom  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
Total (2 MSs)  9  11.1  9  0  9  0  9  0  9  0  9  0  9  33.3  9  11.1 
Pigs 
Estonia  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
Meat from pigs 
Ireland  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
Cattle 
Ireland  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
Spain  2  0  2  0  2  0  2  0  2  0  2  0  2  0  2  0 
Total (2 MSs)  3  0  3  0  3  0  3  0  3  0  3  0  3  0  3  0 
Meat from bovine animals 
Ireland  1  0  1  0  1  0  1  0  1  0  1  0  1  100  1  0 
Italy  2  0  2  0  2  0  2  0  2  0  2  0  2  0  2  50.0 
Total (2 MSs)  3  0  3  0  3  0  3  0  3  0  3  0  3  33.3  3  33.3 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
Note: Includes data where fewer than 10 isolates have been tested and fewer than four countries have reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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4.10. Resistance in S. Agona 
 
4.10.1. In humans 
S. Agona resistance data were submitted by 14 MSs for 2011, with Denmark, Spain and the United Kingdom 
accounting for over 60% of isolates  in which antimicrobials were  tested. Overall, levels of resistance to 
ampicillin (10.8 %; N=250), gentamicin, (0.8 %; N=247) and streptomycin (3.3 %; N=246) were low when 
compared with all non-typhoidal Salmonella isolates (Table SAS16). 
4.10.2. In Gallus gallus, turkeys, pigs and meat products thereof 
Five  MSs  submitted  antimicrobial  resistance  data  for  isolates  of  S. Agona  from  Gallus  gallus  in  2011 
(Table SAS17). All of these countries provided information on the production type of the birds. Just over two-
thirds of the S. Agona isolates were collected from laying hens. The five MSs tested a total of 50 isolates 
from Gallus gallus, of which 35 were from laying hens and 11 were from broilers. Ampicillin was the only 
antimicrobial to which any resistance was detected. A single isolate from a broiler in Austria tested resistant, 
resulting in a resistance level in this country of 3.6 % among Gallus gallus and 20.0 % among broilers (one 
out of the five isolates tested). All other isolates were fully susceptible to all antimicrobials. 
Two MSs reported data concerning isolates from meat from broilers. Only five isolates were tested in total 
and they were all fully susceptible to all of the antimicrobials tested. 
Four MSs reported antimicrobial data on S. Agona isolates from turkeys in 2011. Overall, 20 isolates were 
tested although 16 of these were from France, so results from this country dominated those for the reporting 
MS group as a whole. France was the only country that detected any antimicrobial resistance among the 
isolates from turkeys. Half of its isolates were resistant to sulfonamides. France also reported a high level of 
resistance  to  tetracyclines  (43.8 %)  and  ampicillin  (25.0 %)  and  a  moderate  level  of  resistance  to 
chloramphenicol (18.8 %). 
Only two MSs reported data on isolates from pigs in 2011, in a total of five S. Agona isolates. Two of the 
three isolates tested by Estonia were resistant to ampicillin, sulfonamides and/or tetracyclines. No resistance 
to the other antimicrobials was detected. Denmark also reported full sensitivity to all antimicrobials in the two 
isolates that it tested. One MS, Estonia, reported data for S. Agona isolates from pig meat. Three isolates 
were  tested,  one  of  which  was  positive  for  ampicillin,  sulfonamides  and/or  tetracyclines.  The  remaining 
isolates were fully sensitive. 
Sweden and Romania each reported a single isolate from cattle and meat from bovine animals, respectively. 
Both isolates were fully sensitive to all antimicrobials tested. 
 
 
 
S. Agona was the tenth most common serovar isolated in human cases of salmonellosis in the EU in 
2010, responsible for 459 cases in 2011 (EFSA and ECDC, 2013). This serovar is frequently isolated 
from poultry, pigs and cattle, often as a result of animal feed contamination. In 2010, S. Agona was the 
eighth most common serovar in both cattle (responsible for 1.3 % of Salmonella isolations) and pig meat 
(0.9 %)  as  well  as  the  seventh  most  common  in  broiler  meat  (2.0 %).  In  addition,  S. Agona  was 
responsible for a greater proportion of Salmonella isolations from humans and both these animal species 
and food types relative to 2009. A recent international outbreak of 163 laboratory-confirmed cases in 
seven European countries was associated with pre-cooked meat products (Nicolay et al., 2011). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table SAS16.  Antimicrobial resistance in Salmonella Agona from humans per country in 2011, using clinical breakpoints, with some exceptions
1 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  13  15.4  13  0  13  0  13  0  13  0  13  0 
Denmark
1  22  13.6  22  4.5  22  4.5  22  4.5  22  0  22  0 
Estonia  2  NA  2  NA  2  NA  2  NA  2  NA  2  NA 
Germany  3  NA  3  NA  -  -  3  NA  3  NA  3  NA 
Ireland  5  NA  5  NA  5  NA  5  NA  5  NA  5  NA 
Italy  1  NA  1  NA  -  -  -  -  -  -  -  - 
Lithuania  1  NA  1  NA  1  NA  1  NA  1  NA  1  NA 
Luxembourg  1  NA  1  NA  1  NA  1  NA  1  NA  1  NA 
Netherlands
1  5  NA  5  NA  5  NA  5  NA  5  NA  -  - 
Romania  7  NA  7  NA  7  NA  7  NA  7  NA  7  NA 
Slovakia  2  NA  -  -  -  -  -  -  -  -  -  - 
Slovenia  1  NA  1  NA  1  NA  1  NA  1  NA  1  NA 
Spain  37  2.7  37  2.7  37  0  37  0  37  0  37  0 
United Kingdom  150  10.7  149  2.0  149  4.7  150  11.3  150  1.3  149  2.0 
Total (14 MSs)  250  10.8  247  2.4  243  3.7  247  8.1  247  0.8  241  1.7 
Table continued overleaf. 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
– = no data reported. 
NA = not applicable; if fewer than 10 isolates were tested, resistance was not calculated. 
1. ECOFFs were used for interpretation. 
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Table  SAS16  (continued).  Antimicrobial  resistance  in  Salmonella  Agona  from  humans  per  country  in  2011,  using  clinical  breakpoints,  with  some 
exceptions
1 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  13  7.7  13  7.7  13  7.7  13  23.1  13  0 
Denmark
1  22  0  22  13.6  22  9.1  22  4.5  22  4.5 
Estonia  2  NA  2  NA  2  NA  2  NA  2  NA 
Germany  3  NA  3  NA  -  -  -  -  3  NA 
Ireland  5  NA  5  NA  5  NA  5  NA  5  NA 
Italy  -  -  -  -  -  -  -  -  1  NA 
Lithuania  1  NA  1  NA  1  NA  1  NA  1  NA 
Luxembourg  1  NA  1  NA  1  NA  1  NA  1  NA 
Netherlands
1  5  NA  5  NA  5  NA  5  NA  -  - 
Romania  7  NA  7  NA  7  NA  7  NA  7  NA 
Slovakia  -  -  -  -  -  -  1  NA  -  - 
Slovenia  1  NA  1  NA  1  NA  1  NA  1  NA 
Spain  37  0  37  0  37  0  37  2.7  37  0 
United Kingdom  149  9.4  149  0  149  25.5  149  37.6  149  18.8 
Total (14 MSs)  246  7.7  246  3.3  243  18.5  244  28.3  242  12.4 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
– = no data reported. 
NA = not applicable; if fewer than 10 isolates were tested, resistance was not calculated. 
1. ECOFFs were used for interpretation. 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Table SAS17.  Resistance  (%)  to  ampicillin,  cefotaxime,  chloramphenicol,  ciprofloxacin,  gentamicin,  nalidixic  acid,  sulfonamides  and  tetracyclines 
among Salmonella Agona from Gallus gallus, turkeys, pigs, cattle and meat products thereof in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
All Gallus gallus 
Austria  28  3.6  28  0  28  0  28  0  28  0  28  0  28  0  28  0 
France  9  0  9  0  9  0  9  0  9  0  9  0  9  0  9  0 
Hungary  2  0  2  0  2  0  2  0  2  0  2  0  2  0  2  0 
Italy  4  0  4  0  4  0  4  0  4  0  4  0  4  0  4  0 
Spain  7  0  7  0  7  0  7  0  7  0  7  0  7  0  7  0 
Total (5 MSs)  50  2.0  50  0  50  0  50  0  50  0  50  0  50  0  50  0 
Broilers 
Austria  5  20.0  5  0  5  0  5  0  5  0  5  0  5  0  5  0 
France  6  0  6  0  6  0  6  0  6  0  6  0  6  0  6  0 
Total (2 MSs)  11  9.1  11  0  11  0  11  0  11  0  11  0  11  0  11  0 
Laying hens 
Austria  23  0  23  0  23  0  23  0  23  0  23  0  23  0  23  0 
France  3  0  3  0  3  0  3  0  3  0  3  0  3  0  3  0 
Hungary  2  0  2  0  2  0  2  0  2  0  2  0  2  0  2  0 
Italy  2  0  2  0  2  0  2  0  2  0  2  0  2  0  2  0 
Spain  5  0  5  0  5  0  5  0  5  0  5  0  5  0  5  0 
Total (5 MSs)  35  0  35  0  35  0  35  0  35  0  35  0  35  0  35  0 
Table continued overleaf. 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
Note: Includes data where fewer than 10 isolates have been tested and fewer than four countries have reported.  
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Table  SAS17  (continued).  Resistance  (%)  to  ampicillin,  cefotaxime,  chloramphenicol,  ciprofloxacin,  gentamicin,  nalidixic  acid,  sulfonamides  and 
tetracyclines among Salmonella Agona from Gallus gallus, turkeys, pigs, cattle and meat products thereof in 2011, using harmonised epidemiological 
cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Meat from broilers 
Ireland  3  0  3  0  3  0  3  0  3  0  3  0  3  0  3  0 
Slovakia  2  0  2  0  2  0  2  0  2  0  2  0  2  0  2  0 
Total (2 MSs)  5  0  5  0  5  0  5  0  5  0  5  0  5  0  5  0 
Turkeys 
Austria  2  0  2  0  2  0  2  0  2  0  2  0  2  0  2  0 
France  16  25.0  16  0  16  18.8  16  0  16  0  16  0  16  50.0  16  43.8 
Hungary  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
Slovakia  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
Total (4 MSs)  20  20.0  20  0  20  15.0  20  0  20  0  20  0  20  40.0  20  35.0 
Pigs 
Denmark  2  0  2  0  2  0  2  0  2  0  2  0  2  0  2  0 
Estonia  3  66.7  3  0  3  0  3  0  3  0  3  0  3  66.7  3  66.7 
Total (2 MSs)  5  40.0  5  0  5  0  5  0  5  0  5  0  5  40.0  5  40.0 
Meat from pigs 
Estonia  3  33.3  3  0  3  0  3  0  3  0  3  0  3  33.3  3  33.3 
Cattle 
Sweden  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
Meat from bovine animals 
Romania  1  0  1  0  1  0  1  0  1  0  1  0  1  0  1  0 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
Note: Includes data where fewer than 10 isolates have been tested and fewer than four countries have reported.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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4.11. Resistance in S. Java 
 
4.11.1. In humans 
In 2011, a total of 229 S. Java cases were reported at the EU level. This serovar is very common in poultry 
(EFSA and ECDC, 2013). In 2011, nine MSs and Iceland submitted data on the antimicrobial resistance of 
S. Java. Overall resistance to all antimicrobials was low or very low. Over 50 % of all data came from the 
United Kingdom (Table SAS18). 
   
Salmonella  enterica  Paratyphi  B  var  Java  has  the  same  somatic  and  flagellar  antigens  as  other 
S. Paratyphi  B  variants  but  is  differentiated  by  its  use  of  d-tartrate.  It  is  generally  less  virulent, 
although invasive infections can still occur resulting in typhoid-like clinical symptoms. S. Java has 
caused numerous outbreaks through contamination of foods, including a multi-country outbreak in 
2007  involving  over  200  cases  in  Denmark,  Finland,  the  Netherlands,  Norway,  Sweden  and  the 
United Kingdom (Denny et al., 2007). In 2010, there were two strong-evidence outbreaks in the EU 
involving 132 cases, of whom 17 were hospitalised (EFSA and ECDC, 2012). S. Java was the third 
most frequently reported serovar (4.6 %) in broiler meat in the EU in 2010 (EFSA and ECDC, 2012). 
This ranking is partly attributable to the very high prevalence in Germany and the Netherlands, where 
this serovar was responsible for 20.7 % and 53.5 %, respectively, of all Salmonella isolates in broiler 
meat (EFSA and ECDC, 2012). A multi-resistant clone of S. Java became predominant in poultry 
production  in  Germany  during  the  1990s,  and  has  since  been  identified  in  Belgium  and  the 
Netherlands  (Miko  et  al.,  2003).  S. Java  is  the  most  common  serovar  reported  in  poultry  in  the 
Netherlands (EFSA, 2008b, van Asselt et al., 2009) and an increase in the prevalence of this serovar 
in poultry has been reported in Germany (Dorn et al., 2001). 
Two distinct clonal lines of S. Java have been described–one frequently associated with aquaria, in 
particular tropical fish aquaria, and another associated with poultry. Strains associated with tropical 
fish commonly demonstrate resistance to ampicillin, chloramphenicol, streptomycin, sulfonamides and 
tetracyclines (Denny et al., 2007). S. Java is one of the serovars which has been shown to have 
acquired  SGI1,  which  confers  this  pattern  of  resistance  (Velge  et  al.,  2005).  Reports  in 
Eurosurveillance  show  that  in  the  Netherlands  the  proportion  of  Salmonella  isolates  in  poultry 
accounted for by S. Java increased from less than 2 % prior to 1996 to 60 % in 2002. Despite likely 
exposure through the food chain, cases of S. Java infection in humans remain rare in the Netherlands 
(0.3 % of all Salmonella infections), although molecular typing has shown that 50 % of human isolates 
are identical to the poultry clone (van Pelt et al., 2003). The antimicrobial resistance monitoring report 
for the Netherlands for 2009 (MARAN, 2011) records that, of all ESBL-producing isolates, 22 (67 %) 
were S. Java isolates derived either from poultry or from an unspecified source. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table SAS18.  Antimicrobial resistance in Salmonella Java from humans per country in 2011, using clinical breakpoints, with some exceptions
1 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  21  4.8  21  0  21  9.5  21  4.8  21  0  21  0 
Denmark
1  10  0  10  0  10  0  10  0  10  10.0  10  0 
Estonia  1  NA  1  NA  1  NA  1  NA  1  NA  1  NA 
Ireland  1  NA  1  NA  1  NA  1  NA  1  NA  1  NA 
Netherlands
1  14  28.6  14  7.1  14  0  14  7.1  14  0  -  - 
Romania  6  NA  6  NA  6  NA  6  NA  6  NA  6  NA 
Slovenia  22  4.5  22  0  22  0  22  0  22  0  22  0 
Spain  31  0  31  0  31  0  31  0  31  0  31  0 
United Kingdom  111  14.4  111  0  112  5.4  112  4.5  112  0.9  111  0.9 
Total (9 MSs)  217  10.6  217  0.5  218  4.1  218  3.2  218  0.9  203  0.5 
Iceland  3  NA  -  -  3  NA  3  NA  -  -  -  - 
 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  21  4.8  21  14.3  21  9.5  21  9.5  21  4.8 
Denmark
1  10  NA  10  10.0  10  10.0  10  0  10  0 
Estonia  1  NA  1  NA  1  NA  1  NA  1  NA 
Ireland  1  NA  1  NA  1  NA  1  NA  1  NA 
Netherlands
1  14  7.1  14  21.4  14  0  14  0  -  - 
Romania  6  NA  6  NA  6  NA  6  NA  6  NA 
Slovenia  22  0  22  0  22  4.5  22  0  22  0 
Spain  31  0  31  0  31  0  31  0  31  0 
United Kingdom  112  3.6  112  0.9  111  12.6  111  9.0  112  5.4 
Total (9 MSs)  218  2.8  218  4.1  217  9.7  217  5.5  204  3.4 
Iceland  3  NA  -  -  -  -  -  -  3  NA 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
– = no data reported. 
NA = not applicable, if fewer than 10 isolates were tested resistance was not calculated. 
1. ECOFFs were used for interpretation. 
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4.11.2. In Gallus gallus 
In 2011, three MSs reported antimicrobial resistance data for isolates of S. Java (Table SAS19). Germany 
and the Netherlands both submitted data on isolates from Gallus gallus and meat from broilers, and Belgium 
reported data on isolates from meat from broilers only. Among isolates from Gallus gallus in both Germany 
and the Netherlands, the reported resistance levels were generally higher than those reported in 2010. Both 
MSs reported very high levels of resistance to ampicillin and, in Germany, resistance to this antimicrobial 
increased from 4 % in 2010 to 61.5 % in 2011, although only a small number of isolates were tested. An 
extremely  high  level  of  resistance  to  sulfonamides  among  isolates  of  S. Java  from  Gallus  gallus  was 
reported  across  the  two  MSs  (73.0 %)  while  resistance  to  tetracyclines  was  fewer  prevalent  (23.8 %). 
Resistance to chloramphenicol was not observed in the Netherlands but reported at a low level in Germany 
(7.7 %), while both MSs reported low levels of resistance to gentamicin (3.2 % overall). 
Both MSs reported very high to extremely high levels of resistance to nalidixic acid and ciprofloxacin, of 
71.4 % to 73.0 % overall. All isolates of S. Java from Gallus gallus reported by Germany were resistant to 
ciprofloxacin.  Cefotaxime  resistance  was  detected  at  a  low  level  in  Germany  (7.7 %),  but  was  found  in 
16.0 % of isolates from the Netherlands. This was twice the proportion reported by the Netherlands in 2010 
(8 %).  
In  general,  both  Germany  and  the  Netherlands  detected  similar  levels  of  resistance  to  the  tested 
antimicrobials among isolates from meat from broilers as in isolates from Gallus gallus. Belgium reported 
extremely high levels of resistance to ampicillin and sulfonamides among isolates of S. Java from meat from 
broilers (91.7 % and 73.3 % respectively), and moderate resistance to tetracyclines (13.3 %). Across the 
three MSs, extremely high levels of resistance to ciprofloxacin (78.2 %) and nalidixic acid (76.4 %) were 
observed among isolates from meat from broilers. Belgium reported no resistance amongst isolates tested to 
chloramphenicol and gentamicin, while the Netherlands reported a low level of resistance to chloramphenicol 
only  (5.0 %).  Moderate  resistance  to  both  antimicrobials  was  reported  by  Germany  in  2011  (15.0 %  for 
chloramphenicol and 10.0 % for gentamicin). 
Cefotaxime resistance was detected at a low level in Germany (5.0 %) and at a moderate level in Belgium 
(13.3 %). A high level of resistance was reported by the Netherlands (35.0 %) which correlates with the 
increase in resistance observed in this country among isolates from Gallus gallus. 
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Table SAS19.  Resistance  (%)  to  ampicillin,  cefotaxime,  chloramphenicol,  ciprofloxacin,  gentamicin,  nalidixic  acid,  sulfonamides  and  tetracyclines 
among Salmonella Java from Gallus gallus and meat from broilers in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
All Gallus gallus 
Germany  13  61.5  13  7.7  13  7.7  13  100  13  7.7  13  92.3  13  69.2  13  15.4 
Netherlands  50  62.0  50  16.0  50  0  50  66.0  50  2.0  50  66.0  50  74.0  50  26.0 
Total (2 MSs)  63  61.9  63  14.3  63  1.6  63  73.0  63  3.2  63  71.4  63  73.0  63  23.8 
Broiler meat 
Belgium  12  91.7  15  13.3  15  0  15  46.7  15  0  15  46.7  15  73.3  15  13.3 
Germany  20  45.0  20  5.0  20  15.0  20  85.0  20  10.0  20  85.0  20  60.0  20  35.0 
Netherlands  20  60.0  20  35.0  20  5.0  20  95.0  20  0  20  90.0  20  80.0  20  40.0 
Total (3 MSs)  52  61.5  55  18.2  55  7.3  55  78.2  55  3.6  55  76.4  55  70.9  55  30.9 
N = number of isolates tested. 
% Res = percentage of resistant isolates.   
Note: Includes data fewer than four countries have reported.  
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4.12. Resistance in S. Dublin  
 
4.12.1. In humans 
In 2011, a total of 192 S. Dublin cases were isolated. This serovar is known to cause disease in cattle. In 
2011,  six  MSs  submitted  data  on  the  antimicrobial  resistance  of  S. Dublin.  Overall,  resistance  to  all 
antimicrobials was notably lower than resistance levels for all non-typhoidal Salmonella isolates, with the 
exception of increased resistance in streptomycin (36.0 %; N=75) and comparable resistance for ampicillin 
(24.6 %; N=57). Over 70 % of all data came from Denmark (Table SAS20), where susceptibility data are 
interpreted by ECOFFs or other more sensitive interpretive criteria. 
4.12.2. In cattle 
Five MSs submitted data concerning antimicrobial resistance in S. Dublin from cattle in 2011, however only 
two of the reporting MSs tested more than 10 isolates (Table SAS21). The Netherlands tested 28 isolates 
and  Germany  tested  13  isolates.  For  both  sulfonamides  and  tetracyclines,  Germany  reported  23.1 % 
resistance and the Netherlands reported 3.6 % resistance resulting in a low overall level of 7.1 % resistance. 
Germany also reported 23.1 % resistance to chloramphenicol, but the Netherlands reported no resistance, 
so the overall level was lower, at 5.4 %. Both countries reported a low occurrence of resistance to ampicillin, 
of 7.7 % in Germany and 3.6 % in the Netherlands. Thus, the overall level of resistance was 3.6 %. None of 
the MSs reporting fewer than 10 isolates detected any resistance to the antimicrobials tested. In addition, 
neither  Germany  or  the  Netherlands  reported  any  resistance  to  cefotaxime,  ciprofloxacin,  gentamicin  or 
nalidixic acid. 
 
S. Dublin is a common serovar in cattle. In 2010, there were 1,868 reports from cattle in the EU, which 
was an increase relative to the 1,339 reports in 2009 (EFSA and ECDC, 2012). This made S. Dublin the 
most  common  serovar  in  cattle,  responsible  for  44.3 %  of  bovine  Salmonella  reports.  In  addition, 
S. Dublin was the second most common serovar in bovine meat, responsible for 18.1 % of Salmonella 
isolations (EFSA and ECDC, 2012). Human S. Dublin outbreaks have previously been associated with 
infected cows' milk cheese (Maguire et al., 1992; Vaillant et al., 1996). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Table SAS20.  Antimicrobial resistance in Salmonella Dublin from humans per country in 2011, using clinical breakpoints, with some exceptions
1 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  1  NA  1  NA  1  NA  1  NA  1  NA  1  NA 
Denmark
1  41  29.3  41  0  41  0  41  7.3  41  0  41  0 
Germany  3  NA  3  NA  -  -  3  NA  3  NA  3  NA 
Ireland  2  NA  2  NA  2  NA  2  NA  2  NA  2  NA 
Italy  1  NA  1  NA  -  -  1  NA  1  NA  -  - 
Netherlands
1  7  NA  7  NA  7  NA  7  NA  7  NA  -  - 
United Kingdom  2  NA  22  0  21  0  24  8.3  23  0  21  0 
Total (7 MSs)  57  24.6  77  0  72  1.4  79  7.6  78  1.3  68  0 
 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  1  NA  1  NA  1  NA  1  NA  1  NA 
Denmark
1  41  4.9  41  58.5  41  2.4  41  31.7  40  0 
Germany  3  NA  3  NA  -  -  -  -  3  NA 
Ireland  2  NA  2  NA  2  NA  2  NA  2  NA 
Italy  -  -  -  -  -  -  1  NA  1  NA 
Netherlands
1  7  NA  7  NA  7  NA  7  NA  -  - 
United Kingdom  22  9.1  21  0  21  4.8  21  0  24  0 
Total (7 MSs)  76  6.6  75  36.0  72  4.2  73  17.8  71  0 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
– = no data reported. 
NA = not applicable; if fewer than 10 isolates were tested, resistance was not calculated. 
1. ECOFFs were used for interpretation. 
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Table SAS21.  Resistance  (%)  to  ampicillin,  cefotaxime,  chloramphenicol,  ciprofloxacin,  gentamicin,  nalidixic  acid,  sulfonamides  and  tetracyclines 
among Salmonella Dublin from cattle in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Estonia  5  0  5  0  5  0  5  0  5  0  5  0  5  0  5  0 
Germany  13  7.7  13  0  13  23.1  13  0  13  0  13  0  13  23.1  13  23.1 
Ireland  5  0  5  0  5  0  5  0  5  0  5  0  5  0  5  0 
Netherlands  28  3.6  28  0  28  0  28  0  28  0  28  0  28  3.6  28  3.6 
Sweden  5  0  5  0  5  0  5  0  5  0  5  0  5  0  5  0 
Total (5 MSs)  56  3.6  56  0  56  5.4  56  0  56  0  56  0  56  7.1  56  7.1 
N = number of isolates tested. 
% Res = percentage of resistant isolates  . 
Note: Includes data where fewer than 10 isolates have been tested. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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S. STANLEY 
Salmonella enterica serovar Stanley (S. Stanley) is commonly associated with human salmonellosis in 
south-east Asia, and thus human cases within the EU are usually associated with a history of travel to 
this part of the world. A multi-national outbreak of human infection with nalidixic acid-resistant S. Stanley 
occurred in 2012 with almost 700 human cases with an indistinguishable strain reported from ten Member 
States (Austria, Belgium, the Czech Republic, Germany, Greece, Hungary, Italy, Slovakia, Sweden and 
the United Kingdom) (ECDC, 2013). Previously, reports of S. Stanley in food and animals in the EU have 
been rare. In 2011, 311 S. Stanley isolations were reported by EU MSs, Norway and Switzerland from 
turkey  fattening  flocks, turkey  breeding  flocks  and  turkey  meat,  broiler  flocks,  Gallus gallus  breeding 
flocks, broiler meat, pigs, and other poultry and hedgehogs (ECDC and EFSA, 2013). 
Only  two  MSs  reported  antimicrobial  resistance  data  for  S. Stanley  from  animals  or  food  in  2011. 
Hungary  tested  a  single  isolate  from  Gallus  gallus  and  found  it  to  be  resistant  to  ciprofloxacin  and 
nalidixic acid. It also tested 47 isolates from turkeys and reported low to moderate levels of resistance to 
sulfonamides  (8.5 %)  and  tetracyclines  (14.9 %),  high  levels  of  resistance  to  ampicillin  (25.5 %)  and 
gentamicin (21.3 %), and extremely high levels of resistance to ciprofloxacin (97.9 %) and nalidixic acid 
(100 %). Austria tested four isolates from turkeys and found all of the isolates to be resistant to both 
ciprofloxacin and nalidixic acid. A joint ECDC/EFSA report (ECDC and EFSA, 2012) and a recent update 
(ECDC, 2013) concludes that the turkey production chain is strongly implicated as the source of the on-
going outbreak of human infection, although a contribution from other food and animal sources cannot be 
ruled out. 
RESISTANCE IN S. SAINTPAUL FROM TURKEYS 
Salmonella Saintpaul is associated with turkeys, food products and human salmonellosis (Beutlich et al., 
2010).  A  baseline  survey  on  the  prevalence  of  Salmonella  in  turkey  flocks  carried  out  in  2006-2007 
identified Salmonella Saintpaul as the fourth most frequently reported serovar in turkeys (EFSA, 2008b). 
Studies have demonstrated that isolates from turkeys can display resistance to ampicillin, streptomycin, 
sulfonamides, nalidixic acid, ciprofloxacin and gentamicin (Beutlich et al., 2010).  
In  2011,  three  MSs  submitted  quantitative  MIC  data  on  antimicrobial  resistance  among  isolates  of 
S. Saintpaul  from  turkey  meat  and  six  MSs  submitted  data  on  isolates  from  turkeys.  Among  the  39 
isolates  from  meat,  a  high  or  very  high  or  extremely  high  level  of  resistance  to  ampicillin  (59.0 %), 
ciprofloxacin (71.8 %), nalidixic acid (69.2 %), sulfonamides (61.1 %) and tetracyclines (41.0 %) was 
observed. There was also a moderate level of resistance to gentamicin (15.4 %) but only low resistance 
to cefotaxime (5.1 %) and chloramphenicol (2.6 %). Regarding turkeys, sensitivity data were reported for 
a total of 58 isolates; however, Hungary submitted the data for 35 (60 %) of these isolates whilst two 
other MSs submitted data concerning only a single isolate of S. Saintpaul. Similarly to the isolates from 
meat, there was a high or very high or extremely high level of resistance against ampicillin (32.8 %), 
ciprofloxacin (84.5 %), nalidixic acid (79.3 %), sulfonamides (32.8 %) and tetracyclines (32.8 %). There 
was low resistance to chloramphenicol (3.4 %) and gentamicin (8.6 %), and no resistance was observed 
against cefotaxime among the tested isolates. 
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S. POONA 
Salmonella enterica serovar Poona (S. Poona) was the eighth most common Salmonella serovar isolated 
in Europe in 2011 with 548 cases (EFSA and ECDC, 2013). Data on the antimicrobial resistance of 
S. Poona isolates were submitted by seven MSs for 2011, but over 75 % of all isolates reported were 
from Spain. Overall resistance levels to all antimicrobials were low to very low. 
S. GOLDCOAST 
Salmonella  enterica  serovar Goldcoast  (S. Goldcoast)  was  first  isolated  in  1953  and  has  since  been 
responsible  for  a  number  of  outbreaks  of  salmonellosis,  including  outbreaks  in  the  United  Kingdom 
(Threlfall et al., 1986), Germany, where an outbreak in 2001 was thought to be caused by consumption of 
raw fermented sausage (Bremer et al., 2004) and internationally, in tourists returning from Majorca (HPA, 
2005). S. Goldcoast was among the 10 most commonly isolated serovars from pig production holdings in 
the EU in 2008 and from cattle in the EU in 2009 (EFSA and ECDC, 2011), although it was poorly 
represented amongst the serotypes tested by MSs in 2011 and included in this report. 
In 2011, only Hungary reported quantitative MIC data on the antimicrobial resistance of S. Goldcoast, 
reporting on a single isolate from pigs. This isolate expressed resistance to ampicillin, chloramphenicol, 
sulfonamides and tetracyclines. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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4.13. Discussion 
The resistance shown by a number of different individual Salmonella serovars has been included in this 
report  and  the  findings  are  discussed  below.  The  serovars  presented  were  selected  based  upon  their 
importance to human health as reported in the last two European Summary Reports on the Trends and 
Sources of Zoonoses, Zoonotic agents and Food-borne Outbreaks (EFSA and ECDC, 2012 and 2013), or on 
their predominance within a particular species (e.g. S. Dublin in cattle).  
For  the  year  2011,  a  limited  number  of  MSs  are  now  providing  isolate-based  data,  i.e.  data  where  the 
susceptibility result for each antimicrobial can be linked back to an individual isolate. This will allow analysis 
and investigation of the patterns of multi-resistance, which can also be related to the serovar of Salmonella 
involved. Many of the findings for the analysis at serovar level accurately reflect phenotypic resistance traits 
previously reported in the scientific literature, for example in S. Infantis and monophasic S. Typhimurium 
(Nógrády et al., 2007; Hopkins et al., 2010). 
The  continued  emergence  of  monophasic  S.  Typhimurium  strains,  such  as  S. 1,4,[5],12:i:-,  that  are 
resistant to ampicillin, streptomycin, sulfonamides and tetracyclines is evident from the data reported on 
isolates from pigs and pig meat in 2011. The four typical resistances carried by the monophasic strains of 
S. Typhimurium are located on a resistance island and appear to be rather frequently deleted, accounting for 
the rather variable occurrence of resistance to all four antimicrobials (ampicillin, streptomycin, sulfonamides 
and tetracyclines) observed in these isolates (Hopkins et al., 2010). 
There was notably higher resistance to ciprofloxacin, nalidixic acid, sulfonamides and tetracyclines in human 
S. Infantis  isolates  when  compared  with  all  non-typhoidal  Salmonella  isolates,  a  pattern  that  also  was 
observed in Gallus gallus. However, prevalence of S. Infantis in Gallus gallus at the EU level was rare in 
breeding flocks to low in laying hen and broiler flocks. The most common resistances observed in S. Infantis 
from broilers were to sulfonamides, tetracyclines and ciprofloxacin/nalidixic acid. The molecular basis of the 
resistance is unknown for these isolates, though qnrS genes have been reported in S. Infantis (Veldman et 
al., 2011). S. Infantis isolates resistant to streptomycin, sulfonamides, tetracyclines and nalidixic acid have 
been described in Hungary in broiler chickens, where their numbers, compared with the numbers of other 
serotypes have proportionately increased in recent years (Nógrády et al., 2007). An interesting feature in the 
EUSR  is  that  isolates  from  Central  Europe  (Austria,  Hungary  and  Slovakia)  tended  to  share  a  similar 
resistance  profile,  whereas  isolates  from  the  Netherlands  and  Spain  had  a  different  profile,  perhaps 
suggesting the involvement of different regional clones. Recent work in which S. Infantis isolates from nine 
European countries were examined (Nógrády et al., 2012) has suggested that there are two large related 
clusters  of  S. Infantis  in  broilers,  one  which  is  largely  susceptible  and  one  which  shows  resistance  to 
streptomycin, sulfonamides, tetracyclines and nalidixic acid and which was detected in various European 
countries. Isolates from Austria and Poland were found to be closely related to the dominant clone present in 
Hungary. 
S. Virchow is a Salmonella serovar in which ESBLs have been detected, including TEM-52, CTX-M-2 from 
poultry in the Netherlands (Hasman et al. 2005) and CTX-M-9 from poultry in France (Weill et al. 2004). It is 
therefore  of  interest  that  resistance  to  cefotaxime  was  not  detected  in  isolates  of  this  serovar  in  the 
monitoring of Gallus gallus performed in 2011. The numbers of isolates reported from Gallus gallus by some 
MSs  were  low.  In some  MSs  (Poland  and  Spain) a  high  proportion  of isolates  from  Gallus  gallus were 
resistant to ciprofloxacin. Bertrand et al. (2006) describe a clone of S. Virchow affecting man and poultry in 
Belgium over the period 2000-2003, which showed reduced susceptibility to ciprofloxacin and resistance to 
tetracyclines and trimethoprim/sulfonamides and carried the ESBL CTX-M-2. In a recent study of human 
S. Virchow isolates in Switzerland (Bonalli et al., 2011) nalidixic acid resistance/reduced susceptibility to 
ciprofloxacin was noted in a particular PFGE cluster of isolates, which were also commonly resistant to 
tetracyclines, trimethoprim and sulfonamides. The monitoring appears to highlight a further permutation in 
that isolates have been detected with nalidixic acid resistance/reduced susceptibility to ciprofloxacin, but 
without  resistance  to  tetracyclines  or,  in  many  cases,  sulfonamides.  Salmonella  Hadar  isolates  from 
Gallus gallus  (mainly  from  broilers)  were  consistently  resistant  to  nalidixic  acid  and  ciprofloxacin  and 
commonly also resistant to tetracyclines and ampicillin. 
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S. Hadar resistant to nalidixic acid has previously been reported from Germany, where the percentage of 
Salmonella isolates from poultry resistant to nalidixic acid rose from 0.3 % in 1989 to 14.4 % in 1994 and 
most  of  these  nalidixic  acid  resistant  isolates  were  S. Hadar  (Malorny  et  al.,  1999).  Aubry-Damon  and 
Courvalin (1999) commented that fluoroquinolone resistance was not observed in S. Hadar before 1987, 
prior to the introduction of ciprofloxacin and enrofloxacin into human and veterinary medicine respectively. 
An outbreak of S. Hadar in Spain associated with the consumption of pre-cooked chicken occurred in 2005 
and isolates were resistant to ampicillin, cephalothin, streptomycin, nalidixic acid and tetracycline (Lenglet, 
2005). 
Among the specific serovars of public health significance, S. Kentucky isolates from humans exhibited a 
very high or extremely high resistance to all tested antimicrobials, when compared with all non-typhoidal 
Salmonella isolates, except for cefotaxime. This could reflect the clonal spread of S. Kentucky in humans but 
also in animals, e.g. turkeys, in Europe.  
Most isolates of S. Agona were susceptible to the panel of antimicrobials tested; a proportion of isolates 
from  France  originating  from  turkeys,  showed  resistance  to  ampicillin,  chloramphenicol,  sulfonamides  or 
tetracyclines. Isolate-level data are required to determine whether individual isolates were resistant to all of 
these compounds. Salmonella genomic island 1 (SGI1) is an antimicrobial resistance gene cluster carried by 
S. Typhimurium DT104, which has also been detected in certain other serotypes, notably S. Agona, S. Java 
and  S. Newport  (Velge  et  al.,  2005)  and  which  confers  resistance  to  ampicillin,  chloramphenicol, 
streptomycin, sulfonamides and tetracyclines. There are at least two other variant SGI1 clusters described in 
S. Agona (Velge et al., 2005), one of which carries only the gene conferring resistance to ampicillin and it is 
interesting  to  note  that  isolates  form  some  MSs  showed  resistance  only  to  ampicillin,  amongst  those 
antimicrobials tested. 
Although S. Java causes relatively few human infections, the occurrence of resistance to cefotaxime is likely 
to have treatment implications, since this antimicrobial, as well as ciprofloxacin, may be used as the first-line 
treatment for human salmonellosis, where this is necessary. 
S. Dublin remained susceptible to the majority of antimicrobials in reporting MSs in 2011. 
Some  serovars  in  which  third-generation  cephalosporin  resistance  has  previously  been  detected,  for 
example S. Virchow in poultry from Belgium and France in 2000–2003 (Bertrand et al., 2006) do not show 
cefotaxime resistance in the current EFSA monitoring programme. Analysis of detailed national reports and 
case  studies  may  help  to  determine  whether  these  resistant  organisms  are  no  longer  present  in  food-
producing  animal  populations  or  are  present  but  occur  at  a  frequency  below  the  limits  of  currently 
recommended detection procedures. Clearly, the monitoring programme is capable of detecting new and 
emerging organisms (S. Kentucky with ciprofloxacin resistance and S. Stanley with nalidixic acid resistance 
are good examples), but statistical considerations indicate that resistant organisms occurring at a very low 
prevalence of between 1 % and 2 % might not be detected when following the recommendations of sampling 
and testing 170 isolates. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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5. ANTIMICROBIAL RESISTANCE IN CAMPYLOBACTER 
5.1. Introduction 
The Campylobacter species most commonly associated with human infection are C. jejuni followed by C. coli 
and C. lari, but other species are also known to cause infections in humans. The infective dose of these 
bacteria is generally low. 
The incubation period in humans ranges from two to five days. Patients may experience mild to severe 
symptoms, commonly including watery, sometimes bloody, diarrhoea, abdominal pain, fever, headache and 
nausea. Infections are usually self-limiting and last only a few days; treatment with antimicrobials is therefore 
usually not required. Extra-intestinal infections, invasive infections or post-infection complications such as 
reactive arthritis and neurological disorders can occur, but these are infrequent. C. jejuni is a recognised 
antecedent cause of Guillain–Barré syndrome, a form of paralysis that can sometimes result in dysfunction 
of the respiratory and neurological systems and can even be fatal. 
Thermotolerant Campylobacter species are widespread in nature. The primary reservoirs are the alimentary 
tract  of  birds  and  mammals  including  food-producing  animals  (poultry,  cattle,  pigs  and  sheep). 
Campylobacter species have been isolated from pet animals, including cats and dogs, from wild birds, from 
water and from various environmental samples. Clinical disease resulting from infection with thermotolerant 
Campylobacter species is rare in animals. 
Campylobacter can readily contaminate various food-stuffs including meat, raw milk and dairy products and 
less frequently fish and fish products, mussels and fresh vegetables. Considering sporadic human cases, 
contact with live poultry, consumption  of poultry meat, drinking water from untreated water sources and 
contact with pets and other animals have been identified as significant and major sources of infection. Raw 
milk and drinking water contaminated with Campylobacter have caused large outbreaks. 
Campylobacteriosis continues to be the most commonly reported zoonosis in humans in the EU since 2005. 
In  2011,  the  number  of  notified  cases  of  thermotolerant  Campylobacter  in  the  EU  increased  by  2.3 % 
compared with 2010. The EU notification rate of confirmed cases of human campylobacteriosis shows a 
statistically significant increasing trend in the last four years, 2008–2011 (EFSA and ECDC, 2013). In 2011, 
fresh broiler and other poultry meat were again the foodstuffs in which Campylobacter was most frequently 
reported. Overall, more than one-third of the samples were reported positive, even though there were large 
differences between the MSs (EFSA and ECDC, 2013). As in previous years, most MSs reported high to 
extremely high prevalence of Campylobacter in broiler flocks (EFSA and ECDC, 2013). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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5.2. Overview of reported data in humans, animals and food 
Thirteen MSs and Iceland provided data for 2011 from Campylobacter isolates from human cases. These 
countries reported qualitative data, i.e. interpreted AST results for tested isolates (S, I or R), mainly derived 
from diffusion methods, but no MIC values or inhibition zone diameters. 
In  2011,  17  MSs  and  two  non-MSs  (Norway  and  Switzerland)  reported  quantitative  dilution  data  on 
antimicrobial resistance in Campylobacter isolates from animals and food. Antimicrobial susceptibility testing 
was  carried  out  only  for  C. jejuni  and  C. coli,  all  other  Campylobacter  species  were  excluded  from  the 
monitoring programme of antimicrobial resistance in Campylobacter. Twelve MSs reported data where no 
method was specified.  
Table CA1 presents an overview of the countries reporting antimicrobial resistance data on Campylobacter 
spp. from humans and various animal and food categories in 2011. 
Table CA1.  Overview  of  countries  reporting  antimicrobial  resistance  data  using  MIC  and  disc 
inhibition zones on Campylobacter coli and Campylobacter jejuni from humans and various animal 
and food categories in 2011 
Bacterial 
species  Method  Origin  Total number of 
MSs reporting  Countries 
C. coli 
Diffusion 
Human  8  MSs: AT, EE, FR, IT, LT
4, LU, RO, SI 
Gallus gallus (fowl)  2  MSs: FR
1, SK
2 
Pigs  2  MSs: FR
1, SK
2 
Meat from broilers (Gallus gallus)  3  MSs: ES
3, LU
1, PL
1 
Dilution 
Human  5  MSs: EE, ES, SK
4, SI, UK 
Gallus gallus (fowl)  10 
MSs: AT, CZ, DE, ES, FI, FR, HU, IE, 
IT, NL 
Non-MS: CH 
Turkeys  1  MS: NL 
Pigs  6 
MSs: DK, ES, FR, HU, NL, SE 
Non-MS: CH 
Cattle (bovine animals)  4  MSs: AT, ES, IT, NL 
Meat from broilers (Gallus gallus)  10  MSs: AT, BE, DE, EE, HU, IT, NL, 
PL, PT, RO 
Meat from turkey  4  MSs: HU, NL, PL, RO 
Meat from pig  3  MSs: BE, DE, PL 
Meat from bovine animals  1  MS: PL 
C. jejuni 
Diffusion 
Human  8  MSs: AT, EE, FR, IT, LT
4, LU, RO, SI 
Gallus gallus (fowl)  2  MSs: FR
1, SI
2 
Pigs  1  MS: SK
2 
Cattle (bovine animals)  2  MSs: LU
3, SK
2 
Meat from broilers (Gallus gallus)  4  MSs: ES
3, LU
1, PL
1, SI
2 
Meat from pig  1  MS: BE
2 
Dilution 
Human  5  MSs: EE, ES, SK
4, SI, UK 
Gallus gallus (fowl)  11 
MSs: AT, CZ, DE, DK, ES, FI, FR, 
HU, IE, IT, NL 
Non-MSs: CH, NO 
Turkeys  1  MS: NL 
Pigs  3  MSs: HU, IT, NL 
Cattle (bovine animals)  5  MSs: AT, DK, ES, IT, NL 
Meat from broilers (Gallus gallus)  11  MSs: AT, BE, DE, DK, EE, HU, IT, 
NL, PL, PT, RO 
Meat from turkey  3  MSs: HU, NL, PL 
Meat from pig  1  MS: PL 
Meat from bovine animals  1  MS: PL 
1. These data were submitted with no test method specified and this information could not be obtained from the National Zoonoses 
Reports. 
2. These data were submitted with the test method listed as dilution but no MIC distribution data were supplied. 
3. These data were submitted with no test method specified but are believed to have been tested by disc diffusion based on information 
in the National Zoonoses Report. 
4. Clinical breakpoints shown are from the 2010 report; clinical breakpoints for 2011 were not reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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5.3. Antimicrobial resistance in Campylobacter isolates from humans 
METHODS  AND  INTERPRETATIVE  THRESHOLDS  OF  RESISTANCE  IN  CAMPYLOBACTER  IN 
HUMANS 
The method of testing for antimicrobial susceptibility varied between countries. Disc diffusion was the 
most common method, but often a combination of disc diffusion and dilution was used, depending on the 
reason for the testing. In several countries, the reference laboratories typed only a fraction of the isolates. 
The remaining isolates were typed by hospitals or local laboratories and the methods used by these are 
not reported. The guidelines used for the methodology and interpretation of antimicrobial susceptibility 
testing for Campylobacter differed between countries and also within countries for different antimicrobials, 
but were more harmonised in 2011 than in 2010 (for detailed information, see Materials and methods, 
Table MM2). The guidelines used by several countries were from the CLSI, EUCAST and the French 
Society for Microbiology (CA-SFM).  
Of the five  antimicrobials  tested  in  both  human  and  animal/food  isolates,  resistance according  to  the 
EUCAST  clinical  breakpoints  and  ECOFFS  were  at  the  same  MIC  value  or  only  differing  by  one 
concentration step for ciprofloxacin, erythromycin and tetracycline, while no EUCAST clinical breakpoints 
were available for gentamicin and nalidixic acid. The CA-SFM breakpoints differed from the ECOFFS by 
two concentration steps for tetracycline, the combination of C. coli/erythromycin and the combination of C. 
jejuni/gentamicin. In all other cases the breakpoints for CA-SFM and the ECOFFs were at the same MIC 
value or only differing by one concentration step. The level of resistance determined by CLSI breakpoints 
and  ECOFFS  were  at  the  same  MIC  value  or  only  differing  by  one  concentration  step  except  for 
tetracycline and the combination of C. jejuni/erythromycin where there was a two step difference. CLSI 
clinical breakpoints were not available for gentamicin or nalidixic acid (Figure CA1). Due to the variety of 
breakpoints used under each set of guidelines, results should be interpreted with caution in the case of 
antimicrobials  where  there  are  major  differences  in  the  interpretive  criteria  and  direct  comparisons 
between countries should be avoided.  
Figure CA1.  Comparison  of  clinical  breakpoints  and  epidemiological  cut-off  values  used  to 
interpret MIC data reported for Campylobacter spp. from humans, animals or food 
 
Note: CLSI from 2011, EUCAST from 2011, CASFM from 2010, EUCAST ECOFFS as utilised by EFSA in 2011. 
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5.3.1. Antimicrobial resistance in Campylobacter spp. in humans 
Thirteen MSs and Iceland submitted 2011 data on the antimicrobial susceptibility of Campylobacter spp. 
isolates from human clinical cases to ECDC. Twelve MSs and Iceland reported susceptibility results for more 
than 20 isolates, which was the limit set for presenting the level of resistance. One MS (Romania), reported 
susceptibility results for fewer than 20 isolates and was included only in the analysis totals. 
A large variation was observed among the reporting countries with regard to the number of antimicrobials 
tested,  ranging  from  six  countries  testing  for  amoxicillin  to  all  13  countries  testing  for  ciprofloxacin 
(Table CA2).  This  most  likely  reflects  the  variation  in  the  clinical  importance  of  the  antimicrobials. 
Fluoroquinolone antibiotics, such as ciprofloxacin, are also being increasingly used in many countries in the 
treatment  of  severe  campylobacteriosis  while  the  macrolide  substance  erythromycin  remains  the  most 
commonly used antimicrobial for this purpose. The antibiotic for which the greatest number of Campylobacter 
spp. isolates were tested for susceptibility was erythromycin, at 34,888, representing 15.8 % of the total 
number of confirmed cases of campylobacteriosis reported in 25 countries in EU (N=220,209) (EFSA and 
ECDC, 2013). 
The highest frequency of resistance in all Campylobacter spp. isolates tested was observed for nalidixic acid 
(47.8 %;  N=21,240)  and  ciprofloxacin  (44.4 %;  N=34,395)  followed  by  ampicillin  (35.3 %;  N=7,583)  and 
tetracyclines (30.5 %; N=4,722) (Table CA2). Campylobacter jejuni and C. coli were the most commonly 
reported  Campylobacter  spp.  in  reporting  MSs  in  2011,  accounting  for,  respectively,  81,975  and  5,623 
reported  human  cases.  Results  for  antimicrobial  resistance  are  presented  separately  for  these  two 
Campylobacter species. 
Levels of multi-drug resistance to six antimicrobials among C. jejuni and C. coli isolates from human are also 
presented.  The  six  antimicrobials  were  amoxicillin,  ampicillin,  ciprofloxacin/nalidixic  acid,  erythromycin, 
gentamicin and tetracyclines. Of these, amoxicillin and ampicillin are not on the list of antimicrobials tested 
for in food and animal isolates. Multi-drug resistance is defined as non-susceptibility to at least three different 
antimicrobial  classes.  Co-resistance  to  ciprofloxacin  and  erythromycin  was  also  estimated  as  these  two 
antimicrobials are considered the most important for treatment of severe campylobacteriosis (EFSA, 2009d). 
In order to assess whether there were any differences in resistance levels between human Campylobacter 
infections  acquired  within  the  EU/EEA  and  infections  acquired  when  travelling  outside  the  EU/EEA, 
resistance data are presented by region based on most likely country of infection. 
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Table CA2.  Antimicrobial resistance in Campylobacter spp. from humans per country in 2011, using clinical breakpoints 
Country 
Amoxicillin  Ampicillin  Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic Acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  429  0  429  27.0  429  65.7  429  0.9  429  0.5  429  64.8  429  30.3 
Estonia  61  9.8  62  35.5  190  57.4  189  2.1  65  1.5  26  42.3  156  28.8 
France  5,196  0  5,198  31.0  5,196  51.5  5,196  2.6  5,196  0  5,198  53.4  -  - 
Hungary  -  -  -  -  94  75.5  -  -  -  -  -  -  -  - 
Italy  -  -  120  60.0  213  65.7  233  7.7  131  2.3  123  74.8  169  56.8 
Lithuania  -  -  -  -  378  81.2  428  0.5  -  -  -  -  -  - 
Luxembourg  -  -  -  -  684  53.9  684  2.6  -  -  684  54.7  -  - 
Malta  -  -  -  -  202  64.9  204  2.9  -  -  -  -  -  - 
Romania  -  -  -  -  3  NA  3  NA  3  NA  3  NA  3  NA 
Slovakia  -  -  100  15.0  929  20.1  1,030  0.5  11  NA  -  -  1,009  8.1 
Slovenia  790  4.9  997  37.4  997  64.2  997  1.3  997  0.4  790  58.7  996  17.7 
Spain  221  9.0  221  50.7  221  84.6  221  11.3  214  4.2  236  93.6  221  79.2 
United Kingdom  162  14.2  456  77.9  24,859  41.0  25,274  3.9  1,067  0.7  13,751  43.1  1,739  42.2 
Total (13 MSs)  6,859  1.3  7,583  35.3  34,395  44.4  34,888  3.5  8,113  0.4  21,240  47.8  4,722  30.5 
Iceland  -  -  -  -  122  45.9  123  0  -  -  -  -  -  - 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
– = no data reported. 
NA = not applicable; if fewer than 20 isolates were tested, resistance was not calculated. 
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5.3.2. Antimicrobial resistance in C. jejuni in humans 
In 2011, 12 MSs and Iceland reported data on antimicrobial resistance in C. jejuni for ≥20 isolates (ranging 
from six MSs for amoxicillin to all 13 countries for ciprofloxacin (Table CA3)). The highest frequencies of 
resistance in C. jejuni isolates were observed for nalidixic acid (52.7 %; N=6,865) and ciprofloxacin (52.5 %; 
N=8,647) (Table CA3). Erythromycin, or another suitable macrolide, is the first choice drug for the treatment 
of campylobacteriosis in humans (EFSA, 2009d). In 2011, the level of resistance for erythromycin reported in 
humans was low, on average 1.5 % (N=8,808). In the EU, the highest proportions of resistant isolates were 
reported by Italy with 6.3 % (N=189), and Spain, with 4.8 % (N=166) (Table CA3), although in the case of 
Italy a lower breakpoint was applied for resistance to erythromycin (see Table MM2). 
Ciprofloxacin  is  the  second-choice  drug  for  treatment  of  campylobacteriosis  in  humans  (EFSA,  2009d) 
although resistance evolves rapidly. The resistance to ciprofloxacin reported in each country was moderate 
to extremely high ranging from 20.9 % to 87.3 %. The highest levels of resistance, 87.3 % (N=166) and 
83.1 % (N=260), were observed in Spain and Lithuania, respectively (Table CA3). 
Nalidixic acid is normally used as an indicator of ciprofloxacin resistance. Resistance to nalidixic acid and 
ciprofloxacin was comparable and the levels of resistance to nalidixic acid ranged from 45.4 % to 94.9 % 
(Table CA3), although the breakpoints used differed between countries.  
Country-specific trends for erythromycin over the years 2007–2011 are presented in Figure CA3. There were 
few common trends between countries over the years. The exception was a peak in resistance observed in 
2010  in  both  Iceland  (5.5 %;  N=54)  and  Malta  (10.2 %;  N=127).  In  the  years  before  and  after  2010, 
resistance levels in both countries were at, or close to, 0 % (Figure CA2). Some of the fluctuations observed 
over time could be attributed to a low number of isolates being tested in these countries and it is likely that 
the resistance levels will become more stable when the number of isolates tested increases. A possible 
example of this is Estonia, where  the number of isolates tested increased over the five-year period and 
where  the resistance in  C. jejuni  to erythromycin  decreased  from  8.1 %  (N=37)  in  2007  to  0 %  in  2009 
(N=143) and 2010 (N=178) and, in 2011, was at 2.2 % (N=183). 
Country-specific trends in resistance to ciprofloxacin over the years 2007–2011 are presented in Figure CA2. 
There were few noticeable changes in resistance to ciprofloxacin in the reporting countries over this period; 
however, a trend of increasing resistance was observed in Iceland, Italy, Lithuania and Slovenia since 2009 
and  in  Estonia  since  2008.  In  contrast  to  Salmonella,  the  breakpoints  used  for  MIC  determination  for 
ciprofloxacin  for  Campylobacter  differed  less  between  the  countries,  with  a  maximum  of  two  dilutions 
difference. The disc diffusion zones used were also comparable, with the exception of one country (Italy) 
assigning a more sensitive breakpoint for resistance to ciprofloxacin. 
Four MSs, Austria, Estonia, Slovenia and Spain, tested at least 10 isolates for the full range of antimicrobials 
included  in  the  human  data  collection  for  C.  jejuni,  and  these  isolates  were  included  in  the  multi-drug 
resistance analysis. Overall, 18.4 % (N=1,299) of the human C. jejuni isolates were susceptible to all six 
antimicrobials, with particularly low levels of susceptibility reported from Spain (1.2 %; N=161) and Estonia 
(2.2 %; N=45) (Table CA4). Multi-drug resistance was, on average, high in the four MSs (23.2 %; N=1,299; 
country average 31.3 %). There was large variation in the level of multi-resistance between countries ranging 
from 14.8 % (N=393) in Austria to 55.3 % (N=161) in Spain (Table CA4). The proportions of C. jejuni isolates 
susceptible to all or resistant (non-susceptible) to any one up to six antimicrobials by MS are presented in 
Figure CA4. Isolates resistant to up to five antimicrobials were reported from two MSs and isolates resistant 
to up to all six antimicrobials in one MS. Few isolates exhibited co-resistance to both ciprofloxacin and 
erythromycin in the three MSs (1.2 %; N=1,299) (Table CA4).  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table CA3.  Antimicrobial resistance in Campylobacter jejuni from humans per country in 2011, using clinical breakpoints 
Country 
Amoxicillin  Ampicillin  Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic Acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  393  0  393  28.0  393  65.4  393  0.3  393  0.5  393  64.4  393  30.0 
Estonia  58  10.3  59  37.3  183  58.5  183  2.2  62  1.6  23  47.8  150  29.3 
France  4,278  0  4,279  32.1  4,278  51.3  4,278  1.6  4,278  0  4,279  49.4  -  - 
Hungary  -  -  -  -  27  59.3  -  -  -  -  -  -  -  - 
Italy  -  -  91  70.3  162  69.8  189  6.3  104  1.9  103  75.7  136  59.6 
Lithuania  -  -  -  -  260  83.1  296  0.3  -  -  -  -  -  - 
Luxembourg  -  -  -  -  623  51.8  623  0.6  -  -  623  52.5  -  - 
Malta  -  -  -  -  147  69.4  149  0.7  -  -  -  -  -  - 
Slovakia  -  -  74  18.9  868  20.9  962  0.5  4  NA  -  -  937  7.9 
Slovenia  701  5.3  882  39.9  882  67.2  882  1.0  882  0.2  701  58.2  881  18.4 
Spain  166  10.8  166  56.6  166  87.3  166  4.8  161  3.1  175  94.9  166  80.1 
United Kingdom  1  NA  3  NA  658  44.1  687  2.2  6  NA  568  45.4  83  34.9 
Total (12 MSs)  5,597  1.1  5,947  34.2  8,647  52.5  8,808  1.5  5,890  0.2  6,865  52.7  2,746  23.3 
Iceland  -  -  -  -  120  45.8  121  0  -  -  -  -  -  - 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
– = no data reported. 
NA = not applicable; if fewer than 20 isolates were tested, resistance was not calculated. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Figure CA2.  Resistance to ciprofloxacin in C. jejuni in humans in reporting MSs in the EU, 2007-2011, 
using clinical breakpoints 
Direct comparisons between countries should be avoided owing to the use of different interpretative criteria
1 
 
1.  Guidelines  used  for  AST:  Estonia  (CLSI  dilution,  SRGA-M  disc  diffusion),  Lithuania  (BSAC),  Italy  (CLSI),  the  Netherlands 
(unspecified), Slovenia (CLSI dilution, CA-SFM disc diffusion), UK (modified BSAC). See also Table MM2. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure CA3.  Resistance  to  erythromycin  in  C. jejuni  in  humans  in  reporting  MSs  in  the  EU, 
2007-2011, using clinical breakpoints 
Direct  comparisons  between  countries  should  be  avoided  owing  to  the  use  of  different  interpretative 
criteria
1 
 
1.  Guidelines used for AST: Estonia (SRGA-M), Lithuania (BSAC), Italy (CLSI), Malta (CA-SFM), the Netherlands (unspecified), 
Slovenia (CLSI dilution, CA-SFM disc diffusion), UK (CLSI). See also Table MM2. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table CA4.  Complete  susceptibility,  multi-resistance  and  co-resistance  (non-susceptibility)  in 
ciprofloxacin and erythromycin, as determined by clinical breakpoints, in C. jejuni from humans by 
MS, 2011 
Country  Susceptible to all (%)  Multi-resistant (%)  Co-resistant to  
CIP and ERY (%) 
Austria (N=393)  1.2  14.8  0.3 
Estonia (N=45)  2.2  35.6  6.7 
Slovenia (N=700)  17.9  19.7  0.6 
Spain (N=161)  1.2  55.3  5.0 
Total (4 MSs) (N=1,299)  18.4  23.2  1.2 
N = total number of isolates tested for susceptibility against the whole common antimicrobial set for Campylobacter. 
CIP = ciprofloxacin; ERY = erythromycin. 
Susceptible to all = proportion of isolates susceptible to all antimicrobial substances of the ECDC common set for Campylobacter. 
Multi-resistant = proportion of isolates resistant to at least three different antimicrobial substances, belonging to any three antimicrobial 
families from the ECDC common antimicrobial set for Campylobacter. 
Co-resistant to CIP and ERY = proportion of isolates not susceptible to both CIP and ERY. 
 
Figure CA4.  Frequency distribution of completely susceptible isolates and resistant isolates to from 
one to six antimicrobials, as determined by clinical breakpoints, in C. jejuni from humans by MS, 
2011 
 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances for C. jejuni. 
Susceptible = total number of isolates susceptible to all antimicrobial substances of the common set for C. jejuni. 
res1/res6 = total number of isolates resistant to between one and six antimicrobial substances of the common set for C. jejuni. 
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5.3.3. Antimicrobial resistance in C. coli in humans 
The number of reported isolates of C. coli tested for antimicrobial susceptibility in 2011 varied from 152 
tested for tetracyclines to 1,116 tested for erythromycin out of the 5,473 confirmed reported human cases of 
campylobacteriosis due to C. coli in the EU. In 2011, eight MSs reported data on antimicrobial resistance on 
≥20 isolates (ranging from three MSs for tetracyclines to eight MSs for ciprofloxacin (Table CA5)). 
The  highest  percentage  of  resistance  among  C. coli  isolates  was  observed  for  nalidixic  acid  (69.2 %; 
N=1,018) followed by ciprofloxacin (59.6 %; N=1,115) and tetracyclines (48.7 %; N=152) (Table CA5). The 
percentage of resistance to ciprofloxacin was highly correlated with resistance to nalidixic acid in each of the 
six  countries  which  tested  both  antimicrobials.  The  percentage  of  human  C. coli  isolates  resistant  to 
erythromycin was 10.3 % (N=1,116), which was considerably higher than for C. jejuni (1.4 %). The highest 
levels of resistance to erythromycin were reported from Spain (33.3 %; N=51) and Luxembourg (23.3 %; 
N=60), but the number of isolates tested was low in each case (Table CA5).  
Country-specific  trends  in  resistance  to  erythromycin  over  the  years  2007–2011  were  relatively  stable, 
except for a peak observed in the United Kingdom in 2009, when only 3 isolates were tested (Figure CA6). A 
notable trend of decreasing C. coli resistance to erythromycin was observed in Italy, although only a small 
number of isolates were tested (N=19-22). 
There were few similarities in resistance trends for ciprofloxacin between countries over the years 2007–
2011. The trends in resistance to ciprofloxacin during 2007–2011 were less stable among C. coli isolates 
than among C. jejuni isolates across three countries (Italy, Lithuania and the United Kingdom), although this 
may be explained by the small number of C. coli isolates tested. In Slovenia and Spain, the trend was more 
stable  and  was  similar  to  that  for  C. jejuni.  An  increasing  trend  of  resistance  was  observed  in  the 
Netherlands, although data for 2011 were not reported (Figure CA5). 
Three  MSs,  Austria,  Slovenia  and  Spain  tested  at  least  10  isolates  for  the  full  range  of  antimicrobials 
included in the human data collection for C. coli and these isolates were included in the multi-drug resistance 
analysis. Overall, only 13.4 % (N=119) of the human C. coli isolates were susceptible to all six antimicrobials, 
with particularly low levels of susceptibility reported in Spain (4.1 %; N=49) and higher levels of susceptibility 
reported in Austria (25.0 %; N=36) (Table CA6). On average, the level of multi-drug resistance was high 
(26.1 %;  N=119)  (Table  CA6).  The  proportions  of  C.  coli  isolates  susceptible  to  all  or  resistant  (non-
susceptible) to any one up to six antimicrobials by MS are presented in Figure CA7. Isolates resistant to up 
to five antimicrobials were reported from two MSs, however no isolates were found to be resistant to all six 
antimicrobials. The overall level of co-resistance to both ciprofloxacin and erythromycin was medium across 
these three countries (16.0 %; N=119) (Table CA4).  
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Table CA5.  Antimicrobial resistance in Campylobacter coli from humans per country in 2011, using clinical breakpoints 
Country 
Amoxicillin  Ampicillin  Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic Acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  36  0  36  16.7  36  69.4  36  8.3  36  0  36  69.4  36  33.3 
Estonia  1  NA  1  NA  1  NA  -  -  1  NA  1  NA  -  - 
France  759  0  760  27.4  759  57.8  759  7.8  759  0.1  760  68.8  -  - 
Hungary  -  -  -  -  5  NA  -  -  -  -  -  -  -  - 
Italy  -  -  8  NA  18  NA  19  NA  13  NA  11  81.8  18  NA 
Lithuania  -  -  -  -  39  74.4  45  2.2  -  -  -  -  -  - 
Luxembourg  -  -  -  -  60  75.0  60  23.3  -  -  60  76.7  -  - 
Malta  -  -  -  -  40  55.0  40  7.5  -  -  -  -  -  - 
Romania  -  -  -  -  3  NA  3  NA  3  NA  3  NA  3  NA 
Slovenia  34  2.9  42  35.7  42  52.4  42  7.1  42  2.4  34  58.8  42  21.4 
Spain  51  3.9  51  35.3  51  78.4  51  33.3  49  8.2  57  89.5  51  80.4 
United Kingdom  1  NA  -  -  61  47.5  61  14.8  3  NA  56  53.6  2  NA 
Total (12 MSs)  882  0.3  898  27.8  1,115  59.6  1,116  10.3  906  0.9  1,018  69.2  152  48.7 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
– = no data reported. 
NA = not applicable; if fewer than 20 isolates were tested, resistance was not calculated. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Figure CA5.  Resistance to ciprofloxacin in C. coli in humans in reporting MSs in the EU, 2007-2011, 
using clinical breakpoints 
Direct comparisons between countries should be avoided owing to the use of different interpretive criteria
1 
 
1.  Guidelines  used  for  AST:  Estonia  (CLSI  dilution,  SRGA-M  disc  diffusion),  Lithuania  (BSAC),  Italy  (CLSI),  the  Netherlands 
(unspecified), Slovenia (CLSI dilution, CA-SFM disc diffusion), UK (modified BSAC). See also Table MM2. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure CA6.  Resistance to erythromycin in C. coli in humans in reporting MSs in the EU, 2007-2011, 
using clinical breakpoints 
Direct comparisons between countries should be avoided owing to the use of different interpretive criteria
1 
 
1.  Guidelines used for AST: the Netherlands (unspecified), Slovenia (CLSI dilution, CA-SFM disc diffusion). See also Table MM2.EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
 
EFSA Journal 2013;11(5):3196  166 
Table CA6.  Complete  susceptibility,  multi-resistance  and  co-resistance  (non-susceptibility)  in 
ciprofloxacin and erythromycin, as determined by clinical breakpoints, in C. coli from humans by MS, 
2011 
Country  Susceptible to all (%)  Multi-resistant (%)  Co-resistant to  
CIP and ERY (%) 
Austria (N=36)  25.0  8.3  5.6 
Slovenia (N=34)  14.7  11.8  11.8 
Spain (N=49)  4.1  49.0  26.5 
Total (3 MSs) (N=119)  13.4  26.1  16.0 
N = total number of isolates tested for susceptibility against the whole common antimicrobial set for Campylobacter. 
CIP = ciprofloxacin; ERY = erythromycin. 
Susceptible to all = proportion of isolates susceptible to all antimicrobial substances of the ECDC common set for Campylobacter. 
Multi-resistant = proportion of isolates resistant to at least three different antimicrobial substances, belonging to any three antimicrobial 
families from the ECDC common antimicrobial set for Campylobacter. 
Co-resistant to CIP and ERY = proportion of isolates not susceptible to both CIP and ERY. 
 
Figure CA7.  Frequency distribution of C. coli isolates completely susceptible or resistant to one to 
six antimicrobials, as determined by clinical breakpoints, from humans by MS, 2011 
 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances for C. coli. 
Susceptible = total number of isolates susceptible to all antimicrobial substances of the common set for C. coli. 
res1/res6 = total number of isolates resistant to between one and six antimicrobial substances of the common set for C. coli. 
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5.3.4. Antimicrobial resistance in Campylobacter spp. from humans by geographical region 
Travel-associated isolates were more often tested for any antimicrobial resistance than isolates from cases 
reported as domestically acquired (59.4 % vs. 25.0 %). Varying levels of resistance were observed among 
Campylobacter spp. infections acquired from different geographical regions around the world (Table CA7). 
Data on resistance to four antimicrobials (ciprofloxacin, erythromycin, nalidixic acid and tetracyclines) were 
reported for ≥10 isolates from infections acquired in three geographical regions (EU/EEA, Africa and Asia). 
Of the isolates tested for resistance to these antimicrobials, less than 3 % came from geographical regions 
other than the EU/EEA. 
The highest frequency of resistance to all four antimicrobials was observed among isolates that had been 
acquired in Asia, with resistance being highest to nalidixic acid (84.0 %; N=50) and ciprofloxacin (84.4 %; 
N=90).  In  all  three  regions  the  proportion  of  isolates  resistant  to  ciprofloxacin  was  comparable  to  the 
proportion resistant to nalidixic acid. The level of resistance to erythromycin was comparable  in isolates 
acquired in Asia (8.8 %; N=91) and Africa (10.3 %; N=39) but notably lower in isolates from the EU/EEA 
(4.6 %; N=9,423) (Table CA7).  
An insufficient number of isolates from cases acquired in non-EU/EEA European countries, Northern and 
Central America, South America or Oceania were tested to allow these data to be included in the analysis 
(Table CA7).  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table CA7.  Antimicrobial resistance in Campylobacter spp. reported to be acquired within the EU and in other geographical regions in 2011, using 
clinical breakpoints 
Country 
Amoxicillin  Ampicillin  Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic Acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Europe (EU/EEA Countries)  1,280  1.9  1,472  34.2  9,864  46.6  9,423  4.6  1,411  0.6  3,379  49.9  4,499  26.4 
Europe (non-EU/EEA Countries)  2  NA  3  NA  7  NA  7  NA  2  NA  No Observations  3  NA 
Africa  1  NA  2  NA  40  67.5  39  10.3  2  NA  21  57.1  11  54.5 
Asia  4  NA  7  NA  90  84.4  91  8.8  6  NA  50  84.0  15  46.7 
Northern & Central America  No Observations  No Observations  9  NA  9  NA  No Observations  4  NA  No Observations 
South America  No Observations  No Observations  5  NA  5  NA  No Observations  2  NA  1  NA 
Oceania  No Observations  No Observations  7  NA  7  NA  No Observations  1  NA  3  NA 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
NA = not applicable; if fewer than 10 isolates were tested, resistance was not calculated. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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5.4. Antimicrobial resistance in Campylobacter isolates from animals and food  
The total number of Campylobacter isolates from animals and food for which quantitative MIC tests have 
been performed in 2011 by MSs and non-MSs was 36,064. Table CA1 presents the countries reporting on 
Campylobacter resistance, and the animal and food sampling origins, in 2011. Antimicrobials selected by the 
different  MSs  and  non-MSs  for  susceptibility  testing  of  C. jejuni  and  C. coli  are  shown  in  Chapter  11, 
Materials and Methods, Table MM6.  
In  this  chapter,  resistance  to  ciprofloxacin,  erythromycin,  gentamicin,  nalidixic  acid  and  tetracyclines  is 
described in detail. Tables of the occurrence of resistance were generated, and multi-resistance analysis 
was performed, if four or more countries reported quantitative data for a given Campylobacter species and 
sampling origin. In addition, only data relating to 10 or more isolates per country, per sampling origin, per 
year are included in the report. 
Where  the  minimum  criteria  were  met,  temporal  trend  graphs  were  generated,  showing  percentage 
resistance to different antimicrobials among Campylobacter isolates from animals and food over the period 
2005–2011, by year of sampling. Only countries which had reported on four or more years in the 2005–2011 
period were included. In the particular case of quinolones, such as ciprofloxacin and nalidixic acid, mutations 
in the gyrA gene are frequently responsible for quinolone resistance, with or without the additional effect of 
efflux  pumps,  and  this  mechanism  of  resistance  usually  confers  resistance  to  both  quinolones  and 
fluoroquinolones in Campylobacter. Because this is the commonest mechanism of resistance, the level of 
resistance to nalidixic acid and ciprofloxacin is generally similar for a given group of isolates. In the light of 
this known correlation between resistance to one and decreased susceptibility to the other agent, temporal 
trends are illustrated with trellis graphs combining data on these two antimicrobial substances. 
The spatial distributions of ciprofloxacin and erythromycin resistance rates in C. jejuni from Gallus gallus and 
C. coli from pigs are presented. For countries where resistance level figures for 2011 were not available, 
2010 figures were used instead. For cattle, the number of reporting countries was lower than in the case of 
the other animal species monitored and, therefore, no spatial distribution maps were generated. 
Where the minimum criteria for detailed analysis were met, multi-resistance was analysed in the isolate-
based  dataset  of  Campylobacter  isolates  tested  for  the  full  harmonised  set  of  five  antimicrobials 
(ciprofloxacin, erythromycin, gentamicin, streptomycin and tetracyclines) belonging to different classes. Multi-
resistance was defined as non-susceptibility to at least three different antimicrobial classes. The proportions 
of  isolates  susceptible  to  all  and  resistant  (non-susceptible)  to  any  one  up  to  nine  antimicrobials  are 
presented. Co-resistance to ciprofloxacin and erythromycin was also estimated as these two antimicrobials 
are of particular interest in human medicine in the treatment of severe campylobacteriosis. The interpretative 
ECOFFs used to address co-resistance to ciprofloxacin and erythromycin were, for C. jejuni, CIP >1 mg/L 
and ERY >4 mg/L and, for C. coli, CIP >1 mg/L and ERY >16 mg/L. These values may be considered as 
very similar to clinical breakpoints. 
Further information on reported MIC distributions and numbers of C. jejuni and C. coli isolates resistant to 
amoxicillin,  ampicillin  chloramphenicol,  ciprofloxacin,  clarithromycin,  colistin,  erythromycin,  gentamicin, 
imipenem,  nalidixic  acid,  neomycin,  streptomycin,  sulfonamides,  tetracyclines  and  tulathromycin  can  be 
found in the Level 3 tables published on the EFSA website. 
Antimicrobial resistance in Campylobacter isolates from food 
5.4.1.1. Meat from broilers (Gallus gallus) 
In reporting MSs, data on antimicrobial resistance in Campylobacter isolates from meat from broilers were 
derived  from  active  monitoring  programmes  based  on  the  random  collection  of  samples  of  broiler  meat 
performed at the slaughterhouse, at the processing plant or at retail outlets. In Austria every business was 
sampled  once  a  year.  In  Hungary,  samples  were  randomly  collected  at  processing  plants  as  part  of  a 
monitoring  scheme.  In  Poland,  sampling  of  broiler  meat  was  performed  at  processing  plants,  while  in 
Denmark sampling was carried out at wholesale or retail outlets. In Belgium, Campylobacter isolates derived 
from carcasses (neck skin samples) were collected at the slaughterhouse and isolates from fresh meat and 
meat preparations were collected at the processing plant. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Resistance levels among C. jejuni 
In 2011, nine MSs provided quantitative antimicrobial resistance data for C. jejuni isolates from broiler meat 
(Table CA8). For tetracyclines the proportion of resistant isolates for all reporting MSs was high, at 46.9 %. 
Resistance ranged from low in Denmark (9.8 %) to extremely high in Italy (76.9 %). Resistance to gentamicin 
and erythromycin was low, at 1.7 % and 3.1%, respectively. Romania reported the highest level of resistance 
to gentamicin and erythromycin, at 17.3 % and 9.6 %, respectively.  
For all reporting MSs, the proportion of resistance to quinolones was very high (59.2 % for ciprofloxacin and 
56.9 %  for  nalidixic  acid).  For  individual  MSs,  resistance  to  ciprofloxacin  and  nalidixic  acid  ranged  from 
moderate in Denmark (11.5 %) to extremely high in Poland (90.2 % and 89.7 %, respectively).  
Table CA8.  Resistance (%)  to  ciprofloxacin,  erythromycin,  gentamicin,  nalidixic  acid  and 
tetracyclines among Campylobacter jejuni from meat from broilers in MSs reporting MIC data in 2011, 
using harmonised epidemiological cut-off values 
Country 
Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  84  53.6  84  0  84  0  84  50.0  84  23.8 
Belgium  259  36.7  259  7.7  259  1.9  259  39.0  259  49.0 
Denmark  61  11.5  61  0  61  0  61  11.5  61  9.8 
Germany  188  64.9  188  0.5  188  0  188  58.5  188  46.3 
Hungary  33  84.8  33  0  33  6.1  -  -  33  54.5 
Italy  13  76.9  13  0  13  0  13  61.5  13  76.9 
Netherlands  83  63.9  83  3.6  83  0  83  63.9  83  49.4 
Poland  174  90.2  174  0  174  0  174  89.7  174  56.9 
Romania  52  84.6  52  9.6  52  17.3  52  82.7  52  69.2 
Total (9 MSs)  947  59.2  947  3.1  947  1.7  914  56.9  947  46.9 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
Multi-resistance among C. jejuni isolates in meat from broilers 
In 2011, four MSs provided isolate-based data regarding resistance in C. jejuni from meat from broilers. 
Analysis  of  the  multi-resistance  showed  that,  among  the  reporting  MSs,  isolates  exhibiting  complete 
susceptibility accounted for about 27.7 % of isolates in Germany, 40.5 % in Austria and Italy and 86.9 % in 
Denmark. Only Germany detected any multi-resistance, i.e. isolates exhibiting reduced susceptibility to at 
least three different antimicrobial substances of the common set, at a level of 2.7 % (Table CA9). Very few 
isolates were resistant to both ciprofloxacin and erythromycin. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table CA9.  Complete susceptibility, multi-resistance and  index  of  diversity  in  C. jejuni  from  meat 
from broilers in MSs reporting isolate-based data, 2011 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to                          
CIP and ERY 
n  %  n  %  n  % 
Austria (N=84)  34  40.5  0  0  0.199  0  0 
Denmark (N=61)  53  86.9  0  0  0.156  0  0 
Germany (N=188)  52  27.7  5  2.7  0.270  1  0.5 
Italy (N=13)  1  7.7  0  0  0.182  0  0 
N = total number of isolates tested for susceptibility against the whole common antimicrobial set for Campylobacter. 
n = number of isolates per category of complete susceptibility or multiple resistance. 
Susceptible to all = isolate susceptible to all antimicrobial substances of the EFSA common set for Campylobacter. 
Multi-resistant = resistant to at least three different antimicrobial substances, belonging to any three antimicrobial families from the 
common antimicrobial set. 
Index of diversity = see definition in section 11.4.2.1 of Materials and Methods. 
Co-resistant to CIP and ERY = the frequencies and percentages of C. jejuni isolates not susceptible to ciprofloxacin concentrations 
>1 mg/L and erythromycin concentrations >4 mg/L. 
Figure CA8.  Frequency distribution of C. jejuni isolates completely susceptible and resistant to one 
to five antimicrobials, in meat from broilers in MSs reporting isolate-based data, 2011 
 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances for Campylobacter. 
Susceptible = susceptible to all antimicrobial substances of the common set for Campylobacter. 
res1/res5 = resistance to one antimicrobial substance/resistance to five antimicrobial substances of the common set for Campylobacter. 
Resistance levels among C. coli 
Quantitative antimicrobial resistance data for C. coli isolates from broiler meat were provided by eight MSs 
for 2011 (Table CA10). For tetracyclines, resistance was extremely high for the MS group (71.5 %) and 
ranged from very high in Austria (53.2 %) to extremely high in Germany (85.4 %). Resistance to gentamicin 
was low for the MS group, at 1.8 %. The range of resistance observed in MSs varied less for gentamicin, 
from 0 % in four MSs to moderate in Romania (10.2 %).  
Overall, resistance to ciprofloxacin and nalidixic acid was extremely high in the reporting MS group (77.7 % 
and 72.2 %, respectively). Resistance to ciprofloxacin ranged from very high in Austria (55.3 %) to extremely 
high  in  Hungary  (90.2 %).  Similarly,  resistance  to  nalidixic  acid  ranged  from  high  in  Italy  (50.0 %)  to 
extremely high in Germany (81.7 %). For erythromycin, resistance was low at 9.8% for the MS group, and 
resistance ranged in the reporting MSs from very low in Poland (0.6 %) to very high in Italy (50.0 %). 
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Table CA10.  Resistance (%)  to  ciprofloxacin,  erythromycin,  gentamicin,  nalidixic  acid  and 
tetracyclines among Campylobacter coli from meat from broilers in MSs reporting MIC data in 2011, 
using harmonised epidemiological cut-off values 
Country 
Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  47  55.3  47  2.1  47  0  47  55.3  47  53.2 
Belgium  81  63.0  81  11.1  81  1.2  81  51.9  81  72.8 
Germany  82  86.6  82  17.1  82  0  82  81.7  82  85.4 
Hungary  61  90.2  61  3.3  61  3.3  -  -  61  63.9 
Italy  14  71.4  14  50.0  14  0  14  50.0  14  78.6 
Netherlands  42  78.6  42  21.4  42  2.4  42  78.6  42  66.7 
Poland  157  82.2  157  0.6  157  0  157  80.9  157  70.7 
Romania  59  79.7  59  16.9  59  10.2  59  78.0  59  76.3 
Total (8 MSs)  543  77.7  543  9.8  543  1.8  482  72.2  543  71.5 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
Multi-resistance among C. coli isolates in meat from broilers 
As only three MSs reported resistance isolate-based data on 10 or more isolates of C. coli from broiler meat, 
the corresponding multi-resistance analysis is not presented in this report. 
Antimicrobial resistance in Campylobacter isolates from animals 
5.4.1.2. Fowl (Gallus gallus) 
In  this  section,  data  on  antimicrobial  resistance  in  Campylobacter  isolates  from  fowl  (Gallus  gallus)  are 
derived from broilers, with the exception of four isolates reported by Italy.
15 The majority of samples were 
collected at the slaughterhouse, with the exception of Italy, where sampling also took place at farm level. For 
the majority of MSs specifying details of the sampling strategy, sampling was randomised throughout the 
year. In Finland, sampling was more intense over the summer months , which corresponds to the period at 
risk, and in Spain sampling was carried out between May and December. Only one representative sample of 
caecal content per flock/batch, derived from either a unique carcass or a number of carcasses, was gathered 
to  account  for  clustering.  Typically,  given  the  relatively  high  prevalence  of  Campylobacter  in  broilers, 
representative subsets of C. jejuni and C. coli isolates recovered from caecal samples, each representing 
one flock, were randomly selected at the laboratory for susceptibility testing.  
Resistance levels among C. jejuni 
For 2011, quantitative data on  C. jejuni from Gallus gallus were provided by 11 MSs and two non-MSs 
(Table CA11). Tetracycline resistance in the reporting MS group was high, at 40.6 %, ranging from 0 % in 
Finland to extremely high in Spain (87.0 %). For gentamicin, reported resistance was very low (0.9 %) at MS 
group level. Resistance varied slightly for gentamicin among reporting MSs. Only 2 of the 11 reporting MSs 
detected resistance to gentamicin at low levels, Hungary (5.6 %) and Spain (7.3 %). The remaining MSs did 
not detect any C. jejuni isolates from Gallus gallus that were resistant to gentamicin.  
Overall, for both ciprofloxacin and nalidixic acid, very high levels of resistance were reported by the MS 
group (57.2 % and 55.5 %, respectively). For both quinolones resistance varied greatly between MSs, from 
0 %  in  Finland  to  94.5 %  in  Spain.  For  erythromycin,  although  the  resistance  reported  was  low  (1.6 %) 
among the MS group, the levels of resistance to erythromycin varied importantly among reporting MSs. Five 
                                                 
15 Two of the Italian samples are C. coli isolates, one from a laying hen and one of unspecified origin, and two are C. jejuni isolates of an 
unspecified sampling origin. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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of the MSs that submitted data for erythromycin did not detect any resistance, while levels among the six 
remaining MSs ranged from very low in Ireland (0.9 %) to moderate in Italy (20.0 %). 
Table CA11.  Resistance (%)  to  ciprofloxacin,  erythromycin,  gentamicin,  nalidixic  acid  and 
tetracyclines among Campylobacter jejuni from Gallus gallus (mainly broilers
1) in countries reporting 
MIC data in 2011, using harmonised epidemiological cut-off values 
Country 
Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  116  69.0  116  0  116  0  116  60.3  116  17.2 
Czech Republic  57  54.4  57  0  57  0  57  54.4  57  14.0 
Denmark  43  23.3  43  0  43  0  43  23.3  43  18.6 
Finland  40  0  40  0  40  0  40  0  40  0 
France  51  56.9  51  0  51  0  51  60.8  51  66.7 
Germany  59  62.7  59  3.4  59  0  59  57.6  59  50.8 
Hungary  36  86.1  36  5.6  36  5.6  36  83.3  36  38.9 
Ireland  114  40.4  114  0.9  114  0  114  39.5  114  49.1 
Italy  10  60.0  10  20.0  10  0  10  60.0  10  80.0 
Netherlands  104  67.3  104  1.9  104  0  104  68.3  104  51.0 
Spain  55  94.5  55  3.6  55  7.3  55  94.5  54  87.0 
Total (11 MSs)  685  57.2  685  1.6  685  0.9  685  55.5  684  40.6 
Norway  48  4.2  48  0  48  0  48  6.3  48  2.1 
Switzerland  150  40.7  150  5.3  150  1.3  150  42.0  150  20.7 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
1. All data relate to isolates from broilers, with the exception of two isolates reported by Italy. One of these was from a laying hen, and 
for the other the production level was not specified. Both isolates were sensitive to all antimicrobials tested. 
Resistance levels among C. coli 
Quantitative data on C. coli isolates from Gallus gallus were submitted by eight MSs and one non-MS in 
2011 (Table CA12).  
Considering the reporting MS group overall, levels of resistance for tetracyclines were extremely high, at 
74.6 %. Resistance to tetracyclines varied greatly between MSs, from high resistance reported by the Czech 
Republic (25.0 %) to extremely high resistance reported by Spain (98.8 %). Regarding gentamicin, the level 
of resistance observed  at  the level of  the reporting  MS group  overall  was  low  (3.8 %). Six  of the eight 
reporting MSs did not detect any resistance, while the remaining two MSs reported resistance at low (the 
Czech Republic 4.2 %) and moderate (Spain 14.8 %) levels. 
Overall, resistance to ciprofloxacin was higher than resistance to nalidixic acid in the reporting MS group 
(76.6 %  and  70.2 %,  respectively).  This  was  also  the  case  in  2010,  when  resistance  was  84 %  for 
ciprofloxacin and 76 % for nalidixic acid. Resistance to ciprofloxacin ranged from 40.6 % in Ireland to 93.8 % 
in Spain, with the majority of MSs reporting extremely high resistance levels. For nalidixic acid, resistance 
varied between 43.8 % in Ireland and 85.7 % in Hungary, again, with the majority of MSs reporting levels 
that were extremely high. For erythromycin, resistance was moderate in the reporting MS group (15.5 %) 
overall, with levels of resistance ranging from none detected in Hungary (0 %) to high in Germany and Spain 
(32.0 % and 33.3 %, respectively). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table CA12.  Resistance (%)  to  ciprofloxacin,  erythromycin,  gentamicin,  nalidixic  acid  and 
tetracyclines among Campylobacter coli from Gallus gallus (mainly broilers
1) in countries reporting 
MIC data in 2011, using harmonised epidemiological cut-off values 
Country 
Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  48  79.2  48  6.3  48  0  48  79.2  48  62.5 
Czech Republic  24  87.5  24  4.2  24  4.2  24  83.3  24  25.0 
France  79  67.1  79  13.9  79  0  79  51.9  79  93.7 
Germany  25  92.0  25  32.0  25  0  25  80.0  25  80.0 
Hungary  35  85.7  35  0  35  0  35  85.7  35  68.6 
Ireland  32  40.6  32  3.1  32  0  32  43.8  32  40.6 
Netherlands  18  44.4  18  11.1  18  0  18  44.4  18  44.4 
Spain  81  93.8  81  33.3  81  14.8  81  85.2  81  98.8 
Total (8 MSs)  342  76.6  342  15.5  342  3.8  342  70.2  342  74.6 
Switzerland  10  20.0  10  0  10  10.0  10  20.0  10  30.0 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
1. All data relate to isolates from broilers, with the exception of two isolates reported by Italy. For both isolates the production level was 
not specified. One of the unspecified isolates was resistant to ciprofloxacin, nalidixic acid and tetracycline. 
Temporal trends in resistance among C. jejuni 
Figures CA9–CA12 present the observed temporal trends in antimicrobial resistance in C. jejuni isolates from 
Gallus gallus over the period 2005–2011. As in previous years, resistance to tetracyclines, ciprofloxacin and 
nalidixic  acid  varied  greatly  among  reporting  MSs  in  2011  (Figures  CA9  and  CA12).  When  considering 
resistance  to  ciprofloxacin  and  nalidixic  acid,  statistically  significant  increasing  trends  were  observed  in 
Denmark,  France,  Italy,  the  Netherlands,  Spain  and  Switzerland  for  five  or  more  years.  For  Austria,  a 
statistically significant increasing trend was observed for ciprofloxacin alone (Figure CA9). For erythromycin 
levels of resistance remained absent or very low over the period 2005–2011, with the exception of Italy in 
2011,  which  reported  a  moderate  level  of  resistance.  No  statistically  significant  trends  in  erythromycin 
resistance  were  detected  over  the  reporting  period.  With  regards  to  gentamicin,  statistically  significant 
decreasing  trends  were  observed  in  France  and  Germany.  For  tetracyclines,  a  statistically  significant 
increase was seen in Denmark, France, Italy and Spain over the period 2005–2011. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure CA9.  Trends  in  ciprofloxacin  and  nalidixic  acid  resistance  in  Campylobacter  jejuni  from 
Gallus gallus in reporting MSs and non-MSs, 2005–2011, quantitative data 
 
Note: A statistically significant increasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in Denmark (↑), France (↑), Italy (↑), the Netherlands (↑), Spain (↑) and Switzerland (↑) for both ciprofloxacin and nalidixic acid and 
in Austria (↑) for ciprofloxacin.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure CA10.  Trends  in  erythromycin  resistance  in  Campylobacter  jejuni  from  Gallus  gallus  in 
reporting MSs and non-MSs, 2005–2011, quantitative data 
 
Note: No statistically significant trends over five or more years, as tested by a logistic regression model (p ≤0.05), were observed in any 
of the reporting countries. 
Figure CA11.  Trends  in  gentamicin  resistance  in  Campylobacter  jejuni  from  Gallus  gallus  in 
reporting MSs and non-MSs, 2005–2011, quantitative data 
 
Note:  A  statistically  significant  decreasing  trend  over  five  or  more  years,  as  tested  by  a  logistic  regression  model  (p  ≤0.05),  was 
observed in France (↓) and Germany (↓). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure CA12.  Trends  in  tetracycline  resistance  in  Campylobacter  jejuni  from  Gallus  gallus  in 
reporting MSs and non-MSs, 2005–2011, quantitative data 
 
Note: A statistically significant increasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in Denmark (↑), France (↑), Italy (↑) and Spain (↑). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Temporal trends in resistance among C. coli 
Figures CA13–CA16 present observed trends in antimicrobial resistance in C. coli from Gallus gallus. In 
2011, as was the case in previous years, a high degree of variation was observed in levels of resistance to 
ciprofloxacin, nalidixic acid and tetracyclines among reporting MSs.  
For ciprofloxacin and nalidixic acid, statistically significant increasing trends for the last five or more years 
were observed in Austria, France and Spain (Figure CA13). France and Spain also exhibited statistically 
increasing trends in resistance to tetracyclines. For erythromycin and gentamicin, resistance was generally 
lower  over  the  reporting  period  than  for  the  other  antimicrobials  presented.  In  Spain,  resistance  to 
erythromycin and gentamicin increased significantly over the seven years  presented, while a statistically 
significant increase was also seen in France and Switzerland for gentamicin.  
Figure CA13.  Trends  in  ciprofloxacin  and  nalidixic  acid  resistance  in  Campylobacter coli  from 
Gallus gallus in reporting MSs and one non-MS, 2005–2011, quantitative data 
 
Note: A statistically significant increasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in Austria (↑), France (↑) and Spain (↑) for both ciprofloxacin and nalidixic acid. 
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Figure CA14.  Trends  in  erythromycin  resistance  in  Campylobacter  coli  from  Gallus  gallus  in 
reporting MSs and one non-MS, 2005–2011, quantitative data 
 
Note: A statistically significant increasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in Spain (↑). 
Figure CA15.  Trends in gentamicin resistance in Campylobacter coli from Gallus gallus in reporting 
MSs and one non-MS, 2005–2011, quantitative data 
 
Note:  Statistically  significant  increasing  and  decreasing  trends  over  five  or  more  years,  as  tested  by  a  logistic  regression  model 
(p ≤0.05), were observed in France (↓), Spain (↑) and Switzerland (↑). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure CA16.  Trends in tetracycline resistance in Campylobacter coli from Gallus gallus in reporting 
MSs and one non-MS, 2005–2011, quantitative data 
 
Note: A statistically significant increasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in France (↑) and Spain (↑). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
 
EFSA Journal 2013;11(5):3196  181 
Spatial distribution of resistance among C. jejuni 
Figures  CA17  and  CA18  show  the  spatial  distributions  of  ciprofloxacin  and  erythromycin  resistance  in 
C. jejuni from Gallus gallus. For both antimicrobials, overall resistance was lower among the reporting Nordic 
countries than in the rest of the European reporting countries.  
Figure CA17.  Spatial  distribution  of  ciprofloxacin  resistance  among  Campylobacter  jejuni  from 
Gallus gallus in countries reporting MIC data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data have been used instead.  
1.  For Slovenia and Sweden, 2010 data were used. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure CA18.  Spatial  distribution  of  erythromycin  resistance  among  Campylobacter jejuni  from 
Gallus gallus in countries reporting MIC data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data have been used instead.  
1.  For Slovenia and Sweden, 2010 data were used. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Multi-resistance among C. jejuni isolates from broilers 
In 2011, five MSs and two non-MSs reported isolate-based data on resistance in C. jejuni from broilers. 
Among the reporting MSs, complete susceptibility was generally found in more than 20 % of the isolates 
tested, and reached up to 74.4 % in Denmark and 91.7 % in Norway. The only exception was Spain, which 
reported a level of complete susceptibility of 3.8 %. Multi-resistance was not recorded or was detected at low 
levels in most reporting countries, although in Spain 15.1 % of isolates exhibited multi-resistance (reduced 
susceptibility  to  three  or  more  antimicrobial  classes)  (Table  CA13).  The  frequency  distributions  (Figure 
CA19)  showed  that  most  of  the  other  reporting  countries  detected  multi-resistance  to  two  or  three 
antimicrobial classes (Table CA13). Very few isolates were resistant to both ciprofloxacin and erythromycin. 
Table CA13.  Complete susceptibility, multi-resistance and index of diversity in C. jejuni from broilers 
in MSs and non-MSs reporting isolate-based data, 2011 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to  
CIP and ERY 
n  %  n  %    n  % 
Austria (N=116)  33  28.5  0  0  0.172  0  0 
Denmark (N=43)  32  74.4  1  2.3  0.318  0  0 
Germany (N=59)  12  20.3  3  5.1  0.321  2  3.4 
Ireland (N=114)  38  33.3  1  0.9  0.245  1  0.9 
Spain (N=53)  2  3.8  8  15.1  0.388  2  3.8 
Norway (N=48)  44  91.7  0  0  0  NA  NA 
Switzerland (N=150)  71  47.3  6  4.0  0.391  2  1.3 
N = total number of isolates tested for susceptibility against the whole common antimicrobial set for Campylobacter. 
n = number of isolates per category of complete susceptibility or multiple resistance. 
Susceptible to all = isolate susceptible to all antimicrobial substances of the EFSA common set for Campylobacter. 
Multi-resistant = resistant to at least 3 different antimicrobial substances, belonging to any three antimicrobial families from the common 
antimicrobial set. 
Index of diversity = see definition in section 11.4.2.1 of Materials and Methods. 
Co-resistant to CIP and ERY = the frequencies and percentages of C. jejuni isolates not susceptible to ciprofloxacin concentrations 
>1 mg/L and erythromycin concentrations >16 mg/L. 
Figure CA19.  Frequency distribution of C. jejuni isolates completely susceptible and resistant to one 
to five antimicrobials in broilers in MSs and non-MSs reporting isolate-based data, 2011 
  
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances for Campylobacter. 
Susceptible = susceptible to all antimicrobial substances of the common set for Campylobacter. 
res1/res5 = resistance to one antimicrobial substance/resistance to five antimicrobial substances of the common set for Campylobacter. 
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Multi-resistance among C. coli isolates from broilers 
In 2011, four MSs and one non-MS provided isolate-based data regarding resistance in C. coli from broilers. 
Analysis  of  the  multi-resistance  showed  that  there  was  a  large  variation  in  the  levels  of  complete 
susceptibility among the reporting countries. Isolates exhibiting complete susceptibility accounted for 40.6 % 
in Ireland and 50.0 % in Switzerland, but only 6.3 % in Austria, and in Germany and Spain none of the 
isolates  tested  were  completely  susceptible  (Table  CA14).  Multi-resistance  was  low  in  Ireland  (3.1 %), 
moderate in Switzerland and Austria (10.0 % and 12.5 %, respectively) and high in Germany (32.0 %) and 
Spain  (70.5 %).  The  frequency  distributions  (Figure  CA20)  showed  an  important  diversity  between  the 
reporting countries, Germany, Switzerland and Spain reporting isolates displaying reduced susceptibility to 
up to four or five different classes of antimicrobials. In addition, important co-resistance to ciprofloxacin and 
erythromycin was observed in isolates from Germany and Spain. 
Table CA14.  Complete susceptibility, multi-resistance and index of diversity in C. coli from broilers 
in MSs and one non-MS reporting isolate-based data, 2011 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to                          
CIP and ERY 
n  %  n  %  n  % 
Austria (N=48)  3  6.3  6  12.5  0.371  3  6.3 
Germany (N=25)  0  0  8  32.0  0.583  7  28.0 
Ireland (N=32)  13  40.6  1  3.1  0.305  1  3.1 
Spain (N=78)  0  0  55  70.5  0.821  25  32.1 
Switzerland (N=10)  5  50.0  1  10.0  0.480  0  0 
N = total number of isolates tested for susceptibility against the whole common antimicrobial set for Campylobacter. 
n = number of isolates per category of complete susceptibility or multiple resistance. 
Susceptible to all = isolate susceptible to all antimicrobial substances of the EFSA common set for Campylobacter. 
Multi-resistant = resistant to at least three different antimicrobial substances, belonging to any three antimicrobial families from the 
common antimicrobial set. 
Index of diversity = see definition in section 11.4.2.1 of Materials and Methods. 
Co-resistant to CIP and ERY = the frequencies and percentages of C. coli isolates not susceptible to ciprofloxacin concentrations 
>1 mg/L and erythromycin concentrations >16 mg/L. 
Figure CA20.  Frequency distribution of C. coli isolates completely susceptible and resistant to one 
to five antimicrobials, in broilers in MSs and one non-MS reporting isolate-based data, 2011 
 
N = total number of isolates tested for susceptibility against the whole common antimicrobial set for Campylobacter. 
Susceptible = susceptible to all antimicrobial substances of the common set for Campylobacter for Campylobacter. 
res1/res5 = resistance to one antimicrobial substance/resistance to five antimicrobial substances of the common set for Campylobacter. 
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5.4.1.3. Pigs 
In the reporting MSs, antimicrobial resistance monitoring in Campylobacter isolates from pigs was based on 
active monitoring plans based on random sampling of healthy pig carcasses at the slaughterhouse. The 
sampling plan was typically stratified per slaughterhouse, by allocating the number of samples collected per 
slaughterhouse  in  proportion  with  the  annual  throughput  of  the  slaughterhouse.  An  approximately  equal 
distribution of the collected samples over the year enabled the different seasons to be covered. Only one 
representative faecal sample per epidemiological unit (batch/farm), either derived from a unique carcass or 
pooled  from  a  number  of  carcasses,  was  gathered  to  account  for  clustering.  In  the  reporting  MSs, 
antimicrobial resistance monitoring in Campylobacter spp. in pigs focused on C. coli, as this is the more 
prevalent Campylobacter species in pigs. Because of the very low C. jejuni prevalence in pigs, the number of 
samples required to be collected to achieve a sufficient number of C. jejuni isolates would have been too 
large  to  be  really  cost-effective.  In  some  reporting  countries,  representative  subsets  of  C. coli  isolates 
recovered from faecal samples were randomly selected at the laboratory for susceptibility testing, whereas, 
in some others, all C. coli isolates were tested for susceptibility. 
Resistance levels among C. coli 
In 2011, quantitative data were provided by six MSs and one non-MS (Switzerland) for C. coli isolates from 
pigs (Table CA15). 
For the reporting MS group overall, the highest level of resistance was observed for tetracyclines (64.8 %). 
As seen in 2010, the range of resistance reported among the MSs varied greatly in 2011. Sweden reported 
the absence of resistance (0 %) and Denmark reported moderate resistance (14.7 %), while all the other 
reporting MSs recorded extremely high levels of resistance. Regarding gentamicin resistance, the overall 
level within the reporting MS group was low (7.2 %). Four of the six MSs did not detect any resistant isolates, 
while resistance was low in Hungary (7.9 %) but high in Spain (44.4 %). 
For both ciprofloxacin and nalidixic acid, resistance was high in the reporting MS group overall (35.5 % and 
32.8 %,  respectively).  The  spread  of  resistance  reported  among  individual  MSs  was  similar  for  both 
antimicrobials, ranging from a low level of resistance reported by Denmark (6.9 %) to an extremely high level 
of resistance reported by Spain (90.1 %). Erythromycin resistance also varied widely among the reporting 
MS group. Overall, a high level of resistance was reported (24.5 %), with individual levels ranging from no 
resistance reported in Sweden (0 %) to a very high level reported by Spain (63.0 %).  
Table CA15.  Resistance  (%)  to  ciprofloxacin,  erythromycin,  gentamicin,  nalidixic  acid  and 
tetracyclines among Campylobacter coli from pigs
1 in countries reporting MIC data in 2011, using 
harmonised epidemiological cut-off values 
Country 
Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Denmark  102  6.9  102  6.9  102  0  102  6.9  102  14.7 
France  82  46.3  82  45.1  82  0  82  30.5  82  95.1 
Hungary  76  52.6  76  15.8  76  7.9  76  48.7  76  88.2 
Netherlands  156  10.9  156  22.4  156  0  156  10.9  156  86.5 
Spain  81  90.1  81  63.0  81  44.4  81  90.1  81  100 
Sweden  83  37.3  83  0  83  0  83  37.3  83  0 
Total (6 MSs)  580  35.5  580  24.5  580  7.2  580  32.8  580  64.8 
Switzerland  185  41.1  185  7.6  185  1.1  185  41.6  185  30.3 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
1. For Denmark, the Netherlands, Spain and Switzerland, the origin of the C. coli isolates was from fattening pigs. For France and 
Hungary, the production level was not specified.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Temporal trends in resistance among C. coli 
Figures CA21–CA23 show the trends in antimicrobial resistance observed in C. coli from pigs over the period 
2005–2011. For all of the antimicrobials considered, levels of resistance have remained relatively stable 
between 2005 and 2011. For ciprofloxacin and nalidixic acid, a statistically significant increasing trend was 
seen for Spain, while France and Switzerland also reported significantly increasing levels of resistance to 
ciprofloxacin over the reporting period. Levels of erythromycin resistance increased significantly in France 
and  the  Netherlands  and,  for  gentamicin,  resistance  increased  significantly  in  Spain.  When  considering 
tetracyclines, a significantly increasing trend was observed in Denmark and France between 2005 and 2011. 
Figure CA21.  Trends in ciprofloxacin and nalidixic acid resistance in Campylobacter coli from pigs 
in reporting MSs and one non-MS, 2005–2011, quantitative data 
 
Note: A statistically significant increasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in Spain (↑) for both ciprofloxacin and nalidixic acid and in France (↑) and Switzerland (↑) for ciprofloxacin.  
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Figure CA22.  Trends in erythromycin resistance in Campylobacter coli from pigs in reporting MSs 
and one non-MS, 2005–2011, quantitative data 
 
Note: A statistically significant increasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in France (↑) and the Netherlands (↑). 
Figure CA23.  Trends in gentamicin resistance in Campylobacter coli from pigs in reporting MSs and 
one non-MS, 2005–2011, quantitative data 
 
Note: A statistically significant increasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in Spain (↑). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure CA24.  Trends in tetracycline resistance in Campylobacter coli from pigs in reporting MSs and 
one non-MS, 2005–2011, quantitative data 
 
Note: A statistically significant increasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in Denmark (↑) and France (↑). 
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Spatial distribution of resistance among C. coli 
Figures CA25 and CA26 show the spatial distributions of ciprofloxacin and erythromycin resistance in C. coli 
from  pigs.  For  both  erythromycin  and  ciprofloxacin,  the  highest  levels  of  resistance  were  reported  by 
southern countries, while northern countries reported lower levels. 
Figure CA25.  Spatial distribution of ciprofloxacin resistance among Campylobacter coli from pigs in 
countries reporting MIC data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data have been used instead. 
1.  For Finland and Poland, 2010 data were used. 
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Figure CA26.  Spatial distribution of erythromycin resistance among Campylobacter coli from pigs in 
countries reporting MIC data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data have been used instead.  
1.  For Finland and Poland, 2010 data were used. 
Multi-resistance among C. coli isolates from pigs 
The multi-resistance analysis for C. coli in pigs was not presented in this report as fewer than four MSs 
reported multi-resistance isolate-based data on more than 10 isolates from this animal species. 
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5.4.1.4. Cattle (bovine animals) 
In 2011, data on antimicrobial resistance among C. jejuni isolates from cattle include samples collected both 
at  the  slaughterhouse  (Austria,  Denmark  and  Spain)  and  at  farm  level  (Italy  and  the  Netherlands).  
Slaughterhouse  sampling  programmes  were  randomised  over  the  year  and  stratified  by  the  number  of 
slaughtered animals by abattoirs across the MS. Sampling in Italy was carried out by active monitoring on a 
voluntary basis. The sampling was evenly distributed throughout the year or a significant part of the year to 
account for a possible seasonal effect. Only one faecal sample per bovine animal carcass was collected. In 
some reporting countries, representative subsets of Campylobacter isolates recovered from animal samples 
were randomly selected at the laboratory for susceptibility testing, while, in some others, all isolates were 
tested for susceptibility. 
Resistance levels among C. jejuni 
For 2011, five MSs provided quantitative data on C. jejuni isolates from cattle (Table CA16).  
For tetracyclines, the overall level of resistance in the reporting MS group was also high (32.4 %), but the 
range  of  resistance  reported  among  individual  MSs  was  greater  than  was  seen  for  the  quinolones. 
Tetracycline resistance varied from a low level in Denmark (4.2 %) to extremely high in Spain (73.7 %). The 
overall level of resistance to gentamicin in the reporting MS group was very low, at 0.8 %. For gentamicin, 
however,  the  majority  of  MSs  reported  no  resistant  isolates  (0 %),  while  two  MSs  reported  a  very  low 
(Austria, 0.6 %) and a low (Spain, 3.9 %) level of resistance. 
For both ciprofloxacin and nalidixic acid, the overall levels of resistance were high, at 38.8 % and 39.2 %, 
respectively. For both antimicrobials, the range of resistance ranged from moderate in Denmark (20.0 %) to 
very high in Spain (60.5 %). When considering erythromycin, the overall level of resistance in the reporting 
MS group was very low (0.8 %). Most MSs reported low or very low levels resistance to erythromycin. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table CA16.  Resistance (%)  to  ciprofloxacin,  erythromycin,  gentamicin,  nalidixic  acid  and 
tetracyclines among Campylobacter jejuni from cattle
1 in countries reporting MIC data in 2011, using 
harmonised epidemiological cut-off values 
Country 
Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Veal calves (under 1 year) 
Netherlands  67  55.2  67  1.5  67  0  67  56.7  67  79.1 
Young meat production animals (1-2 years) 
Austria  57  29.8  57  0  57  0  57  28.1  57  10.5 
Spain  76  60.5  76  1.3  76  3.9  76  60.5  76  73.7 
Total (2 MSs)  133  47.4  133  0.8  133  2.3  133  46.6  133  46.6 
Adult cattle (over 2 years) 
Austria  109  35.8  109  0.9  109  0.9  109  34.9  109  15.6 
Dairy cows 
Netherlands  41  22.0  41  0  41  0  41  24.4  41  19.5 
Unspecified cattle type 
Denmark  95  20.0  95  0  95  0  95  20.0  95  4.2 
Italy  45  51.1  45  2.2  45  0  45  55.6  45  35.6 
Total (2 MSs)  140  30.0  140  0.7  140  0  140  31.4  140  14.3 
All types of cattle  
Austria  170  33.5  170  0.6  170  0.6  170  32.4  170  13.5 
Denmark  95  20.0  95  0  95  0  95  20.0  95  4.2 
Italy  48  52.1  48  2.1  48  0  48  56.3  48  35.4 
Netherlands  108  42.6  108  0.9  108  0  108  44.4  108  56.5 
Spain  76  60.5  76  1.3  76  3.9  76  60.5  76  73.7 
Total (5 MSs)  497  38.8  497  0.8  497  0.8  497  39.2  497  32.4 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
1. Data presented in this table were derived from a variety of production types. These include adult cattle over 2 years (Austria), meat 
production  animals  (Austria  and  Spain),  veal  calves  (Netherlands),  dairy  cows  (Italy  and  the  Netherlands)  and  production  type 
unspecified (Denmark and Italy).  
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Temporal trends in resistance among C. jejuni 
Figures CA27–CA29 show the temporal trends in resistance for C. jejuni in cattle. As seen in C. coli in pigs, 
levels of resistance for C. jejuni in cattle have remained relatively stable over the 2005–2011 reporting period 
for individual MSs. Resistance to ciprofloxacin, nalidixic acid and tetracyclines is relatively higher than levels 
of  resistance  to  erythromycin  and  gentamicin  for  the  reporting  MSs.  When  considering  trends  in 
ciprofloxacin,  nalidixic  acid  and  gentamicin  resistance,  no  significant  changes  were  observed  over  the 
reporting  period.  For  erythromycin,  a  significantly  decreasing  trend  was  observed  in  Austria  and  the 
Netherlands when tested by a logistic regression model, and for tetracyclines a significantly decreasing trend 
was observed in Austria only. 
Figure CA27.  Trends  in  ciprofloxacin  and  nalidixic  acid  resistance  in  Campylobacter  jejuni  from 
cattle in reporting MSs and one non-MS, 2005–2011, quantitative data 
 
Note: No statistically significant trends over five or more years, as tested by a logistic regression model (p ≤0.05), were observed in any 
of the reporting countries. 
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Figure CA28.  Trends  in  erythromycin  resistance  in  Campylobacter  jejuni  from  cattle  in  reporting 
MSs, 2005–2011, quantitative data 
 
Note:  A  statistically  significant  decreasing  trend  over  five  or  more  years,  as  tested  by  a  logistic  regression  model  (p  ≤0.05),  was 
observed in Austria (↓) and the Netherlands. (↓) 
Figure CA29.  Trends in gentamicin resistance in Campylobacter jejuni from cattle in reporting MSs, 
2005–2011, quantitative data 
 
Note: No statistically significant trends over five or more years, as tested by a logistic regression model (p ≤0.05), were observed in any 
of the reporting countries. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure CA30.  Trends in tetracycline resistance in Campylobacter jejuni from cattle in reporting MSs, 
2005–2011, quantitative data 
 
Note:  A  statistically  significant  decreasing  trend  over  five  or  more  years,  as  tested  by  a  logistic  regression  model  (p  ≤0.05),  was 
observed in Austria (↓). 
Multi-resistance among C. jejuni isolates from cattle 
As too few MSs reported resistance isolate-based data on 10 or more isolates of C. jejuni from cattle, multi- 
resistance are not presented in this report. 
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5.5. Overview  of  the  findings  on  antimicrobial  resistance  in  Campylobacter  at  reporting 
MS group level, 2011 
Figure CA31 shows the resistance levels in the reporting MS group based on the quantitative data submitted 
in 2011 for the various animal species and meat derived from those animal species. These data may derive 
from different MS groups, which needs to be considered when interpreting the figure. As was the case in 
previous years, C. coli isolates tend to be more resistant than C. jejuni isolates. Direct comparisons of the 
levels of resistance in Campylobacter from Gallus gallus and in broiler meat may not be entirely appropriate 
because different MSs have reported different types and proportions of isolates tested from meat and live 
fowl. 
Figure CA31.  Resistance to ciprofloxacin, erythromycin, gentamicin, nalidixic acid and tetracyclines 
in Campylobacter jejuni and Campylobacter coli from fowl, pigs and cattle at reporting MS group 
level in 2011 
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5.6. Discussion 
Campylobacter causes a large number of human cases of gastro-enteritis and has been the most frequently 
reported cause of human food-borne zoonoses in the EU since 2004 (EFSA and ECDC, 2013). Resistance 
to antimicrobials in Campylobacter is of concern because of the large numbers of cases of human infection 
and  the  fact  that  some  of  these  require  treatment.  Campylobacter  can  also  cause  invasive  infections, 
although the numbers of such cases are usually extremely low. 
In  2011,  information  on  antimicrobial  resistance  in  Campylobacter  isolates  from  human  cases  of 
campylobacteriosis  was  reported  by  13  MSs  and  one  non-MS  (Iceland).  The  data  submitted  by  these 
countries represented isolates from 16 % of the human campylobacteriosis cases reported within the EU in 
2011. There was a large variation in the guidelines used for interpreting the susceptibility tests for human 
Campylobacter isolates, both among and also within countries. Although the clinical breakpoints used for the 
dilution  test  for  Campylobacter  were  less  variable  than  those  for  Salmonella,  the  breakpoints  for  disc 
diffusion  differed  significantly  depending  on  the  guidelines  used,  and  disc  diffusion  was  still  the  most 
common method of testing for antimicrobial susceptibility in human isolates. The disc diffusion method and 
clinical  breakpoints  established  by  EUCAST  in  2012  are  therefore  much  welcomed  and  will  be 
recommended by the ECDC in its work on harmonisation of antimicrobial susceptibility testing for human 
Campylobacter isolates.  
There was also a large variation with regard to the number of antimicrobials tested among the reporting 
countries, which reflects the variation in the clinical importance of the antimicrobials. Erythromycin was the 
antimicrobial for which the greatest number of human Campylobacter spp. isolates were tested. The levels of 
resistance in human Campylobacter isolates to the clinically important antimicrobial erythromycin was overall 
low, but moderately high in C. coli, although the number of tested isolates for this bacterial species was 
small. High resistance levels to ciprofloxacin continued to be reported in human Campylobacter isolates, with 
increasing trends observed in some MSs.  
In order to assess the importance of travel-associated infections, antimicrobial resistance was also analysed 
based on the most likely country of infection reported. Human isolates acquired in Asia had the highest 
frequency of resistance to the tested antimicrobials, with resistance to both erythromycin and ciprofloxacin 
among these isolates being twice as high as in isolates acquired within the EU/EEA. The number of cases 
associated with travel outside of the EU/EEA was however low (3 % overall in the reporting countries). 
Human antimicrobial susceptibility data were available for the full range of antimicrobials only from three MSs 
for C. jejuni and from two MSs for C. coli. Overall, only one in six (18.4 %) human C. jejuni isolates and one 
in eight (13.4 %) human C. coli isolates were fully susceptible to all antimicrobials. On average, one quarter 
of both C. jejuni and C. coli isolates exhibited multi-drug resistance, meaning that they were clinically non-
susceptible to at least three different antimicrobial groups.  The clinical breakpoints used to interpret the 
human data were in some cases more sensitive than the ECOFFs when intermediate and resistant results 
were combined. The human data also covered two penicillins which were not included in the animal/food 
testing.  All  these  factors  could  explain  the  generally  higher  proportion  of  multi-resistance  observed  in 
humans than in animals, particularly for C. jejuni, which was the most common species in humans. Co-
resistance to the critically important antimicrobials ciprofloxacin and erythromycin was, on average, low for 
C. jejuni but at a moderate level among C. coli isolates, although in the case of C. coli few isolates were 
tested. 
The data relating to the susceptibility of Campylobacter of food and animal origin reported by MSs were, in 
general,  well  harmonised,  with  almost  all  MSs  reporting  the  adoption  of  the  EFSA  guidelines  and 
recommendations. Some MSs reported qualitative data for Campylobacter and did not specify the exact 
methods used in their submissions to EFSA. For the first time, complete susceptibility and multi-resistance 
were analysed in isolate-based resistance data reported by the MSs. 
Among  Campylobacter  isolates  from  food-producing  animals  and  meat  very  to  extremely  high  levels  of 
resistance to one or more antimicrobials were reported by a number of MSs, with the exception of some 
Nordic  countries,  particularly  when  using  ECOFFs  as  interpretative  criteria  of  resistance.  In  particular, 
extremely  high  resistance  rates  to  ciprofloxacin  were  detected.  Overall,  in  2011,  the  highest  level  of 
resistance  at  the  reporting  MS  group  level  was  seen  for  C. coli  isolates  from  meat  from  broilers,  withEU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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resistance to ciprofloxacin being 77.7 %. This figure was remarkably similar to the figure for ciprofloxacin 
resistance for the reporting MS group for C. coli from Gallus gallus, although the contributing MSs were not 
the same. Within a MS, the levels of ciprofloxacin resistance were generally lower in C. coli and C. jejuni 
isolates from meat from broilers than in isolates from broilers. Similarly, the levels of complete susceptibility 
are  higher,  and  of  multi-resistance  are  lower,  in  C. jejuni  isolates  from  broiler  meat  than  in  those  from 
broilers. Generally, resistance levels to all antimicrobials were higher in C. coli than in C. jejuni for the same 
host  species.  Similarly,  the  levels  of  multi-resistance  (reduced  susceptibility  to  at  least  three  different 
antimicrobial classes) in C. coli isolates from broilers were much higher than those detected in C. jejuni 
isolates  of  the  same  origin.  However,  it  should  be  borne  in  mind  that,  despite  the  high  levels  of 
resistance/multi-resistance observed, C. coli is much less prevalent in poultry than C. jejuni. 
The number of MSs reporting statistically significant trends in resistance levels over five or more years by the 
logistic  regression  model  (p ≤0.05)  increased  in  2011.  Significant  trends  were  most  frequently  seen  for 
ciprofloxacin and nalidixic acid resistance in C. jejuni from Gallus gallus, with six MSs reporting an increasing 
trend.  Overall,  levels  of  antimicrobial  resistance  in  Campylobacter  isolates  from  animals  and  food  were 
similar to those in 2010. 
Over the period 2009–2011, the highest levels of resistance to quinolones and fluoroquinolones were in 
general detected in Campylobacter isolates from Gallus gallus. This high level of resistance is of particular 
concern, since the EFSA BIOHAZ Panel, in its recent scientific opinion on the quantification of the risk of 
campylobacteriosis  posed  to  humans  by  broiler  meat,  estimated  that  the  handling,  preparation  and 
consumption of broiler meat may account for 20 % to 30 % of human campylobacteriosis cases, while 50 % 
to 80 % of cases may be attributed to the chicken (broiler) reservoir as a whole (EFSA, 2010a). However, 
Campylobacter strains from the broiler reservoir may also reach humans via routes other than food (e.g. by 
the environment or by direct contact).  
Regarding resistance to erythromycin, the first-choice drug for the treatment of campylobacteriosis, the levels 
observed were mostly low to moderate in food and animal isolates. This situation is similar to that observed 
in 2009 and 2010. 
In  countries  which  reported  results  for  C. coli  from  both  pigs  and  Gallus gallus  and  C. jejuni  from 
Gallus gallus  (France,  Hungary,  the  Netherlands,  Spain  and  Switzerland),  the  level  of  resistance  to 
erythromycin was invariably highest in C. coli isolates from pigs and lower in the isolates from the other 
sources for each MS. These findings mirror those in 2009 and 2010 and in many previous studies, in which 
macrolide-resistant isolates of C. coli from food animals have mainly been of porcine origin (Gibreel and 
Taylor, 2006).  
 
THE RECENT REVISION OF EUCAST ECOFFS FOR CAMPYLOBACTER 
There have been some recent minor revisions to the ECOFFs provided by EUCAST. Thus, the EUCAST 
ciprofloxacin  ECOFF  for  C. coli  is  currently  ≤0.5 mg/L,  a  decline  of  one  log  value  from  the  previous 
ECOFF value of >1 mg/L described on the EUCAST website and recorded in Table MM10. Similarly, the 
ECOFF values for C. coli and erythromycin, C. coli and nalidixic acid and C. jejuni and both ciprofloxacin 
and tetracyclines have declined by one dilution step. Conversely, the ECOFF has increased by one log 
dilution for C. jejuni versus gentamicin and streptomycin. Although deviation from wild-type susceptibility 
is a fixed microbiological characteristic, as greater numbers of bacterial isolates are tested, the wild-type 
distribution may become better defined and minor changes in the ECOFF might therefore be expected. 
The breakpoints used in this report to discriminate between ‘microbiologically resistant’ and wild-type 
bacteria are identical to those used in previous reports for Campylobacter and so there should be no 
effect  of  methodological  changes  when  comparisons  are  made  between  years.  When  EFSA’s 
recommendations are revised to include the latest EUCAST ECOFFs and new legislation incorporating 
those recommendations is subsequently adopted by the European Commission, then the historical data 
are likely to be re-interpreted, using the new EUCAST ECOFF values. Reference to the MIC distribution 
tables  for  C. coli  and  C. jejuni  which  are  published  in  the  appendix,  shows  that  the  effect  of  these 
changes is in most cases likely to be small. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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6. ANTIMICROBIAL RESISTANCE IN INDICATOR ESCHERICHIA COLI 
6.1. Introduction 
Escherichia coli are commensal bacteria normally and naturally present in the intestine of most terrestrial 
farm animals. Commensal E. coli is commonly chosen as an indicator Gram-negative bacterium as it is very 
commonly  present  in  animal  faeces,  is  relevant  to  human  medicine  and  can  often  acquire  conjugative 
plasmids, which can be transferred between enteric bacteria. Commensal E. coli present in the intestine of 
farm animals comprise a reservoir of resistance genes that can spread horizontally to zoonotic and other 
bacteria  occurring  in  the  food  chain.  Most  terrestrial  food  animals  generally  carry  indicator  E. coli,  and 
therefore randomised sampling strategies can be developed, allowing for statistical analysis of data and 
reducing  the  effect  of  sampling  bias,  as  well  as  allowing  inference  to  be  made  from  the  representative 
random  sample  investigated  to  the  target  population  from  which  the  sample  was  derived.  Commensal 
indicator  organisms,  rather  than  pathogenic  types  of  E. coli,  such  as  enterotoxigenic  E. coli  (ETEC)  or 
verotoxigenic E. coli (VTEC), are therefore the target of the monitoring of indicator E. coli. 
The monitoring of antimicrobial resistance in indicator E. coli, isolated from either randomly selected healthy 
animals or derived carcases and meat thereof, and chosen to be representative of the general population, 
provides  valuable  data  on  the  resistance  occurring  in  that  population.  Determining  the  occurrence  of 
resistance to antimicrobials in indicator E. coli provides data useful for investigating relationship with the 
selective  pressure  exerted  by  the  use  of  antimicrobials  on  the  intestinal  population  of  bacteria  in  food-
producing animals. Indicator E. coli are also useful as representatives of the Enterobacteriaceae to monitor 
the emergence and changes in the proportion of bacteria possessing extended-spectrum beta-lactamases 
(ESBLs). 
The EFSA monitoring guidelines (EFSA, 2008a) recommend that monitoring may be carried out at farm or 
slaughterhouse level and that at least 90 % of the animal population in a MS should be included in the 
sampling  frame.  Samples  should  be  collected  randomly  from  selected  holdings  or  flocks  or  randomly 
selected within the slaughterhouse. Samples collected (and subsequently tested) in accordance with the 
EFSA recommendations should therefore be comparable between MSs. 
 
ANTIMICROBIAL RESISTANCE IN VEROTOXIGENIC E. COLI 
In 2011, there were a total of 9,478 confirmed cases of verotoxigenic E. coli in the EU, which was a 
159.2 %  increase  compared  with  2010  (N=3,656)  (EFSA  and  ECDC,  2013).  However,  antimicrobial 
resistance is not usually considered very significant in infections caused by ‘classic’ food-borne E. coli 
pathogens such as VTEC; human VTEC infections are also commonly not treated with antimicrobials. 
Only one country (the Netherlands) submitted data concerning VTEC in 2011, and the results for these 
organisms are presented in section 10.5 of this report. There are a number of different types and strains 
of E. coli causing a range of infections in humans, ranging from urinary tract infections, through enteritis 
to bacteraemia and septic shock. The degree to which animals and humans share or exchange the same 
strains of E. coli is currently the subject of active research and debate. Resistance to key therapeutic 
antimicrobials can seriously compromise treatment of invasive E. coli infections as well as urinary tract 
infections in humans. Infections caused by such antimicrobial-resistant strains are becoming increasingly 
common worldwide and are posing serious health problems for human medicine (EARSS, 2008). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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6.2. Antimicrobial resistance in indicator Escherichia coli isolates from animals and food 
In total, 12 MSs and 2 non-MSs (Norway and Switzerland) reported quantitative MIC data on antimicrobial 
resistance in commensal (indicator) E. coli isolates from animals in 2011. In addition, three of these countries 
provided MIC data on isolates collected from food. The total number of tests performed on E. coli isolates 
from animals and food by MSs and non-MSs and for which quantitative MIC data are available was 123,662. 
In addition, qualitative data were provided by seven MSs, but no specific subsection has been prepared for 
these data. Table EC1 shows the countries that reported data concerning indicator E. coli in 2011.  
Table EC1.  Overview  of  countries  reporting  MIC  and  disc  inhibition  zones  on  indicator 
Escherichia coli from animals and food in 2011 
Method  Origin  Total number of 
MSs reporting  Countries 
Diffusion 
Gallus gallus (fowl)  4  MSs: FR
1, PL
1, SK
2, UK
2 
Turkeys  3  MSs: PL
1, SK
2, UK
2 
Pigs  4  MSs: FR
1, PL
1, SK
2, UK
2 
Cattle (bovine animals)  3  MSs: PL
1, SK
2, UK
2 
Meat from broilers (Gallus gallus)  2  MSs: ES
3, HU 
Meat from turkey  1  MS: HU 
Meat from pig  1  MS: HU 
Meat from bovine animals  3  MSs: ES
3, HU, SI
2 
Dilution 
Gallus gallus (fowl)  10 
MSs: AT, BE, DE, DK, ES, FI, FR, IE, NL, PL 
Non-MSs: CH, NO 
Turkeys  3  MSs: DE, NL, PL 
Pigs  10 
MSs: AT, BE, DE, DK, EE, ES, FR, NL, PL, SE 
Non-MSs: CH, NO 
Cattle (bovine animals)  7 
MSs: AT, BE, DE, DK, ES, NL, PL 
Non-MS: CH 
Meat from broilers (Gallus gallus)  2  MSs: DE, DK 
Meat from pig  3  MSs: DE, DK, SE 
Meat from bovine animals  2  MSs: DE, DK 
1. These data were submitted with no test method specified and this information could not be obtained from the National Zoonoses 
Reports. 
2. These data were submitted with no test method specified but are believed to have been tested by disc diffusion based on information 
in the National Zoonoses Reports. 
3. These data were submitted with the test method listed as dilution but no MIC distribution data were supplied. 
Antimicrobials selected by the different MSs and non-MSs for MIC susceptibility testing of indicator E. coli 
are shown in Chapter 11, Materials and Methods, Table MM7. Proportions of resistance to the antimicrobial 
agents  ampicillin,  cefotaxime,  chloramphenicol,  ciprofloxacin,  gentamicin,  nalidixic  acid,  streptomycin, 
sulfonamides and  tetracyclines  are  described  in  detail  later  in  this  chapter.  The  tables  of  occurrence  of 
resistance were generated, and multi-drug resistance analysis was performed, if more than four countries 
reported  quantitative  data  per  sampling  origin.  In  addition,  only  data  where  10  or  more  isolates  were 
available per country, per sampling origin, per year are included in the report. 
In the graphs illustrating trends in the evolution of antimicrobial resistance over time, results for MIC data 
interpreted  using  epidemiological  cut-off  values  are  shown.  Few  MSs  have  reported  data  for  the  seven 
consecutive years from 2005 to 2011, as the monitoring of resistance in indicator E. coli is performed on a 
voluntary basis. 
Where the minimum criteria for detailed analysis were met, multi-resistance was analysed in the isolate-
based dataset of indicator E. coli isolates tested for the full harmonised set of nine antimicrobials belonging 
to different classes. Multi-resistance was defined as non-susceptibility to at least three different antimicrobial 
classes. The proportions of isolates susceptible to all and resistant (non-susceptible) to any one up to nine 
antimicrobials are presented. Co-resistance to cefotaxime and ciprofloxacin was estimated as these two EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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antimicrobials  are  of  particular  interest  in  human  medicine.  Co-resistance  was  addressed  using  both 
ECOFFs (CTX >0.25 mg/L and CIP >0.03 mg/L) and clinical breakpoints (CTX >2 mg/L and CIP >1 mg/L). 
For  further  information  on  reported  MIC  distributions  and  numbers  of  resistant  isolates  for  ampicillin, 
apramycin, cefotaxime, ceftazidime, ceftiofur, chloramphenicol, ciprofloxacin, colistin, florfenicol, gentamicin, 
imipenem, kanamycin, nalidixic acid, neomycin, spectinomycin, streptomycin, sulphonamides, tetracyclines 
and trimethoprim for E. coli in 2011, please refer to the Level 3 tables published on the EFSA website. 
6.2.1. Antimicrobial resistance in indicator Escherichia coli isolates from food 
6.2.1.1. Meat 
In 2011, Denmark and Germany reported quantitative MIC data for E. coli isolates from meat from bovine 
animals, broilers (Gallus gallus) and pigs, and Sweden reported comparable data for meat from pigs. The 
AMR data in indicator E. coli isolates from the three kinds of meat reported by Denmark, Germany and 
Sweden  derived  from  active  and  representative  monitoring  programmes.  In  Denmark,  E. coli  isolates 
originated from meat sampled at wholesale and retail outlets, collected randomly in all regions of the country 
and  spread  evenly  throughout  the  year,  in  the  framework  of  three  centrally  coordinated  sampling  plans 
corresponding to each kind of meat.  
Resistance levels among E. coli isolates in broiler meat 
Denmark  and  Germany  tested  122  and  172  E. coli  isolates  from  meat  from  broilers  (Gallus  gallus), 
respectively. The highest resistance levels in both countries were reported for ampicillin (23.0 % and 67.4 %, 
respectively)  and  sulfonamides  (22.1 %  and  54.7 %,  respectively).  In  addition,  Germany  reported  high 
resistance  to  nalidixic  acid  (48.8 %),  streptomycin  (44.2 %),  tetracyclines  (44.2 %)  and  trimethoprim 
(44.2 %), while Denmark reported only low or moderate levels of resistance, at 5.7 %, 11.5 %, 18.9 % and 
12.3 %, respectively. There was a lower level of resistance to chloramphenicol in both countries, with 16.9 % 
of  isolates  in  Germany  and  1.6 %  of  isolates  in  Denmark  expressing  resistance.  Low  resistance  to 
gentamicin (4.1 %) was reported by Germany, while all isolates from Denmark were fully susceptible to this 
antimicrobial.  Germany  also  reported  very  high  resistance  to  ciprofloxacin  (52.3 %),  whereas  Denmark 
reported 5.7 % resistance to this antimicrobial. Both countries reported low resistance to cefotaxime (2.5 % 
in Denmark and 4.7 % in Germany).
16 
Resistance levels among E. coli isolates in meat from pigs 
Denmark,  Germany  and  Sweden  tested  for  susceptibility  92,  52  and  20  isolates  from  meat  from  pigs, 
respectively. The highest overall resistance levels for all three MSs combined were reported for streptomycin 
(31.1 %),  ampicillin  (28.0 %),  tetracyclines  (28.0 %),  sulfonamides  (25.0 %)  and  trimethoprim  (22.0  %). 
Regarding  ampicillin,  all  three  countries  reported  comparable  resistance  levels.  For  the  other  four 
antimicrobials, Sweden reported relatively lower resistance levels of only 10 % or less compared with the 
high resistance levels recorded in Denmark and Germany. There was low or very low overall resistance to 
cefotaxime (0.6 %), chloramphenicol (1.2 %), gentamicin (0.6 %) and nalidixic acid (1.2 %), with only one 
country reporting one or two resistant isolates for each: Germany reported 3.8 % resistance to nalidixic acid 
and  1.9 %  resistance  to  cefotaxime  and  gentamicin,  and  Denmark  reported  2.2 %  resistance  to 
chloramphenicol, while all other isolates from the three countries were susceptible to these antimicrobials. 
Only Denmark and Germany tested ciprofloxacin and both reported low resistance levels (1.1 % and 5.8 %, 
respectively).
17 
Resistance levels among E. coli isolates in meat from bovine animals 
Denmark  and  Germany  tested  for  susceptibility  37  and  68  isolates  from  meat  from  bovine  animals, 
respectively. Germany tended to report higher resistance than Denmark, although the difference was not as 
extreme  as  for  meat  from  broilers.  The  highest  resistance  levels  were  reported  for  ampicillin  and 
                                                 
16 In addition, of the other aminoglycosides tested, Denmark reported low resistance to both neomycin (4.1 %) and spectinomycin 
(1.6 %), while Germany reported full sensitivity to kanamycin. Denmark also reported 2.5 % resistance to ceftiofur. 
17 Moreover, Denmark reported moderate resistance to spectinomycin (15.2  %) but low resistance to neomycin (2.2 %). Germany and 
Sweden both reported low resistance to kanamycin (9.6 % and 5.0 %, respectively). Denmark found no resistance to ceftiofur. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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tetracyclines (5.4 % resistance to both in Denmark and 11.8 % resistance to both in Germany). Germany 
reported moderate levels of resistance to streptomycin (11.8 %), sulfonamides (16.2 %) and trimethoprim 
(11.8 %), whereas Denmark reported only 2.7 % resistance to the former and full sensitivity to the last two 
antimicrobials.  Both  countries  reported  low  resistance  to  ciprofloxacin  (2.7 %  in  Denmark  and  4.4 %  in 
Germany).  Germany  also  reported  low  resistance  to  chloramphenicol  (1.5 %),  gentamicin  (2.9 %)  and 
nalidixic acid (4.4 %), whereas Denmark reported full sensitivity to all three antimicrobials. Neither country 
reported any resistance to cefotaxime.
18 
Multi-resistance among E. coli from food 
As too few MSs reported multi-resistance isolate-based data on more than 10 isolates of indicator E. coli in 
food, tables and graphs on multi-resistance are not presented in this report. 
6.2.2. Antimicrobial resistance in indicator Escherichia coli isolates from animals 
6.2.2.1. Fowl (Gallus gallus) 
In this section, data on antimicrobial resistance in indicator  E. coli isolates from fowl (Gallus gallus) are 
presented separately for broilers and laying hens. The majority of MSs collected isolates as part of their 
national monitoring programmes. In all reporting MSs, except Germany, active monitoring programmes were 
based on random sampling of healthy broilers at the slaughterhouse. The slaughterhouses included in the 
monitoring programme accounted for a major proportion, typically 80 % or more, of the total production in the 
country. The sampling plan was stratified per slaughterhouse, the sample size per slaughterhouse being 
proportional  to  the  annual  throughput  of  animals  slaughtered.  The  sampling  was  evenly  distributed 
throughout the year or a significant part of the year to account for a possible seasonal effect. Indicator E. coli 
isolates were isolated from caecal contents in Belgium, France, the Netherlands and Sweden, from cloacal 
swabs in Switzerland, and from faecal samples in the other reporting MSs, by sampling healthy broilers at 
slaughter. Only one representative sample of caecal content per flock/batch, derived from either a unique or 
a number of slaughtered animals, was gathered to account for clustering. In Germany, indicator E. coli were 
isolated from faeces sampled from broiler flocks and laying hen flocks on farm. Samples were collected in 
the framework of a national sampling plan, stratified per federal region, and allocated in proportion with 
regard to the total number of broilers and laying hens per land, respectively.  
Resistance levels among Escherichia coli 
In 2011, nine MSs and two non-MSs provided quantitative data concerning antimicrobial resistance in E. coli 
from broilers, and two MSs provided comparable data concerning E. coli from laying hens; only Germany 
provided data concerning both production types of fowl (Table EC2).  
Regarding broiler flocks, a high or very high level of resistance was observed at the reporting MS group level 
for ciprofloxacin (53.1 %), ampicillin (54.4 %), sulfonamides (50.8 %), streptomycin (47.2 %), tetracyclines 
(45.2 %) and nalidixic acid (42.6 %). Resistance levels varied considerably between MSs, for example from 
3.8 % (Finland) to 84.8 % (Belgium) for ampicillin. Denmark and Finland tended to have the lowest levels of 
resistance  to  these  antimicrobials.  There  was  a  moderate  level  of  resistance  to  chloramphenicol  at  the 
reporting  MS  group  level  (13.2 %).  Both  Denmark  and  Finland  reported  no  resistance,  while  Belgium, 
Germany and the Netherlands reported high levels of resistance (24.3 %, 23.6 % and 20.5 %, respectively). 
A low level of resistance was observed to gentamicin overall (4.2 %). Three countries reported full sensitivity 
to  gentamicin  among  broilers,  with  all  other  countries  reporting  low  or  very  low  levels  of  resistance  of 
between 0.3 % and 7.1 %, except for Spain, which reported 25.7 % resistance. 
Regarding  ciprofloxacin  and  nalidixic  acid,  the  overall  resistance  was  also  high,  at  53.1 %  and  42.6 %, 
respectively. Resistance to cefotaxime at MS group level was low, at 8.2 %. Among reporting MSs, Finland 
reported no resistance to this antimicrobial among broilers, and most other countries reported low or very low 
levels of resistance of between 0.4 % and 8.1 %, although Belgium and Spain reported 19.1 % and 20.8 % 
resistance, respectively. 
                                                 
18 Denmark also reported full sensitivity to ceftiofur as well as neomycin and spectinomycin, and Germany reported full sensitivity to 
kanamycin. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Among E. coli isolates from laying hens tested in the two reporting MSs, Poland and Germany, only a low or 
moderate  overall  resistance  was  recorded  to  ampicillin  (18.1 %),  sulfonamides  (14.3 %),  streptomycin 
(9.7 %), tetracyclines (17.1 %), as well as to ciprofloxacin (13.6 %) and nalidixic acid (11.2 %). However, 
Poland tended to report resistance levels at least twice as high as those recorded in Germany for these 
antimicrobials,  with  the  difference  most  extreme  for  ciprofloxacin  (46.8 %  vs.  5.6 %)  and  nalidixic  acid 
(38.3 % vs. 4.7 %). There was low resistance among laying hens to chloramphenicol (3.0 %), and gentamicin 
(1.6 %),  as  well  as  to  cefotaxime  (1.9 %),  with  slightly  higher  resistances  recorded  by  Poland  than  by 
Germany. 
Table EC2.  Resistance  (%)  to  ampicillin,  cefotaxime,  chloramphenicol,  ciprofloxacin,  gentamicin, 
nalidixic acid, streptomycin, sulfonamides and tetracyclines among indicator Escherichia coli from 
Gallus  gallus  in  countries  reporting  MIC  data  in  2011,  using  harmonised  epidemiological  cut-off 
values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Broilers 
Austria  173  26.6  173  1.7  173  5.2  173  68.8  173  0 
Belgium  420  84.8  419  19.1  420  24.3  420  64.0  420  4.0 
Denmark  134  20.1  134  0.7  134  0  134  9.0  134  0 
Finland  316  3.8  316  0  316  0  -  -  316  0.3 
France  192  56.8  192  6.8  192  6.3  192  40.1  192  1.0 
Germany  246  77.6  246  7.7  246  23.6  246  48.4  246  6.1 
Ireland  154  64.3  154  3.9  154  5.2  154  39.0  154  2.6 
Netherlands  283  66.1  283  8.1  283  20.5  283  56.2  283  7.1 
Spain  101  70.3  101  20.8  101  19.8  101  89.1  101  25.7 
Total (9 MSs)  2,019  54.4  2,018  8.2  2,019  13.2  1,703  53.1  2,019  4.2 
Norway
1  244  18.0  244  0.4  244  0.8  -  -  244  0 
Switzerland  176  27.8  176  2.3  176  1.7  176  40.3  176  2.3 
Laying hens 
Germany  642  14.6  642  1.6  642  2.8  642  5.6  642  1.2 
Poland  154  32.5  154  3.2  154  3.9  154  46.8  154  3.2 
Total (2 MSs)  796  18.1  796  1.9  796  3.0  796  13.6  796  1.6 
All types of fowl (Gallus gallus) 
Austria  173  26.6  173  1.7  173  5.2  173  68.8  173  0 
Belgium  420  84.8  419  19.1  420  24.3  420  64.0  420  4.0 
Denmark  134  20.1  134  0.7  134  0  134  9.0  134  0 
Finland  316  3.8  316  0  316  0  -  -  316  0.3 
France  192  56.8  192  6.8  192  6.3  192  40.1  192  1.0 
Germany  888  32.1  888  3.3  888  8.6  888  17.5  888  2.6 
Ireland  154  64.3  154  3.9  154  5.2  154  39.0  154  2.6 
Netherlands  283  66.1  283  8.1  283  20.5  283  56.2  283  7.1 
Poland  154  32.5  154  3.2  154  3.9  154  46.8  154  3.2 
Spain  101  70.3  101  20.8  101  19.8  101  89.1  101  25.7 
Total (10 MSs)  2,815  44.1  2,814  6.4  2,815  10.3  2,499  40.5  2,815  3.5 
Norway
1  244  18.0  244  0.4  244  0.8  -  -  244  0 
Switzerland  176  27.8  176  2.3  176  1.7  176  40.3  176  2.3 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
1.   Thirty-eight of the isolates tested by Norway were from clinical samples. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table  EC2  (continued).  Resistance  (%)  to  ampicillin,  cefotaxime,  chloramphenicol,  ciprofloxacin, 
gentamicin,  nalidixic  acid,  streptomycin,  sulfonamides  and  tetracyclines  among  indicator 
Escherichia  coli  from  Gallus  gallus  in  countries  reporting  MIC  data  in  2011,  using  harmonised 
epidemiological cut-off values 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res 
Broilers 
Austria  173  65.3  173  41.6  173  30.6  173  26.0 
Belgium  420  62.9  419  69.0  420  75.0  420  64.8 
Denmark  134  9.0  134  11.2  134  16.4  134  10.4 
Finland  316  0.6  316  12.7  316  10.8  316  7.9 
France  192  30.7  192  50.0  192  55.7  192  81.3 
Germany  246  44.3  246  54.5  246  69.1  246  48.4 
Ireland  155  36.8  154  45.5  154  59.1  154  50.6 
Netherlands  283  55.8  283  62.2  283  63.3  283  51.6 
Spain  101  85.1  101  59.4  101  54.5  101  57.4 
Total (9 MSs)  2,020  42.6  2,018  47.2  2,019  50.8  2,019  45.2 
Norway
1  244  2.9  244  5.7  244  14.3  244  7.0 
Switzerland  176  38.6  176  17.6  176  35.8  176  26.1 
Laying hens 
Germany  642  4.7  642  8.4  642  12.1  642  14.0 
Poland  154  38.3  154  14.9  154  23.4  154  29.9 
Total (2 MSs)  796  11.2  796  9.7  796  14.3  796  17.1 
All types of fowl (Gallus gallus) 
Austria  173  65.3  173  41.6  173  30.6  173  26.0 
Belgium  420  62.9  419  69.0  420  75.0  420  64.8 
Denmark  134  9.0  134  11.2  134  16.4  134  10.4 
Finland  316  0.6  316  12.7  316  10.8  316  7.9 
France  192  30.7  192  50.0  192  55.7  192  81.3 
Germany  888  15.7  888  21.2  888  27.9  888  23.5 
Ireland  155  36.8  154  45.5  154  59.1  154  50.6 
Netherlands  283  55.8  283  62.2  283  63.3  283  51.6 
Poland  154  38.3  154  14.9  154  23.4  154  29.9 
Spain  101  85.1  101  59.4  101  54.5  101  57.4 
Total (10 MSs)  2,816  33.7  2,814  36.6  2,815  40.5  2,815  37.3 
Norway
1  244  2.9  244  5.7  244  14.3  244  7.0 
Switzerland  176  38.6  176  17.6  176  35.8  176  26.1 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
1. Thirty-eight of the isolates tested by Norway were from clinical samples. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Temporal trends in resistance among indicator Escherichia coli 
Figures EC1-EC6 display the temporal trends in resistance to the selected antimicrobials in indicator E. coli 
from  Gallus  gallus,  data  derived  from  broilers  and  laying  hens  being  combined.  The  2010  and  2011 
resistance levels for Germany presented in these figures combine data for broilers and laying hens, while for 
the other reporting countries resistance data derive from broilers only. The figures illustrate the wide variation 
in resistance between MSs for many of the antimicrobials. The Netherlands and Spain tended to report 
relatively high resistance levels for most antimicrobials, although France consistently reported the highest 
resistance to tetracyclines between 2005 and 2011. Denmark often reported the lowest resistance levels. 
The  resistance  to  ciprofloxacin  reported  over  the  seven-year  study  period  was  high  to  very  high  for  all 
reporting countries, with the exception of Denmark for the whole period and of Germany for the years 2010 
and  2011,  which  in  both  cases  was  below  20 %.  There  was  less  variation  between  countries  in  the 
resistance to cefotaxime and chloramphenicol, which, in most countries, was at a moderate or low level. 
Figure EC4 clearly demonstrates the close similarity in resistance levels for ciprofloxacin and nalidixic acid in 
most MSs. 
In addition, compared with the year 2010, resistance levels observed in 2011 tended to be broadly similar, 
although there were a few exceptions; for example, in Germany resistance to sulfonamides in broiler flocks 
increased from 4 % in 2010 to 69.1 % in 2011. Such inter-annual evolutions need to be confirmed by longer-
term trends. 
Resistance levels for many of the antimicrobials were broadly stable or had shown only gradual increases or 
decreases. Nevertheless, there was evidence of statistically significant trends in the occurrence of resistance 
to some of the antimicrobials over five or more years. Austria reported significant increases in resistance to 
ciprofloxacin, nalidixic acid and streptomycin, and France reported significant increases in resistance to both 
ampicillin  and  ciprofloxacin.  In  contrast,  Germany  reported  significant  declines  in  resistance  to  many 
antimicrobials,  including  ampicillin,  ciprofloxacin,  nalidixic  acid  and  tetracyclines,  but  with  an  increase  in 
resistance  to  chloramphenicol.  Switzerland  also  reported  a  decline  in  resistance  to  tetracyclines  but  an 
increase in resistance to ampicillin. In addition, there were statistically significant increases in resistance to 
nalidixic  acid  in  the  Netherlands,  and  to  tetracyclines  in  Denmark.  There  were  no  significant  trends  in 
resistance to cefotaxime in any of the reporting countries.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
 
 
EFSA Journal 2013;11(5):3196  206 
Figure EC1.  Trends  in  ampicillin  resistance  in  indicator  Escherichia  coli  from  Gallus  gallus
1  in 
reporting MSs and one non-MS, 2005–2011, quantitative data 
 
Note: Statistically significant increasing or decreasing trends over five or more years, as tested by a logistic regression model (p ≤0.05), 
were observed in France (↑), Germany (↓) and Switzerland (↑). 
1.  The data from Germany in 2010 and 2011 originated from broilers and laying hens. 
Figure EC2.  Trends  in  cefotaxime  resistance  in  indicator  Escherichia  coli  from  Gallus  gallus  in 
reporting MSs, 2005–2011, quantitative data 
 
Note: No  statistically  significant  increasing  or  decreasing  trends  over  five  or  more  years,  as  tested  by  a  logistic  regression  model 
(p ≤0.05), were observed in any of the reporting countries. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EC3.  Trends in chloramphenicol resistance in indicator Escherichia coli from Gallus gallus
1 
in reporting MSs and one non-MS, 2005–2011, quantitative data 
 
Note: A statistically significant increasing trend over five years, as tested by a logistic regression model (p ≤0.05), was observed in 
Germany (↑). 
1.  The data from Germany in 2010 and 2011 originated from broilers and laying hens. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EC4.  Trends in ciprofloxacin and nalidixic acid resistance in indicator Escherichia coli from 
Gallus gallus
1 in reporting MSs and one non-MS, 2005–2011, quantitative data 
 
Note: Statistically significant increasing or decreasing trends over five or more years, as tested by a logistic regression model (p ≤0.05), 
were observed in Austria (↑), France (↑) and Germany (↓) for ciprofloxacin, and in Austria (↑), Germany (↓) and the Netherlands (↑) 
for nalidixic acid. 
1.  The data from Germany in 2010 and 2011 originated from broilers and laying hens. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EC5.  Trends in streptomycin resistance in indicator Escherichia coli from Gallus gallus
1 in 
reporting MSs and one non-MS, 2005–2011, quantitative data 
 
Note: A statistically significant increasing trend over six years, as tested by a logistic regression model (p ≤0.05), was observed in 
Austria (↑). 
1.  The data from Germany in 2010 and 2011 originated from broilers and laying hens. 
Figure EC6.  Trends  in  tetracycline  resistance  in  indicator  Escherichia  coli  from  Gallus  gallus
1  in 
reporting MSs and one non-MS, 2005–2011, quantitative data 
 
Note: Statistically  significant  increasing  and  decreasing  trends  over  five  or  more  years,  as  tested  by  a  logistic  regression  model 
(p ≤0.05), were observed in Denmark (↑), Germany (↓) and Switzerland (↓). 
1.  The data from Germany in 2010 and 2011 originated from broilers and laying hens. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Spatial distribution of resistance among indicator Escherichia coli 
The spatial distributions of nalidixic acid and tetracycline resistance in E. coli from Gallus gallus are shown in 
Figures EC7 and EC8. The Nordic countries reported the lowest levels of resistance to both antimicrobials. 
The highest resistance to tetracyclines tended to be reported by the most western countries. However, the 
spatial pattern for nalidixic acid was less clear. 
Figure EC7.  Spatial distribution of nalidixic acid resistance among indicator Escherichia coli from 
Gallus gallus in countries reporting MIC data in 2011
1,2 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data were used instead.  
1.  For Sweden, 2010 data were used.  
2.  For Germany, data from broilers and laying hens have been aggregated. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EC8.  Spatial  distribution  of  tetracycline  resistance  among  indicator  Escherichia  coli  from 
Gallus gallus in countries reporting MIC data in 2011
1,2 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data were used instead. The countries labelled as ‘qualitative data’ therefore 
include those reporting MIC data for fewer than 10 isolates or purely qualitative data (as proportion of resistant isolates).  
1.  For Sweden, 2010 data were used.  
2.  For Germany, data from broilers and laying hens have been aggregated. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Multi-resistance among indicator E. coli isolates from broilers 
In 2011, four MSs and two non-MSs provided isolate-based data regarding resistance in indicator E. coli 
from  broilers.  Among  the  reporting  countries,  important  variations  were  observed  in  the  percentages  of 
completely  susceptible  isolates,  which  varied  from  5.9 %  in  Spain  to  56.7 %  in  Denmark.  Although  all 
reporting  countries  recorded  multi-resistant  isolates,  their  proportions  differed  substantially  between 
countries, reaching up to 74.4 % in Germany and 79.2 % in Spain (Table EC3). The frequency distributions 
(Figure EC9) showed that isolates resistant to as many as six antimicrobials were reported from all reporting 
countries,  and  one  MS  even  reported  a  few  isolates  resistant  to  nine  substances.  Co-resistance  to 
cefotaxime and ciprofloxacin was undetected or detected at only low levels, with the exception of Spain, 
where about 20 % of the isolates tested exhibited co-resistance to these substances. 
Table EC3.  Complete susceptibility, multi-resistance and index of diversity in E. coli from broilers in 
MSs and non-MSs reporting isolate-based data, 2011 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to 
CIP and CTX 
n  %  n  %  n  % 
Austria (N=173)  24  13.9  62  35.8  0.417  2  (0)  1.2  (0) 
Denmark (N=134)  76  56.7  12  9.0  0.261  0  (0)  0  (0) 
Germany (N=246)  22  8.9  183  74.4  0.683  11  (2)  4.5  (0.8) 
Spain (N=101)  6  5.9  80  79.2  0.757  21  (11)  20.8  (10.9) 
Norway (N=244)  96  39.3  25  10.3  0.248  1  (0)  0.4  (0) 
Switzerland (N=176)  44  25.0  49  27.8  0.361  3  (0)  1.7  (0) 
N = total number of isolates tested for susceptibility against the whole common antimicrobial set for E. coli. 
n = number of isolates per category of complete susceptibility or multiple resistance. 
Susceptible to all = isolate susceptible to all antimicrobial substances of the EFSA common set for E. coli. 
Multi-resistant = resistant to at least 3 different antimicrobial substances, belonging to any three antimicrobial families from the common 
antimicrobial set for E. coli. 
Index of diversity = see definition in section 11.4.2.1 of Materials and Methods. 
Co-resistant  to  cefotaxime  (CTX)  and  ciprofloxacin  (CIP)  =  the  effectives  and  percentages  of  E.  coli  isolates  non-susceptible  to 
concentrations greater than ECOFFs (CTX >0.25 mg/L and CIP >0.03 mg/L). Figures in parentheses indicate the occurrence of co-
resistance to CIP and CTX determined using clinical breakpoints (CTX >2 mg/L and CIP >1 mg/L). 
Figure EC9.  Frequency distribution of E. coli isolates completely susceptible and resistant to one to 
nine antimicrobials in broilers in MSs and non-MSs reporting isolate-based data, 2011 
 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances for E. coli. 
Susceptible = susceptible to all antimicrobial substances of the common set for E. coli. 
res1/res9 = resistance to one antimicrobial substance/resistance to nine antimicrobial substances of the common set for E. coli. 
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6.2.2.2. Pigs 
In 2011, ten MSs and two non-MSs (Norway and Switzerland) provided quantitative antimicrobial resistance 
data on indicator E. coli in pigs and were included in the following analysis (Table EC4). These data were not 
split by production type, as all isolates originated from fattening pigs or the production type was not specified. 
The majority of MSs collected isolates as part of their national resistance monitoring programmes. The AMR 
monitoring in indicator E. coli isolates from pigs was based on active monitoring plans based on random 
sampling of healthy slaughter pig carcasses at the slaughterhouse. The slaughterhouses included in the 
monitoring programme accounted for a major proportion, typically 80 % or more, of the total production in the 
country. The sampling plan was typically stratified per slaughterhouse by allocating the number of samples 
collected  per  slaughterhouse  in  proportion  with  the  annual  throughput  of  the  slaughterhouse.  An 
approximately equal distribution of the collected samples over the year enabled the different seasons to be 
covered.  Only  one  representative  faecal  sample  per  epidemiological  unit  (batch),  either  derived  from  a 
unique carcass or pooled from a number of carcasses, was gathered to account for clustering. 
Resistance levels among Escherichia coli 
In 2011, resistance to streptomycin and tetracyclines was very high overall in the reporting MS group, at 
53.1 % and 57.0 %, respectively (Table EC4). Resistance levels varied considerably between MSs, from 
16.2 % to 71.8 % for the former and from 8.4 % to 90.0 % for the latter. There was also a high level of 
resistance to ampicillin (37.1 %) and sulfonamides (45.8 %). Again, resistance levels differed widely between 
reporting countries, from 7.8 % to 72.4 % in the case of ampicillin. For all four of these antimicrobials, Spain 
recorded the highest resistance, while Norway and Sweden reported the lowest levels. Overall, resistance to 
chloramphenicol was moderate at 14.5 %, with most countries reporting low or moderate levels of resistance 
to this antimicrobial, and only Belgium, France and Spain recording high resistance. The overall resistance to 
gentamicin  in  the  reporting  MS  group  was  low  (2.2 %).  Four  countries  reported  full  sensitivity  to  this 
antimicrobial while all other countries reported low levels of resistance of between 1.1 % and 4.5 %. 
At the reporting MS group level, the occurrence of resistance to nalidixic acid was low (4.8 %), with most 
countries reporting either no resistance or low to very low resistance, although Belgium and Spain reported 
moderate resistance, at levels of 11.5 % and 20.1 %, respectively. Overall, resistance to ciprofloxacin was 
low, with only 8.3 % of isolates in the reporting MS group expressing resistance. The majority of countries 
reported low resistance, although Belgium, Estonia and France reported moderate levels and Spain reported 
high  levels.  Cefotaxime  resistance  was  also  low  at  the  reporting  MS  group  level  (1.7 %).  Belgium  and 
Estonia reported the highest level of resistance, at 4.5 %, with all other countries reporting low or very low 
levels of resistance of between 0.5 % and 1.9 %. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table EC4.  Resistance  (%)  to  ampicillin,  cefotaxime,  chloramphenicol,  ciprofloxacin,  gentamicin, 
nalidixic acid, streptomycin, sulfonamides and tetracyclines among isolates of indicator Escherichia 
coli  from  pigs in  countries  reporting  MIC  data  in 2011, using harmonised  epidemiological  cut-off 
values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  162  14.8  162  1.2  162  6.2  162  4.3  162  0 
Belgium  157  49.0  157  4.5  157  26.8  157  15.3  157  3.8 
Denmark  157  26.8  157  1.3  157  4.5  157  1.3  157  0 
Estonia  22  36.4  22  4.5  22  13.6  22  13.6  22  4.5 
France  184  21.2  184  1.1  184  23.9  184  10.9  184  0 
Germany  859  44.7  859  1.9  859  14.6  859  5.9  859  3.1 
Netherlands  287  35.5  287  1.7  287  12.2  287  2.1  287  2.1 
Poland  172  26.7  172  1.2  172  7.0  172  9.3  172  3.5 
Spain  170  72.4  170  0.6  170  31.2  170  30.6  170  2.4 
Sweden  167  13.2  167  0.6  167  4.2  -  -  167  1.2 
Total (10 MSs)  2,337  37.1  2,337  1.7  2,337  14.5  2,170  8.3  2,337  2.2 
Norway  192  7.8  192  0.5  192  0.5  -  -  192  0 
Switzerland  175  24.6  175  1.1  175  10.3  175  8.0  175  1.1 
 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res 
Austria  162  3.7  162  49.4  162  25.9  162  54.3 
Belgium  157  11.5  157  54.1  157  58.6  157  56.7 
Denmark  157  0.6  157  35.7  157  28.0  157  29.3 
Estonia  22  0  22  45.5  22  45.5  22  22.7 
France  184  1.6  184  57.1  184  51.6  184  73.9 
Germany  859  3.7  859  59.4  859  47.7  859  62.5 
Netherlands  287  1.0  287  57.8  287  54.7  287  66.9 
Poland  172  5.8  172  47.1  172  40.7  172  41.3 
Spain  169  20.1  170  71.8  170  72.4  170  90.0 
Sweden  167  2.4  167  16.2  167  16.8  167  8.4 
Total (10 MSs)  2,336  4.8  2,337  53.1  2,337  45.8  2,337  57.0 
Norway  192  0  192  17.2  192  10.4  192  9.4 
Switzerland  175  6.9  175  51.4  175  50.9  175  31.4 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
 
 
EFSA Journal 2013;11(5):3196  215 
Temporal trends in resistance among indicator Escherichia coli 
Figures EC10-EC15 display the trends in resistance to selected antimicrobials in indicator E. coli from pigs.  
There was variation in the resistance levels in different MSs, particularly for tetracyclines (Figure EC15). 
However,  the  differences  between  MSs  were  often  not  as  extreme  as  was  observed  for  isolates  from 
Gallus gallus. In some cases, this was because the resistance levels tended to be lower than those observed 
in Gallus gallus (e.g. ampicillin; Figure EC10), whereas, for others, it was due to the resistance levels all 
being higher than those recorded in Gallus gallus (e.g. streptomycin; Figure EC14). As in the previous year, 
France,  the  Netherlands  or  Spain  tended  to  report  the  highest  occurrence  of  resistance.  Resistance  to 
cefotaxime has been below 5 % in all countries since 2005, and at a lower level than in Gallus gallus (Figure 
EC11). Resistance to both ciprofloxacin and nalidixic acid has also generally been at a low level since 2005 
(Figure EC13). 
For many of the antimicrobials, the resistance levels were relatively stable with only fairly minor fluctuations 
or gradual changes. There were fewer statistically significant trends than were observed among isolates from 
Gallus  gallus.  Austria  and  Denmark  both  reported  significant  increases  in  resistance  to  ampicillin  and 
chloramphenicol, with the latter also showing a significant increase in resistance to tetracyclines. There has 
also been a significant decline in resistance to tetracyclines among isolates from France. No statistically 
significant trends were observed in resistance to cefotaxime, ciprofloxacin, nalidixic acid or streptomycin. 
In addition, comparing the last years in certain MSs, there were relatively large increases in resistance to 
ampicillin and sulfonamides in Estonia between 2010 and 2011, but a large concurrent decline in resistance 
to gentamicin. 
Figure EC10.  Trends in ampicillin resistance in indicator Escherichia coli from pigs in reporting MSs 
and one non-MS, 2005–2011, quantitative data 
 
Note: Statistically significant increasing trends over seven years, as tested by a logistic regression model (p ≤0.05), were observed in 
Austria (↑) and Denmark (↑). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EC11.  Trends in cefotaxime resistance in indicator Escherichia coli from pigs in reporting 
MSs, 2005–2011, quantitative data 
 
Note: No statistically significant trends over five or more years, as tested by a logistic regression model (p ≤0.05), were observed in any 
of the reporting countries. 
Figure EC12.  Trends  in  chloramphenicol  resistance  in  indicator  Escherichia  coli  from  pigs  in 
reporting MSs and one non-MS, 2005–2011, quantitative data 
 
Note: Statistically significant increasing trends over seven years, as tested by a logistic regression model (p ≤0.05), were observed in 
Austria (↑) and Denmark (↑). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EC13.  Trends in ciprofloxacin and nalidixic acid resistance in indicator Escherichia coli from 
pigs in reporting MSs and one non-MS, 2005–2011, quantitative data 
 
Note: No statistically significant trends over five or more years, as tested by a logistic regression model (p ≤0.05), were observed for 
either ciprofloxacin or nalidixic acid in any of the reporting countries. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EC14.  Trends in streptomycin resistance in indicator Escherichia coli from pigs in reporting 
MSs and one non-MS, 2005–2011, quantitative data 
 
Note: No statistically significant trends over five or more years, as tested by a logistic regression model (p ≤0.05), were observed for any 
of the reporting countries. 
Figure EC15.  Trends in tetracycline resistance in indicator Escherichia coli from pigs in reporting 
MSs and one non-MS, 2005–2011, quantitative data 
 
Note: Statistically significant increasing and decreasing trends over seven years, as tested by a logistic regression model (p ≤0.05), 
were observed in Denmark (↑) and France (↓). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Spatial distribution of resistance among indicator Escherichia coli 
The spatial distribution of nalidixic acid and tetracycline resistance in indicator E. coli from pigs is shown in 
Figures EC16 and EC17, respectively. For nalidixic acid, most countries reported low levels of resistance so 
the spatial pattern was less clear, although both countries reporting 0 % resistance were in northern Europe 
while the highest resistance was in the southern European reporting MS. With regard to tetracyclines, the 
northern European countries tended to report the lowest occurrence of resistance whereas most western or 
southern European countries reported very or extremely high resistance.  
Figure EC16.  Spatial distribution of nalidixic acid resistance among indicator Escherichia coli from 
pigs in countries reporting MIC data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data were used instead.  
1.  For Finland, 2010 data were used.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EC17.  Spatial distribution of tetracycline resistance among indicator Escherichia coli from 
pigs in countries reporting MIC data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data were used instead. The countries labelled as ‘qualitative data’ therefore 
include those reporting MIC data for fewer than 10 isolates or purely qualitative data (as proportion of resistant isolates).  
1.  For Finland, 2010 data were used.  
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Multi-resistance among indicator E. coli isolates from pigs 
Five MSs and two non-MSs had tested for the complete harmonised set of antimicrobials for E. coli and 
reported isolate-based data. Between about one quarter and half of the indicator E. coli isolates from pigs 
were susceptible to the nine antimicrobials of the set in the reporting countries, the only exception being 
Spain, where only 3.6 % of the isolates were categorised as susceptible. Multi-resistance levels were high to 
very high in all reporting countries, except in Norway, where less than 10 % of the isolates showed multi-
resistance (i.e. reduced susceptibility to three or more antimicrobial classes) (Table EC5). The frequency 
distributions (Figure EC18) showed that all reporting countries detected multi-resistance to as many as six or 
seven antimicrobial classes. Very few isolates exhibited co-resistance to cefotaxime and ciprofloxacin using 
either ECOFFs or clinical breakpoints as interpretative criteria (Table EC5). 
Table EC5.  Complete susceptibility, multi-resistance and index of diversity in E. coli from fattening 
pigs in MSs and non-MSs reporting isolate-based data, 2011 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to                       
CIP and CTX 
n  %  n  %  n  % 
Austria (N=162)  51  31.5  45  27.8  0.383  0    (0)  0  (0) 
Denmark (N=157)  76  48.4  42  26.8  0.445  0    (0)  0  (0) 
Estonia (N=22)  6  27.3  8  36.4  0.446  1    (0)  4.6  (0) 
Germany (N=859)  204  23.8  460  53.6  0.574  3    (2)  0.4  (0.2) 
Spain (N=169)  6  3.6  143  84.6  0.658  1    (0)  0.6   (0) 
Norway (N=192)  103  53.7  19  9.9  0.280  0    (0)  0  (0) 
Switzerland (N=175)  59  33.7  74  42.3  0.528  1    (1)  0.6  (0.6) 
N = total number of isolates tested for susceptibility against the whole common antimicrobial set for E. coli. 
n = Number of isolates per category of complete susceptibility or multiple resistance. 
Susceptible to all = isolate susceptible to all antimicrobial substances of the EFSA common set for E. coli. 
Multi-resistant = resistant to at least three different antimicrobial substances, belonging to any three antimicrobial families from the 
common antimicrobial set for E. coli. 
Index of diversity = see definition in section 11.4.2.1 of Materials and Methods. 
Co-resistant  to  cefotaxime  (CTX)  and  ciprofloxacin  (CIP)  =  the  effectives  and  percentages  of  E.  coli  isolates  non-susceptible  to 
concentrations greater than ECOFFs (CTX >0.25 mg/L and CIP >0.03 mg/L). Figures in parentheses indicate the occurrence of co-
resistance to CIP and CTX determined using clinical breakpoints (CTX >2 mg/L and CIP >1 mg/L). 
Figure EC18.  Frequency distribution of E. coli isolates completely susceptible and resistant to one 
to nine antimicrobials in pigs in MSs and non-MSs reporting isolate-based data, 2011 
 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances for E. coli. 
Susceptible = susceptible to all antimicrobial substances of the common set for E. coli. 
res1/res9 = resistance to one antimicrobial substance/resistance to nine antimicrobial substances of the common set for E. coli.  
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6.2.2.3. Cattle (bovine animals) 
In 2011, quantitative data for E. coli in cattle were provided by seven MSs and one non-MS (Switzerland) 
(Table EC6). These countries tested different production types and ages of cattle, including veal calves, 
young meat production animals, adult cattle and dairy cows; Denmark and Poland did not specify the type of 
cattle that were tested. The overall results for cattle presented in Table EC6 include all isolates of E. coli that 
were collected from this animal species by MSs which tested more than 10 isolates from cattle in total. 
Results  are  also  presented  for  the  specific  production  levels  of  cattle  from  which  these  E. coli  isolates 
originated. Some MSs tested fewer than 10 isolates from individual production types. In such cases, the data 
for these production types are included in the overall results for cattle but are not presented in the production 
level-specific sections of this table. 
In the reporting MSs, AMR monitoring in indicator E. coli isolates from cattle was chiefly based on active 
monitoring  plans  of  healthy  bovine  animals  either  sampled  from  randomly  selected  herds  (Belgium, 
Germany, the Netherlands) or randomly selected within the slaughterhouses (Austria, Denmark, Spain and 
Switzerland). In both cases samples are of faecal origin. The sampling plans performed at slaughter were 
stratified  per  slaughterhouse  and  the  number  of  samples  allocated  in  proportion  to  the  annual 
slaughterhouse  throughput.  In  any  case,  the  sampling  was  evenly  distributed  throughout  the  year  or  a 
significant part of the year to account for a possible seasonal effect. Only one representative faecal sample 
was gathered per epidemiological unit, either individual bovine animal or herd, to account for clustering. In 
Germany, the monitoring programme in 2011 focused specifically on young meat production animals (1-2 
years).  
Resistance levels among Escherichia coli 
The Netherlands reported much higher resistance levels among veal calves (aged less than one year) than 
among  dairy  cows.  However,  Austria  and  Switzerland  both  submitted  data  concerning  young  meat 
production animals (aged 1-2 years) and either adult cattle or dairy cows, and there was less difference in 
the resistance levels between these age groups in both countries. Belgium tended to report much higher 
resistance  among  isolates  from  veal  calves  than  young  meat  production  animals.  Denmark  and  Poland 
generally reported low resistance levels but, as the cattle type was not specified, the results may merge 
more than one age group, and therefore these data are difficult to interpret. Germany was responsible for 
nearly half of all the samples from MSs in 2011, so its results will have had a major influence on the overall 
results. 
Combining all types of cattle, the highest levels of resistance tended to be recorded against streptomycin, 
sulfonamides and  tetracyclines; the overall  resistance  levels  for  these  three  antimicrobials  were  17.4 %, 
19.5 % and 20.2 %, respectively, at the reporting MS group level. Belgium, Spain and Switzerland reported 
high levels of resistance to these antimicrobials among young meat production animals, while Belgium and 
the Netherlands reported very high or extremely high resistance levels among veal calves. There was also a 
moderate level of resistance  to  ampicillin  at the  MS group reporting  level when  all  types of cattle were 
combined (13.3 %). Most countries reported a slightly lower resistance level for this antimicrobial than for the 
previous three.  
The  occurrence  of  resistance  to  chloramphenicol,  ciprofloxacin,  gentamicin  and  nalidixic  acid  was  less 
common, with an overall level at the reporting MS group of 7.3 %, 6.0 %, 2.5 % and 4.8 %, respectively. The 
highest resistance  levels  to  all  four antimicrobials were reported by  Belgium  for  veal  calves  (50.0 %  for 
chloramphenicol, 44.1 % for ciprofloxacin, 20.6 % for gentamicin and 41.2 % for nalidixic acid); most other 
countries  reported  low  levels  of  resistance  to  these  four  antimicrobials.  Many  countries  reported  no 
resistance  to  cefotaxime,  with  the  highest  resistance  level  being  3.0 %  and  4.5 %,  recorded  by  the 
Netherlands and Belgium among veal calves and young meat production animals (under one year of age), 
respectively.  
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Table EC6.  Resistance  (%)  to  ampicillin,  cefotaxime,  chloramphenicol,  ciprofloxacin,  gentamicin, 
nalidixic acid, streptomycin, sulfonamides and tetracyclines among isolates of Escherichia coli from 
cattle in countries reporting MIC data
1 in 2011, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Veal calves (under one year)                   
Belgium  34  70.6  34  0  34  50.0  34  44.1  34  20.6 
Netherlands  166  48.8  166  3.0  166  26.5  166  24.1  166  11.4 
Total (2 MSs)  200  52.5  200  2.5  200  30.5  200  27.5  200  13.0 
Young meat production animals (under one year)                   
Belgium  154  25.3  154  4.5  154  14.3  154  13.0  154  2.6 
Young meat production animals (1-2 years)                   
Austria  41  0  41  0  41  2.4  41  0  41  2.4 
Germany  909  10.7  909  0.4  909  5.4  909  3.6  909  2.0 
Spain  109  14.7  109  0  109  11.0  109  4.6  109  2.8 
Total (3 MSs)  1,059  10.7  1,059  0.4  1,059  5.9  1,059  3.6  1,059  2.1 
Switzerland  164  17.7  164  0  164  11.6  164  4.9  164  3.7 
Adult cattle (over 2 years)                         
Austria  125  1.6  125  0  125  0.8  125  4.0  125  0 
Dairy cows                          
Netherlands  265  1.1  265  0  265  1.1  265  1.1  265  0 
Switzerland  18  27.8  18  0  18  5.6  18  0  18  0 
Unspecified cattle type                          
Denmark  93  2.2  93  0  93  2.2  93  0  93  0 
Poland  173  5.8  173  1.2  172  0  173  2.3  173  0 
Total (2 MSs)  266  4.5  266  0.8  265  0.8  266  1.5  266  0 
All types of cattle                             
Austria  172  2.9  172  0  172  1.2  172  2.9  172  0.6 
Belgium  188  33.5  188  3.7  188  20.7  188  18.6  188  5.9 
Denmark  93  2.2  93  0  93  2.2  93  0  93  0 
Germany  909  10.7  909  0.4  909  5.4  909  3.6  909  2.0 
Netherlands  431  19.5  431  1.2  431  10.9  431  10.0  431  4.4 
Poland  173  5.8  173  1.2  172  0  173  2.3  173  0 
Spain  109  14.7  109  0  109  11.0  109  4.6  109  2.8 
Total (7 MSs)  2,075  13.3  2,075  0.9  2,074  7.3  2,075  6.0  2,075  2.5 
Switzerland  182  18.7  182  0  182  11.0  182  4.4  182  3.3 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
1. Some MSs tested fewer than 10 isolates from individual production types. In such cases, the data for these production types are 
included in the overall results for cattle but are not presented in the production level-specific sections of this table. 
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Table  EC6  (continued).  Resistance  (%)  to  ampicillin,  cefotaxime,  chloramphenicol,  ciprofloxacin, 
gentamicin,  nalidixic  acid,  streptomycin,  sulfonamides  and  tetracyclines  among  isolates  of 
Escherichia  coli  from  cattle  in  countries  reporting  MIC  data
1  in  2011,  using  harmonised 
epidemiological cut-off values 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res 
Veal calves (under one year)                   
Belgium  34  41.2  34  55.9  34  79.4  34  73.5 
Netherlands  166  22.3  166  57.2  166  56.0  166  73.5 
Total (2 MSs)  200  25.5  200  57.0  200  60.0  200  73.5 
Young meat production animals (under one year)             
Belgium  154  11.7  154  27.3  154  30.5  154  19.5 
Young meat production animals (1-2 years)                
Austria  41  0  41  2.4  41  2.4  41  7.3 
Germany  909  2.0  909  15.1  909  16.9  909  17.2 
Spain  109  4.6  109  33.9  108  38.0  109  45.0 
Total (3 MSs)  1,059  2.2  1,059  16.5  1,058  18.6  1,059  19.6 
Switzerland  164  3.7  164  31.7  164  35.4  164  36.6 
Adult cattle (over 2 years)                   
Austria  125  3.2  125  8.8  125  6.4  125  8.8 
Dairy cows                          
Netherlands  265  0.4  265  1.1  265  0.8  265  1.5 
Switzerland  18  0  18  27.8  18  16.7  18  11.1 
Unspecified cattle type                    
Denmark  93  0  93  5.4  93  3.2  93  5.4 
Poland  173  1.2  173  5.8  173  15.0  173  6.4 
Total (2 MSs)  266  0.8  266  5.6  266  10.9  266  6.0 
All types of cattle  
Austria  172  2.3  172  8.1  172  7.0  172  9.9 
Belgium  188  17.0  188  32.4  188  39.4  188  29.3 
Denmark  93  0  93  5.4  93  3.2  93  5.4 
Germany  909  2.0  909  15.1  909  16.9  909  17.2 
Netherlands  431  8.8  431  22.7  431  22.0  431  29.2 
Poland  173  1.2  173  5.8  173  15.0  173  6.4 
Spain  109  4.6  109  33.9  108  38.0  109  45.0 
Total (7 MSs)  2,075  4.8  2,075  17.4  2,074  19.5  2,075  20.2 
Switzerland  182  3.3  182  31.3  182  33.5  182  34.1 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
1. Some MSs tested fewer than ten isolates from individual production types. In such cases, the data for these production types are 
included in the overall results for cattle but are not presented in the production level-specific sections of this table. 
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Temporal trends in resistance among indicator Escherichia coli 
Figures EC19-EC24 display the trends in resistance to selected antimicrobials in E. coli from cattle. It should 
be noted that the figures presented for each country merge the results for all cattle production types and/or 
ages  submitted  each  year.  As  in  the  other  livestock  species,  the  resistance  levels  varied  substantially 
between MSs for several of the antimicrobials, including ampicillin, streptomycin and tetracyclines. Austria 
and Denmark reported the lowest levels of resistance for many of the antimicrobials. As in pigs, cefotaxime 
resistance has been below 5 % in all countries since 2005 (Figure EC20). 
Considering  the  last  years  of  reporting,  the  resistance  levels  reported  by  Austria,  Denmark  and  the 
Netherlands in 2010 and 2011 were broadly comparable. Switzerland reported declines in resistance to most 
antimicrobials between 2010 and 2011, which is most probably because the study population in 2010 was 
veal calves less than six months old whereas in 2011 older cattle (>12 months) were sampled. In Germany, 
an extreme decline was reported despite only veal calves being sampled in 2010 and young meat production 
animals in 2011.  
Some countries, such as Austria, Denmark and the Netherlands, have shown relatively stable resistance 
levels or only minor fluctuations or trends since 2006 whereas other countries, such as France, Germany 
and Switzerland, have shown more substantial fluctuations in resistance levels that are at least partially due 
to the sampling of different cattle production types in different years. There have been numerous statistically 
significant  trends  in  resistance  levels  since  2005;  for  example,  Germany  showed  significant  declines  in 
resistance  to  six  of  the  antimicrobials.  Significant  decreasing  trends  were  also  observed  in  both  the 
Netherlands and Switzerland. In Switzerland this is most probably because calves under six months of age 
were sampled in 2010, while cattle over 12 months of age were sampled in 2011. The only antimicrobial for 
which no countries showed any significant increasing or decreasing trends was cefotaxime. 
Figure EC19.  Trends in ampicillin resistance in indicator Escherichia coli from cattle in reporting 
MSs and one non-MS, 2005–2011, quantitative data 
 
Note:  Statistically  significant  decreasing  trends  over  five  or  more  years,  as  tested  by  a  logistic  regression  model  (p  ≤0.05),  were 
observed in Austria (↓), Germany (↓), the Netherlands (↓) and Switzerland (↓). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EC20.  Trends in cefotaxime resistance in indicator Escherichia coli from cattle in reporting 
MSs, 2005–2011, quantitative data 
 
Note: No statistically significant trends over five or more years, as tested by a logistic regression model (p ≤0.05), were observed in any 
of the reporting countries. 
Figure EC21.  Trends  in  chloramphenicol  resistance  in  indicator  Escherichia  coli  from  cattle  in 
reporting MSs and one non-MS, 2005–2011, quantitative data 
 
Note:  Statistically  significant  decreasing  trends  over  five  or  more  years,  as  tested  by  a  logistic  regression  model  (p  ≤0.05),  were 
observed in Germany (↓), the Netherlands (↓) and Switzerland (↓). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EC22.  Trends in ciprofloxacin and nalidixic acid resistance in indicator Escherichia coli from 
cattle in reporting MSs and one non-MS, 2005–2011, quantitative data 
 
Note:  Statistically  significant  decreasing  trends  over  five  or  more  years,  as  tested  by  a  logistic  regression  model  (p  ≤0.05),  were 
observed in Denmark (↓), Estonia (↓), Germany (↓) and the Netherlands (↓) for ciprofloxacin, and in Germany (↓) for nalidixic acid. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EC23.  Trends in streptomycin resistance in indicator Escherichia coli from cattle in reporting 
MSs and one non-MS, 2005–2011, quantitative data 
 
Note:  Statistically  significant  decreasing  trends  over  five  or  more  years,  as  tested  by  a  logistic  regression  model  (p  ≤0.05),  were 
observed in Denmark (↓), Estonia (↓), Germany (↓) and Switzerland (↓). 
Figure EC24.  Trends in tetracycline resistance in indicator Escherichia coli from cattle in reporting 
MSs and one non-MS, 2005–2011, quantitative data 
 
Note:  Statistically  significant  decreasing  trends  over  five  or  more  years,  as  tested  by  a  logistic  regression  model  (p  ≤0.05),  were 
observed in Austria (↓), Germany (↓), the Netherlands (↓) and Switzerland (↓). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Spatial distribution of resistance among indicator Escherichia coli 
The spatial distributions of nalidixic acid and tetracycline resistance among E. coli from cattle are shown in 
Figures EC25 and EC26. Fewer countries have reported data for E. coli from cattle than for E. coli from 
Gallus gallus or pigs. Nevertheless, there was still some evidence that the lowest resistance to tetracyclines 
occurred in the northern countries and the highest occurred in the southern and western countries. With 
respect to nalidixic acid, the majority of countries reported low levels of resistance and no spatial pattern was 
evident. 
Figure EC25.  Spatial distribution of nalidixic acid resistance among indicator Escherichia coli from 
cattle in countries reporting MIC data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data were used instead.  
1.  For Estonia and Norway, 2010 data were used.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EC26.  Spatial distribution of tetracycline resistance among indicator Escherichia coli from 
cattle in countries reporting MIC data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data were used instead. The countries labelled as ‘qualitative data’ therefore 
include those reporting MIC data for fewer than 10 isolates or purely qualitative data (as proportion of resistant isolates).  
1.  For Estonia and Norway, 2010 data were used.  
Multi-resistance among indicator E. coli isolates from cattle 
No tables and graphs on multi-resistance are presented in this report for E. coli in cattle because too few 
MSs reported multi-resistance isolate-based data on more than 10 isolates in the different production types 
of cattle animal species. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
 
 
EFSA Journal 2013;11(5):3196  231 
6.3. Overview of findings on indicator E. coli resistance at reporting MS group level, 2011 
Figure  EC27  displays  the  resistance  levels  among  E. coli  isolates  in  the  reporting  MS group,  based on 
quantitative data submitted in 2011 for the various animal species. It should be borne in mind that the data 
for the different species are derived from different groups of MSs. 
The  resistance  levels  observed  in  E. coli  isolates  from  cattle  were  lower  than  in  E. coli  from  either 
Gallus gallus  or  pigs,  most  notably  for  ampicillin,  streptomycin,  sulfonamides  and  tetracyclines.  This 
contrasts with the previous year, when the resistance levels were fairly similar among the different livestock 
types, but is similar to preceding years, when the levels in cattle were also lower. In 2011, compared with 
2010, resistance levels increased at the reporting MS group level in Gallus gallus and pigs but decreased in 
cattle. This is in direct contrast to the situation in 2010, relative to 2009, when resistance levels decreased in 
both  Gallus  gallus  and  pigs  but  increased  in  cattle.  This  would  partly  explain  the  greater  and  lesser 
distinction between the resistance levels in different production types in 2011 and 2010, respectively. The 
variations at the reporting MS group level between years could be attributable to different MSs contributing 
data and different production types of livestock being sampled. The MSs that provided data for all three 
livestock species in both 2010 and 2011 usually reported the lowest resistance levels among cattle. 
As in previous years, isolates from pigs had the highest levels of resistance to streptomycin, sulfonamides 
and tetracyclines, while isolates from Gallus gallus had the highest resistance to ampicillin, ciprofloxacin and 
nalidixic acid. Resistance to chloramphenicol and gentamicin was relatively low in all types of livestock, with 
the highest resistance level occurring in pigs and Gallus gallus, respectively. This differs to 2010, when the 
highest resistance levels for these two antimicrobials were observed in cattle. Chloramphenicol has not been 
used for food production animals in the EU for several years; thus, the resistance observed must either 
indicate persistence of resistance genes or co-selection resulting from use of related compounds (such as 
florfenicol).  The  lowest  levels  of  resistance  were  usually  observed  to  cefotaxime;  the  highest  level  of 
resistance to this antimicrobial occurred in isolates from Gallus gallus, which was also the case in previous 
years. 
Figure EC27.  Resistance  in  indicator  Escherichia  coli  from  fowl,  pigs  and  cattle  to  ampicillin, 
cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, streptomycin, sulfonamides 
and tetracyclines at reporting MS group level, in 2011 
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6.4. Discussion 
Antimicrobial resistance in indicator, commensal E. coli from animals and food can be used to examine the 
reservoir  of  resistance  genes  occurring  in  those  bacteria  that  could  be  transferred  to  bacteria  that  are 
pathogenic  for  humans  and/or  animals.  The  major  factor  influencing  the  occurrence  of  resistance  to 
antimicrobials in indicator E. coli is likely to be the selective pressures exerted by use of antimicrobials in the 
different food animal populations; variations in usage between animal species may also contribute to the 
observed  differences  in  resistance  levels  between  the  animal  species.  Indicator  E. coli  are  thus  also  of 
interest when investigating possible associations between the usage of antimicrobials in a given country and 
the occurrence of resistance in an animal species, because of their ubiquity in food-producing animals. Multi-
resistance data, available for the first time in 2011, indicates that the co-resistance phenomenon is to be 
accounted for when analysing the relationship between antimicrobial use and resistance in animals. 
A total of 12 MSs and 2 non-MSs provided quantitative MIC data in 2011 on at least one of the livestock 
species. For both Gallus gallus and pigs, 12 countries provided quantitative dilution data in 2011 compared 
with seven in 2010; for cattle, eight countries provided quantitative data concerning E. coli compared with 
seven  in  2010.  The  EFSA  recommendations  (EFSA,  2008a)  state  that  different  animal  species  may  be 
sampled once every three years, and this may account for the variation in the number of countries reporting 
data for each animal species between years. Reported AMR data in E. coli isolates from food-producing 
animals and food derived mainly from active and representative monitoring programmes, chiefly based on 
sampling performed at the slaughterhouse. 
At the reporting MS group level, a high level of resistance was observed to several antimicrobials among 
food-producing animals, with some countries reporting a very or extremely high occurrence of resistance. 
Few MSs reported on antimicrobial resistance in meat, but those which did generally reported comparable 
resistance levels in meat as in the corresponding source animal species. Indeed, Denmark and Germany 
reported  resistance  in  isolates  from  broiler  meat  broadly  comparable  to  that  recorded  in  isolates  from 
broilers. Resistance recorded by Denmark, Germany and Sweden in isolates from pork is roughly similar to 
that reported from pigs. However, the most notable exceptions are for Germany, which reported somewhat 
higher resistance among isolates from pigs than in isolates from pig meat to ampicillin (44.7 % vs. 25.0 %), 
chloramphenicol (14.6 % vs. 0 %), streptomycin (59.4 % vs. 28.8 %), sulfonamides (47.7 % vs. 26.9 %) and 
tetracyclines (62.5 % vs. 30.8 %). Similarly, in cattle, resistance in isolates from meat from cattle recorded in 
Denmark and Germany was roughly comparable to that reported for bovine animals in the same MSs (Table 
EC6), for which Germany reported on isolates from young meat production animals and Denmark reported 
on isolates from unspecified cattle type.  
In 2011, resistance levels were higher among E. coli isolates from Gallus gallus and pigs than isolates from 
cattle. This differs to the situation in 2010, when resistance levels were comparable in the different livestock 
species, but it is similar to the preceding years. In 2011, resistance at the reporting MS group level was 
higher than in 2010 for isolates from Gallus gallus and pigs but lower in isolates from cattle. In contrast, 
resistance levels in 2010 were lower than in 2009 in isolates from both Gallus gallus and pigs but higher 
among isolates from cattle. As resistance levels tend to vary substantially between countries, the variation in 
resistance in Gallus gallus, pigs and cattle observed between the years 2009, 2010 and 2011 at the overall 
MS group level may partly result from different MSs contributing to data as well as different production types 
of livestock being sampled.  
This  was  the  first  year  that  resistance  data  were  reported  separately  for  different  production  types  of 
Gallus gallus and cattle. However, only two countries provided data on laying hens, and only one of these 
MSs also provided data on broilers. Although there is limited information available in 2011 on which to draw 
firm conclusions, resistance levels appeared to be higher among broilers than in laying hens. Similarly, in 
2011, few MSs reported on more than one production type or age group of cattle. Two countries also did not 
report which type of cattle were tested. Therefore, it is difficult to determine the extent to which differences 
observed between the age groups are real or simply an artefact of differing resistance levels between those 
countries. While the Netherlands reported much higher resistance levels among younger animals, the same 
was not found in Austria or Switzerland. 
Generally, the highest resistance levels were identified for ampicillin, sulfonamides and tetracyclines, which 
are commonly used therapeutically in animals. Moreover, some countries have shown statistically significant 
increasing trends in resistance to these antimicrobials over five or more years since 2006. However, all of the 
trends in resistance to sulfonamides that were found to be statistically significant in all three of the food-EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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producing animal species were actually decreasing trends. At the MS group level, resistance to gentamicin 
was highest in Gallus gallus (3.5 %) and lowest in pigs (2.2 %).  
Resistance was also identified to antimicrobials recognised to be critically important in human medicine, 
including fluoroquinolones (ciprofloxacin) and third-generation cephalosporins (cefotaxime). Resistance to 
ciprofloxacin in meat was generally at a low level, although Germany reported 52.3 % resistance in isolates 
from broiler meat. Only Denmark reported data on isolates from meat in both 2010 and 2011, and reported 
only  a  marginal  increase  in  resistance  levels;  for  example,  2.7 %  of  isolates  from  bovine  meat  tested 
resistant to ciprofloxacin in 2011 compared with none in 2010. At the reporting MS group level, resistance to 
ciprofloxacin in E. coli was much higher in isolates from Gallus gallus (40.5 %) than from pigs (8.3 %) or 
cattle  (6.0 %).  Although  the  level  in  Gallus  gallus  and  pigs  was  higher  than  in  2010  (29 %  and  2 %, 
respectively),  the  level  in  cattle  was  lower  than  in  2010  (15 %).  While  Austria  and  France  have  shown 
statistically significant increases in resistance to this antimicrobial in Gallus gallus since 2006, no statistically 
significant trends were observed in pigs and only statistically significant decreasing trends were identified in 
cattle.  
The occurrence of resistance to nalidixic acid was often similar to that for ciprofloxacin, suggesting that 
mutation in the topoisomerase enzymes (gyrA or parC) may, in those cases, have been responsible for 
resistance. However, in some MSs, the occurrence of resistance to ciprofloxacin was slightly higher than that 
obtained  for  nalidixic  acid.  In  these  cases,  mechanisms  such  as  transferable  fluoroquinolone  resistance 
conferred  by  qnr  genes  may  have  been  the  responsible  for  resistance,  as  such  plasmid-mediated 
mechanisms can result in that phenotypic pattern of resistance. 
The occurrence of third-generation cephalosporin resistance was still generally low, although Belgium and 
Spain did report 19.1 % and 20.8 % resistance in E. coli from Gallus gallus, respectively. Third-generation 
cephalosporin  resistance  was  higher  in  isolates  from  Gallus  gallus  than  in  pigs  or  cattle.  Cefotaxime 
resistance was marginally higher than in 2010 at the reporting MS group level for isolates from Gallus gallus 
(6.4 % vs. 5 %) and pigs (1.7 % vs. 1 %) but slightly lower for isolates from cattle (0.9 % vs. 3 %). Resistance 
was also low in isolates from meat. Denmark was the only country to report on isolates from meat in both 
2010 and 2011: cefotaxime resistance in broiler meat increased from 0.6 % to 2.5 %, and 2.5 % of broiler 
meat isolates were also resistant to ceftiofur, but none of the isolates from pig or bovine meat were resistant 
to cefotaxime or ceftiofur in 2011. Considering the data reported by MSs, there have been no statistically 
significant trends observed in resistance to cefotaxime since 2005 in any of the livestock species, with less 
than 5 % of isolates from pigs or cattle expressing resistance in all countries since 2005. The findings in 
relation  to  third-generation  cephalosporin  resistance  are  discussed  further  in  Chapter 9.  EFSA  (EFSA, 
2012b)  has  also  published  recommendations  for  surveillance  of  indicator  E. coli  resistant  to  cefotaxime, 
which would extend the scope of the current monitoring by including selective culture for such organisms. 
Current procedures rely on random selection of indicator E. coli isolates from primary culture plates; selective 
culture could additionally be used to detect the presence or absence of isolates resistant to cefotaxime in a 
sample (within the detection limit of the chosen method). Monitoring using selective media for cefotaxime 
resistance would thus detect cefotaxime-resistant E. coli present as a minor component of the total bacterial 
flora  in  the  test  sample  and  which  might  only  occasionally  be  detected  by  random  sampling  from  non-
selective culture plates. 
The resistance trends in each MS since 2006 were tested for statistical significance whenever five or more 
years of data were available. More statistically significant increasing trends were observed than decreasing 
trends in isolates from Gallus gallus. In contrast, all of the significant trends in cattle were decreasing. Since 
2006,  Germany  has  shown  significant  declines  in  resistance  to  four  antimicrobials  in  isolates  from 
Gallus gallus  and  six  antimicrobials  in  isolates  from  cattle.  Germany  also  reported  substantially  lower 
resistance in isolates from cattle in 2011 compared with 2010 for all antimicrobials despite only sampling veal 
calves in 2010 and young meat production animals in 2011. 
Multi-resistance levels (proportions of isolates showing reduced susceptibility to at least three antimicrobial 
classes according to ECOFFs) were relatively high in indicator E. coli isolates from both broilers and pigs in 
most reporting countries. Co-resistance to cefotaxime and ciprofloxacin was detected at very low levels in 
both broilers and pigs, although more co-resistant strains were isolated from broilers than from pigs in the 
reporting countries. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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7. ANTIMICROBIAL RESISTANCE IN ENTEROCOCCI 
7.1. Introduction 
A number of commensal bacteria are naturally present in the intestine of farm animals and some of these, 
such  as  E. coli  and  certain  species  of  Enterococcus,  tend  to  be  consistently  present,  occurring  in  the 
intestine of all, or the majority, of animals. These bacterial organisms (E. coli representing the Gram-negative 
organisms  and  Enterococcus  spp.  representing  the  Gram-positive  organisms)  are  therefore  selected  as 
indicator organisms which reflect the degree of resistance borne by the commensal flora of animals. They 
are considered a potential reservoir of resistance genes that can spread horizontally to zoonotic and other 
bacteria through the food chain (Neidhardt, 1996; Winokur et al., 2001; Wang et al., 2006). Of course, some 
antimicrobials have a largely Gram-negative or Gram-positive spectrum and the inclusion of both E. coli and 
Enterococcus spp. in the monitoring programme ensures that a broad range of important antimicrobials with 
a different spectrum of action can be covered. The generally ubiquitous occurrence of indicator organisms in 
many  food-producing  animal  species  means  that  randomised  sampling  strategies  can  be  developed, 
allowing for statistical analysis of data and reducing the effect of sampling bias, as well as allowing inference 
to be made from the representative random sample investigated to the target population from which the 
sample was derived. 
The Enterococcus species, E. faecium and E. faecalis, are suitable as indicator bacteria since both species 
are commonly isolated from animal faeces; furthermore, these species of Enterococcus are also important in 
human medicine. Enterococcus species can occur in the intestinal tract of animals at a different prevalence, 
dependent upon the animal species concerned, as well as varying, in some cases, with the age of the 
animal. The occurrence of E. faecium and E. faecalis in the intestinal tract of animals or on food, even if not 
directly significant for man, may constitute a reservoir of resistance genes which could be transferred either 
to pathogenic bacteria or to other commensal bacteria. In addition, they are considered good indicators of 
the selective pressure exerted by the use of antimicrobials on intestinal populations of Gram-positive bacteria 
in food animals. 
According  to  current  EU  legislation,  the  monitoring  of  AMR  in  enterococci  in  animals  and  food  is  not 
mandatory. However, harmonised technical specifications for this monitoring, including sampling protocols, 
have  been  proposed  to  volunteering  MSs  in  the  EFSA  guidelines  (EFSA,  2008a).  These  encourage 
development of randomised sampling strategies allowing for robust statistical analysis of data and reducing 
the effect of sampling bias. Monitoring in accordance with the recommendations may be carried out at the 
farm or slaughterhouse level. 
7.2. Antimicrobial resistance in indicator enterococci isolates from animals and food 
A  total  of  10  MSs  and  two  non-MSs  (Norway  and  Switzerland)  reported  quantitative  MIC  data  on 
antimicrobial resistance in enterococci isolated from animals and food in 2011. Only one country provided 
qualitative data, so no specific subsection for these data has been prepared. Tables EN1 and EN2 show the 
countries that reported E. faecium and E. faecalis MIC values in 2011. The total number of tests performed 
on enterococci isolates from animals and food in 2011 by MSs and non-MSs and for which quantitative MIC 
data are available was 69,166.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table EN1.  Overview  of  countries  reporting  antimicrobial  resistance  data  using  MIC  and  disc 
inhibition zones on Enterococcus faecium from animals and food in 2011 
Method  Origin  Total number of 
MSs reporting  Countries 
Dilution 
Gallus gallus (fowl)  8 
MSs: AT, BE, DK, ES, FI, FR, IE, NL 
Non-MSs: CH, NO 
Turkeys  1  MS: NL 
Pigs  8 
MSs: AT, BE, DK, EE, ES, FR, NL, SE 
Non-MSs: CH 
Cattle (bovine animals)  4 
MSs: AT, BE, ES, NL 
Non-MS: CH 
Meat from broilers (Gallus gallus)  2  MSs: DK, NL 
Meat from turkey  1  MS: NL 
Meat from pig  2  MSs: DK, NL 
Meat from bovine animals  1  MS: NL 
Meat from sheep  1  MS: NL 
Fruit  1  MS: NL 
Vegetables  1  MS: NL 
Spices and herbs  1  MS: NL 
 
Table EN2.  Overview  of  countries  reporting  antimicrobial  resistance  data  using  MIC  and  disc 
inhibition zones on Enterococcus faecalis from animals and food in 2011 
Method  Origin  Total number of 
MSs reporting  Countries 
Diffusion 
Meat from broilers (Gallus gallus)  1  MS: HU 
Meat from turkey  1  MS: HU 
Meat from pig  1  MS: HU 
Meat from bovine animals  1  MS: HU 
Dilution 
Gallus gallus (fowl)  8 
MSs: AT, BE, DK, ES, FI, FR, IE, NL 
Non-MSs: CH, NO 
Turkeys  1  MS: NL 
Pigs  7 
MSs: AT, BE, DK, EE, ES, FR, NL 
Non-MS: CH 
Cattle (bovine animals)  4 
MSs: AT, BE, ES, NL 
Non-MS: CH 
Meat from broilers (Gallus gallus)  2  MSs: DK, NL 
Meat from turkey  1  MS: NL 
Meat from pig  3  MSs: DK, NL, SE 
Meat from bovine animals  2  MSs: DK, NL 
Meat from sheep  1  MS: NL 
Fruit  1  MS: NL 
Vegetables  1  MS: NL 
Spices and herbs  1  MS: NL 
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The antimicrobials selected by the different MSs and non-MSs for susceptibility testing of E. faecium and 
E. faecalis are shown in Chapter 11, Materials and Methods, Table MM9. 
The  occurrence  of  resistance  to  ampicillin,  chloramphenicol,  erythromycin,  gentamicin,  linezolid, 
quinupristin/dalfopristin (E. faecium only), streptomycin, tetracyclines and vancomycin is presented in Tables 
EN3, EN4, EN6, EN7, EN9 and EN10 and described in detail in the text below. Chloramphenicol, gentamicin, 
linezolid  and  quinupristin/dalfopristin  have  not  been  included  in  previous  years’  reports.  The  tables 
presenting occurrence of resistance were generated if four or more MSs reported quantitative data for each 
Enterococcus  species  and  sampling  origin;  tables  showing  resistance  in  isolates  from  cattle  were  also 
generated even though fewer than four countries reported data. In addition, only data where 10 or more 
isolates were available per country, per sampling origin and per year are included in the report. 
Where the minimum criteria were met, temporal trend graphs have been generated, showing the percentage 
of isolates resistant to different antimicrobials for Enterococcus isolates from animals and food between 2006 
and 2011. Only countries which had reported for four or more years in the 2006–2011 period were included. 
These trends are presented in Figures EN1–EN10, EN15–EN24 and EN29–EN38. 
The spatial distributions of the tetracycline, erythromycin and vancomycin resistance levels are presented in 
Figures EN11–EN13 for E. faecium from Gallus gallus and Figures EN25–EN27 for E. faecium from pigs. 
Where data were unavailable for 2011 for a particular country, the data from 2010 were used instead. These 
antimicrobials are highlighted because of the public health importance of vancomycin and because of the 
differences in the levels of resistance frequently observed in different MSs to erythromycin and tetracyclines. 
Further information on reported MIC distributions and numbers of isolates resistant to amoxicillin/clavulanic 
acid, ampicillin, bacitracin, chloramphenicol, ciprofloxacin, daptomycin, erythromycin, florfenicol, gentamicin, 
kanamycin,  lincomycin,  linezolid,  narasin,  neomycin,  nitrofurantoin,  penicillin,  quinupristin/dalfopristin 
(E. faecium  only),  salinomycin,  streptomycin,  teicloplanin,  tetracyclines,  tigecycline,  vancomycin  and 
virginiamycin among E. faecium and E. faecalis can be found in the Level 3 tables published on the EFSA 
website. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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7.2.1. Antimicrobial resistance in indicator enterococci isolates from food 
7.2.1.1. Meat 
In 2011, the Netherlands provided quantitative MIC data for E. faecium and E. faecalis isolates from meat 
from bovine animals, broilers (Gallus gallus) and pigs. Denmark also provided all of these data, except for 
E. faecium from meat from bovine animals. Sweden provided only data concerning E. faecalis isolates from 
meat from pigs. Data on antimicrobial resistance in indicator enterococci isolates reported by Denmark and 
Sweden  were  derived  from  active  and  representative  monitoring  programmes.  In  Denmark,  enterococci 
isolates  originated  from  meat  sampled  at  wholesale  and  retail  outlets,  and  were  collected  randomly 
throughout  all  regions  of  the  country  in  the  framework  of  three  centrally  coordinated  sampling  plans 
corresponding to each type of meat. In Sweden, the programme is based on a sampling plan of broiler fillets, 
stratified  by  slaughterhouses  that  participate  and  proportional  to  slaughterhouse  broiler  meat  production 
capacity. The sampling strategies employed by the Netherlands were not detailed. 
Resistance levels among tested enterococci isolated in broiler meat 
Denmark and the Netherlands tested 83 and 24 isolates of E. faecium, respectively, as well as 34 and 110 
isolates of E. faecalis, respectively, from meat from broilers (Gallus gallus). The Netherlands tended to report 
higher resistance levels than Denmark for both species of Enterococcus. The highest resistance among 
E. faecium isolates was to quinupristin/dalfopristin, for which Denmark reported high resistance (34.9 %) and 
the Netherlands reported extremely high resistance (75.0 %). Regarding erythromycin, Denmark and the 
Netherlands reported resistance levels of 19.3 % and 66.7 %, respectively, for E. faecium and 17.6 % and 
62.2 %, respectively, for E. faecalis. For tetracyclines they reported resistance levels of 9.6 % and 45.8 %, 
respectively,  for  E. faecium  and  26.5 %  and  74.5 %,  respectively,  for  E. faecalis.  With  respect  to 
streptomycin, the Netherlands reported a high level of resistance among E. faecium (25.0 % resistance) and 
E. faecalis (50.0 % resistance) isolates, whereas Denmark reported no resistance among the former and 
only low resistance among E. faecalis (5.9 %). Both countries reported a low level of resistance to ampicillin 
in E. faecium (2.4 % for Denmark and 8.3 % for the Netherlands). Resistance among E. faecalis was lower, 
with all Danish isolates showing full sensitivity and only 0.9 % of isolates from the Netherlands expressing 
resistance.  The  Netherlands  reported  a  low  level  of  resistance  to  both  chloramphenicol  (4.5 %)  and 
gentamicin (2.7 %) among E. faecalis isolates but found no resistance among E. faecium; Denmark reported 
no resistance to either of these two antimicrobials in either Enterococcus species. Neither country reported 
any resistance to linezolid or vancomycin among either enterococci species.  
Resistance levels among tested enterococci isolated in pig meat 
Denmark and the Netherlands tested 27 and 106 isolates of E. faecium, respectively, from meat from pigs, 
while Denmark, the Netherlands and Sweden tested 133, 233 and 29 isolates of E. faecalis, respectively. 
There  was  a  moderate  level  of  resistance  to  erythromycin  among  E. faecium  (14.8 %  in  isolates  from 
Denmark and 16.0 % in isolates from the Netherlands). Both countries reported only low levels of resistance 
among  E. faecalis  (8.3 %  and  5.6 %,  respectively),  and  Sweden  reported  no  resistance.  Resistance  to 
tetracyclines  among  E. faecium  was  low  for  isolates  from  both  Denmark  (7.4 %)  and  the  Netherlands 
(8.5 %). Both countries reported slightly higher levels of resistance among E. faecalis (17.3 % and 18.9 %, 
respectively)  while  Sweden  reported  6.9 %  resistance.  Resistance  to  streptomycin  was  low  for  both 
E. faecium  (3.7 %  and  1.9 %  resistance  in  Denmark  and  the  Netherlands,  respectively)  and  E. faecalis 
(5.3 %,  4.3 %  and  3.4 %  resistance  in  Denmark,  the  Netherlands  and  Sweden,  respectively).  The 
Netherlands reported 0.9 % resistance to ampicillin among E. faecium whereas all isolates from Denmark 
were fully sensitive. All three countries also reported full sensitivity to ampicillin among  E. faecalis. With 
respect  to  chloramphenicol  and  gentamicin,  Denmark  and  the  Netherlands  both  reported  full  sensitivity 
among E. faecium. Sweden also reported no resistance to either of these antimicrobials among E. faecalis, 
whereas Denmark and the Netherlands reported a low or very low occurrence of resistance, of 3.8 % and 
1.7 %, respectively, for chloramphenicol, and 1.5 % and 0.4 %, respectively, for gentamicin. No resistance 
was reported to linezolid or vancomycin in either of the enterococci species. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Resistance levels among tested enterococci isolated in bovine meat 
The Netherlands tested 146 and 216 isolates of E. faecium and E. faecalis, respectively, from meat from 
bovine animals, while Denmark tested only 20 isolates of E. faecalis. The Netherlands reported very high 
resistance (61.6 %) to quinupristin/dalfopristin and a high level of resistance (22.6 %) to erythromycin among 
E. faecium. In contrast, both Denmark and the Netherlands reported only low levels of resistance to the latter 
antimicrobial  among  E. faecalis  (5.0 %  and  5.6 %,  respectively).  A  moderate  level  of  resistance  to 
tetracyclines was reported for both E. faecium (13.0 %) and E. faecalis (20.0 % and 19.9 %, respectively). 
With regard to streptomycin, resistance was low for both E. faecium (6.8 %) and E. faecalis (10.0 % and 
6.5 %, respectively). The Netherlands also reported a low level of resistance to ampicillin among E. faecium 
(1.4 %),  whereas  both  countries  reported  full  sensitivity  among  isolates  of  E. faecalis.  Regarding 
chloramphenicol,  the  Netherlands  reported  very  low  resistance  among  E. faecium  (0.7 %),  while  both 
Denmark and the Netherlands reported low resistance among E. faecalis (5.0 % and 2.3 %, respectively). 
The Netherlands also reported very low resistance to gentamicin among E. faecium (0.7 %) and E. faecalis 
(0.9 %)  whereas  Denmark  reported  no  resistance  among  E. faecalis.  A  very  low  level  of  resistance  to 
linezolid among E. faecium (0.7 %) was reported by the Netherlands, while no resistance was reported by 
Denmark, and neither country reported any resistance to vancomycin among either E. faecium or E. faecalis. 
Multi-resistance among enterococci isolates from food 
As fewer than four MSs reported resistance isolate-based data on more than 10 isolates of either E. faecalis 
or E. faecium in food, tables and graphs on multi-drug resistance are not presented in this report. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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7.2.2. Antimicrobial resistance in indicator enterococci isolates from animals 
7.2.2.1. Fowl (Gallus gallus) 
In this report, data for fowl (Gallus gallus) include only data from broilers. Some countries collected samples 
at the farm, but in the majority of the reporting MSs enterococci isolates were collected from broiler carcases 
randomly sampled at the slaughterhouse as part of a national monitoring programme of resistance. The 
slaughterhouses included in the monitoring programme accounted for a major proportion, typically around 
80 % or more, of the total production in the country. The sampling plan was stratified by slaughterhouse, the 
sample size per slaughterhouse being proportional to the annual throughput of animals slaughtered. For 
Denmark, Finland, Spain, Norway and Switzerland sampling was evenly spread throughout the year or a 
significant part of the year to account for any possible seasonal effect. Indicator enterococci isolates were 
isolated from caecal contents in France and the Netherlands, from cloacal swabs in Switzerland and from 
faecal samples in  most other reporting MSs, by sampling healthy broilers at slaughter or environmental 
faeces  with  boot  swabs  at  the  farm.  Only  one  representative  sample  of  caecal  content  per  flock/batch, 
derived either from a unique animal or from a number of slaughtered animals, was gathered to account for 
clustering. Information on the sampling strategy was not presented by Ireland. 
Resistance levels in tested isolates 
In 2011, eight MSs and two non-MSs reported quantitative antimicrobial resistance data on enterococci from 
Gallus gallus. Four of the MSs (Austria, Denmark, France and the Netherlands) and one of the non-MSs 
(Switzerland) that submitted data in 2011 also provided data in 2010. Belgium, Finland, Ireland, Spain and 
Norway submitted data in 2011 but did not in the previous year. In contrast, Sweden reported data in 2010 
but did not submit any data in 2011. Tables EN3 and EN4 present, respectively, the occurrence of resistance 
to the selected nine antimicrobials among E. faecium and E. faecalis in these countries. As in previous years, 
resistance levels to many of the antimicrobials varied markedly between countries. 
At  the  reporting  MS  group  level,  there  was  an  extremely  high  level  of  resistance  (73.5 %)  to 
quinupristin/dalfopristin  among  E. faecium.  Resistance  levels  in  the  individual  reporting  countries  ranged 
between  43.9 %  and  100 %,  although  three  countries  did  not  report  any  data  for  this  antimicrobial. 
Resistance to tetracyclines was very high among both E. faecium (59.7 %) and E. faecalis (61.9 %) at the 
reporting MS group level. These resistance levels are similar to those reported in 2010 (56 % and 60 %, 
respectively). Resistance levels in the individual countries ranged between 5.6 % and 91.8 % for E. faecium 
and between 7.1 % and 94.6 % for E. faecalis. Belgium, France and Spain reported the highest resistance 
levels  for  both  species  of  Enterococcus,  while  Denmark  and  Finland  reported  the  lowest  for  both.  Six 
countries  reported  either  very  high  or  extremely  high  resistance  levels  against  E. faecium  and  seven 
countries  against  E. faecalis.  Denmark,  Norway  and  Switzerland  reported  higher  resistance  levels  in 
E. faecalis than in E. faecium; in other countries resistance levels were more similar in both species. 
There was also a very high level of resistance to erythromycin for both E. faecium (54.6 %) and E. faecalis 
(65.2 %) at the reporting MS group level. These levels were marginally higher than those reported in 2010, 
when 47 % and 56 % of isolates, respectively, expressed resistance. Spain and the Netherlands reported the 
highest resistance levels in both species of enterococci while Denmark and Norway reported the lowest in 
both. Norway reported a low level of resistance in E. faecium (5.7 %) and Denmark reported a moderate 
level (15.0 %) but all other countries reported high, very high or extremely high levels of resistance, ranging 
between  21.5 %  and  88.9 %.  Regarding  E. faecalis,  Denmark  reported  a  moderate  level  of  resistance 
(14.5 %) but all other countries reported an occurrence of resistance of between 25.8 % and 85.7 %. In 
Austria, Finland, Ireland, Norway and Switzerland, the level of resistance for E. faecalis was higher than that 
in E. faecium, the difference being more significant in Finland and Ireland. 
Resistance to streptomycin was high at the reporting MS group level: 34.0 % of E. faecium isolates and 
33.0 %  of  E. faecalis  isolates  expressed  resistance.  These  levels  are  only  marginally  higher  than  those 
reported in 2010 (28 % and 25 %, respectively). Again, there was extensive variation in the resistance levels 
reported by individual countries, ranging from 0.6 % (Norway) to 60.6 % (Belgium) for E. faecium and from 
0.0 % (Finland) to 59.3 % (Belgium) for E. faecalis. Norway reported much higher resistance in E. faecalis 
(16.1 %) than in E. faecium (0.6 %). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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There was also a high level of resistance to ampicillin at the reporting MS group level in E. faecium (25.9 %), 
whereas  the  overall  resistance  level  in  E. faecalis  was  low  (1.0 %).  Regarding  E. faecium,    half  of  the 
countries reported low or very low resistance rates, with Finland and Norway reporting 0.5 % and 0.6 % 
resistance, respectively. However, Ireland reported extremely high resistance to this antimicrobial (74.8 %) 
and  both  the  Netherlands  and  Spain  reported  a  high  resistance  level  of  36.1 %.  Regarding  E. faecalis, 
Belgium and Spain were the only countries to detect any resistance, reporting that 11.1 % and 1.6 % of 
isolates were resistant, respectively. 
Resistance  to  gentamicin  was  at  a  low  level  among  E. faecium  (1.7 %)  and  E. faecalis  (2.8 %)  at  the 
reporting MS group level. With respect to E. faecium, six countries reported no resistance while three others 
reported resistance levels ranging between 0.8 % and 11.1 %. For E. faecalis, most countries reported no or 
low resistance levels although Spain reported a high level of 27.0 % resistance.  
At  the  reporting  MS  group  level,  there  was  very  low  resistance  to  chloramphenicol  (0.6 %)  among 
E. faecium, with only four MSs reporting low or very low levels of 0.5 % to 9.1 % resistance. There was also 
low  resistance  among  E. faecalis  (4.2 %)  although  eight  countries  reported  resistance  and  at  marginally 
higher levels of between 2.0 % and 15.9 %.  
Concerning vancomycin, resistance was very low overall at the reporting MS group level in both E. faecium 
(0.7 %) and E. faecalis (0.6 %), which is comparable to the levels reported in 2010. Only Austria (1.4 %), 
Belgium (9.1 %), Finland (1.0 %) and the Netherlands (0.5 %) detected any resistance in the former, while 
only Belgium (3.7 %), Ireland (2.0 %) and Spain (1.6 %) reported resistance in the latter.  
Belgium was the only country to report resistance to linezolid for both E. faecium (6.1 %) and E. faecalis 
(6.2 %). 
Table EN3.  Resistance  (%)  to  ampicillin,  chloramphenicol,  erythromycin,  gentamicin,  linezolid, 
quinupristin/dalfopristin, streptomycin, tetracyclines and vancomycin among Enterococcus faecium 
from broilers (Gallus gallus) in countries reporting MIC data in 2011 
Country 
Ampicillin  Chloramphenicol  Erythromycin  Gentamicin  Linezolid 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  72  4.2  72  0  72  41.7  72  0  72  0 
Belgium  33  24.2  33  9.1  33  72.7  33  0  33  6.1 
Denmark  107  2.8  107  0  107  15.0  107  0  107  0 
Finland  191  0.5  191  0.5  191  21.5  191  0  191  0 
France  170  15.3  170  0.6  170  61.2  170  0  170  0 
Ireland  123  74.8  123  0  123  41.5  123  0.8  -  - 
Netherlands  427  36.1  427  0.5  427  78.5  427  3.5  427  0 
Spain  36  36.1  36  0  36  88.9  36  11.1  36  0 
Total (8 MSs)  1,159  25.9  1,159  0.6  1,159  54.6  1,159  1.7  1,036  0.2 
Norway  176  0.6  176  0  176  5.7  176  0  176  0 
Switzerland  13  7.7  13  0  13  23.1  -  -  13  0 
 
Country  Quinupristin/dalfopristin  Streptomycin  Tetracyclines  Vancomycin 
N  % Res  N  % Res  N  % Res  N  % Res 
Austria  72  70.8  72  11.1  72  54.2  72  1.4 
Belgium  33  100  33  60.6  33  87.9  33  9.1 
Denmark  107  43.9  107  3.7  107  5.6  107  0 
Finland  -  -  191  2.6  191  6.3  191  1.0 
France  170  65.3  170  31.2  170  91.8  170  0 
Ireland  -  -  123  39.8  123  82.9  122  0 
Netherlands  427  80.8  427  56.0  427  73.8  427  0.5 
Spain  36  94.4  36  44.4  36  91.7  36  0 
Total (8 MSs)  845  73.5  1159  34.0  1159  59.7  1158  0.7 
Norway  -  -  176  0.6  176  12.5  176  0 
Switzerland  13  84.6  13  15.4  13  46.2  13  0 
Belgium reported isolates from Gallus gallus, production level is unknown. 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table EN4.  Resistance  (%)  to  ampicillin,  chloramphenicol,  erythromycin,  gentamicin,  linezolid, 
streptomycin,  tetracyclines  and  vancomycin  among  Enterococcus  faecalis  from  broilers  (Gallus 
gallus) in countries reporting MIC data in 2011 
Country 
Ampicillin  Chloramphenicol  Erythromycin  Gentamicin  Linezolid 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  101  0  101  7.9  101  58.4  101  1.0  101  0 
Belgium  81  11.1  81  9.9  81  76.5  81  3.7  81  6.2 
Denmark  110  0  110  0  110  14.5  110  0  110  0 
Finland  169  0  169  0  169  58.0  169  0  169  0 
France  112  0  112  5.4  112  66.1  112  0.9  112  0 
Ireland  100  0  100  2.0  100  79.0  100  1.0  -  - 
Netherlands  276  0  276  3.3  276  79.0  276  1.8  276  0 
Spain  63  1.6  63  15.9  63  85.7  63  27.0  63  0 
Total (8 MSs)  1,012  1.0  1,012  4.2  1,012  65.2  1,012  2.8  912  0.5 
Norway  62  0  62  11.3  62  25.8  62  0  62  0 
Switzerland  117  0  117  1.7  117  39.3  -  -  117  0 
 
Country 
Streptomycin  Tetracyclines  Vancomycin 
N  % Res  N  % Res  N  % Res 
Austria  101  16.8  101  58.4  101  0 
Belgium  81  59.3  81  90.1  81  3.7 
Denmark  110  3.6  110  17.3  110  0 
Finland  169  0  169  7.1  169  0 
France  112  31.3  112  94.6  112  0 
Ireland  100  47.0  100  84.0  101  2.0 
Netherlands  276  56.2  276  79.0  276  0 
Spain  63  44.4  63  87.3  63  1.6 
Total (8 MSs)  1,012  33.0  1,012  61.9  1,013  0.6 
Norway  62  16.1  62  45.2  62  0 
Switzerland  117  12.8  117  65.0  117  0 
Belgium reported isolates from Gallus gallus, production level is unknown. 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Temporal trends in resistance among indicator enterococci 
Figures EN1–EN10 show the trends in resistance to ampicillin, erythromycin, streptomycin, tetracyclines and 
vancomycin in E. faecium and E. faecalis isolated from Gallus gallus between 2006 and 2011. Countries are 
included in the graphs only when they have reported resistance data for at least four years over the 2006–
2011 period and trends could only be assessed when resistance data were reported for five years or more.  
Resistance to vancomycin was low in all countries over this period in both E. faecium (Figure EN5) and 
E. faecalis  (Figure  EN10),  as  was  resistance  to  ampicillin  in  E. faecalis  (Figure  EN6).  However,  the 
remaining  seven  graphs  showed  considerable  variation  in  resistance  levels  between  MSs.  This  was 
particularly noticeable for erythromycin and tetracycline resistance in both species of Enterococcus. The 
Netherlands  and/or  Spain  tended  to  report  relatively  high  resistance  levels,  while  Denmark  and/or 
Switzerland often reported the lowest. In addition, overall, there were no major changes from 2010 to 2011. 
However, compared with 2010, the more notable changes were a relatively large decline in resistance in 
Gallus gallus to both streptomycin (11.1 % vs. 40 %) and tetracyclines (54.2 % vs. 73 %) in E. faecium in 
Austria, and a concurrent increase in resistance to these two antimicrobials in this species in Switzerland 
(15.4 % vs. 0 % and 46.2 % vs. 30 %). These evolutions need to be confirmed by longer-term trends. 
Since 2006, most countries have shown only minor random fluctuations or gradual increases or decreases in 
resistance. The Netherlands and Switzerland were responsible for many of the statistically significant trends 
since  2006.  In  the  Netherlands,  there  has  been  a  statistically  significant  increase  in  resistance  to 
erythromycin in both species of Enterococcus, as well as to tetracyclines in E. faecium and streptomycin in 
E. faecalis. In contrast, Switzerland has recorded a statistically significant decrease in resistance to ampicillin 
and vancomycin in E. faecium as well as to streptomycin and tetracyclines in E. faecalis, although there has 
also been a significant increase in resistance to erythromycin in E. faecalis from this country. In addition, 
there has been a significant increase in resistance to ampicillin in E. faecium in France; otherwise resistance 
levels  reported  by  this  country  did  not  change  significantly  over  the  reporting  period.  There  have  been 
significant declines in resistance to both vancomycin in E. faecium and tetracyclines in E. faecalis in Austria, 
as  well  as  to  streptomycin  in  E. faecium  from  Denmark.  There  were  no  statistically significant  trends  in 
resistance to either ampicillin or vancomycin in E. faecalis, as all countries expressed very low levels of, or 
no, resistance. 
Figure EN1.  Trends in ampicillin resistance in Enterococcus faecium from Gallus gallus in reporting 
MSs and one non-MS, 2006–2011, quantitative data 
 
Note: A statistically significant increasing or decreasing trend over six years, as tested by a logistic regression model (p ≤0.05), was 
observed in France (↑) and Switzerland (↓). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
 
EFSA Journal 2013;11(5):3196  243 
Figure EN2.  Trends  in  erythromycin  resistance  in  Enterococcus  faecium  from  Gallus  gallus  in 
reporting MSs and one non-MS, 2006–2011, quantitative data 
 
Note: A statistically significant increasing trend over six years, as tested by a logistic regression model (p ≤0.05), was observed in the 
Netherlands (↑). 
Figure EN3.  Trends  in  streptomycin  resistance  in  Enterococcus  faecium  from  Gallus  gallus  in 
reporting MSs and one non-MS, 2006–2011, quantitative data 
 
Note: A statistically significant decreasing trend over five years, as tested by a logistic regression model (p ≤0.05), was observed in 
Denmark (↓). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
 
EFSA Journal 2013;11(5):3196  244 
Figure EN4.  Trends  in  tetracycline  resistance  in  Enterococcus  faecium  from  Gallus  gallus  in 
reporting MSs and one non-MS, 2006–2011, quantitative data 
 
Note: A statistically significant increasing trend over six years, as tested by a logistic regression model (p ≤0.05), was observed in the 
Netherlands (↑). 
Figure EN5.  Trends  in  vancomycin  resistance  in  Enterococcus  faecium  from  Gallus  gallus  in 
reporting MSs and one non-MS, 2006–2011, quantitative data 
 
Note: A  statistically  significant  decreasing  trend  over  five  or  more  years,  as  tested  by  a  logistic  regression  model  (p  ≤0.05),  was 
observed in Austria (↓) and Switzerland (↓). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EN6.  Trends in ampicillin resistance in Enterococcus faecalis from Gallus gallus in reporting 
MSs and one non-MS, 2006–2011, quantitative data 
 
Note: No significant increasing or decreasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was 
observed in any of the reporting countries. 
Figure EN7.  Trends  in  erythromycin  resistance  in  Enterococcus  faecalis  from  Gallus  gallus  in 
reporting MSs and one non-MS, 2006–2011, quantitative data 
 
Note: A statistically significant increasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in the Netherlands (↑) and Switzerland (↑). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EN8.  Trends  in  streptomycin  resistance  in  Enterococcus  faecalis  from  Gallus  gallus  in 
reporting MSs and one non-MS, 2006–2011, quantitative data 
 
Note: A  statistically  significant  increasing  or  decreasing  trend,  over  five  or  more  years,  as  tested  by  a  logistic  regression  model 
(p ≤0.05), was observed in the Netherlands (↑) and Switzerland (↓). 
Figure EN9.  Trends  in  tetracycline  resistance  in  Enterococcus  faecalis  from  Gallus  gallus  in 
reporting MSs and one non-MS, 2006–2011, quantitative data 
 
Note: A  statistically  significant  decreasing  trend,  over  five  or  more  years,  as  tested  by  a  logistic  regression  model  (p ≤0.05),  was 
observed in Austria (↓) and Switzerland (↓). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
 
EFSA Journal 2013;11(5):3196  247 
Figure EN10.  Trends  in  vancomycin  resistance  in  Enterococcus  faecalis  from  Gallus  gallus  in 
reporting MSs and one non-MS, 2006–2011, quantitative data 
 
Note: No significant increasing or decreasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was 
observed in any of the reporting countries. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Spatial distribution of resistance among Enterococcus faecium 
The spatial distributions of erythromycin, tetracycline and vancomycin resistance in E. faecium are shown in 
Figures  EN11–EN13.  Resistance  to  both  erythromycin  and  tetracyclines  tended  to  be  the  lowest  in  the 
Nordic countries. Most of the other countries, which were either western or southern European, tended to 
report very high or extremely high resistance, with the highest levels often observed in the most westerly 
countries.  Resistance  levels  were  usually  higher  for  tetracyclines  than  erythromycin.  With  respect  to 
vancomycin, four countries reported low or very low resistance while the remainder reported full sensitivity 
and there was no clear spatial pattern. 
Figure EN11.  Spatial  distribution  of  erythromycin  resistance  among  Enterococcus  faecium  from 
Gallus gallus in countries reporting quantitative data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data were used instead.  
1.  For Sweden, 2010 data were used.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EN12.  Spatial  distribution  of  tetracycline  resistance  among  Enterococcus  faecium  from 
Gallus gallus in countries reporting quantitative data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data were used instead.  
1.  For Sweden, 2010 data were used.  
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EN13.  Spatial  distribution  of  vancomycin  resistance  among  Enterococcus  faecium  from 
Gallus gallus in countries reporting quantitative data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data were used instead.  
1.  For Sweden, 2010 data were used.  
Multi-resistance among E. faecium isolates from broilers of Gallus gallus 
In 2011, three MSs and one non-MS reported isolate-based data regarding resistance in indicator E. faecium 
from  broilers.  Among  the  reporting  countries,  important  variations  were  observed  in  the  percentages  of 
completely susceptible isolates. Although all reporting countries recorded multi-resistant isolates (isolates 
exhibiting reduced susceptibility according to ECOFFs to at least three different antimicrobial classes), their 
proportions differed substantially between countries, from 2.8 % in Denmark up to 29.2 % in Austria and 
83.3 % in Spain (Table EN5). The frequency distributions (Figure EN14) showed that isolates resistant to as 
many as five antimicrobials were reported from all reporting countries. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table EN5.  Complete  susceptibility,  multi-resistance  and  index  of  diversity  in  E. faecium  from 
broilers of Gallus gallus in MSs and one non-MS reporting isolate-based data, 2011 
Country 
Susceptible to all  Multi-resistant 
Index of diversity 
n  %  n  % 
Austria (N=72)  10  13.9  21  29.2  0.282 
Denmark (N=107)  55  51.4  3  2.8  0.142 
Spain (N=36)  0  0  30  83.3  0.448 
Switzerland (N=13)  1  7.7  3  23.1  0.234 
N = total number of isolates tested for susceptibility against the whole common antimicrobial set for E. faecium. 
n = number of isolates per category of complete susceptibility or multiple resistance. 
Susceptible to all = isolate susceptible to all antimicrobial substances of the EFSA common set for E. faecium. 
Multi-resistant = resistant to at least three different antimicrobial substances, belonging to any three antimicrobial families from the 
common antimicrobial set for E. faecium. 
Index of diversity = see definition in section 11.4.2.1 of Materials and Methods. 
Figure EN14.  Frequency distribution of E. faecium isolates completely susceptible and resistant to 
one to nine antimicrobials in broilers of Gallus gallus in MSs and one non-MS reporting isolate-based 
data, 2011 
 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances for E. faecium. 
Susceptible = susceptible to all antimicrobial substances of the common set for E. faecium. 
res1/res9 = resistance to one antimicrobial substance/resistance to nine antimicrobial substances of the common set for E. faecium. 
Multi-resistance among E. faecalis isolates from broilers of Gallus gallus 
No tables and graphs on multidrug resistance are presented in this report since fewer than four MSs reported 
multi-resistance isolate-based data on more than 10 isolates of E. faecalis in broilers of Gallus gallus. 
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7.2.2.2. Pigs 
The results for pigs were not split into production type as either all results related to fattening pigs or the 
production  type  was  not  specified.  In  the  reporting  MSs,  antimicrobial  resistance  monitoring  in  indicator 
enterococci isolates from pigs was based on active monitoring plans based on random sampling of healthy 
slaughter pig carcasses at the slaughterhouse, with the exception of the Netherlands, for which the sampling 
strategy is unknown. The slaughterhouses included in the monitoring programme accounted for a major 
proportion, typically 80 % or more, of the total production in the country. The sampling plan was typically 
stratified  by  slaughterhouse  (Denmark,  Spain  and  Switzerland)  by  allocating  the  number  of  samples 
collected per slaughterhouse in proportion to the annual throughout of the slaughterhouse. An approximately 
equal distribution of the collected samples over the year enabled the different seasons to be covered. Only 
one representative faecal sample per epidemiological unit (batch), either derived from a unique carcass or 
pooled from a number of carcasses, was gathered to account for clustering. 
Resistance levels in tested isolates 
In 2011, seven MSs and one non-MS (Switzerland) provided quantitative data concerning enterococci from 
pigs. Sweden and Estonia provided data only for E. faecium and E. faecalis, respectively, while all other 
countries provided data for both species (Tables EN6 and EN7). Austria, Denmark, France, the Netherlands 
and Switzerland submitted data concerning Enterococcus isolates from pigs in both 2010 and 2011. Spain 
submitted data for E. faecium and E. faecalis in 2011, and Sweden also submitted data for E. faecium in 
2011, whereas neither of these countries submitted data concerning enterococci in 2010. In contrast, Finland 
submitted data in 2010 for both species but not in 2011 and Estonia submitted data for E. faecalis in 2011, 
while this country reported data for E. faecium in 2010. As in previous years and other livestock species, in 
2011 levels of resistance to most of the antimicrobials varied markedly between countries. 
As in isolates from Gallus gallus, the highest resistance levels among E. faecium from pigs were recorded for 
quinupristin/dalfopristin. The overall reporting MS group level of resistance was 86.5 %, and all reporting 
countries had extremely high resistance levels, ranging between 72.4 % and 97.6 %.  
At the reporting MS group level, there was a very high level of resistance to tetracyclines among E. faecium 
(63.6 %) and an extremely high level of resistance to this antimicrobial among E. faecalis (78.9 %). These 
resistance  levels  are  slightly  higher  than  those  reported  in  2010  (53 %  for  E. faecium  and  71 %  for 
E. faecalis). Regarding E. faecium, Sweden reported a moderate level of resistance (13.6 %) but all other 
countries  reported  high,  very  high  or  extremely  high  levels  of  resistance,  ranging  between  26.2 %  and 
85.4 %. All countries reported resistance levels between 50.0 % and 96.6 % for E. faecalis. Spain and the 
Netherlands reported the highest resistance levels for both species of Enterococcus. Most countries reported 
a relatively higher occurrence of resistance in E. faecalis than E. faecium, except France, which reported the 
opposite.   
There was a high level of resistance to erythromycin at the reporting MS group level for both E. faecium and 
E. faecalis  (34.8 %  and  49.0 %,  respectively).  Resistance  levels  in  the  former  ranged  between  9.1 % 
(Sweden) and 75.6 % (Spain), with most countries reporting a high occurrence of resistance. Resistance 
levels in the latter ranged between 22.7 % (France) and 82.8 % (Spain), with three countries reporting a very 
or  extremely  high  occurrence  of  resistance.  The  overall  resistance  level  observed  for  E. faecium  was 
comparable to that in 2010 (35 %) whereas that observed for E. faecalis was marginally higher than in 2010 
(38 %). Just as for tetracyclines, most countries reported comparatively higher resistance among E. faecalis 
than in E. faecium, except for Austria and France. 
Regarding  streptomycin,  the  resistance  levels  in  both  E. faecium  and  E. faecalis  were  also  high  at  the 
reporting MS group level (26.4 % and 32.6 %, respectively). Just under half of the countries reported low or 
moderate levels of resistance in E. faecium, ranging between 8.0 % and 13.6 %, while Spain reported the 
highest resistance level of 75.6 %. Concerning E. faecalis, Spain, again, reported an extremely high level of 
resistance (79.3 %), but all other countries reported comparatively lower resistance levels of between 18.2 % 
and 40.6 %. As for erythromycin, the overall resistance level for E. faecium was similar to that in 2010 (23 %) 
whereas the level of resistance in E. faecalis was higher than that in 2010 (21 %). 
Overall, there was a moderate level of resistance to ampicillin among E. faecium (11.5 %), which is roughly 
comparable to, though slightly higher than, in 2010 (7 % resistance). Three countries reported no resistance EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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to  this  antimicrobial,  with  the  remainder  reporting  levels  between  2.3 %  (France)  and  23.4 %  (the 
Netherlands). As in 2010, no isolates of E. faecalis expressed resistance to ampicillin. 
In contrast, there was a very low level of resistance to chloramphenicol (1.0 %) at the reporting MS group 
level  among  E. faecium  but  a  moderate  level  of  resistance  (17.0 %)  among  E. faecalis.  Four  countries 
reported no resistance in E. faecium while the other three countries reported low levels of 1.1 % to 4.9 %. All 
reporting countries reported resistance in E. faecalis, at levels between 4.5 % and 31.0 %. 
Overall,  there  was  very  low  resistance  to  gentamicin  in  E. faecium  (0.6 %).  Three  MSs  reported  no 
resistance and three others reported resistance levels of 0.9 % to 2.4 %. All countries reported resistance in 
E. faecalis, resulting in a slightly higher overall resistance level of 12.3 %. The majority of MSs reported low 
resistance, although two reported high resistance levels of 21.4 % (Denmark) and 31.0 % (Spain). 
Only two countries (Denmark and the Netherlands) reported resistance to vancomycin among E. faecium, 
resulting in a very low level of resistance at the reporting MS group level (0.4 %). All countries reported full 
sensitivity to vancomycin in E. faecalis. In comparison, 0.9 % of E. faecium isolates and 0 % of E. faecalis 
isolates were resistant to vancomycin in 2010. 
No  countries  reported  linezolid  resistance  in  E. faecalis,  and  only  France  reported  resistance  among 
E. faecium (1.1 %), resulting in a very low overall resistance level of 0.2 %. 
The higher resistance levels observed in E. faecalis for erythromycin, streptomycin and tetracyclines are 
likely to be, at least partly, attributable to the fact that Sweden reported relatively low levels of resistance to 
these antimicrobials in E. faecium but did not report any data for E. faecalis. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Table EN6.  Resistance  (%)  to  ampicillin,  chloramphenicol,  erythromycin,  gentamicin,  linezolid, 
quinupristin/dalfopristin, streptomycin, tetracyclines and vancomycin among Enterococcus faecium 
from pigs in countries reporting MIC data in 2011 
Country 
Ampicillin  Chloramphenicol  Erythromycin  Gentamicin  Linezolid 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  61  0  61  4.9  61  49.2  61  0  61  0 
Denmark  116  10.3  116  0  116  32.8  116  0.9  116  0 
France  87  2.3  87  1.1  87  28.7  87  1.1  87  1.1 
Netherlands  184  23.4  184  0  184  28.3  184  0  184  0 
Spain  41  4.9  41  2.4  41  75.6  41  2.4  41  0 
Sweden  22  0  22  0  22  9.1  22  0  22  0 
Total (6 MSs)  511  11.5  511  1.0  511  34.8  511  0.6  511  0.2 
Switzerland  25  0  25  0  25  20.0  -  -  25  0 
 
Country 
Quinupristin/dalfopristin  Streptomycin  Tetracyclines  Vancomycin 
N  % Res  N  % Res  N  % Res  N  % Res 
Austria  61  95.1  61  11.5  61  26.2  61  0 
Denmark  116  80.2  116  40.5  116  62.1  116  0.9 
France  87  72.4  87  25.3  87  65.5  87  0 
Netherlands  184  91.8  184  13.6  184  77.2  184  0.5 
Spain  41  97.6  41  75.6  41  85.4  41  0 
Sweden  -  -  22  13.6  22  13.6  22  0 
Total (6 MSs)  489  86.5  511  26.4  511  63.6  511  0.4 
Switzerland  25  80.0  25  8.0  25  40.0  25  0 
N = number of isolates tested. 
% Res = percentage of resistant isolates.  
- = no data reported. 
Table EN7.  Resistance  (%)  to  ampicillin,  chloramphenicol,  erythromycin,  gentamicin,  linezolid, 
streptomycin, tetracyclines and vancomycin among Enterococcus faecalis from pigs in countries 
reporting MIC data in 2011 
Country 
Ampicillin  Chloramphenicol  Erythromycin  Gentamicin  Linezolid 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  112  0  112  13.4  112  39.3  112  2.7  112  0 
Denmark  117  0  117  23.1  117  53.8  117  21.4  117  0 
Estonia  11  0  11  9.1  11  27.3  11  9.1  11  0 
France  22  0  22  4.5  22  22.7  22  9.1  22  0 
Netherlands  74  0  74  12.2  74  54.1  74  6.8  74  0 
Spain  29  0  29  31.0  29  82.8  29  31.0  29  0 
Total (6 MSs)  365  0  365  17.0  365  49.0  365  12.3  365  0 
Switzerland  64  0  64  6.3  64  32.8  -  -  64  0 
 
Country 
Streptomycin  Tetracyclines  Vancomycin 
N  % Res  N  % Res  N  % Res 
Austria  112  25.9  112  68.8  112  0 
Denmark  117  36.8  117  86.3  117  0 
Estonia  11  18.2  11  63.6  11  0 
France  22  22.7  22  50.0  22  0 
Netherlands  74  23.0  74  86.5  74  0 
Spain  29  79.3  29  96.6  29  0 
Total (6 MSs)  365  32.6  365  78.9  365  0 
Switzerland  64  40.6  64  56.3  64  0 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Temporal trends in resistance among indicator enterococci 
Figures EN15–EN24 show the trends in resistance to ampicillin, erythromycin, streptomycin, tetracyclines 
and vancomyin in E. faecium and E. faecalis from pigs between 2006 and 2011. Similarly to the isolates from 
Gallus  gallus,  there  was  substantial  variation  between  countries  in  the  reported  levels  of  resistance  to 
several  of  the  antimicrobials,  particularly  to  tetracyclines  in  E. faecium  (Figure  EN18).  France,  the 
Netherlands and/or Spain often reported relatively high resistance levels whereas Austria and/or Switzerland 
tended  to  report  comparatively  low  resistance  levels  for  many  antimicrobials.  Whereas  Denmark  often 
reported the lowest resistance levels among isolates from Gallus gallus, this country reported relatively high 
resistance levels among isolates from pigs (e.g. Figure EN23). No resistance to ampicillin in E. faecalis has 
been recorded since 2006 (Figure EN20). Resistance to vancomycin among both E. faecium (Figure EN19) 
and E. faecalis (Figure EN24) has also been low in all countries since 2006. 
One of the most obvious trends visible from the graphs is the sharp decline in resistance to streptomycin 
among E. faecium in the Netherlands (Figure EN17). As only four data points are available, this finding was 
not tested for statistical significance, but several other significant trends were identified in this country as well 
as others. Both France and the Netherlands have shown statistically significant declines in resistance to 
three  antimicrobials.  Both  countries  have  shown  significant  declines  in  resistance  to  erythromycin  and 
tetracyclines in E. faecium. The third decline for both countries involved streptomycin, but in France the 
decline was among E. faecium, whilst in the Netherlands the decline was recorded in E. faecalis. The only 
other statistically significant trends that were detected related to an increase in resistance to tetracyclines 
among E. faecium in Switzerland, and a decline in resistance to erythromycin in E. faecium from Denmark. 
No statistically significant trends in resistance to ampicillin or vancomycin were recorded in either species of 
Enterococcus, or to erythromycin or tetracyclines in E. faecalis. 
Compared with 2010, the resistance levels of individual countries were usually broadly comparable or higher. 
One exception was France, which reported lower resistance levels in 2011 than in 2010 in E. faecium to 
erythromycin (28.7 % vs. 53 %), streptomycin (25.3 % vs. 37 %) and tetracyclines (65.5 % vs. 77 %), while 
this was not observed among E. faecalis isolates, in which resistance levels were higher than in the previous 
year (erythromycin: 22.7 % vs. 6 %; streptomycin: 22.7 % vs. 6 %; tetracyclines: 50.0 % vs. 31 %). These 
data were not plotted in the trend graphs as France reported resistance data in E. faecalis for fewer than four 
years. These inter-annual evolutions need to be confirmed by longer-term trends. 
Figure EN15.  Trends in ampicillin resistance in Enterococcus faecium from pigs in reporting MSs 
and one non-MS, 2006–2011, quantitative data 
 
Note: No significant increasing or decreasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was 
observed in any of the reporting countries. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EN16.  Trends in erythromycin resistance in Enterococcus faecium from pigs in reporting MSs 
and one non-MS, 2006–2011, quantitative data 
 
Note: A  statistically  significant  decreasing  trend  over  five  or  more  years,  as  tested  by  a  logistic  regression  model  (p  ≤0.05),  was 
observed in Denmark (↓), France (↓) and the Netherlands (↓). 
Figure EN17.  Trends in streptomycin resistance in Enterococcus faecium from pigs in reporting MSs 
and one non-MS, 2006–2011, quantitative data 
 
Note: A statistically significant decreasing trend over six years, as tested by a logistic regression model (p ≤0.05), was observed in 
France (↓). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EN18.  Trends in tetracycline resistance in Enterococcus faecium from pigs in reporting MSs 
and one non-MS, 2006–2011, quantitative data 
. 
Note: A  statistically  significant  increasing  or  decreasing  trend,  over  five  or  more  years,  as  tested  by  a  logistic  regression  model 
(p ≤0.05), was observed in France (↓), the Netherlands (↓) and Switzerland (↑). 
Figure EN19.  Trends in vancomycin resistance in Enterococcus faecium from pigs in reporting MSs 
and one non-MS, 2006–2011, quantitative data 
 
Note: No significant increasing or decreasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was 
observed in any of the reporting countries. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EN20.  Trends in ampicillin resistance in Enterococcus faecalis from pigs in reporting MSs 
and one non-MS, 2006–2011, quantitative data 
 
Note: No significant increasing or decreasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was 
observed in any of the reporting countries. 
Figure EN21.  Trends in erythromycin resistance in Enterococcus faecalis from pigs in reporting MSs 
and one non-MS, 2006–2011, quantitative data 
 
Note: No significant increasing or decreasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was 
observed in any of the reporting countries. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EN22.  Trends in streptomycin resistance in Enterococcus faecalis from pigs in reporting MSs 
and one non-MS, 2006–2011, quantitative data 
 
Note: A statistically significant decreasing trend over six years, as tested by a logistic regression model (p ≤0.05), was observed in the 
Netherlands (↓). 
Figure EN23.  Trends in tetracycline resistance in Enterococcus faecalis from pigs in reporting MSs 
and one non-MS, 2006–2011, quantitative data 
 
Note:  No significant increasing or decreasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was 
observed in any of the reporting countries. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EN24.  Trends in vancomycin resistance in Enterococcus faecalis from pigs in reporting MSs 
and one non-MS, 2006–2011, quantitative data 
 
Note: No significant increasing or decreasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was 
observed in any of the reporting countries. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Spatial distribution of resistance among Enterococcus faecium 
The spatial distributions of erythromycin, tetracycline and vancomycin resistance among E. faecium from 
pigs  are  presented  in  Figures  EN25–EN27.  The  spatial  patterns  were  less  clear  than  for  isolates  from 
Gallus gallus. The most western countries still tended to report the highest resistance levels for tetracyclines. 
Sweden reported the lowest resistance to tetracyclines and erythromycin while Spain reported the highest 
resistance level for both. Denmark and the Netherlands reported very low resistance to vancomycin while all 
other countries reported full sensitivity. 
Figure EN25.  Spatial distribution of erythromycin resistance among Enterococcus faecium from pigs 
in countries reporting quantitative data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data were used instead.  
1.  For Estonia and Finland, 2010 data were used.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EN26.  Spatial distribution of tetracycline resistance among Enterococcus faecium from pigs 
in countries reporting quantitative data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data were used instead.  
1.  For Estonia and Finland, 2010 data were used.   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EN27.  Spatial distribution of vancomycin resistance among Enterococcus faecium from pigs 
in countries reporting quantitative data in 2011
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2011. When 
quantitative 2011 data were not available, 2010 data were used instead.  
1.  For Estonia and Finland, 2010 data were used.  
 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Multi-resistance among E. faecium isolates from pigs 
In 2011, three MSs and one non-MS reported isolate-based data regarding resistance in indicator E. faecium 
from  pigs.  Among  the  reporting  countries,  important  variations  were  observed  in  the  percentages  of 
completely susceptible isolates. Although all reporting countries recorded multi-resistant isolates (isolates 
exhibiting reduced susceptibility according to ECOFFs to at least three different antimicrobial classes), their 
proportions differed substantially between countries, from 14.8 % in Austria up to 44.8 % in Denmark and 
82.9 % in Spain (Table EN8). The frequency distributions (Figure EN28) showed that isolates resistant to as 
many as five antimicrobials were reported from all reporting MSs. 
Table EN8.  Complete susceptibility, multi-resistance and index of diversity in E. faecium from pigs in 
MSs and one non-MS reporting isolate-based data, 2011 
Country 
Susceptible to all  Multi-resistant 
Index of diversity 
n  %  n  % 
Austria (N=61)  1  1.6  9  14.8  0.241 
Denmark (N=116)  19  16.4  52  44.8  0.347 
Spain (N=41)  1  2.4  34  82.9  0.286 
Switzerland (N=25)  5  20.0  6  24.0  0.227 
N = total number of isolates tested for susceptibility against the whole common antimicrobial set for E. faecium. 
n = number of isolates per category of complete susceptibility or multiple resistance. 
Susceptible to all = isolate susceptible to all antimicrobial substances of the EFSA common set for E. faecium. 
Multi-resistant = resistant to at least three different antimicrobial substances, belonging to any three antimicrobial families from the 
common antimicrobial set for E. faecium. 
Index of diversity = see definition in section 11.4.2.1 of Materials and Methods. 
Figure EN28.  Frequency distribution of E. faecium isolates completely susceptible and resistant to 
one to nine antimicrobials in pigs in MSs and one non-MS reporting isolate-based data, 2011 
 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances for E. faecium. 
Susceptible = susceptible to all antimicrobial substances of the common set for E. faecium. 
res1/res9 = resistance to one antimicrobial substance/resistance to nine antimicrobial substances of the common set for E. faecium. 
Multi-resistance among E. faecalis isolates from pigs 
No tables and graphs on multidrug resistance are presented in this report since fewer than four MSs reported 
multi-resistance isolate-based data on more than 10 isolates of E. faecalis in pigs. 
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7.2.2.3. Cattle (bovine animals) 
In 2011, four MSs provided quantitative data concerning E. faecium from cattle, and three MSs and one non-
MS provided quantitative data concerning E. faecalis from cattle. These countries tested different production 
types and ages of cattle, including veal calves (aged under one year), young meat production animals, and 
adult or dairy cattle. The antimicrobial resistance data for cattle have been presented by production type. The 
overall results for cattle presented in Tables EN9 and EN10 include all isolates of enterococci that were 
collected from this animal species by MSs which tested more than 10 isolates from cattle in total. Results are 
also presented for the specific production levels of cattle from which these enterococci isolates originated. 
Some MSs tested fewer than 10 isolates from individual production types. In such cases, the data for these 
production types are included in the overall results for cattle but are not presented in the production level-
specific sections of these tables.   
Enterococci  sampling  was  carried  out  in  Spain  and  Switzerland  according  to  their  national  monitoring 
programmes. Sample collection was conducted at slaughterhouses, stratified by slaughterhouse capacity 
and  spread  evenly  throughout  the  year.  In  Austria,  sampling  was  carried  out  according  to  a  federal 
monitoring programme. Details of the Belgian and Dutch sampling strategy are unknown. 
Austria and the Netherlands submitted data for E. faecium in both 2010 and 2011. Belgium and Spain only 
submitted data in 2011, whereas Estonia and Switzerland submitted data for this species in 2010 but not in 
2011. With respect to E. faecalis, Belgium also only submitted data in 2011 but otherwise the same countries 
submitted data in both 2010 and 2011. 
Resistance levels in tested isolates 
For E. faecium, both Austria and the Netherlands reported data for two different age groups of cattle. In the 
Netherlands, there was much higher resistance among younger cattle, whereas there was no such difference 
apparent in Austria, with all young meat production animals from that country testing fully sensitive (except 
for  quinupristin/dalfopristin).  For  E. faecalis,  three  of  the  four  reporting  countries  provided  data  on  two 
different age categories. As for E. faecium, the Netherlands reported much higher resistance among younger 
cattle whereas in Austria and Switzerland there was less contrast between age groups. 
As  in  both  Gallus  gallus  and  pigs,  the  highest  resistance  levels  among  E. faecium  were  recorded  for 
quinupristin/dalfopristin.  Combining  all  types  of  cattle,  there  was  a  very  high  occurrence  of  resistance 
(64.1 %) at the reporting MS group level. Resistance was at a high, very high or extremely high level in all 
reporting countries. 
The overall proportion of isolates from cattle that tested resistant to tetracyclines was 34.2 % for E. faecium 
and 35.6 % for E. faecalis. For E. faecium, resistance levels ranged between 0 % and 72.0 %, while for 
E. faecalis resistance ranged between 17.9 % and 78.9 %. Austria and Belgium reported relatively higher 
levels of resistance among E. faecalis than in E. faecium, which was also the case for isolates from adult 
cattle in the Netherlands, but not for young cattle. 
There was also  a  moderate to  high  level of resistance  to erythromycin  and streptomycin:  overall  at the 
reporting MS group level, 30.5 % of E. faecium and 22.9 % of E. faecalis isolates from cattle were resistant 
to the former, and 21.3 % of E. faecium and 18.6 % of E. faecalis isolates were resistant to the latter. As for 
tetracyclines,  resistance  levels  varied  markedly  between  countries  and  production  types.  Resistance  to 
erythromycin tended to be slightly higher than resistance to streptomycin, except in Switzerland, where the 
opposite  was  true.  Countries  tended  to  report  broadly  similar  resistance  levels  for  both  E. faecium  and 
E. faecalis from the same production type of cattle. The Netherlands reported much higher resistance to both 
antimicrobials among Enterococcus obtained from younger cattle than from adult cattle, whereas in Austria 
and Switzerland, the resistance levels in young and adult animals were roughly comparable. 
Regarding E. faecium, the Netherlands and Belgium reported a moderate level of resistance to ampicillin 
among isolates from veal calves and young meat production animals, respectively, and Spain reported a low 
level  of  resistance  (4.0 %)  to  this  antimicrobial  among  isolates  from  young  meat  production  animals;  in 
contrast, Austria reported full sensitivity among both young meat production animals and adult cattle, and the 
Netherlands  also  reported  no  resistance  among  dairy  cattle.  Belgium  reported  8.3  %  resistance  to  this EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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antimicrobial  in  E. faecalis  from  young  meat  production  animals  but  no  other  E. faecalis  isolates  were 
resistant to ampicillin, regardless of production type. 
At the reporting MS group level, there was a low level of resistance to chloramphenicol in both E. faecium 
(4.2 %) and E. faecalis (9.9 %). Regarding E. faecium, Belgium reported moderate resistance in young meat 
production animals, and the Netherlands and Spain reported low resistance levels in veal calves and young 
meat  production  animals,  respectively,  whereas  Austria  reported  no  resistance  in  any  age  groups. 
Resistance  levels  were  slightly  higher  in  E. faecalis,  particularly  from  the  younger  age  groups  of  cattle, 
although there was still no resistance detected in adult cattle among MSs. 
Regarding gentamicin, there was a low overall level of resistance in isolates of both E. faecium (2.2 %) and 
E. faecalis (2.4 %) from cattle. Concerning E. faecium, resistance was reported only by the Netherlands for 
veal calves under one year of age (4.8 %) and by Spain for young meat production animals aged 1-2 years 
(4.0 %). For E. faecalis, Austria, Belgium and the Netherlands reported low levels of resistance in adult cattle 
(3.2 %), young meat production animals (4.2 %) and veal calves (3.3 %), respectively. 
There was a low level of linezolid resistance in E. faecium from cattle (1.4 %). The Netherlands and Spain 
reported low resistance among veal calves (2.1 %) and young meat production animals (8.0 %), but Austria 
and Belgium found no resistance in any age group. Regarding E. faecalis, there was a very low overall level 
of resistance in cattle (0.4 %). The Netherlands was the only country to detect any resistance, at a low level 
of 1.7 % in veal calves. 
The Netherlands also reported a low level of resistance to vancomycin (1.7 %) among E. faecalis isolates 
from veal calves, but all other countries reported full sensitivity to this antimicrobial in both E. faecium and 
E. faecalis. 
Table EN9.  Resistance  (%)  to  ampicillin,  chloramphenicol,  erythromycin,  gentamicin,  linezolid, 
quinupristin/dalfopristin, streptomycin, tetracyclines and vancomycin among Enterococcus faecium 
from cattle in countries reporting MIC data in 2011 
Country 
Ampicillin  Chloramphenicol  Erythromycin  Gentamicin  Linezolid 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Veal calves (under one year)                            
Netherlands  145  12.4  145  6.2  145  46.9  145  4.8  145  2.1 
Young meat production animals (under one year)                      
Belgium  29  13.8  29  17.2  29  58.6  29  0  29  0 
Young meat production animals (1-2 years)                         
Austria  11  0  11  0  11  0  11  0  11  0 
Spain  25  4.0  25  4.0  25  40.0  25  4.0  25  8.0 
Total (2 MSs)  36  2.8  36  2.8  36  27.8  36  2.8  36  5.6 
Adult cattle (over 2 years)                            
Austria  36  0  36  0  36  5.6  36  0  36  0 
Dairy cows                                
Netherlands  108  0  108  0  108  9.3  108  0  108  0 
All types of cattle                              
Austria  47  0  47  0  47  4.3  47  0  47  0 
Belgium  32  12.5  32  15.6  32  59.4  32  0  32  0 
Netherlands  253  7.1  253  3.6  253  30.8  253  2.8  253  1.2 
Spain  25  4.0  25  4.0  25  40.0  25  4.0  25  8.0 
Total (4 MSs)  357  6.4  357  4.2  357  30.5  357  2.2  357  1.4 
Table continued overleaf. 
N = number of isolates tested. 
% Res = percentage of resistant isolates. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table  EN9  (continued).  Resistance  (%)  to  ampicillin,  chloramphenicol,  erythromycin,  gentamicin, 
linezolid, quinupristin/dalfopristin, streptomycin, tetracyclines and vancomycin among Enterococcus 
faecium from cattle in countries reporting MIC data in 2011 
Country 
Quinupristin/dalfopristin  Streptomycin  Tetracyclines  Vancomycin 
N  % Res  N  % Res  N  % Res  N  % Res 
Veal calves (under one year) 
Netherlands  145  65.5  145  35.2  145  55.2  145  0 
Young meat production animals (under one year) 
Belgium  29  96.6  29  44.8  29  65.5  29  0 
Young meat production animals (1-2 years) 
Austria  11  36.4  11  0  11  0  11  0 
Spain  25  92.0  25  28.0  25  72.0  25  0 
Total (2 MSs)  36  75.0  36  19.4  36  50.0  36  0 
Adult cattle (over 2 years) 
Austria  36  36.1  36  2.8  36  2.8  36  0 
Dairy cows                          
Netherlands  108  58.3  108  1.9  108  1.9  108  0 
All types of cattle                          
Austria  47  36.2  47  2.1  47  2.1  47  0 
Belgium  32  96.9  32  46.9  32  65.6  32  0 
Netherlands  253  62.5  253  20.9  253  32.4  253  0 
Spain  25  92.0  25  28.0  25  72.0  25  0 
Total (4 MSs)  357  64.1  357  21.3  357  34.2  357  0 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table EN10.  Resistance  (%)  to  ampicillin,  chloramphenicol,  erythromycin,  gentamicin,  linezolid, 
streptomycin, tetracyclines and vancomycin among Enterococcus faecalis from cattle in countries 
reporting MIC data in 2011 
Country 
Ampicillin  Chloramphenicol  Erythromycin  Gentamicin 
N  % Res  N  % Res  N  % Res  N  % Res 
Veal calves (under one year)                      
Netherlands  60  0  60  31.7  60  43.3  60  3.3 
Young meat production animals (under one year)                
Belgium  24  8.3  24  8.3  24  62.5  24  4.2 
Young meat production animals (1-2 years)                      
Austria  28  0  28  3.6  28  7.1  28  0 
Switzerland  37  0  37  27.0  37  35.1  -  - 
Adult cattle (over 2 years)                      
Austria  95  0  95  0  95  7.4  95  3.2 
Dairy cows                          
Netherlands  36  0  36  0  36  8.3  36  0 
Switzerland  19  0  19  5.3  19  26.3  -  - 
All types of cattle                         
Austria  129  0  129  1.6  129  7.8  129  2.3 
Belgium  28  7.1  28  14.3  28  67.9  28  3.6 
Netherlands  96  0  96  19.8  96  30.2  96  2.1 
Total (3 MSs)  253  0.8  253  9.9  253  22.9  253  2.4 
Switzerland  56  0  56  19.6  56  32.1  -  - 
 
Country 
Linezolid  Streptomycin  Tetracyclines  Vancomycin 
N  % Res  N  % Res  N  % Res  N  % Res 
Veal calves (under one year) 
Netherlands  60  1.7  60  35.0  60  56.7  60  1.7 
Young meat production animals (under one year) 
Belgium  24  0  24  62.5  24  75.0  24  0 
Young meat production animals (1-2 years)                         
Austria  28  0  28  0  28  32.1  28  0 
Switzerland  37  0  37  45.9  37  70.3  37  0 
Adult cattle (over 2 years) 
Austria  95  0  95  6.3  95  17.9  95  0 
Dairy cows                          
Netherlands  36  0  36  0  36  19.4  36  0 
Switzerland  19  0  19  42.1  19  78.9  19  0 
All types of cattle                         
Austria  129  0  129  5.4  129  21.7  129  0 
Belgium  28  0  28  67.9  28  75.0  28  0 
Netherlands  96  1.0  96  21.9  96  42.7  96  1.0 
Total (3 MSs)  253  0.4  253  18.6  253  35.6  253  0.4 
Switzerland  56  0  56  44.6  56  73.2  56  0 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
Note: Includes data when fewer than four countries have reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Temporal trends in resistance among indicator enterococci 
Figures EN29–EN38 show the trends in resistance to ampicillin, erythromycin, streptomycin, tetracyclines 
and vancomycin observed in E. faecium and E. faecalis from cattle from 2006 to 2011. The results for all 
types of cattle are merged together. Often only three MSs submitted sufficient data to warrant their inclusion 
in the trend graphs, but there was still wide variation between the different countries’ resistance levels for 
some of the antimicrobials, such as tetracyclines. For most of the antimicrobials, there were only minor 
differences between the resistance levels that were reported in 2010 and 2011. Similarly to the Enterococcus 
isolates  from  pigs,  no  ampicillin  resistance  has  been  detected  among  E. faecalis  since  2006,  and 
vancomycin resistance has been at a low level in both species of Enterococcus.   
For  many  antimicrobials,  the  Netherlands  (or  Spain  for  E. faecium  only)  reported  the  highest  resistance 
levels among enterococci from cattle. However, there have been declines in the resistance levels reported by 
the former since 2006; as in pigs, there was a large decline in resistance to streptomycin among E. faecium 
from the Netherlands but there were insufficient data points to test for statistical significance. Nevertheless, 
statistically  significant  declines  have  been  identified  in  this  country  for  resistance  to  erythromycin  and 
tetracyclines in E. faecium, as well as to streptomycin in E. faecalis. The only other statistically significant 
trends since 2006 were recorded in Austria: a decrease in vancomycin resistance in E. faecium and an 
increase in tetracycline resistance in E. faecalis. No statistically significant trends were detected for five of 
the trend graphs, including resistance to ampicillin in both species of Enterococcus, with most countries 
simply showing random fluctuations or fairly stable resistance levels. 
Figure EN29.  Trends in ampicillin resistance in Enterococcus faecium from cattle in reporting MSs 
and one non-MS, 2006–2011, quantitative data 
 
Note: No significant increasing or decreasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was 
observed in any of the reporting countries. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EN30.  Trends in erythromycin resistance in Enterococcus faecium from cattle in reporting 
MSs and one non-MS, 2006–2011, quantitative data 
 
Note: A statistically significant decreasing trend over six years, as tested by a logistic regression model (p ≤0.05), was observed in the 
Netherlands (↓). 
Figure EN31.  Trends in streptomycin resistance in Enterococcus faecium from cattle in reporting 
MSs and one non-MS, 2006–2011, quantitative data 
 
Note: No significant increasing or decreasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was 
observed in any of the reporting countries. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EN32.  Trends in tetracycline resistance in Enterococcus faecium from cattle in reporting MSs 
and one non-MS, 2006–2011, quantitative data 
 
Note: A statistically significant decreasing trend over six years, as tested by a logistic regression model (p ≤0.05), was observed in the 
Netherlands (↓). 
Figure EN33.  Trends in vancomycin resistance in Enterococcus faecium from cattle in reporting MSs 
and one non-MS, 2006–2011, quantitative data 
 
Note: A statistically significant decreasing trend over five years, as tested by a logistic regression model (p ≤0.05), was observed in 
Austria (↓). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EN34.  Trends in ampicillin resistance in Enterococcus faecalis from cattle in reporting MSs 
and one non-MS, 2006–2011, quantitative data 
 
Note: No significant increasing or decreasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was 
observed in any of the reporting countries. 
Figure EN35.  Trends in erythromycin resistance in  Enterococcus faecalis from cattle in reporting 
MSs and one non-MS, 2006–2011, quantitative data 
 
Note: No significant increasing or decreasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was 
observed in any of the reporting countries. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EN36.  Trends  in streptomycin resistance  in  Enterococcus  faecalis  from  cattle  in reporting 
MSs and one non-MS, 2006–2011, quantitative data 
 
Note: A statistically significant decreasing trend over six years, as tested by a logistic regression model (p ≤0.05), was observed in the 
Netherlands (↓). 
Figure EN37.  Trends in tetracycline resistance in Enterococcus faecalis from cattle in reporting MSs 
and one non-MS, 2006–2011, quantitative data 
 
Note: A statistically significant increasing trend over five years, as tested by a logistic regression model (p ≤0.05), was observed in 
Austria (↑). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Figure EN38.  Trends in vancomycin resistance in Enterococcus faecalis from cattle in reporting MSs 
and one non-MS, 2006–2011, quantitative data 
 
Note: No significant increasing or decreasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was 
observed in any of the reporting countries. 
Spatial distribution of resistance among Enterococcus faecium 
Relatively few countries have reported on E. faecium from cattle so it was not possible to identify any spatial 
patterns: for this reason spatial distributions of tetracycline, erythromycin and vancomycin resistance are not 
presented.  It  was  noted,  however,  that  Belgium  and  Spain  reported  the  highest  resistance  levels  to 
tetracyclines and erythromycin while Austria reported the lowest level of resistance to both. None of the 
countries reported any resistance to vancomycin.  
Multi-resistance among enterococci isolates from cattle 
As fewer than four MSs reported multi-resistance isolate-based data on more than 10 isolates of enterococci 
in cattle, tables and graphs on multi-drug resistance are not presented. 
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7.3. Overview of the findings on enterococci resistance at reporting MS group level, 2011 
Figure EN39 shows the resistance levels in the reporting MS group based on MIC data submitted in 2011 for 
the  various  food  production  animal  species.  It  should  be  borne  in  mind  that  the  data  are  derived  from 
different numbers and groups of MSs. 
As in 2010, resistance to erythromycin was higher among E. faecalis isolates than in E. faecium isolates from 
Gallus gallus and pigs, whereas the opposite was true for cattle. Resistance to tetracyclines was also higher 
among E. faecalis isolates than in E. faecium isolates from all species. As in the previous year, resistance to 
ampicillin was much higher among isolates of E. faecium for all three livestock species, with virtually no 
resistance being detected among E. faecalis. For quinupristin/dalfopristin, resistance was at a very high or 
extremely  high  level  in  E. faecium  from  all  livestock  species.  Resistance  to  both  chloramphenicol  and 
gentamicin was generally at a low level, although moderate resistance levels were reported for E. faecalis 
from pigs and chloramphenicol resistance was slightly higher among E. faecalis than in E. faecium from all 
three livestock species. There was very little resistance to linezolid and vancomycin in either species of 
Enterococcus. The highest linezolid resistance levels were in E  faecium from cattle, yet these levels were 
still very low, with a MS average of 1.4 %. More commonly, though, both E. faecium and E. faecalis isolates 
collected from Gallus gallus or pigs expressed greater resistance than isolates from cattle. 
Figure EN39.  Resistance  to  ampicillin,  chloramphenicol,  erythromycin,  gentamicin,  linezolid, 
quinupristin/dalfopristin (E. faecium only), streptomycin, tetracyclines and vancomycin in indicator 
Enterococcus faecium and Enterococcus faecalis from fowl, pigs and cattle at reporting MS group 
level in 2011 
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7.4. Discussion 
Antimicrobial resistance in commensal Enterococcus isolates from animals and food is used as an indicator 
of the reservoir of resistance genes in the Gram-positive flora and which could be transferred to bacteria that 
are pathogenic for humans and/or animals. As with indicator E. coli, Enterococcus isolates can also be used 
to  investigate  the  relationship  between  antimicrobial  resistance  levels  and  the  extent  of  usage  of 
antimicrobials in food-producing animal species. It is recommended that both E. faecium and E. faecalis are 
included in MSs’ antimicrobial resistance monitoring programmes because, in some animal species, one of 
these  bacterial  species  is  much  more  common  than  the  other,  and  changes  in  the  prevalence  of  each 
enterococcal species to be monitored can also occur with age in some animal species. Both enterococcal 
species can cause human disease and they differ in the antimicrobials to which they show intrinsic (i.e. 
naturally  occurring)  resistance.  One  of  the  most  important  antimicrobials  to  monitor  in  these  bacteria  is 
vancomycin, and enterococcal species can differ in their propensity to carry resistance to this antimicrobial, 
as discussed in more detail below. Low-level intrinsic resistance to aminoglycosides is an inherent property 
of enterococci (Murray, 1990), accounting for the higher epidemiological cut-off values evident for these 
bacteria in comparison with the other bacteria monitored in this report (Table MM10). 
In  2011,  a  total  of  10  MSs  and  two  non-MSs  provided  quantitative  data  on  antimicrobial  resistance  in 
Enterococcus  from  animals  and  food;  most  of  the  countries  provided  information  on  both  species  of 
Enterococcus but two MSs only provided data for either E. faecium or E. faecalis. This is a marginal increase 
on the figures for 2010, when seven MSs and one non-MS provided data. Resistance levels tend to vary 
markedly between MSs. Only three MSs reported MIC data on isolates collected from food in 2011, one of 
which reported only on E. faecalis from pig meat. Countries usually used dilution methods to determine MIC 
values, in accordance with EFSA recommendations (EFSA, 2008a). However, Hungary tested E. faecalis 
from meat from bovine animals, broilers, pigs and turkeys using disc diffusion methods. As only one country 
provided  qualitative  data  derived  from  a  diffusion  method,  these  data  were  not  included  in  the  present 
analysis. 
In MSs which reported resistance to enterococcal isolates from meat, resistance levels tended to be higher 
in meat from broilers than in meat from pigs and bovine meat, particularly in the Netherlands. One exception 
was quinupristin/dalfopristin resistance among E. faecium, which Denmark reported to be higher in meat 
from pigs than in meat from broilers. In general, resistance levels in bovine meat were comparable to the 
levels in meat from pigs. Resistance levels were commonly lower in isolates from meat than in isolates from 
the  corresponding  source  animal  species,  with  the  exception  of  resistance  to  vancomycin  and  linezolid, 
which was consistently very low, and isolates of E. faecalis, among which there was less discrepancy in 
resistance levels between those from meat and animals. In MSs which reported resistance to enterococcal 
isolates  from  broiler  meat  and  broilers  (Denmark  and  the  Netherlands),  there  were  (in  general)  parallel 
differences in the levels of resistance to E. faecalis and E. faecium from broiler meat and broilers within each 
of those MSs. Thus, resistance to erythromycin in E. faecalis from broilers in Denmark and the Netherlands 
was 14.5 % and 79.0 %, respectively, while it was 17.6 % and 62.2 % in isolates from broiler meat. The 
degree  to  which  the  isolates  from  meat  reflect  domestic  animal  production  within  a  MS,  as  well  as the 
relatively low sample size for some categories and the expected variation within a given sample size, are all 
likely to account for at least some of the observed variation between isolates from meat and animals. 
When considering resistance in E. faecium at the reporting MS group level, the highest levels of resistance 
for all animal categories was recorded for quinupristin/dalfopristin (73.5 % for Gallus gallus, 86.5 % for pigs 
and  64.1 %  for  cattle).  Resistance  levels  for  quinupristin/dalfopristin  in  E. faecalis  were  not  presented 
because of the intrinsic resistance in this species. Microbiological resistance to erythromycin, streptomycin 
and tetracyclines in farm animals was usually at a high level in both species of Enterococcus when using the 
ECOFFs, with resistance in some MSs reaching extremely high levels. There was often substantial variation 
in the levels of resistance observed in the reporting MSs, which could reflect variation in usage patterns or in 
the production types of livestock that were sampled. Resistance occurred more commonly in isolates from 
Gallus gallus and pigs than in isolates from cattle. Similarly, multi-resistance levels in E. faecium isolates 
from pigs differed substantially between the reporting countries. However, very few MSs reported data on the 
latter food-producing animal species, so the observed difference should be treated with caution.  
This was the first year that data were presented separately for the different production types of each food-
producing animal species. In the case of Enterococcus, this applied only to cattle. The Netherlands reported 
much higher resistance among isolates from fattening veal calves (typically of less than one year of age) EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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than in adult dairy cattle, whereas the other countries that reported on more than one age group (Austria and 
Switzerland) found much less disparity in resistance levels between young cattle of one to two years of age 
and adult cattle. As well as differences in age, differences in rearing and husbandry systems, and treatment 
regimes employed, may have also contributed to the different figures observed in fattening veal calves, 
young cattle and adult cattle. 
Regarding Enterococcus isolates from Gallus gallus, 54.6 % of E. faecium and 65.2 % of E. faecalis from the 
reporting group of MSs expressed resistance to erythromycin (macrolides). This compares with 34.8 % of 
E. faecium and 49.0 % of E. faecalis from pigs, and 30.5 % of E. faecium and 22.9 % of E. faecalis from 
cattle. Resistance was also more common among isolates from broiler meat than bovine or pig meat, with 
the highest resistance of 66.7 % reported by the Netherlands for E. faecium from broiler meat. The high 
observed levels of resistance to macrolides are of importance, as these substances have been defined as 
critically important antimicrobials in human medicine. Differences in the occurrence of macrolide resistance 
in enterococcal isolates from poultry, calves and pigs have been considered to reflect the different levels and 
patterns  of  usage  of  antimicrobials  in  those  species.  This  also  probably  accounts  for  the  widespread 
occurrence of tetracycline resistance in Gallus gallus and pigs, which have frequently received treatment 
with this antimicrobial (van den Bogaard et al., 2000; Cauwerts et al., 2007). In 2011, 63.6 % of E. faecium 
isolates and 78.9 % of E. faecalis isolates from pigs expressed resistance to this antimicrobial, as well as 
59.7 % of E. faecium and 61.9 % of E. faecalis isolates from Gallus gallus. This compares with only 34.2 % 
of  E. faecium  and  35.6 %  of  E. faecalis  from  cattle.  All  of  the  trends  in  erythromycin  resistance  among 
Enterococcus from Gallus gallus that were found to be statistically significant were increasing trends. In 
contrast, only decreasing trends were found to be statistically significant in isolates from either pigs or cattle. 
With  respect  to  tetracyclines,  there  has  been  a  mix  of  statistically  significant  increasing  and  decreasing 
trends  from  all  livestock  and  Enterococcus  species.  In  the  Netherlands,  there  has  been  a  statistically 
significant increase in resistance to both erythromycin and tetracyclines in E. faecium from Gallus gallus 
since 2006, whereas isolates from pigs and cattle have shown a significant decline in resistance to both of 
these antimicrobials. 
Because cross-resistance occurs between avoparcin and the important human antimicrobial vancomycin 
(used  for  treating  Gram-positive  infections  in  humans),  the  use  of  avoparcin  as  an  antimicrobial  growth 
promoter was banned in the EU in 1997. All Enterococcus isolates collected from bovine, broiler and pig 
meat in 2011 were fully susceptible to vancomycin. In addition, none of the E. faecium isolates from cattle or 
E. faecalis isolates from pigs expressed resistance to this antimicrobial, and only 0.4-0.7 % of the remaining 
isolates were resistant. Only two or three countries usually identified resistance per species and livestock 
combination. Vancomycin resistance has generally been at a low, stable level in all countries since 2006, 
although Austria has shown a significant decline in resistance in E. faecium from both Gallus gallus and 
cattle while Switzerland has also shown a significant decline in the former. Fluctuations in the occurrence of 
vancomycin resistance in E. faecium from various animal species can be related to the spread of single 
clones  of  E. faecium  carrying  the  vanA  gene  (Nilsson  et  al.,  2009).  The  results  reported  here  are  in 
agreement with most other studies that have previously been carried out, which show that vanA resistance is 
more common in E. faecium isolates from animals and meat derived from those animals, whereas it is more 
rarely found in E. faecalis.  
Resistance to ampicillin in E. faecalis isolates from Gallus gallus, pigs and cattle was uncommon or not 
observed in all reporting MSs, whereas it was much more widespread in isolates of E. faecium and was 
observed in a number of different MSs, in broilers, pigs and cattle. The highest levels of ampicillin resistance 
in E. faecium from broilers were observed in Ireland (74.8 %), the Netherlands (36.1 %) and Spain (36.1 %). 
Ampicillin resistance was also found to be common in a study of E. faecium from bacteraemias in the United 
Kingdom and Ireland between 2001 and 2006, with a significant increasing trend being identified as well as a 
strong association with vancomycin resistance (Brown et al., 2008). Enterococci tend to show a degree of 
intrinsic resistance to penicillins, probably because of their low affinity to penicillin-binding proteins (Murray, 
1990). The ECOFF separates isolates with intrinsic resistance from those with acquired resistance.  
Resistance  to  linezolid  was  rare  for  both  E. faecalis  and  E. faecium  in  all  of  the  host  animal  species 
considered. A low level of resistance was observed for E. faecium and E. faecalis from Gallus gallus in 
Belgium  (6.1 %  and  6.2 %,  respectively)  and  in  E. faecium  in  pigs  from  France  (1.1 %).  Low  levels  of 
resistance were also observed for E. faecium in cattle from the Netherlands (1.2 %) and Spain (8.0 %) and 
E. faecalis in cattle from the Netherlands (1.0 %). Levels of resistance to chloramphenicol and gentamicin 
at the reporting group level was low or very low for both E. faecalis and E. faecium isolates in all animal EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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categories considered, with the exception of E. faecalis isolates from pigs where resistance was reported at 
17.0 % and 12.3 %, respectively.  
A number of MSs showed significant increasing or decreasing trends to particular antimicrobials. Many of 
these changes are being observed against a background of initiatives either to reduce antimicrobial usage or 
to influence the prescribing of antimicrobials in certain ways. Correlation of trends with trends in usage has 
not been done in this report, but is the logical next step in analysing the resistance figures in more detail. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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8.  METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 
8.1. Introduction 
Methicillin-resistant Staphylococcus aureus (MRSA) has been recognised as an important cause of hospital-
associated infections in humans for decades. Treatment of these infections has become an important public 
health matter owing to the development of resistance to many commonly used antimicrobials. Strains of 
MRSA have also emerged which are particularly associated with community-acquired infections in humans. 
Moreover,  in  recent  years,  MRSA  has  also  been  detected  in  several  animal  species  including  pigs, 
companion animals and other farm animal species. Hospital-associated MRSA and community-associated 
MRSA are those strains predominantly affecting humans, although livestock-associated MRSA may also be 
harboured by humans, especially where there is occupational contact with affected livestock. Antimicrobial 
susceptibility in European invasive S. aureus isolates is reported by the MSs to the European Antimicrobial 
Resistance Surveillance Network (EARS-Net) (ECDC, 2012). Molecular typing data are not reported and 
thus possible links to the animal reservoir can not easily be determined. Recent EARS-Net data showed 
decreasing or stabilising MRSA percentages in most European countries, which might indicate the impact of 
improved hospital infection control routines which have been implemented in several countries. However, 
MRSA remains a human public health priority, as the percentage of MRSA remains above 25 % in eight out 
of 28 countries, mainly in Southern Europe (ECDC, 2012).  
Pigs are acknowledged as an important source of colonisation of a particular strain of MRSA (designated 
ST398-multi-locus sequence type 398) for pig farmers and veterinarians, and their families, through direct or 
indirect  contact  with  pigs.  This  recently  recognised  strain,  MRSA  ST398,  which  appears  to  be  primarily 
acquired by occupational exposure, can on occasion cause infections in humans and also on occasion be 
introduced into healthcare settings. In order to increase awareness and to assess the occurrence of MRSA in 
pig  primary  production  across  the  EU,  the  occurrence  and  diversity  of  MRSA  and  MRSA  ST398  in  pig 
holdings in MSs were assessed through an EU-wide baseline survey (EFSA, 2009b, 2010b). 
The EFSA’s assessment of the public health significance of MRSA in animals and food (EFSA, 2009c) and 
the Joint scientific report of ECDC, EFSA and EMEA on MRSA in livestock, companion animals and food 
(EFSA,  2009a)  provide  more  background  information  and  recommendations  on  MRSA.  A  principal 
recommendation was that monitoring of food-producing animals, in particular intensively reared animals, is 
carried out periodically in conjunction with a systematic surveillance of MRSA in humans so that trends in the 
diffusion and evolution of zoonotically acquired MRSA in humans can be identified. In particular, isolate 
samples representative of various animal and food origins should be analysed for lineage determination, 
antimicrobial susceptibility and virulence-associated traits. These issues were reviewed in the recent EFSA 
Scientific  Report  presenting  technical  specifications  for  the  harmonised  monitoring  and  reporting  of 
antimicrobial  resistance  in  MRSA  in  food-producing  animals  and  food  (EFSA,  2012c).  The  technical 
specifications make recommendations to improve the harmonisation of the monitoring of the prevalence, 
genetic diversity and multi-resistance profile of MRSA in food-producing animals and food derived from those 
animals.  
Molecular typing techniques, such as spa-typing and multi-locus sequence typing (MLST), are commonly 
used in S. aureus to sub-type strains and determine lineages. In spa-typing, different genetic types or strains 
of MRSA are designated by a number with the prefix t, while in MLST, strains are designated by a sequence 
type number. Using such typing results, often in conjunction with certain other virulence and antimicrobial 
resistance characteristics, it is possible to sub-divide strains of MRSA into groups characterised by differing 
epidemiology. These techniques are of particular relevance, for instance, in the investigation of outbreaks, 
such as in the case of hospital-associated MRSA, and of transmission events, for example of livestock-
associated MRSA, and in the detection of emergence of strains showing new or multiple resistance patterns. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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8.2. Methicillin-resistant Staphylococcus aureus–reports from individual MSs 
Livestock-associated MRSA isolates are the principal focus of this chapter, which summarises the monitoring 
results of MRSA in various animal species and food reported by MSs to EFSA in 2011. Data on antimicrobial 
resistance of MRSA isolates and S. aureus from food and animal origin were reported by only two countries 
in 2011. The methods for the isolation of MRSA from animals and foods to date have not been harmonised 
at the EU level and, therefore, the methods used by individual reporting MSs may differ in sensitivity. 
Six MSs–Belgium (Gallus gallus), Cyprus (food), Germany (cattle and food), Ireland (cattle, pigs, sheep, 
goats Gallus gallus and turkeys), the Netherlands (cattle, pigs, sheep, goats and Gallus gallus) and Spain 
(fattening  pigs  and  food)–and  Switzerland  (dairy  cattle  and  fattening  pigs)  submitted  data  on  MRSA 
prevalence in animals and food in their national zoonoses reports for 2011 (Table MRSA1). This is a marked 
reduction compared with 2010, when 12 countries submitted MRSA prevalence data. 
Table MRSA1.  Overview of countries reporting data on MRSA in animals and food in 2011 
Data  Total number of MSs reporting  Countries 
Food  3  MSs: CY, DE, ES 
Animals  5 
MSs: BE, DE, ES, IE, NL 
Non-MS: CH 
 
8.2.1. Methicillin-resistant Staphylococcus aureus in food 
In 2011, three MSs-Cyprus, Germany and Spain-reported information regarding the occurrence of MRSA in 
food. The results are summarised in Table MRSA2. 
Cyprus examined samples of meat from rabbits and products of animal origin used to make the local product 
τραχανάς,
19 and, to a larger extent, samples of cheeses made from a mixture of bovine, ovine or caprine milk 
for the presence of S. aureus and MRSA. Six of the cheese samples tested positive for MRSA of unspecified 
spa-type; the other samples were negative for MRSA.  
Germany investigated a wide range of food for MRSA, among which a number of samples of red meat from 
various animal species, different kinds of poultry meat, wild boar meat and raw or low-heat-treated bovine 
milk cheeses tested positive for MRSA. The corresponding spa-typing data were not available.  
Spain examined a range of food products for MRSA, and the single positive isolate obtained from fresh pig 
meat belonged to spa-type t011. 
                                                 
19 τραχανάς (trachanas): is made by mixing flour, yoghurt or sour milk, and optionally cooked vegetables, salt, and spices (notably 
tarhana herb), letting the mixture ferment, then drying, and usually grinding and sieving the result. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table MRSA2.  MRSA in food, 2011 
Food species/Country  Production type/ description (where specified)  Sample  
unit 
Number of units 
tested 
Number (%) positive 
for MRSA 
Cheese             
Cyprus  pasteurised mixed milk, at processing plant, surveillance  Batch  1,483  6 (0.4)
1 
Germany  soft and semi-soft cheese from raw or low heat treated cow milk, at retail  Single  322  5 (1.6)
1 
Milk             
Spain 
raw milk from cow  Single  7  0 
raw milk from goat  Single  15  0 
Meat from bovine animals          
Germany  fresh meat at retail, monitoring  Single  509  41 (8.1)
1 
Spain  fresh meat(n=4)/mined meat(n=21)/meat products(n=2)  Single  27  0 
Meat from broilers             
Germany 
carcass at slaughterhouse, monitoring  Flock  331  160 (48.3)
1 
fresh meat , at retail, monitoring  Single  404  107 (26.5)
1 
Spain  fresh meat(n=1)/mined meat(n=5)/meat products(n=1)  Single  7  0 
Meat from pigs             
Spain 
fresh meat  Single  42  1 (2.4)
2 
minced meat  Single  13  0 
meat products  Single  50  0 
Meat from rabbit             
Cyprus  chilled carcass at slaughterhouse, surveillance  Batch  10  0 
Meat from turkey             
Spain  official sampling  Single  8  0 
Meat from wild boar             
Germany  fresh meat, at retail, monitoring  Single  351  17 (4.8)
1 
Other foods             
Cyprus  other products of animal origin, at processing plant, surveillance (for the 
production of the local 'Trachanas')  Batch  30  0 
1. spa-types unspecified. 
2. spa-types t011. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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8.2.2. Methicillin-resistant Staphylococcus aureus in animals 
MRSA in food-producing animals 
Belgium, Germany, Ireland, the Netherlands, Spain and Switzerland reported information on the prevalence 
of MRSA in food-producing animals and/or their immediate environment. The results are summarised in 
Table MRSA3.  Of  particular  note  is  the  extremely  high  MRSA  prevalence  recorded  in  fattening  pigs  in 
sampled at slaughter (nasal swabs) in Spain and in the Netherlands, and in cattle sampled at slaughter 
(nasal swabs) in the Netherlands in 2011. 
Table MRSA3.  MRSA in animals, 2011 
Animal 
species/ 
Country 
Production type/ 
description (where 
specified) 
Sample  
unit 
Number 
of units 
tested 
Number 
(%) 
positive for 
MRSA 
MLST: spa-types 
(number of 
isolates) 
Poultry 
Belgium 
Broilers, nasal swabs  Farm (20 animals 
per farm) 
92  3 (3.3)  ST398: t011 (2) 
ST239: t037 (1) 
Laying hens, nasal swabs  280  0  Not applicable 
Netherlands  Broilers at slaughter, nasal 
swabs 
Flock (10 birds per 
flock)  48  14 (29.2)  Unspecified 
Pigs 
Netherlands  Fattening pigs, at 
slaughter, nasal swabs 
Herd (10 animals 
per herd)  110  88 (80.0)  Unspecified 
Spain  Fattening pigs, at 
slaughter, nasal swabs  Slaughter batch  227  191 (84.1) 
t011 (97) 
t034 (8) 
t108 (3) 
t1197 (7) 
t1451(5) 
t2346(3) 
Unspecified (68) 
Switzerland  Fattening pigs, at 
slaughter, nasal swabs  Animals  392  22 (5.6) 
ST398: t034 (19) 
ST398: t011 (1) 
ST49: t208 (1) 
ST1: t2279 (1) 
Cattle 
Germany  Beef cattle, at slaughter, 
nasal swabs  Animals  288  25 (8.7)  Unspecified 
Ireland 
Dairy cattle, on farm, 
clinical mastitis 
investigations 
Animals  76  1 (1.3)  Unspecified 
Netherlands  Unspecified, at slaughter, 
nasal swabs 
Animals (10 
animals per herd)  100  83 (83.0)  Unspecified 
Switzerland  Dairy cows, bulk milk  Herd  200  3 (1.5)  t011 (3) 
Sheep and Goats 
Netherlands  Unspecified, on farm  Animal  564  0  Not applicable 
Netherlands  Unspecified, on farm  Animal  214  0  Not applicable 
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MRSA in companion animals 
Sweden was the only MS to report MRSA data for pets and companion animals. MRSA was confirmed in two 
horses and one cat in Sweden in 2011. The isolates from horses were of spa-type t011 and the isolate from 
the  cat  was  of  spa-type  t022.  All  of  these  cases  were  isolated  from  clinical  specimens  sent  for  routine 
bacteriology. 
Temporal occurrence in MRSA  
Two countries reported consistently on the occurrence of MRSA in fattening pigs; over the period 2009–2011 
for Switzerland and in both 2010 and 2011 for Spain (Table MRSA4). Methodological differences may occur 
between reporting countries, but where longitudinal studies have been performed then the same methods 
have usually been used, and this is the case for Spain and Switzerland. Spain sampled one animal (nasal 
swab) from slaughter batches containing 10 or more pigs and cultured swabs on Baird-Parker Chromogenic 
media, whereas Switzerland performed  pre-enrichment in  Mueller-Hinton  broth supplemented with  6.5 % 
salt,  then  culture  through  selective  broth  containing  cefoxitin  and  aztreonam  and  finally  plating  onto  an 
MRSA–selective agar. 
Table MRSA4.  Temporal occurrence of MRSA in animals 
Country  Year 
Production type/ 
description (where 
specified) 
Sample 
unit 
Number 
of units 
tested 
Number 
(%) 
positive 
for MRSA 
MLST: spa-types 
(number of 
isolates) 
Spain 
2010  Fattening pigs, at 
slaughter, nasal swabs  Animals  276  159 (58.0) 
t011 (121) 
t034 (3) 
t108 (17) 
Unspecified (18) 
2011  Fattening pigs, at 
slaughter, nasal swabs  Animals  227  191 (84.1) 
t011 (97) 
t034 (8) 
t108 (3) 
t1197 (7) 
t1451(5) 
t2346(3) 
Unspecified (68) 
Switzerland 
2009  Fattening pigs, at 
slaughter, nasal swabs  Animals  405  8 (2.2)  Unspecified (8) 
2010  Fattening pigs, at 
slaughter, nasal swabs  Animals  392  23 (5.9) 
t011 (1)  
t034 (17) 
ST49: t208(5) 
2011  Fattening pigs, at 
slaughter, nasal swabs  Animals  392  22 (5.6) 
ST398: t034 (19) 
ST398: t011 (1) 
ST49: t208 (1) 
ST1: t2279 (1) 
 
In  Switzerland,  the  MRSA  prevalence  in  2009,  2010  and  2011  was  2.2 %  (95 % CI  1.0–4.2 %),  5.9 % 
(95 % CI 3.8–9.7 %) and 5.6 % (95 % CI 3.6–8.4 %), respectively. There has therefore been a significant 
increase in the percentage of fattening pigs positive, although the percentage remains low. The continuing 
presence of ST49; t208 in pigs was also noted among the frequently prevalent ST398 MRSA strains. 
Spain also reported results for fattening pigs in both 2010 and 2011, when 58 % of 276 slaughter pigs and 
84 % of 227 nasal swab samples from pigs at slaughter were positive. In Spain, 76 % (121/159) isolates 
were spa-type t011 in 2010, and this remained the predominant type in 2011, accounting for 79 % (97/123) 
of the isolates typed.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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8.2.3. Susceptibility testing of MRSA isolates 
In 2011, data relating to the susceptibility of MRSA and S. aureus isolates were reported only by Belgium 
and  Switzerland.  Both  countries  used  a  broth  dilution  method  and  EUCAST  ECOFFs  to  determine  the 
susceptibility  of  isolates  to  beta-lactams  (penicillin  and  oxacillin-only  Switzerland),  ciprofloxacin, 
chloramphenicol,  cefotoxin  (only  Belgium),  clindamycin,  erythromycin,  gentamicin,  kanamycin,  linezolid, 
fusidic  acid,  quinupristin/dalfopristin,  mupirocin  (only  Belgium),  rifampicin,  streptomycin,  tetracyclines, 
tiamulin, trimethoprim, vancomycin and sulfamethoxazole. 
MRSA isolates from broilers 
Of the three MRSA isolates from broilers in Belgium, two belonged to spa-type t011 and the remaining one to 
spa-type t037. All the three isolates were resistant to erythromycin, cefotoxin, penicillin and tetracyclines. 
Two of these isolates were resistant to chloramphenicol, clindamycin, kanamycin, rifampicin, streptomycin, 
sulfamethoxazole and trimethoprim, whereas the third isolate was resistant to ciprofloxacin, fusidic acid and 
gentamicin.  
MRSA isolates from cow’s bulk milk 
The three MRSA isolates from cow’s bulk milk reported by Switzerland all belonged to spa-type t011 and all 
were resistant to the beta-lactam compounds penicillin and oxacillin, as expected. Two of these isolates were 
resistant  to  gentamicin,  kanamycin,  tetracycline  and  trimethoprim,  while  the  third  was  resistant  to 
clindamycin,  erythromycin,  tiamulin,  fusidic  acid,  quinupristin/dalfopristin,  trimethoprim,  streptomycin  and 
sulfamethoxazole. Susceptibility results for methicillin/susceptible S. aureus (MSSA) from cow’s bulk milk 
were  also  reported  by  Switzerland  and  of  31  isolates,  18  (58 %)  were  susceptible  to  the  antimicrobials 
tested.  Penicillin  resistance  was  observed  in  seven  isolates  (23 %)  and  was  the  commonest  resistance 
detected. 
MRSA isolates from fattening pigs 
Considering  the  susceptibility  of  MRSA  isolates  from  fattening  pigs  reported  by  Switzerland,  15  isolates 
belonging to the most commonly detected genotype, ST398-t034-V, shared an identical resistance profile, 
which was resistance to beta-lactams, tetracycline, macrolides, lincosamides, trimethoprim, pleuromutilins, 
streptomycin and quinupristin/dalfopristin. Three additional isolates were resistant to all these antimicrobials 
except streptomycin whereas one isolate had additional resistance to all of the aminoglycosides tested. 
Among MRSA isolates (N=22) from pigs in Switzerland, tested using the same methodology, breakpoints 
and panel of antimicrobials in 2011, resistance was detected to tetracyclines (100 % resistant), erythromycin, 
trimethoprim,  tiamulin  (90.9 %  resistant)  clindamycin,  quinupristin/dalfopristin  (86.4 %  resistant), 
streptomycin (81.8 % resistant), gentamicin, kanamicin (9.1 % resistant), sulfhamethoxazole, ciprofloxacin 
(4.5 % resistant) and confirmed to beta-lactams (penicillin: 100 % resistant). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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8.3. Discussion 
Although food is not currently considered to be a source of MRSA infection or colonisation of humans (EFSA, 
2009c), the monitoring of MRSA in various food products performed consistently in several MSs indicates 
that MRSA can be detected quite frequently in some foods. A very high MRSA prevalence in poultry meat 
was recorded by Germany in 2009, 2010 and 2011, while the prevalence was lower in meat from cattle and 
pigs.  For  broiler  meat  the  prevalence  observed  in  2011  was  similar  to  that  reported  in  2009.  Broiler 
carcasses were frequently positive for MRSA at flock/batch level both in the Netherlands, where nasal swabs 
were collected, and in Germany, where carcasses were sampled. 
The positive findings of MRSA in meat from wild boar might indicate cross-contamination during processing, 
as so far MRSA has not frequently been detected in wild boar. This needs to be elucidated further; cross-
contamination of animals immediately prior to slaughter during transport and lairage and of products derived 
from animals after slaughter seems likely to account at least in part for the high prevalence obtained in some 
situations. 
In 2011, MRSA was also detected in various kind of cheeses in Cyprus and Germany. Isolates from raw milk 
cheese (1.6 % positive) in Germany in 2011 were in line with the detection of MRSA in bulk tank milk in 2009 
and 2010.  
In Germany, MRSA was less frequently isolated from beef animals than from veal calves or pigs. Both Spain 
and the Netherlands reported extremely high MRSA prevalence in fattening pigs sampled through nasal 
swabs at slaughter. The prevalence of MRSA in slaughter pigs in Spain in 2011 was much higher than that 
observed  2010.  Switzerland  also  recorded  a  significant  increase  in  MRSA  prevalence  in  fattening  pigs 
sampled at slaughter, although the percentage colonised or transiently colonised animals remains low. 
In 2011, Belgium performed an extensive monitoring of MRSA in laying hens and broilers; from 372 farms 
investigated, only three tested positive for MRSA. 
 
Belgium and Switzerland were the only countries to report the susceptibility of MRSA isolates and used a 
broth dilution method and EUCAST ECOFFs to determine susceptibility in 2010 (Switzerland) and in 2011 
(both countries). None of the three MRSA strains isolated from broilers in Belgium was resistant to more than 
four antimicrobials of the panel tested. In 2010 Switzerland reported results for MRSA of spa-type t011 from 
calves and in 2011 results for the same spa-type were reported for bovine bulk milk. The t011 isolates from 
calves in 2010 (n=5) were resistant to beta-lactams, clindamycin, erythromycin and tetracyclines, but, with 
the exception of one isolate, susceptible to the other antimicrobials tested. The susceptibility pattern of t011 
observed in calves in 2010 therefore differs from that observed in the low number of isolates recovered from 
bovine bulk milk in 2011. MRSA isolates reported by Switzerland from bovine bulk milk were resistant to 
fewer antimicrobials than MRSA isolates and none was resistant to more than four antimicrobials in the panel 
tested.  
A NOVEL SPA-TYPE OF MRSA REPORTED BY SWITZERLAND IN PIGS 
Switzerland also noted the continuing presence of ST49; t208 in pigs. Switzerland was the first country to 
describe the presence of this type of MRSA in pigs (Overesch et al., 2011). MRSA ST49; t208  is a 
previously  undescribed  clonal  lineage  of  MRSA  which  has  so  far  been  detected  only  in  pigs  in 
Switzerland,  giving  rise  to  the  suggestion  that  selection  may  have  occurred  within  the  Swiss  pig 
population.  Evidence  to  support  the  view  that  MRSA  ST49;  t208  may  have  emerged  in  pigs  in 
Switzerland includes the observation that methicillin-susceptible S. aureus (MSSA) belonging to spa-
type  t208  had  previously  been  described  in  Switzerland  in  pigs.  This  spa-type  is  otherwise  rarely 
recorded in Europe, having been described in only one human infection in the United Kingdom and three 
cases of skin infection and laryngeal ulceration in wild squirrels (Overesch et al., 2011). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
 
EFSA Journal 2013;11(5):3196  286 
 
EFSA  recently  published  a  Scientific  Report  describing  technical  specifications  for  the  harmonised 
monitoring and reporting of antimicrobial resistance in MRSA in food-producing animals and food in October 
2012 (EFSA, 2012c). Currently, there are some issues relating to the differing methodology which MSs may 
use for the isolation of MRSA from foods, animals or the environment of animals in substrates such as dust. 
In circumstances where differing methodologies have been used, then the results obtained by different MSs 
may not be directly comparable. This is exemplified for example by the methods used in Switzerland, where 
a pre-enrichment salt broth culture stage was employed when culturing samples. The technical specifications 
should  enable  harmonised  data  to  be  collected  from  MSs  on  both  the  degree  to  which  food-producing 
animals (and the food produced from them) are colonised with MRSA and the strains of MRSA involved. A 
new  definition  of  MRSA  proposed  that  it  should  include  those  strains  harbouring  mecC  gene  and  the 
laboratoy methods adapted accordingly so that those strains can be also targeted by the harmonised routine 
monitoring.  The  situation  with  regard  to  MRSA  and  some  food-producing  animal  species  has  changed 
substantially over the last decade; therefore, the proposed monitoring aims to provide a means to detect 
without undue delay further developments which may occur, in particular regarding the possible emergence 
of MRSA strains displaying particular virulence or resistance patterns and/or their potential exchange and 
diffusion between human and animal populations. 
S. AUREUS OF HUMAN AND BOVINE ORIGIN CARRYING A NOVEL MECA VARIANT GENE 
Methicillin-resistant Staphylococcus aureus typically gains resistance to methicillin (and most other beta-
lactam antimicrobials) through possession of the mecA gene. Recently, a novel mecA homologue was 
identified in S. aureus isolates from cattle and humans in the United Kingdom and humans in Denmark, 
which  also  confers  methicillin  resistance.  This  has  been  designated  mecALGA251  or  mecC  and  is 
approximately 70 % related to the mecA gene; the gene mecALGA251 occurs in a previously unidentified 
genetic element, which has been designated SCCmec XI (Garcia-Alvarez et al., 2011). The novel mecA 
homologue has been confirmed in an archived human S. aureus isolate from 1975 from Denmark and 
has also been described in humans in Ireland (Shore et al., 2011) and Germany (Cuny et al., 2011). 
Isolates of S. aureus carrying the novel mecA element have until recently not been detected by most 
methods currently employed to detect ‘classical’ MRSA. They have been associated with clinical disease 
in  both  cattle  (mastitis  in  dairy  cows)  and  humans.  The  S. aureus  isolates  carrying  the  novel  mecA 
homologue identified thus far belong to either clonal complex 130 or ST 425 (Garcia-Alvarez et al., 2011; 
Shore et al., 2011). The extent to which transfer of these strains may occur between cattle and humans 
or vice versa is currently unknown. It is also not known whether cattle or humans form the primary host or 
the extent to which the populations of bacteria occurring in cattle and humans exist independently of each 
other. The observation that most previously reported CC130 isolates are from bovine sources has been 
considered to suggest that CC130 isolates are of bovine origin (Shore et al., 2011). 
In 2011, Sweden was the only MS to report findings relating to the divergent homologue mecC, detecting 
this  MRSA  variant  in  milk  samples  from  four  dairy  cows.  The  samples  were  analysed  as  part  of  a 
screening study for MRSA. One of the positive samples was collected in 2011 and three of the samples 
in 2010. These findings indicate that MRSA carrying the novel mecA variant gene occurs among animals 
in Sweden but that the prevalence so far is low. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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9. THIRD-GENERATION CEPHALOSPORIN RESISTANCE IN E. COLI AND SALMONELLA 
9.1. Introduction 
Extended-spectrum beta-lactamases (ESBLs) are considered to be an important emerging issue in Gram-
negative bacteria of public health significance. Bacteria which possess ESBL resistance are usually resistant 
to third-generation cephalosporins, which are critically important antibiotic drugs for the treatment of systemic 
or invasive Gram-negative bacterial infections in humans. These drugs play a critical role in the treatment of 
certain invasive Salmonella infections, particularly in children, in whom the use of fluoroquinolones may not 
be  favoured  because  of  certain  potential  adverse  effects.  A  low  level  of  resistance  may  therefore  still 
constitute  an  important  finding.  Commensal  bacteria,  such  as  indicator  E. coli,  may  contribute  to  the 
dissemination of ESBL resistance because such resistance is usually transferable.  
Salmonella  and  E. coli  may  develop  resistance  to  third-generation  cephalosporins  by  several  different 
mechanisms. Among these different mechanisms, the most common is the acquisition of beta-lactamase 
enzymes on plasmids (small covalently closed circles of DNA which can be transferred between bacteria 
during  bacterial  conjugation).  There  are  several  different  types  of  beta-lactamase  which  can  confer 
resistance  to  third-generation  cephalosporins.  These  are  conveniently  sub-divided  into  four  classes, 
designated A to D: ESBL enzymes of the TEM, SHV and CTX-M families belong to class A, while class C 
includes the AmpC beta-lactamases. 
Wild-type Salmonella isolates never possess a beta-lactamase of any class. For beta-lactamases to occur in 
Salmonella, acquisition must have happened by conjugation, usually with other Enterobacteriaceae through 
transfer of plasmids. Although all four different types of beta-lactamase classes have been described in 
Salmonella  globally,  within  the  EU  the  most  important  types  of  beta-lactamase  resistance  acquired  by 
Salmonella are first ESBL resistance and, secondly, AmpC resistance. E. coli can acquire beta-lactamases 
from other bacteria, in a similar fashion to Salmonella but since it also possesses an endogenous AmpC 
beta-lactamase,  in  some  circumstances  this  can  be  activated,  conferring  resistance  to  third-generation 
cephalosporins. 
The EFSA guidelines for monitoring resistance in indicator E. coli (EFSA, 2008a) state that cefotaxime is a 
good substrate for what are currently the most common and important ESBLs in humans in Europe, the 
CTX-M enzymes, and can therefore be used as an indicator for ESBL resistance. Epidemiological cut-off 
values for Salmonella and E. coli for the antimicrobial cefotaxime facilitate detection of CTX-M ESBLs, but 
resistance to cefotaxime may, of course, be conferred by mechanisms of resistance other than ESBLs, such 
as certain other types of beta-lactamase, including AmpC beta-lactamases. In this chapter, the occurrence of 
resistance is given, where available, for cefotaxime and ceftazidime. As very few MSs reported data on 
resistance to ceftiofur, and because this compound is not considered optimal for the detection of ESBL 
enzymes, results for ceftiofur are not included in this chapter. Furthermore, because this report covers only 
phenotypic monitoring, it is not possible to determine the class or exact type of beta-lactamase enzyme 
which is likely to confer the resistance detected to third-generation cephalosporins. 
The monitoring reported here and performed in accordance with EFSA’s guidelines (EFSA, 2008a), does not 
utilise  selective  primary  isolation  media  containing  cephalosporins  and  so  the  results  generally relate  to 
organisms chosen effectively at random from primary culture media. In certain types of monitoring, selective 
media containing cephalosporins may be used to investigate the presence or absence of cephalosporin-
resistant organisms in a particular sample (within the limit of detection) and, in that case, a different type of 
result would be obtained from such monitoring, which has a greater sensitivity. Ideally, the establishment of 
optimum phenotypic testing systems for sensitive, specific and rapid detection of ESBLs would be a very 
important component of antimicrobial resistance monitoring programmes. 
These factors and others have been considered in detail in EFSA’s Scientific Report on the harmonised 
monitoring and reporting of antimicrobial resistance in Salmonella, Campylobacter and indicator E. coli and 
Enterococcus spp. bacteria transmitted through food (EFSA, 2012b). In particular, detailed recommendations 
have been made for the isolation and identification of ESBL and AmpC E. coli and methods described which 
would promote a harmonised and therefore comparable approach to monitoring across the EU. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
 
 
EFSA Journal 2013;11(5):3196  288 
9.2. Third-generation cephalosporin resistance in Salmonella from food and animals 
9.2.1. Third-generation cephalosporin resistance in Salmonella isolates from food 
Eight MSs reported the results for resistance to cefotaxime in Salmonella spp. isolates recovered from meat 
from broilers (Table ESBL1). Resistance was reported at a low level in all MSs except the Netherlands, 
where the level of resistance was 31.9 % to both cefotaxime and ceftazidime; the figures for the Netherlands 
also represent an increase on the figures obtained for 2010, when 11 % and 8 % of isolates were resistant to 
cefotaxime and ceftazidime, respectively. In most MSs, the prevalence of resistance to cefotaxime was equal 
to that observed to ceftazidime; however, the figures differed slightly for Belgium and Romania, suggesting 
that enzymes which were preferentially cefotaximases or ceftazidimases may have been responsible.  
Table ESBL1.  Resistance (%) to cefotaxime and ceftazidime in Salmonella spp. isolates from meat 
from broilers tested by MSs in 2011 
Country 
Cefotaxime  Ceftazidime 
N  % Res  N  % Res 
Belgium  256  1.6  256  2.3 
Germany  145  2.8  145  2.8 
Greece  10  0  -  - 
Hungary  170  0  -  - 
Ireland  47  8.5  47  8.5 
Latvia  20  0  -  - 
Netherlands  47  31.9  47  31.9 
Romania  172  1.2  172  0.6 
Total (8 and 5 MSs)  867  3.3  667  4.5 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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The results of testing for third-generation cephalosporin resistance in Salmonella spp. isolates recovered 
from meat from pigs are shown in Table ESBL2. Resistance was either not detected or reported at a low 
level  in  all  reporting  MSs.  The  prevalence  of  resistance  to  cefotaxime  was  equal  to  that  observed  to 
ceftazidime for all MSs except Romania, where ceftazidime but not cefotaxime resistance was detected, 
suggesting  that  a  ceftazidimase  enzyme  may  have  been  responsible.  In  2009,  Belgium  reported  4 % 
cefotaxime resistance and 3 % ceftazidime resistance, while Germany reported 1 % cefotaxime resistance 
and  0 %  ceftazidime  resistance.  Belgium  and  Germany  did  not  report  resistance  to  either  compound  in 
Salmonella spp. isolates from pig meat in 2010, although resistance re-appeared in 2011 at a low level. The 
higher level of resistance to cefotaxime in Portugal (8.3 %) may be linked to the small sample size tested. 
Table ESBL2.  Resistance (%) to cefotaxime and ceftazidime in Salmonella spp. isolates from meat 
from pigs tested by MSs in 2011 
Country 
Cefotaxime  Ceftazidime 
N  % Res  N  % Res 
Belgium  244  0.4  244  0.4 
Denmark  49  0  -  - 
Estonia  22  0  -  - 
Germany  115  2.6  115  2.6 
Hungary  17  0  -  - 
Ireland  139  0  139  0 
Italy  67  3.0  67  3.0 
Netherlands  15  0  15  0 
Portugal  12  8.3  -  - 
Romania  87  0  87  1.1 
Total (10 and 6 MSs)  767  0.9  667  1.0 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
As  shown  in  Table  ESBL3,  resistance  to  cefotaxime  in  S. Typhimurium  from  meat  from  pigs  was  not 
detected by any of the reporting MSs; the situation was similar in 2010.  
Table ESBL3.  Resistance (%) to cefotaxime in S. Typhimurium isolates from meat from pigs tested 
by MSs in 2011 
Country 
Cefotaxime  Ceftazidime 
N  % Res  N  % Res 
Belgium  103  0  103  0 
Denmark  28  0  -  - 
Germany  20  0  20  0 
Hungary  12  0  -  - 
Ireland  57  0  57  0 
Italy  12  0  12  0 
Romania  18  0  18  0 
Total (7 and 5 MSs)  250  0  210  0 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported.   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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9.2.2. Third-generation cephalosporin resistance in Salmonella isolates from animals 
Resistance  to  third-generation  cephalosporins  in  Salmonella  spp.  from  Gallus  gallus  is  shown  in  Table 
ESBL4. A low level of resistance to cefotaxime, of 1.5 %, and to ceftazidime, of 1.4 %, was reported in 
Salmonella spp. isolates from all reporting MSs. The level of resistance to cefotaxime in Salmonella spp. 
from fowl in Ireland and the Netherlands was 1.5 % and 10.0 % respectively, which may be compared with 
the figures reported in 2010 of 6 % (Ireland) and 5 % (the Netherlands). Spain detected 26 % resistance to 
ceftazidime in Salmonella spp. in 2009; resistance was not detected to cefotaxime or ceftazidime in 2010 or 
2011. 
Table ESBL4.  Resistance  (%)  to  cefotaxime  and  ceftazidime  in  Salmonella spp.  isolates  from 
Gallus gallus tested by MSs in 2011 
Country 
Cefotaxime  Ceftazidime 
N  % Res  N  % Res 
Austria  176  1.1  176  1.1 
Denmark  48  0  -  - 
France  326  0  326  0 
Germany  291  0.7  291  0.7 
Greece  48  2.1  -  - 
Hungary  249  2.0  249  0.8 
Ireland  65  1.5  65  1.5 
Italy  199  3.5  198  2.5 
Latvia  12  0  -  - 
Netherlands  180  10.0  180  10.0 
Poland  340  0  340  0 
Portugal  170  1.2  -  - 
Slovakia  54  0  54  0 
Spain  220  0  220  0 
United Kingdom  221  0.9  -  - 
Total (15 and 10 MSs)  2,599  1.5  2,099  1.4 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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The occurrence of resistance to cefotaxime and ceftazidime in S. Enteritidis isolates from Gallus gallus is 
shown  in  Table  ESBL5.  Eleven  MSs  reported  results  for  cefotaxime  and  nine  MSs  reported  results  for 
ceftazidime; the overall level of resistance in all reporting MSs was 0.6 % for cefotaxime and 0.6 % for 
ceftazidime, Austria and Hungary being the only MSs to report resistance amongst the quantitative data 
submitted from all MSs for analysis. Resistance to third-generation cephalosporin was detected by Belgium 
and the Czech Republic in 2010; these MSs did not report results for S. Enteritidis isolates from Gallus gallus 
in 2011.  
Table ESBL5.  Resistance (%) to cefotaxime and ceftazidime in Salmonella Enteritidis isolates from 
Gallus gallus tested by MSs in 2011 
Country 
Cefotaxime  Ceftazidime 
N  % Res  N  % Res 
Austria  53  3.8  53  3.8 
France  41  0  41  0 
Germany  133  0  133  0 
Greece  17  0  -  - 
Hungary  32  6.3  32  6.3 
Italy  15  0  15  0 
Netherlands  31  0  31  0 
Poland  274  0  274  0 
Portugal  41  0  -  - 
Slovakia  18  0  18  0 
Spain  67  0  67  0 
Total (11 and 9 MSs)  722  0.6  664  0.6 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
Resistance to cefotaxime and ceftazidime in S. Typhimurium isolates from Gallus gallus is shown in Table 
ESBL6. Six MSs reported results for cefotaxime and five MSs reported results for ceftazidime; the overall 
level of resistance in all reporting MSs was 0 % for both cefotaxime and ceftazidime, with no MSs reporting 
resistance. The situation was similar amongst reporting MSs in 2010. 
Table ESBL6.  Resistance  (%)  to  cefotaxime  and  ceftazidime  in  Salmonella  Typhimurium  isolates 
from Gallus gallus tested by MSs in 2011 
Country 
Cefotaxime  Ceftazidime 
N  % Res  N  % Res 
France  33  0  33  0 
Germany  29  0  29  0 
Hungary  10  0  10  0 
Netherlands  15  0  15  0 
Poland  15  0  15  0 
United Kingdom  10  0  -  - 
Total (6 and 5 MSs)  112  0  102  0 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported.   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Resistance to cefotaxime and ceftazidime in Salmonella spp. isolates from pigs is shown in Table ESBL7. 
Eight MSs reported results for cefotaxime and six MSs reported results for ceftazidime; the overall level of 
resistance in all reporting MSs was 1.0 % for cefotaxime and 1.1 % for ceftazidime, similar to the figures 
obtained in 2010 and 2009. Considering the number of MSs reporting resistance, the figures differ from 
those reported in 2010, when only Germany reported resistance to cefotaxime and ceftazidime, at 2 %, 
which was the same as the figure Germany reported in 2009.  
Table ESBL7.  Resistance (%) to cefotaxime and ceftazidime in Salmonella spp. isolates from pigs 
tested by MSs in 2011 
Country 
Cefotaxime  Ceftazidime 
N  % Res  N  % Res 
Denmark
1  371  0.3  -  - 
Denmark
2  23  0  -  - 
Estonia  17  0  -  - 
Germany  614  1.3  614  1.3 
Hungary  35  2.9  35  2.9 
Ireland  39  0  39  0 
Italy  86  1.2  86  0 
Netherlands  19  0  19  0 
Spain  82  2.4  82  1.2 
Total (8 and 6 MSs)  1,286  1.0  875  1.1 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
1. Fattening pigs, pigs unspecified and mixed herds. 
2. Breeding pigs. 
Resistance to third-generation cephalosporins in S. Typhimurium from pigs is shown in Table ESBL8. Four 
MSs tested S. Typhimurium isolates for cefotaxime resistance and three for ceftazidime resistance. The 
overall level of resistance for all reporting MSs was 0.2 % for cefotaxime and 0 % for ceftazidime, identical to 
the figures obtained in 2010. Spain was the only country to report cefotaxime resistance in S. Typhimurium, 
at a level of 5.3 %, although the number of isolates was low. Germany reported cefotaxime resistance in 
0.6 % of isolates in 2010, although no resistance was detected in 2011. 
Table ESBL8.  Resistance (%) to cefotaxime and ceftazidime in S. Typhimurium isolates from pigs 
tested by MSs in 2011 
Country 
Cefotaxime  Ceftazidime 
N  % Res  N  % Res 
Denmark  131  0  -  - 
Germany  237  0  237  0 
Ireland  17  0  17  0 
Spain  19  5.3  19  0 
Total (4 and 3 MSs)  404  0.2  273  0 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
 
 
EFSA Journal 2013;11(5):3196  293 
Eight MSs and Norway tested Salmonella spp. isolates from cattle for cefotaxime resistance and the results 
are  shown  in  Table  ESBL9.  No  MSs  reported  cefotaxime  or  ceftazidime  resistance  in  Salmonella  spp. 
isolates from cattle in 2011.  
Table ESBL9.  Resistance (%) to cefotaxime and ceftazidime in Salmonella spp. isolates from cattle 
tested by MSs and non-MS in 2011 
Country 
Cefotaxime  Ceftazidime 
N  % Res  N  % Res 
Estonia  15  0  -  - 
Finland  11  0  -  - 
Germany  146  0  146  0 
Ireland  44  0  44  0 
Italy  28  0  28  0 
Netherlands  69  0  69  0 
Spain  13  0  13  0 
Sweden  24  0  -  - 
Total (8 and 5 MSs)  350  0  300  0 
Norway  12  0  -  - 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
Resistance to cefotaxime and ceftazidime in Salmonella Typhimurium isolates from cattle is shown in Table 
ESBL10.  Five  MSs  reported  results  for  cefotaxime  and  three  MSs  reported  results  for  ceftazidime;  no 
resistance was detected to either antimicrobial.  
Table ESBL10.  Resistance (%) to cefotaxime and ceftazidime in Salmonella Typhimurium isolates 
from cattle tested by MSs in 2011 
Country 
Cefotaxime  Ceftazidime 
N  % Res  N  % Res 
Finland  11  0  -  - 
Germany  37  0  37  0 
Ireland  25  0  25  0 
Netherlands  24  0  24  0 
Sweden  10  0  -  - 
Total (5 and 3 MSs)  107  0  86  0 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
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9.2.3. Salmonella  serovars  from  animals  demonstrating  resistance  to  third-generation 
cephalosporins  
Third-generation  cephalosporin  resistance  was  identified  in  a  range  of  Salmonella  serovars  in  2011. 
Reporting MSs do not necessarily list all of the Salmonella serovars identified, and so the list of affected 
serovars is likely to be incomplete. Among the serovars that were identified as resistant to third-generation 
cephalosporins was a monophasic Salmonella, 1,4,[5],12:i:-, which was identified in pigs from Germany. 
Similarly, in 2010, two monophasic serovars were identified in pigs from Germany, Salmonella 4,12:i:- and 
4,5,12:i:-. 
As was the case in 2010, in 2011 the following third-generation cephalosporin-resistant serovars from one or 
more  sources  (pigs,  Gallus  gallus  and/or  cattle)  and  from  one  or  more  MSs  were  identified:  S.  Derby, 
S. Enteritidis, S. Infantis, S. Kentucky, S. Livingstone, S. London, S. Java and S. Typhimurium. In addition, 
S.  1,9,12:l,v:-,  S.  Cholerae-suis,  S.  Lamberhurst,  S.  Montevideo  and,  S.  Ordonez  with  third-generation 
cephalosporin resistance were identified in 2011. Isolates from turkeys (S. Bovismorbificans from France, 
S. Bredeney from Hungary and S. Muenchen from Spain) and domestic solipeds (S. Typhimurium, DT104 
from Ireland) were also found to express resistance to third-generation cephalosporins in 2011. 
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9.3. Third-generation cephalosporin resistance in indicator E. coli from food and animals 
9.3.1. Third-generation cephalosporin resistance in indicator E. coli isolates from food 
The number of indicator E. coli isolates recovered from meat from animals in 2011 and tested by MSs for 
inclusion in the report was extremely low and so these data did not qualify for the inclusion in this report.  
9.3.2. Third-generation cephalosporin resistance in indicator E. coli isolates from animals 
Table ESBL11 summarises data on resistance in indicator E. coli isolates from Gallus gallus tested by ten 
reporting MSs, Norway and Switzerland. All reporting countries tested isolates for cefotaxime resistance and, 
in addition, six reporting MSs also tested isolates for ceftazidime resistance. Overall, for the reporting MS 
group,  the  observed  resistance  to  cefotaxime  was  6.4 %,  similar  to  the  figure  of  5 %  reported  in  2010. 
However,  the  figures  of  8.1 %  and  7.7 %  for  the  Netherlands  and  Germany  represent  a  decline  on  the 
percentage resistance reported in 2010, when 18 % and 14 % resistance to cefotaxime was reported in 
E. coli  from  broilers  in  the  Netherlands  and  Germany,  respectively.  The  overall  level  of  resistance  to 
ceftazidime for all reporting MSs was 5.4 % 
Table ESBL11.  Resistance  (%)  to  cefotaxime  and  ceftazidime  in  indicator  E. coli  isolates  from 
Gallus gallus tested by MSs and non-MSs in 2011 
Country 
Cefotaxime  Ceftazidime 
N  % Res  N  % Res 
Austria  173  1.7  -  - 
Belgium  419  19.1  -  - 
Denmark  134  0.7  -  - 
Finland  316  0  -  - 
France  192  6.8  192  6.8 
Germany
1  246  7.7  246  7.3 
Germany
2  642  1.6  642  1.7 
Ireland  154  3.9  154  4.5 
Netherlands  283  8.1  283  8.1 
Poland  154  3.2  154  3.2 
Spain  101  20.8  101  17.8 
Total (10 and 6 MSs)  2,814  6.4  1,772  5.4 
Norway  244  0.4  244  2.0 
Switzerland  176  2.3  176  2.3 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
1. Isolates from broilers. 
2. Isolates from laying hens. 
Table ESBL12 shows resistance to cefotaxime and ceftazidime in indicator E. coli from pigs. The overall 
level of resistance for all reporting MSs was 1.7 % for cefotaxime and 1.5 % for ceftazidime, with six MSs 
reporting results for ceftazidime. All reporting countries detected resistance in indicator E. coli from pigs. 
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Table ESBL12.  Resistance (%) to cefotaxime and ceftazidime in indicator E. coli isolates from pigs 
tested by MSs and non-MSs in 2011 
Country 
Cefotaxime  Ceftazidime 
N  % Res  N  % Res 
Austria  162  1.2  -  - 
Belgium  157  4.5  -  - 
Denmark  157  1.3  -  - 
Estonia  22  4.5  22  4.5 
France  184  1.1  184  1.1 
Germany  859  1.9  859  1.5 
Netherlands  287  1.7  287  2.4 
Poland  172  1.2  172  0.6 
Spain  170  0.6  170  0.6 
Sweden  167  0.6  -  - 
Total (10 and 6 MSs)  2,337  1.7  1,694  1.5 
Norway  192  0.5  192  0.5 
Switzerland  175  1.1  175  1.7 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
The results of examinations for third-generation cephalosporin resistance in indicator E. coli from cattle are 
shown  in  Table  ESBL13.  Seven  MSs  tested  indicator  E. coli  isolates  from  cattle  for  cefotaxime  and/or 
ceftazidime resistance. The overall occurrence of resistance to cefotaxime was 0.9 % and to ceftazidime was 
0.6 % in all reporting MSs, a decrease on the figures of 3 % and 4 % reported in 2010. Austria, Denmark and 
Spain did not detect cefotaxime resistance in indicator E. coli from cattle in 2011, and in the remaining MSs a 
low or very low level (0.4-3.7 %) of resistance to both antimicrobials was detected. Resistance to cefotaxime 
in  isolates  from  young  meat  production  animals  (1-2  years)  was  0.4 %  in  Germany  in  2011,  a  marked 
difference with figures reported in 2010, when all isolates derived from veal calves and the occurrence of 
resistance to cefotaxime and ceftazidime was 10 % and 8 %, respectively.  
Table ESBL13.  Resistance (%) to cefotaxime and ceftazidime in indicator E. coli isolates tested from 
cattle by MSs and non-MS in 2011 
Country 
Cefotaxime  Ceftazidime 
N  % Res  N  % Res 
Austria  172  0  -  - 
Belgium  188  3.7  -  - 
Denmark  93  0  -  - 
Germany  909  0.4  909  0.6 
Netherlands  431  1.2  431  0.9 
Poland  173  1.2  173  0.6 
Spain  109  0  109  0 
Total (7 and 4 MSs)  2,075  0.9  1,622  0.6 
Switzerland  182  0  182  0.5 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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9.4. Discussion 
In 2011, as in 2010, resistance to third-generation cephalosporins was generally detected at only low levels 
in Salmonella and indicator E. coli isolates recovered from food and animals. Among reporting MSs overall, 
the occurrence of resistance to third-generation cephalosporins, as determined by resistance to cefotaxime 
in Salmonella spp. from Gallus gallus, pigs and cattle, was 1.5 %, 1.0 % and 0 % respectively, very similar to 
the figures of 1 %, 0.8 % and 0.3 %, respectively, obtained in 2010, and 2 %, 0.7 % and 0.4 %, respectively, 
obtained in 2009. In E. coli the corresponding figures were 6.4 %, 1.7 % and 0.9 % in 2011, 5 %, 1 % and 
3 % in 2010 and 9 %, 2 % and 0.7 % in 2009. Among Salmonella spp. in broiler and pig meat, the level of 
resistance was 3.3 % and 0.9 %, respectively, in 2011 and 4 % and 0.2 %, respectively in 2010. 
Therefore, although  the summary figures show  limited  fluctuation  in  the occurrence  of resistance,  some 
trends  are  evident  in  particular  MSs.  For  example,  eight  MSs  reported  the  results  for  resistance  to 
cefotaxime in Salmonella spp. isolates recovered from meat from broilers (Table ESBL1). Resistance was 
reported at a low level in all MSs except the Netherlands, where the level of resistance was 31.9 % to both 
cefotaxime and ceftazidime; the figures also represent an increase on the figures obtained for 2010, when 
11 %  and  8 %  of  isolates  were  resistant  to  cefotaxime  and  ceftazidime,  respectively.  The  figures  for 
cefotaxime resistance in Salmonella spp. from Gallus gallus (Table ESBL4) show a much lower level of 
cefotaxime resistance (10.0 %) for the Netherlands than was observed for isolates from poultry meat. The 
reason for this difference is not known, but it might reflect issues such as sampling retail meat, which may 
include  not  only  domestic  poultry  production,  but  also  production  from  other  countries,  or,  alternatively, 
cross-contamination of carcases at slaughter with resistant organisms. 
The indicator E. coli population in healthy animals may constitute a reservoir of resistance genes which can 
be transferred to zoonotic organisms such as Salmonella, and this process may be particularly enhanced in 
some  circumstances  (for  example,  under  selection  pressure  resulting  from  antimicrobial  usage).  Once 
Salmonella  isolates  have  acquired  plasmids  which  carry  genes  conferring  resistance  to  third-generation 
cephalosporins (either ESBL or AmpC resistance genes) then dissemination of such resistant Salmonella 
clones will also play a major part in influencing the occurrence of third-generation cephalosporin resistance. 
Considering the prevalence of resistance to cefotaxime resistance in MSs to Salmonella spp. and E. coli in 
Gallus gallus, then in all reporting MSs, with the exception of the Netherlands, the prevalence of resistance is 
higher in E. coli than it is in Salmonella spp. The reason for this difference is not known, but it might reflect 
the dissemination of cefotaxime-resistant clones in poultry in the Netherlands, for example serovars such as 
Salmonella Java. 
The situation is similar considering cefotaxime resistance in isolates from pigs: in all MSs with the exception 
of Spain, the prevalence of cefotaxime resistance is higher in E. coli isolates, than it is in Salmonella spp. In 
cattle, all Salmonella spp. isolates were susceptible to cefotaxime, whereas for MSs also reporting resistance 
to E. coli, resistance in E. coli was detected in all of those MSs. Therefore, in most MSs, it appears that 
E. coli is a reservoir of beta-lactamase resistance, which is less frequently observed in Salmonella spp. 
In most MSs, in both Salmonella spp. and E. coli, the prevalence of resistance to cefotaxime was equal to 
that observed to ceftazidime; however, the figures differed slightly in some cases, suggesting that beta-
lactamase enzymes which were preferentially cefotaximases or ceftazidimases may have been responsible.  
Resistance to cefotaxime in Salmonella spp. from broiler meat was 3.3 %, whereas it was 0.9 % in meat from 
pigs. In general, cefotaxime resistance was therefore more common in Salmonella isolates from broilers than 
from pigs, and this was particularly marked in some countries, for example the Netherlands, where 31.9 % of 
isolates from broiler meat were resistant, whereas resistance was not detected in isolates from pig meat. The 
small sample size may account for some of this variation; however, it does reflect findings described for 
E. coli in the literature: when the occurrence of cephalosporin-resistant E. coli from retail broiler meat and pig 
meat were compared in the Netherlands, the ESBL prevalence was found to be 79.8 % in broiler meat and 
1.8 % in pork (Overdevest et al., 2011). 
Considering the Salmonella serovars of particular public health importance, no resistance to cefotaxime was 
detected in S. Typhimurium in meat from pigs in 2010 or 2011. Austria and Hungary detected cefotaxime 
resistance  in  S.  Enteritidis  from Gallus  gallus  in  2011;  Austria also reported  data  for  S. Enteritidis  from 
Gallus gallus  in  2010,  but  did  not  detect  cefotaxime  resistance.  In  2010,  cefotaxime  resistance  in 
S. Enteritidis from Gallus gallus was reported only by the Czech Republic. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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A noteworthy trend is that the number of MSs reporting cefotaxime resistance in Salmonella spp. from pigs 
has  increased.  Resistance  to  cefotaxime  in  E.  coli  from  young  meat  production  animals  (1-2  years)  in 
Germany,  was  0.4 %  in  2011;  a  marked  difference  with  the  figures  reported  in  2010  when  all  isolates 
originated from veal calves and the occurrence of resistance to cefotaxime and ceftazidime was 10 % and 
8 %, respectively. Reporting the results by animal production type provides a means where differences in the 
occurrence of resistance which are related to husbandry methods, age or stage of production may become 
apparent, and this is the first year in which animal production type has been included in this way.  
Spain detected 26 % resistance to ceftazidime in  Salmonella spp. from Gallus gallus in 2009; however, 
resistance  was  not  detected  to  cefotaxime  or  ceftazidime  in  2010  or  2011.  Such  fluctuations  in  the 
occurrence of resistance could be related to a number of factors, including the general measures which are 
applied throughout the EU to control Salmonella in poultry. 
Resistance to third-generation cephalosprins was detected in a number of serovars of particular public health 
importance,  including  S.  Typhimurium,  S.  Enteritidis,  S.  Infantis,  S.  Kentucky,  S.  Java  and  monophasic 
Salmonella.  Previous  outbreaks  of  ESBL-producing  salmonellae  affecting  poultry  and  humans  have 
occurred, for example involving S. Virchow (Weill et al., 2004; Bertrand et al., 2006), and it is important that 
the monitoring performed can identify such serovars. It may be assumed, that even though the monitoring 
has not been designed to detect outbreaks, it should hopefully reflect indirectly serovars involved in large 
outbreak(s). 
EFSA recently published a report providing detailed recommendations and discussions relating to how future 
surveillance for third-generation cephalosporin, ESBL, AmpC and carbapenem resistance monitoring could 
be  enhanced.  The  introduction  provides  further  details  on  the  methods  by  which  surveillance  could  be 
revised in the future. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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10. FARM-TO-FORK ANALYSIS 
10.1. Introduction 
A number of MSs reported the occurrence of antimicrobial resistance in Salmonella and Campylobacter in 
humans,  animals  and  food  products  derived  from  those  animals  in  2011.  This  chapter  collates  and 
summarises the available data, showing the occurrence of resistance which was reported along the food 
chain and in humans. This is the third year in which this type of analysis has been included in the EU 
Summary Report on antimicrobial resistance. The aim is to highlight potential connections or associations 
which may exist between resistance occurring in the bacterial isolates from animals, foods derived from 
those animals and humans. The direct comparison of the figures along the food chain for a MS is likely to 
simplify  the  complexity  of  the  inputs  which  determine  the  occurrence  of  resistance  observed  in  human 
isolates (for example, no account may have been taken of imported foods or infections resulting from foreign 
travel). Also, because the breakpoints used to assess the resistance of human isolates have not yet been 
fully harmonised, inter-country comparisons may not always be valid. For this reason, this analysis should 
perhaps best be viewed as an exploratory investigation, which will hopefully provide a degree of stimulus 
towards greater harmonisation. 
In addition to differences in the methodology and breakpoints used, direct comparison of the occurrence of 
resistance in animals food and man, may also be problematic because of some differences in the methods 
by which isolates have been collected, for example in the case of food-producing animals, whether they were 
collected  during  routine  surveillance,  random  sampling  of  carcasses  at  slaughterhouses,  or  through 
diagnostic clinical work. On the human side, similar considerations apply, relating to whether the isolate has 
been examined and typed for treatment purposes or as part of antimicrobial resistance surveillance. Ideally, 
the methodology and breakpoints used for the testing of isolates from humans, food and animals should be 
standardised and systematic screening of representative strains (i.e. involving a random sample of isolates 
and  an  appropriate  sample  size)  undertaken.  In  relation  to  isolates  from  food,  a  further  difficulty  in 
interpreting data is the relative importance of antimicrobial-resistant organisms in imported food in relation to 
human infection, as compared to the contribution of domestically-produced food. The relative quantities of 
imported and domestically-produced food may therefore be relevant in relation to human infections for a 
particular MS. Many of these concerns have previously been addressed in the joint opinion on antimicrobial 
resistance  focused  on  zoonotic  infections,  published  in  November  2009  (EFSA,  2009d).  In  some 
circumstances,  even  though  the  results  obtained  for  humans,  animals  and  food  may  not  be  directly 
comparable, they may indicate developing and consistent trends between the different types of samples 
examined.  In  this  chapter,  results  from  humans,  animals  and  food  have  only  been  included  where 
representative numbers of isolates are available from each sampling category for each country. 
In this section of the report, antimicrobial resistance data from humans, animals and food stuffs (meat) are 
described for the following antimicrobial/micro-organism combinations: 
  Erythromycin and ciprofloxacin in C. jejuni and C. coli from humans, poultry (Gallus gallus) and from 
food products derived from poultry, where relevant data are available. 
  Cefotaxime  and  ciprofloxacin  in  S. Typhimurium  from  humans,  poultry  (Gallus  gallus),  meat  from 
broilers,  pigs,  meat  from  pigs  and  cattle  and  in  S. Enteritidis  from  humans,  poultry  and  meat  from 
broilers, where relevant data are available. 
There  were  only  data  available  from  a  few  MSs  for  these  combinations  of  antimicrobials  from  humans, 
animal  and  food.  Human  data  are  generally  qualitative  and  cannot  therefore  be  re-interpreted  using  an 
appropriate revised breakpoint. The majority of MSs reporting human data used CLSI methods and clinical 
breakpoints and in order to harmonise the farm-to-fork analysis for the above antimicrobial/micro-organism 
combinations, the quantitative MIC data from animals and food have been re-interpreted using the recent 
clinical breakpoints defined by CLSI and listed in the tables below. Therefore, the occurrence of resistance 
shown  in  this  chapter  for  bacterial  isolates  from  animals  and  food  may  differ  from  that  shown  in  other 
chapters and that is because this chapter analyses the data using clinical breakpoints whereas the other 
quantitative  chapters  have  used  epidemiological  cut-off  values  to  analyse  data.  All  MSs  submitting 
quantitative  data  for  animals  or  food  for  the  selected  antimicrobial  organism  combinations  have  been 
included in the tables; the corresponding data for humans from MSs for the respective relevant categories in  
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animals and/or food has been included wherever this is available. The human, animal and food data in this 
chapter  has  therefore  been  analysed  for  most  MSs  after  applying  CLSI  clinical  breakpoints;  those 
breakpoints were selected to enable the inclusion of the greatest amount of data available. For the optimal 
detection  of  emerging  resistance,  analysis  using  the  epidemiological  cut-off  values  would  have  been 
preferable;  however,  the  data  have  also  been  analysed  after  applying  EUCAST  epidemiological  cut-off 
values wherever this is possible and the resulting figures are given in parentheses in the results tables 
below. 
10.2. Breakpoints used for the farm-to-fork analysis 
The clinical breakpoints (CBP) defined by CLSI (Campylobacter CLSI document M45-A, Salmonella CLSI 
document M100 S21) were used to re-analyse the quantitative MIC susceptibility data submitted by MSs for 
bacterial isolates obtained from animals and food for the analysis performed in this chapter. The CLSI clinical 
breakpoints are shown in Table FFA1, together with EUCAST clinical breakpoints and epidemiological cut-off 
values.  Over  the  reporting  period,  some  of  the  breakpoints  have  been  revised  and  the  pre-2011  CLSI 
breakpoints (CLSI documents M100 S17-S19) were used by some MSs and the post-2011 CLSI breakpoints 
(CLSI documents M100 S20-S21) by others for susceptibility testing of human isolates. The analysis used 
the  more  recent  CLSI  breakpoints,  which  are  more  congruent  with  the  clinical  breakpoints  derived  by 
EUCAST. 
The data have also been analysed after applying EUCAST epidemiological cut-off values wherever this is 
possible and the resulting figures are given in parentheses in tables FFA3-10 below. 
Table FFA1.  CLSI Clinical breakpoints used for the farm-to-fork analysis 
Organism  Antimicrobial 
Pre-2011 
CLSI MIC 
Breakpoint 
in mg/L (R≥) 
Post-2011 CLSI 
MIC Breakpoint 
in mg/L (R≥) 
EUCAST Clinical 
MIC Breakpoint 
in mg/L (R>) 
EUCAST / EFSA 
Epidemiological 
Cut-off Value 
in mg/L (R>) 
Salmonella  Ciprofloxacin  ≥4  ≥4  >1  >0.06 
Salmonella  Cefotaxime  ≥64  ≥4  >2  >0.5 
Campylobacter spp.  Ciprofloxacin  ≥4  ≥4  NA  >1 
C. coli  Erythromycin  ≥32  ≥32  NA  >16 
C. jejuni  Erythromycin  ≥32  ≥32  NA  >4 
NA = not available at the time of production of the report. 
Human  isolates  were  tested  mainly  in  accordance  with  CLSI  disc  diffusion  recommendations.  The 
breakpoints used to interpret human data are listed in Table FFA2 for the MSs that are included in this 
analysis. 
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Table FFA2.  Breakpoints (mg/L) used for the analysis of human data for MSs also submitting data 
for  animals  or  food,  including  equivalent  MIC  breakpoints  for  disc  diffusion  test  results,  where 
available. 
Member State 
Salmonella  Campylobacter coli and C. jejuni 
Cefotaxime  Ciprofloxacin  Ciprofloxacin  Erythromycin 
Austria  >2  >1  ≥4  ≥32 
Denmark  >0.5  >0.06  -  - 
Estonia  ≥1  ≥0.125  ≥1  ≥4 
France  -  -  ≥1  NS 
Germany  >8  >2  -  - 
Greece  ≥4  ≥4  -  - 
Hungary  ≥4  ≥4  ≥1  - 
Ireland  >2  >1  -  - 
Italy  ≥64  ≥4  ≥4  ≥32 
Latvia  -  ≥4  -  - 
Lithuania  ≥64  ≥4  >1  >0.5 
Luxembourg  ≥4  ≥4  ≥1  ≥4 
Malta  -  ≥2  ≥1  ≥4 
Netherlands  >0.5  >0.06  -  - 
Romania  ≥4  ≥4  -  - 
Slovakia  ≥64  ≥4  ≥4  ≥32 
Slovenia  ≥4  ≥4  ≥4  ≥32 
Spain  ≥4  ≥4  ≥4  ≥32 
United Kingdom  ≥1  ≥0.125  ≥1  ≥4 
NS = Equivalent breakpoint concentration not stated in disc diffusion method. 
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10.3. Campylobacter jejuni and C. coli 
Erythromycin and ciprofloxacin resistance were analysed in isolates of C. jejuni and C. coli from humans, 
animals and from food products derived from animals, where relevant data were available. The data are 
shown in tables FFA3-6. 
Table FFA3.  Resistance (%) to erythromycin in C. coli from humans, Gallus gallus, food derived from 
poultry and pigs in 2011, interpreted using CLSI clinical breakpoints for animals and food 
Country 
Erythromycin Resistance (CBP ≥32 mg/L) 
Humans  Gallus gallus  Broiler meat  Pigs 
N  % Res  N  % Res  N  % Res  N  % Res 
Austria  36  8.3  48  6.3  47  2.1  -  - 
Belgium  -  -  -  -  81  11.1  -  - 
Czech Republic  -  -  24  4.2  -  -  -  - 
Denmark  -  -  -  -  -  -  102  6.9 
France  759  7.8  79  13.9  -  -  82  45.1 
Germany  -  -  25  32.0  82  17.1  -  - 
Hungary  -  -  35  0  61  3.3  76  15.8 
Ireland  -  -  32  3.1  -  -  -  - 
Italy  -  -  -  -  14  50.0  -  - 
Lithuania  45  2.2  -  -  -  -  -  - 
Luxembourg  60  23.3  -  -  -  -  -  - 
Malta  40  7.5  -  -  -  -  -  - 
Netherlands  -  -  18  11.1  42  21.4  156  22.4 
Poland  -  -  -  -  157  0.6  -  - 
Romania  -  -  -  -  59  16.9  -  - 
Slovenia  42  7.1  -  -  -  -  -  - 
Spain  51  33.3  81  33.3  -  -  81  63.0 
Sweden  -  -  -  -  -  -  83  0 
United Kingdom  61  14.8  -  -  -  -  -  - 
Total MSs*  1,094  10.0  342  15.5  543  9.8  580  24.5 
Switzerland  -  -  10  0  -  -  185  7.6 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
* = total MSs represents all MSs contributing to each column in this table. 
Note: Table FFA2 shows the breakpoints used for human isolates. The CLSI breakpoint of ≥32 corresponds to the EUCAST ECOFF of 
>16 when a doubling dilution series is used to determine MIC values.  
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Table FFA4.  Resistance  (%)  to  erythromycin  in  C. jejuni  from  humans,  Gallus  gallus  and  food 
derived from poultry in 2011, interpreted using CLSI clinical breakpoints for animals and food 
Country 
Erythromycin Resistance (CBP ≥32 mg/L) 
Humans  Gallus gallus  Broiler meat 
N  % Res  N  % Res  N  % Res 
Austria  393  0.3  116  0 (0)  84  0 (0) 
Belgium  -  -  -  -  259  7.7(7.7) 
Czech Republic  -  -  57  0(0)  -  - 
Denmark  -  -  43  0(0)  61  0 (0) 
Estonia  183  2.2  -  -  -  - 
France  4,278  1.6  51  0(0)  -  - 
Finland  -  -  40  0(0)  -  - 
Germany  -  -  59  3.4(3.4)  188  0.5(0.5) 
Hungary  -  -  36  5.6(5.6)  33  0(0) 
Ireland  -  -  114  0.9(0.9)  -  - 
Italy  189  6.3  -  -  -  - 
Lithuania  296  0.3  -  -  -  - 
Luxembourg  623  0.6  -  -  -  - 
Malta  149  0.7  -  -  -  - 
Netherlands  -  -  104  0(1.9)  83  3.6(3.6) 
Poland  -  -  -  -  174  0(0) 
Romania  -  -  -  -  52  9.6(9.6) 
Slovakia  962  0.5  -  -  -  - 
Slovenia  882  1.0  -  -  -  - 
Spain  166  4.8  55  3.6(3.6)  -  - 
United Kingdom  687  2.2  -  -  -  - 
Total MSs*  8,808  1.5  685  1.0(1.6)  947  3.1(3.1) 
Switzerland  -  -  150  2.0(5.3)  -  - 
Iceland  121  0  -  -  -  - 
Norway  -  -  48  0(0)  -  - 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
* = total MSs represents all MSs contributing to each column in this table. 
Note: Table  FFA2  shows  the  breakpoints  used  for  human  isolates.  Figures  in  parentheses  indicate  the  occurrence  of  resistance 
determined using EUCAST epidemiological cut-off values. 
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Table FFA5.  Resistance (%) to ciprofloxacin in C. coli from humans, Gallus gallus, food derived from 
poultry in 2011, interpreted using CLSI clinical breakpoints for animals and food 
Country 
Ciprofloxacin Resistance (CBP ≥4 mg/L) 
Humans  Gallus gallus  Broiler meat 
N  % Res  N  % Res  N  % Res 
Austria  36  69.4  48  75.0(79.2)  47  48.9(55.3) 
Belgium  -  -  -  -  81  61.7(63.0) 
Czech Republic  -  -  24  87.5(87.5)  -  - 
France  759  57.8  79  67.1(67.1)  -  - 
Germany  -  -  25  92.0(92.0)  82  86.6(86.6) 
Hungary  -  -  35  85.7(85.7)  61  86.9(90.2) 
Ireland  -  -  32  37.5(40.6)  -  - 
Italy  -  -  -  -  14  71.4(71.4) 
Lithuania  39  74.4  -  -  -  - 
Luxembourg  60  75.0  -  -  -  - 
Malta  40  55.0  -  -  -  - 
Netherlands  -  -  18  44.4(44.4)  42  78.6(78.6) 
Poland  -  -  -  -  157  81.5(82.2) 
Romania  -  -  -  -  59  79.7(79.7) 
Slovenia  42  52.4  -  -  -  - 
Spain  51  78.4  81  93.8(93.8)  -  - 
United Kingdom  61  47.5  -  -  -  - 
Total MSs*  1,088  59.8  342  75.7(76.6)  543  76.4(77.7) 
Switzerland  -  -  10  20.0(20.0)  -  - 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
* = total MSs represents all MSs contributing to each column in this table. 
Note: Table  FFA2  shows  the  breakpoints  used  for  human  isolates.  Figures  in  parentheses  indicate  the  occurrence  of  resistance 
determined using EUCAST epidemiological cut-off values. 
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Table FFA6.  Resistance (%) to ciprofloxacin in C. jejuni from humans, Gallus gallus and food derived 
from poultry in 2011, interpreted using CLSI clinical breakpoints for animals and food 
Country 
Ciprofloxacin Resistance (CBP ≥4 mg/L) 
Humans  Gallus gallus  Broiler meat 
N  % Res  N  % Res  N  % Res 
Austria  393  65.4  116  69.0(69.0)  84  53.6(53.6) 
Belgium  -  -  -  -  259  36.7(36.7) 
Czech Republic  -  -  57  52.6(54.4)  -  - 
Denmark  -  -  43  23.3(23.3)  61  11.5(11.5) 
Estonia  183  58.5  -  -  -  - 
France  4,278  51.3  51  56.9(56.9)  -  - 
Finland  -  -  40  0(0)  -  - 
Germany  -  -  59  62.7(62.7)  188  64.9(64.9) 
Hungary  27  59.3  36  86.1(86.1)  33  81.8(84.8) 
Ireland  -  -  114  39.5(40.4)  -  - 
Italy  162  69.8  10  60.0(60.0)  13  76.9(76.9) 
Lithuania  260  83.1  -  -  -  - 
Luxembourg  623  51.8  -  -  -  - 
Malta  147  69.4  -  -  -  - 
Netherlands  -  -  104  66.3(67.3)  83  63.9(63.9) 
Poland  -  -  -  -  174  89.1(90.2) 
Romania  -  -  -  -  52  84.6(84.6) 
Slovakia  868  20.9  -  -  -  - 
Slovenia  882  67.2  -  -  -  - 
Spain  166  87.3  55  94.5(94.5)  -  - 
United Kingdom  658  44.1  -  -  -  - 
Total MSs*  8,647  52.5  685  56.8(57.2)  947  58.9(59.2) 
Switzerland  -  -  150  40.7(40.7)  -  - 
Iceland  120  45.8  -  -  -  - 
Norway  -  -  48  4.2(4.2)  -  - 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
* = total MSs represents all MSs contributing to each column in this table. 
Note: Table  FFA2  shows  the  breakpoints  used  for  human  isolates.  Figures  in  parentheses  indicate  the  occurrence  of  resistance 
determined using EUCAST epidemiological cut-off values. 
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10.4. Salmonella Enteritidis and S. Typhimurium 
Cefotaxime and ciprofloxacin resistance were analysed in isolates of S. Typhimurium from humans, poultry 
(Gallus gallus), meat from broilers, pigs, meat from pigs and cattle and in S. Enteritidis from humans, poultry 
and meat from broilers, where relevant data are available. The data are shown in tables FFA7-10. 
Table FFA7.  Resistance (%) to cefotaxime in S. Typhimurium from humans, Gallus gallus, meat from 
broilers,  pigs,  meat  from  pigs  and  cattle  in  2011,  interpreted  using  CLSI  clinical  breakpoints  for 
animals and food 
Country 
Cefotaxime Resistance (CBP ≥4 mg/L) 
Humans  Gallus gallus  Broiler meat  Pigs  Pig meat  Cattle 
N  % 
Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  302  1.3  -  -  -  -  -  -  -  -  -  - 
Belgium  -  -  -  -  34  0(0)  -  -  103  0(0)  -  - 
Denmark  244  0.4  -  -  -  -  131  0(0)  28  0(0)  -  - 
Estonia  38  0  -  -  -  -  -  -  -  -  -  - 
Finland  -  -  -  -  -  -  -  -  -  -  11  0(0) 
France  -  -  33  0(0)  -  -  -  -  -  -  -  - 
Germany  811  1.1  29  0(0)  -  -  237  0(0)  20  0(0)  37  0(0) 
Hungary  320  0  10  0(0)  -  -  -  -  12  0(0)  -  - 
Ireland  87  0  -  -  -  -  17  0(0)  57  0(0)  25  0(0) 
Italy  412  2.7  -  -  -  -  -  -  12  0(0)  -  - 
Lithuania  174  0  -  -  -  -  -  -  -  -  -  - 
Luxembourg  31  0  -  -  -  -  -  -  -  -  -  - 
Netherlands  314  0  15  0(0)  -  -  -  -  -  -  24  0(0) 
Poland  -  -  15  0(0)  -  -  -  -  -  -  -  - 
Romania  94  1.1  -  -  -  -  -  -  18  0(0)  -  - 
Slovakia  21  4.8  -  -  -  -  -  -  -  -  -  - 
Slovenia  56  0  -  -  -  -  -  -  -  -  -  - 
Spain  274  0.7  -  -  -  -  19  0(5.3)  -  -  -  - 
Sweden  -  -  -  -  -  -  -  -  -  -  10  0(0) 
United Kingdom  2,147  1.2  10  0(0)  -  -  -  -  -  -  -  - 
Total MSs*  5,325  1.0  112  0(0)  34  0(0)  404  0(0.2)  250  0(0)  107  0(0) 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
* = total MSs represents all MSs contributing to each column in this table. 
Note: Table  FFA2  shows  the  breakpoints  used  for  human  isolates.  Figures  in  parentheses  indicate  the  occurrence  of  resistance 
determined using EUCAST epidemiological cut-off values. 
Note: Data for Gallus gallus includes S. Typhimurium isolates from broiler flocks and laying hen flocks. 
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Table FFA8.  Resistance (%) to ciprofloxacin in S. Typhimurium from humans, Gallus gallus, meat 
from broilers, pigs, meat from pigs and cattle in 2011, interpreted using CLSI clinical breakpoints for 
animals and food 
Country 
Ciprofloxacin Resistance (CBP ≥4 mg/L) 
Humans  Gallus gallus  Broiler meat  Pigs  Pig meat  Cattle 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  302  0  -  -  -  -  -  -  -  -  -  - 
Belgium  -  -  -  -  34  0(11.8)  -  -  103  0(3.9)  -  - 
Denmark  244  4.9  -  -  -  -  131  0(0)  28  0(0)  -  - 
Estonia  39  0  -  -  -  -  -  -  -  -  -  - 
Finland  -  -  -  -  -  -  -  -  -  -  11  0(0) 
France  -  -  33  0(0)  -  -  -  -  -  -  -  - 
Germany  811  0.4  29  0(0)  -  -  237  0(3.8)  18  0(10.0)  37  0(2.7) 
Greece  54  0  -  -  -  -  -  -  -  -  -  - 
Hungary  320  0  10  0(10.0)  -  -  -  -  12  0(8.3)  -  - 
Ireland  87  0  -  -  -  -  17  0(23.5)  57  0(7.0)  25  0(0) 
Italy  486  13  -  -  -  -  -  -  12  0(25.0)  -  - 
Lithuania  194  0  -  -  -  -  -  -  -  -  -  - 
Luxembourg  31  3.2  -  -  -  -  -  -  -  -  -  - 
Malta  24  4  -  -  -  -  -  -  -  -  -  - 
Netherlands  314  12.7  15  0(0)  -  -  -  -  -  -  24  0(0) 
Poland  -  -  15  0(73.3)  -  -  -  -  -  -  -  - 
Romania  94  0  -  -  -  -  -  -  18  5.6(33.3)  -  - 
Slovakia  29  10.3  -  -  -  -  -  -  -  -  -  - 
Slovenia  56  0  -  -  -  -  -  -  -  -  -  - 
Spain  273  0  -  -  -  -  19  0(26.3)  -  -  -  - 
Sweden  -  -  -  -  -  -  -  -  -  -  10  0(0) 
UK  2,196  6.6  10  0(0)  -  -  -  -  -  -  -  - 
Total MSs*  5,554  4.8  112  0(10.7)  34  0(11.8)  404  0(4.5)  250  0.4(8.0)  107  0(0.9) 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
* = total MSs represents all MSs contributing to each column in this table. 
Note: Table  FFA2  shows  the  breakpoints  used  for  human  isolates.  Figures  in  parentheses  indicate  the  occurrence  of  resistance 
determined using EUCAST epidemiological cut-off values. 
Note: Data for Gallus gallus includes S. Typhimurium isolates from broiler flocks and laying hen flocks. 
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Table FFA9.  Resistance (%) to cefotaxime in S. Enteritidis from humans, Gallus gallus and meat from 
broilers in 2011, interpreted using CLSI clinical breakpoints for animals and food 
Country 
Cefotaxime Resistance (CBP ≥4 mg/L) 
Humans  Gallus gallus  Broiler meat 
N  % Res  N  % Res  N  % Res 
Austria  1,266  0.2  53  3.8(3.8)  -  - 
Belgium  -    -  -  57  0(0) 
Denmark  288  0.7  -  -  -  - 
Estonia  185  1.1  -  -  -  - 
France  -    41  0(0)  -  - 
Germany  191  0  133  0(0)  16  0(0) 
Greece  39  0  17  0(0)  -  - 
Hungary  20  0  32  6.3(6.3)  -  - 
Ireland  58  0  -  -  -  - 
Italy  120  1.7  16  0(0)  -  - 
Lithuania  1,496  0.2  -  -  -  - 
Luxembourg  30  0  -  -  -  - 
Netherlands  317  0  31  0(0)  -  - 
Poland  -  -  274  0(0)  -  - 
Portugal  -  -  41  0(0)  -  - 
Latvia  -  -  -  -  19  0(0) 
Romania  120  0  -  -  -  - 
Slovakia  169  3  18  0(0)  -  - 
Slovenia  210  0  -  -  -  - 
Spain  613  0.2  67  0(0)  -  - 
United Kingdom  2,566  0.3  -  -  -  - 
Total MSs*  7,688  0.3  723  0.6(0.6)  92  0(0) 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
* = total MSs represents all MSs contributing to each column in this table. 
Note: Table  FFA2  shows  the  breakpoints  used  for  human  isolates.  Figures  in  parentheses  indicate  the  occurrence  of  resistance 
determined using EUCAST epidemiological cut-off values. 
Note: Data for Gallus gallus includes S. Typhimurium isolates from broiler flocks and laying hen flocks. 
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Table FFA10.  Resistance (%) to ciprofloxacin in S. Enteritidis from humans, Gallus gallus and meat 
from broilers in 2011, interpreted using CLSI clinical breakpoints for animals and food 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
- = no data reported. 
* = total MSs represents all MSs contributing to each column in this table. 
Note: Table  FFA2  shows  the  breakpoints  used  for  human  isolates.  Figures  in  parentheses  indicate  the  occurrence  of  resistance 
determined using EUCAST epidemiological cut-off values. 
   
Country 
Ciprofloxacin Resistance (CBP ≥4 mg/L) 
Humans  Gallus gallus  Broiler meat 
N  % Res  N  % Res  N  % Res 
Austria  1,266  0.1  53  0(5.7)  -  - 
Belgium  -  -  -  -  57  0(1.8) 
Denmark  288  23.6  -  -  -  - 
Estonia  217  1.4  -  -  -  - 
France  -  -  41  0(2.4)  -  - 
Germany  191  0  133  0(0)  16  0(25.0) 
Greece  111  0  17  0(11.8)  -  - 
Hungary  20  0  32  0(9.4)  -  - 
Ireland  58  0  -  -  -  - 
Italy  148  15.5  16  0(6.3)  -  - 
Latvia  97  0  -  -  19  0(15.8) 
Lithuania  1,464  0.6  -  -  -  - 
Luxembourg  30  3.3  -  -  -  - 
Malta  47  6.4  -  -  -  - 
Netherlands  317  9.1  31  0(6.5)  -  - 
Poland  -  -  274  0(47.4)  -  - 
Portugal  -  -  41  0(90.2)  -  - 
Romania  120  0  -  -  -  - 
Slovakia  172  1.7  18  0(0)  -  - 
Slovenia  210  0  -  -  -  - 
Spain  613  0.2  67  0(65.7)  -  - 
United Kingdom  2,596  33.7  -  -  -  - 
Total MSs*  7,965  12.8  723  0(30.8)  92  0(8.7) EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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10.5. Resistance data from the Netherlands relating to Verotoxigenic E. coli O157 
In  2010  and  2011  the  Netherlands  voluntarily  submitted  data  on  the  occurrence  of  resistance  in 
verotoxigenic E. coli isolates from cattle, meat and humans in 2010 and from a number of sources in 2011. 
The results provide a good illustration of how antimicrobial resistance results may be used to investigate 
possible relationships between bacteria occurring in different epidemiological niches and whether organisms 
are being shared between those different niches. Use of antimicrobial resistance data in this way provides a 
means by which potential sources of human infection can be identified or eliminated from investigations. In 
this case, the striking similarity between the prevalence of resistance in isolates cattle, meat and humans, 
supports the view that cattle are a probable source, via the food chain for at least some of the human 
infections. In combination with other secondary typing methods, the antimicrobial resistance data therefore 
provides a powerful investigatory screening tool and can support (as in this case) or refute current thinking 
on the likely epidemiology of infection. 
Table FFA11.  Resistance (%) to antimicrobials in verotoxigenic E. coli O157 from cattle, cattle hides 
and humans from the Netherlands in 2010, interpreted using ECOFFs 
Antimicrobial 
Humans  Cattle Hides  Calves < 1 Year 
N  % Res  N  % Res  N   % Res 
Chloramphenicol  58  2  35  6  67  4 
Tetracyclines  58  5  35  11  67  15 
Ciprofloxacin  58  0  35  0  67  0 
Nalidixic acid  58  0  35  0  67  0 
Trimethoprim  58  2  35  6  67  6 
Streptomycin  58  10  35  11  67  12 
Gentamicin  58  0  35  0  67  0 
Ampicillin  58  5  35  6  67  7 
Cefotaxime  58  2  35  0  67  0 
Ceftazidime  58  3  35  0  67  0 
Sulfonamides  58  10  35  11  67  16 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
In this case, the resistance figures are broadly similar from the different sources which were examined; 
however, particular resistances (for example to third generation cephalosporins in the human isolates) might 
assist further tracing in case investigations. 
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Table FFA12.  Resistance (%)  to  antimicrobials  in  verotoxigenic  E. coli  O157  from  diverse  sources  in  the  Netherlands  in  2011,  interpreted  using 
Breakpoints
1 as shown 
Antimicrobial 
Breakpoint Used 
(R>x mg/L) 
Vegetables 
at Retail 
Fruits at 
Retail 
Herbs at 
Retail 
Bovine Meat 
at Retail 
Bovine Meat 
(Veal) at 
Retail 
Ovine meat 
at Retail 
Porcine Meat 
at Retail 
Meat from 
Turkeys at 
Retail 
Meat from 
Broilers at 
Retail 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Chloramphenicol 16 mg/L  56  0  9  0  33  24.2  224  3.1  31  12.9  7  0  178  6.2  46  23.9  191  16.2 
Tetracyclines 8 mg/L  56  3.6  9  0  33  42.4  224  14.7  31  45.2  7  28.6  178  30.3  46  69.6  191  52.9 
Ciprofloxacin 0.06 mg/L  56  1.8  9  0  33  33.3  224  4.0  31  6.5  7  0  178  2.8  46  39.1  191  56.5 
Nalidixic acid 16 mg/L  56  1.8  9  0  33  21.2  224  4.0  31  6.5  7  0  178  2.2  46  37.0  191  52.4 
Trimethoprim 2 mg/L  56  1.8  9  0  33  33.3  224  13.8  31  29.0  7  14.3  178  24.2  46  34.8  191  40.8 
Streptomycin 16 mg/L  56  1.8  9  0  33  36.4  224  15.2  31  35.5  7  14.3  178  25.8  46  50.0  191  55.0 
Gentamicin 2 mg/L  56  0  9  0  33  6.1  224  0.4  31  0  7  0  178  5.1  46  13.0  191  13.1 
Ampicillin 8 mg/L  56  1.8  9  0  33  33.3  224  11.6  31  32.3  7  14.3  178  23.0  46  76.1  191  66.0 
Cefotaxime 0.25 mg/L  56  0  9  0  33  0  224  1.8  31  3.2  7  0  178  1.7  46  2.2  191  22.5 
Ceftazidime 0.5 mg/L  56  1.8  9  0  33  3.0  224  1.8  31  0  7  0  178  2.2  46  2.2  191  20.9 
Sulfonamides 64 mg/L  56  1.8  9  0  33  33.3  224  21.0  31  32.3  7  28.6  178  33.7  46  56.5  191  58.1 
N = number of isolates tested. 
% Res = percentage of resistant isolates. 
1. The breakpoints used equate to EUCAST ECOFFs for E. coli described in the EFSA recommendations (EFSA, 2008b) except for ciprofloxacin and sulfonamides where breakpoints differing from those 
described in the EFSA recommendations were used. 
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10.6. Discussion 
This chapter reports the occurrence of resistance obtained for isolates of S.Typhimurium and S. Enteritidis 
as well as for C. jejuni and C. coli from humans, animals and food. Results have been included wherever 
these are available from the reporting MSs, subject to certain criteria relating to minimum numbers of isolates 
tested. There are numerous gaps in the data available reported by MSs in relation to the reporting of isolates 
from humans or from the various animal or food categories; few countries reported data for isolates from 
man, animals and food. In addition, data were only available for a small number of isolates for many of these 
combinations. The relative importance of imported foods (for example in relation to pathogen prevalence, 
occurrence of resistance and relative quantity of food imported) within a given MS for human infections 
occurring in that MS has not been considered and will play a role in the resistance figures obtained for 
isolates of Salmonella and Campylobacter originating from humans. Likewise, the impact on the results of 
travel-acquired human infections from other countries where antimicrobial resistance can differ from that in 
the EU has not been considered. 
A major problem encountered in the analysis is the difference in interpretative criteria applied to human 
isolates  from  different  MSs.  Different MSs  apply  differing  breakpoints  to  interpret  their  susceptibility  test 
results  and  this  makes  comparative  analysis  of  the  data  for  bacterial  isolates  originating  from  different 
sources complex, because the human data is qualitative. The tables have attempted to interpret the findings 
using CLSI clinical breakpoints, which are used by a number of MSs to interpret their data, as well as by 
EUCAST ECOFFs. However, not all MSs use EUCAST or CLSI breakpoints to interpret the susceptibility of 
isolates from humans, particularly for Campylobacter. The usefulness of reporting quantitative resistance 
values for isolates from animals and food, in accordance with EFSA’s recommendations (EFSA, 2007), is 
underlined in that this has enabled the occurrence of resistance to be re-evaluated in accordance with the 
relevant CLSI breakpoints (which have been used to generate the results for human isolates in a number of 
MSs). Some data gaps remain in relation to certain methodological aspects (for example, the methods used 
to  collect  some  samples  may  not  have  been  reported)  and  this  will  influence  the  overall  degree  of 
harmonisation attained; no account has been taken of such factors. 
The influence of differences in the breakpoint used to interpret the results can be clearly seen in relation to 
the tables showing the level of resistance to ciprofloxacin in S. Typhimurium and S. Enteritidis, where little or 
no resistance is reported using the CLSI clinical breakpoint in any isolates from food or animals, whereas the 
situation  is  often  quite  different when  the  EUCAST epidemiological cut-off  value  is  applied  to the same 
isolates  to  determine  resistance.  This  is  particularly  evident  in  Table  FFA 10  in  relation  to  ciprofloxacin 
resistance. Breakpoint differences are much less marked when erythromycin or ciprofloxacin resistance in 
C. jejuni or C. coli are considered and although the cefotaxime CLSI breakpoint and EUCAST ECOFF differ, 
the  effect  of these  disparities  is  also slight  in  relation  to  the data  for  S. Typhimurium  and  S. Enteritidis, 
because cefotaxime resistance is rare. 
In relation to ciprofloxacin resistance in S. Typhimurium, resistance was rare in animal or food isolates from 
when the figures were interpreted using the CLSI breakpoint, although some resistance was detected in 
human isolates. This could indicate other sources of human infection for these resistant isolates such as 
infection  through  consumption  of  other  alimentary  sources  than  pork,  chicken  or  beef,  consumption  of 
imported foods, infection associated with foreign travel or contact with pets. The higher level of resistance 
observed in human isolates from Denmark, the Netherlands and the United Kingdom, is a reflection of the 
low breakpoint used in these MSs. Similar considerations can also be applied to S. Enteritidis. 
Spain reported an occurrence of erythromycin resistance in C. coli from Gallus gallus of 33.3 % and the 
same figure in humans, while considering C. coli isolates from pigs 63 % were resistant. Spain was the only 
MS which reported the breakpoints used for human C. coli isolates, reported results for isolates from man 
and which also tested isolates from Gallus gallus and pigs in accordance with EFSA’s recommendations. 
Erythromycin  resistance  in  isolates  of  C. jejuni  from  Gallus  gallus  and  humans  were  3.6 % and 4.8 % 
respectively; similar figures and perhaps to be expected in that poultry are considered a major source of 
C. jejuni. Spain was also the only MS for which all relevant data was available in relation to ciprofloxacin 
resistance in C. jejuni and C. coli isolates from Gallus gallus and humans. While 87.3 % of C. jejuni from 
humans were resistant to ciprofloxacin, 94.5 % of isolates were resistant from Gallus gallus, a rather similar 
figure. There was a greater disparity between isolates of C. coli from humans and Gallus gallus, with 78.4 % 
and 93.8 % of isolates showing ciprofloxacin resistance respectively. 
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The Netherlands provided information on resistance to antimicrobials in verotoxigenic E. coli O157 isolates 
from a range of sources in 2011 and had also provided data from human and animal isolates  in 2010. 
Isolates from different sources show differences in their resistance to certain antimicrobials, for example, 
resistance to cefotaxime and ceftazidime was observed in isolates from meat from broilers more frequently 
than in isolates from other sources. 
There still remains much scope for refinement and improvement of the degree of harmonisation attained by 
reporting MSs to optimise the outputs and their comparability and also to maximise the inclusion of suitably 
harmonised data, particularly for human isolates, where the reporting of quantitative data is required to allow 
better analysis of the results. These fundamental improvements in monitoring need to be put in place before 
further development of the monitoring, such as investigating similarities in multi-drug resistance patterns 
between human, animal and food isolates can take place.  
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11. MATERIALS AND METHODS 
11.1. Antimicrobial susceptibility data from humans available in 2011 
MSs  report  results  from  antimicrobial  susceptibility  testing  (AST)  to  ECDC  through  The  European 
Surveillance System (TESSy). The data used in this report were submitted in connection to the annual data 
collection  for  the  European  Union  Summary  Report  of  Trends  and  Sources  of  Zoonoses  and  Zoonotic 
Agents. 
11.1.1. Salmonella data of human origin  
Nineteen  MSs  and  Iceland  provided  data  for  2011.  The  antimicrobials  reported  on  for  Salmonella  are 
ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic acid, streptomycin, 
sulfonamides, tetracyclines and trimethoprim. Some countries reported on all of these and others on only a 
few.  Countries  reported  qualitative  data,  i.e.  interpreted  AST  results  for  tested  isolates  (susceptible  (S), 
intermediate (I) or resistant (R)), but no quantitative data on minimum inhibitory concentration (MIC) values 
or zone diameters. 
The public health reference laboratories were asked via e-mail to provide an update about which methods 
and which guidelines were being used for testing and interpretation. It should be noted that the public health 
reference laboratories in many countries type only a fraction of the isolates. The remaining isolates are typed 
by hospitals or local laboratories, and the methods used by these are often unknown. Six MSs plus Iceland 
used disc diffusion methods, six other MSs used dilution methods and another six MSs used a combination 
of  the  two,  depending  on  the  situation  and  the  antimicrobial  (Table  SA1).  The  guidelines  used  for  the 
interpretation differed between countries (Table MM1). Many countries employed a mixture of CLSI and 
EUCAST breakpoints. Eleven countries primarily used guidelines from the Clinical and Laboratory Standards 
Institute (CLSI), where these were available. Four countries used guidelines with generally more sensitive 
breakpoints (i.e. lower threshold to classify an isolate as resistant) or even  lower epidemiological cut-off 
values (ECOFFs) from the European Committee on Antimicrobial Susceptibility Testing (EUCAST), which 
compares the isolates with the wild-type population. For four of the 11 antimicrobials addressed, the CLSI 
MIC breakpoints and EUCAST ECOFFs are equivalent: chloramphenicol, nalidixic acid, sulfonamides and 
tetracyclines (i.e. resistance defined as ≥32 mg/L in CLSI and as >16 mg/L in EUCAST guidelines; see Table 
MM1). For three antimicrobials (cefotaxime, ciprofloxacin and gentamicin), the MIC values or zone diameters 
differ  markedly  between  the  clinical  breakpoints  and  the  ECOFFs.  This  is  particularly  the  case  for 
ciprofloxacin, for which the ECOFF is three times more sensitive than the EUCAST clinical breakpoint and 
five  times  more  sensitive  than  the  CLSI  clinical  breakpoint  (Figure  SA1).  Results  for  these  three 
antimicrobials  must  therefore  be  interpreted  with  caution,  and  no  direct  comparison  between  countries 
should be made.  
Results  are  shown  only  for  countries  reporting  data  for  more  than  20  isolates  for  the  antimicrobial  in 
question. Trend lines for 2007–2011 are shown for those countries where data were available for at least 
four years. Countries reporting 0 % resistance during this period are mentioned but are not shown in the 
graphs. 
The AST results of a total of 14 serovars, including the top 10 serovars in humans in 2010 and 2011 and 
some additional serovars of importance in animals, are presented separately. 
In  order  to  assess  whether  there  were  any  differences  in  resistance  levels  between  human  Salmonella 
infections  acquired  within  the  EU/EEA  and  infections  acquired  when  travelling  outside  the  EU/EEA, 
resistance data were presented by region based on most likely country of infection.  
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Table MM1.  Breakpoints used by MSs
1 for the interpretation of 2011 susceptibility data on Salmonella of human origin 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
Comment 
MIC  mm  MIC  mm  MIC  mm  MIC  mm  MIC  mm  MIC  mm 
Austria  -  ≤13  -  ≤17  -  ≤16  -  ≤18  -  ≤13  -  ≤13 
EUCAST 2011 for AMP, CTX, CHL, CIP, 
GEN, TRI. CLSI 2011 for KAN, NAL, STR, 
SSS, TCY  
Denmark  >8  -  >0.5  -  >16  -  >0.06  -  >2  -  >4  -  EUCAST ECOFFS. CIP is Danmap, KAN is 
NEO. 
Estonia  ≥32  ≤13  ≥1  ≤27  ≥32  ≤12  ≥0.125  ≤18  ≥16  ≤12  ≥64  ≤13  CLSI, EUCAST Enterobacteriaceae for CIP, 
DTU Food/CLSI for STR 
Germany  >8  -  >8  -  NA  NA  >2  -  >4  -  >16  -  German standard. For NAL CLSI. 
Greece  -  ≤13  -  ≤22  -  ≤12  -  ≤15  -  ≤12  -  ≤13  CLSI 2011 
Hungary  -  ≤13  -  ≤22  -  ≤12  -  ≤15  -  ≤12  -  ≤13  CLSI 2011 
Ireland  >8  -  >2  -  >8  -  >1  -  >4  -  ≥64  -  EUCAST (where available, otherwise CLSI; 
Streptomycin = EFSA) 
Italy  ≥32  ≤13  ≥64  ≤14  ≥32  ≤12  ≥4  ≤15  ≥16  ≤12  ≥64  ≤13  CLSI M100 S17 S19 
Latvia
2  ≥32  ≤13  NA  NA  NA  NA  ≥4  ≤15  NA  NA  NA  NA  CLSI 
Lithuania
2  ≥32  ≤13  ≥64  ≤14  ≥32  ≤12  ≥4  ≤15  ≥16  ≤12  ≥64  ≤13  CLSI M100-S17-S19. According to earlier 
survey use disc diffusion. 
Luxembourg  -  ≤13  -  ≤22  -  ≤12  -  ≤15  -  ≤12  -  ≤13  CLSI 2011 
Malta  ≥16  -  NA  NA  NA  NA  ≥2  -  ≥8  -  NA  NA  Biomerieux Vitek system, EUCAST 2010. 
Netherlands  >4  -  >0.5  -  >16  -  >0.06  -  >2  -  NA  NA  EUCAST ECOFFS from 2007. For STR 
EFSA and SSS CLSI. 
Romania  ≥32  ≤13  ≥4  ≤22  ≥32  ≤12  ≥4  ≤15  ≥16  ≤12  ≥64  ≤13  CLSI 2012 for disc diffusion and E-test. 
Slovakia
2  ≥32  ≤13  ≥64  ≤14  ≥32  ≤12       ≥4  ≤15  ≥16  ≤12  NA  NA  CLSI M100-S19. For KAN and STR 2003 
(STR MIC from Sensitrite) 
Slovenia  -  ≤13  -  ≤22  -  ≤12  -  ≤15  -  ≤12  -  ≤13  CLSI M100-S21 
Spain  -  ≤13  -  ≤22  -  ≤12  -  ≤15  -  ≤12  -  ≤13  CLSI M100-S-20 
United Kingdom  ≥8  -  ≥1  -  ≥8  -  ≥0.125  -  ≥4  -  ≥16  -  HPA methodology based on Frost 1994. 
Iceland 
2  -  ≤13  NA  NA  -  ≤12  -  ≤15  NA  NA  NA  NA  In lab survey mention CLSI for disc diffusion. 
Table continued overleaf. 
- = this method is not used for the antimicrobial in question.  
NA = not applicable since this antimicrobial is not reported to TESSy or fewer than 20 isolates tested.  
1. Cyprus provided data for only one isolate tested for one antimicrobial and no information was provided regarding interpretive criteria. Cyprus is therefore not represented in the table. 
2. Clinical breakpoints and comments shown are from the 2010 report; clinical breakpoints for 2011 were not reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Table MM1 (continued). Breakpoints used by MSs
1 for the interpretation of 2011 susceptibility data on Salmonella of human origin 
Country 
Naladixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim  Comment 
MIC  mm  MIC  mm  MIC  mm  MIC  mm  MIC  mm   
Austria  -  ≤13  -  ≤11  -  ≤12  -  ≤11  -  ≤14  EUCAST 2011 for AMP, CTX, CHL, CIP, GEN, TRI. 
CLSI 2011 for KAN, NAL, STR, SSS, TCY  
Denmark  >16  -  >16  -  >256  -  >8  -  >2  -  EUCAST ECOFFS. CIP is Danmap, KAN is NEO. 
Estonia  ≥32  ≤13  ≥32  ≤11  ≥512  ≤12  ≥16  ≤11  ≥16  ≤10  CLSI, EUCAST Enterobacteriaceae for Cipro, DTU 
Food/CLSI for STR 
Germany  >16  -  >16  -  NA  NA  NA  NA  ND  -  German standard. For NAL CLSI. 
Greece  -  ≤13  -  ≤11  NA  NA  -  ≤11  -  ≤10  CLSI 2011 
Hungary  -  ≤13  -  ≤11  -  ≤12  -  ≤11  -  ≤10  CLSI 2011 
Ireland  >16  -  >32  -  ≥512  -  ≥16  -  >4  -  EUCAST (where available, otherwise CLSI; 
Streptomycin = EFSA) 
Italy  ≥32  ≤13  -  ≤11  ≥512  ≤12  ≥16  ≤11  ≥16  ≤10  CLSI M100 S17 S19 
Latvia
2  NA  NA  NA  NA  NA  NA  NA  NA  ≥16  ≤10  CLSI 
Lithuania
2  ≥32  ≤13  -  ≤11  ≥512  ≤12  ≥16  ≤11  ≥16  ≤10  CLSI M100-S17-S19. According to earlier survey use 
disc diffusion. 
Luxembourg  -  ≤13  -  ≤11  -  ≤12  -  ≤11  -  ≤10  CLSI 
Malta  NA  NA  NA  NA  NA  NA  ≥16  -  -  -  Biomerieux Vitek system, EUCAST 2010. 
Netherlands  >16  -  >32  -  -  -  >8  -  NA  NA  EUCAST ECOFFS. For STR EFSA and SSS CLSI. 
Romania  ≥32  ≤13  ≥32  ≤11  ≥512  ≤12  ≥16  ≤11  ≥16  ≤10  CLSI 2012 for disc diffusion and E-test. 
Slovakia
2  NA  NA  NA  NA  ≥512  ≤12  ≥16  ≤14  NA  NA  CLSI M100-S19. For KAN and STR 2003 (STR MIC 
from Sensitrite) 
Slovenia  -  ≤13  -  ≤11  -  ≤12  -  ≤11  -  ≤10  CLSI M100-S21 
Spain  -  ≤13  -  ≤11  -  -  -  ≤11  -  -  CLSI M100-S-20 
United Kingdom  ≥16  -  ≥16  -  ≥64  -  ≥8  -  ≥2  -  HPA methodology based on Frost 1994. 
Iceland
2  -  ≤13  NA  NA  NA  NA  NA  NA  -  ≤10  In lab survey mention CLSI for disc diffusion. 
- = this method is not used for the antimicrobial in question. 
NA = not applicable since this antimicrobial is not reported to TESSy or fewer than 20 isolates tested. 
ND = not detected. 
1. Cyprus provided data for only one isolate tested for one antimicrobial and no information was provided regarding interpretive criteria. Cyprus is therefore not represented in the table. 
2. Clinical breakpoints and comments shown are from the 2010 report; clinical breakpoints for 2011 were not reported.  
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11.1.2. Campylobacter data of human origin 
Thirteen MSs and Iceland provided data for 2011. The antimicrobials reported on for Campylobacter were 
amoxicillin,  ampicillin,  ciprofloxacin,  erythromycin,  gentamicin,  nalidixic  acid  and  tetracyclines.  Some 
countries  reported  on  all  of  these  and  others  on  only  a  few.  Countries  reported  qualitative  data,  i.e. 
interpreted AST results for tested isolates (S, I or R), but no MIC values or zone diameters. 
National  reference  laboratories  were  asked  to  provide  the  methods  and  guidelines  used  for  testing  and 
interpretation. As for Salmonella, the methods and guidelines used for AST in local laboratories are often 
unknown, but could represent a high proportion of the data submitted to TESSy. Eight countries primarily 
used disc diffusion for their routine testing, while six countries used dilution or gradient strip (Table CA1). 
Three countries used both disc diffusion and dilution, depending on the circumstances. The few guidelines 
that  were  used  by  several  countries  were  the  CLSI  M45-A  criteria  (covering  the  three  most  clinically 
important antimicrobials) and recommendations from the French Society for Microbiology (CA-SFM).  The 
guidelines used for the interpretation differed between countries (Table MM2). CA-SFM, CLSI and EUCAST 
breakpoints were all used, with mixtures being employed in some countries. Four countries primarily used 
guidelines  from  CLSI,  where  available.  Five  countries  used  guidelines  from  the  French  Society  of 
Microbiology. Of the five antimicrobials reported on from both human and animal/food isolates, the EUCAST 
clinical breakpoints and ECOFFS were at the same MIC values except for ciprofloxacin and the combination 
C. coli/erythromycin, where the ECOFF was one dilution higher than the clinical breakpoint.   No clinical 
breakpoints were available for gentamicin and nalidixic acid. The CA-SFM breakpoints were generally also in 
the  same  range  or  one  dilution  higher  or  lower  than  the  ECOFF  except  for  the  combination 
C. coli/erythromycin, and tetracycline, where it was two dilution steps higher than the ECOFFs. The CLSI 
breakpoints were  often  set  at up  to two  dilutions higher than  the  ECOFF  (Figure CA1).  Results  for  the 
antimicrobials for which there are major differences in the interpretive criteria should be interpreted with 
caution, and direct comparisons between countries should be avoided. 
Results  are  shown  only  for  countries  reporting  data  for  more  than  20  isolates  for  the  antimicrobial  in 
question. Trend lines for 2007–2011 are shown for those countries where data were available for at least 
four years. Countries reporting 0 % resistance during this period are mentioned but not shown in the graphs. 
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Table MM2.  Breakpoints used by MSs for the interpretation of 2011 susceptibility data on Campylobacter of human origin 
Country 
Amoxicillin  Ampicillin  Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic acid  Tetracyclines 
Comments 
MIC  mm  MIC  mm  MIC  mm  MIC  mm  MIC  mm  MIC  mm  MIC  mm 
Austria  ≥32/ 
16  -  >8
1 
>16
2  -  ≥4  ≤15  ≥32  ≤13  >1
1 
>2
2  NA  -  ≤13  ≥16  ≤14 
National guideline for disc diffusion and CLSI 
M45A dilution test for CIP, ERY, TCY and 
NAL; CLSI for AMC+ClA; EUCAST for AMP 
and GEN 
Estonia  -  -  ≥16  ≤14  ≥1  ≤22  ≥4  ≤17  ≥4  ≤16  ≥16  ≤15  ≥1  ≤17  Disc diffusion, CASFM 
France  -  -  -  ≤19  -  ≤22  -  ≤22  -  ≤18  -  ≤20  NA  NA  CASFM 
Italy  NA  NA  -  ≤6  -  ≤6  -  ≤6  -  ≤6  -  ≤6  -  ≤6 
CLSI M45-A vol.26 no 19 for CIP and ERY. 
Local labs adapted same criteria for remaining 
ab. Disc diffusion. 
Hungary  NA  NA  NA  NA  ≥1  -  NA  NA  NA  NA  NA  NA  NA  NA  CLSI 2011 E test 
Lithuania
3  NA  NA  NA  NA  -  ≤17  -  ≤19  NA  NA  NA  NA  NA  NA 
BSAC for disc diffusion. Local laboratories 
providing data for some antimicrobials now 
closed down, so impossible to get information. 
Luxembourg  NA  NA  NA  NA  ≥1  -  ≥4  -  NA  NA  -  ≤15  NA  NA  SFM, E-test for CIP, ERY 
Malta  NA  NA  NA  NA  ≥1  -  ≥4  -  NA  NA  NA  NA  NA  NA  E-test (CA-SFM) 
Romania  NA  NA  NA  NA  NA  NA  NA  NA  NA  NA  NA  NA  NA  NA  CASFM 2010 
Slovakia
3  NA  NA  NA  NA  ≥4  -  ≥32  -  NA  NA  NA  NA  ≥16  -  CLSI for dilution test. 
Slovenia  -  <14  -  <14  ≥4  <22  ≥32  <17  -  <16  -  <15  -  <17 
AMC is AMC+clavulanic acid. CA-SFM 2010 
for disc diffusion. CLSI M45-A for CIP and 
ERY 
Spain  >16  -  NA  NA  ≥4  -  ≥32  -  ≥4  -  NA  NA  ≥16  -  CASFM for AMX, GEN, CLSI-2010 M45AE for 
CIP, ERY, TCY 
United Kingdom  -  -  ≥16  -  ≥1  -  ≥4  -  >1  -  >16  -  ≥2  -  EUCAST 
Iceland
3  NA  NA  NA  NA  ≥4  -  ≥32  -  NA  NA  NA  NA  NA  NA  No reply 2011. In other survey mention CLSI 
for E-test. 
- = this method is not used for the antimicrobial in question. 
NA = not applicable since this antimicrobial is not reported to TESSy or fewer than 20 isolates tested. 
1. 
 Breakpoint used for C. jejuni. 
2. Breakpoint used for C. coli. 
3. Clinical breakpoints and comments shown are from the 2010 report; clinical breakpoints for 2011 were not reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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11.1.3. Analysis of multi-drug resistance and co-resistance in human isolates 
An analysis of multi-drug resistance, similar to that done for animal and food isolates (see section 11.4.2), 
was undertaken with the human data. Only countries which reported to TESSy the results of tests on the full 
range  of  antimicrobials  in  10  or  more  isolates  of  Salmonella  and  Campylobacter  were  included  in  the 
analysis.  Fully  susceptible  isolates  were  those  susceptible  to  all  of  the  antimicrobial  substances.  Non-
susceptibility to an antimicrobial was defined as resistance or intermediate resistance to the antimicrobial 
drug when using clinical breakpoints as interpretive criteria (Magiorakos et al., 2012). Multi-drug resistance 
was defined as non-susceptibility to at least any three of the antimicrobials tested. Co-resistance to the most 
important drugs for human treatment was also calculated, independently of other resistance patterns. These 
co-resistance combinations were ciprofloxacin and cefotaxime for  Salmonella spp. and ciprofloxacin and 
erythromycin for Campylobacter spp.  
Resistance  to  nalidixic  acid  and  ciprofloxacin  was  addressed  together:  in  the  event  that  an  isolate  was 
resistant or exhibited intermediate resistance to either of these antimicrobials, the isolate was classified as 
non-susceptible to the combined antimicrobial ciprofloxacin/nalidixic acid, as the two substances belong to 
the same antimicrobial family.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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11.2. Antimicrobial susceptibility data from animals and food available in 2011 
11.2.1. Data reported under Directive 2003/99/EC in 2011 
MSs generated data on antimicrobial susceptibility through the testing of zoonotic and indicator bacteria 
isolated from various animal species/production types and food categories, sampled through a number of 
different national schemes. Isolates may have been collected by different monitoring approaches, either by 
active  monitoring  of  animals  and  foods  or,  in  some  cases,  by  passive  monitoring  based  on  diagnostic 
submission  of  samples  from  clinical  cases  of  disease  in  animals,  or  from  foods  sampled  as  part  of 
investigatory work. In the case of passive monitoring, the isolates tested often constituted a sub-sample of 
the total isolates available at the National Reference Laboratory (NRL). Clinical investigation data were not 
accounted for in this report. 
Dilution and disc diffusion testing methods were used by reporting MSs for susceptibility testing, and both 
quantitative and qualitative data were reported at the EU level.  
  ‘Quantitative  data’  derived  from  dilution  methods  consisted  of  the  number  of  isolates  having  a 
specific  MIC  value  (measured  in  mg/L)  relative  to  the  total  number  of  isolates  tested,  for  each 
antimicrobial agent and in each specific food/animal category. 
  ‘Quantitative  data’  derived  from  diffusion  methods  comprised  the  number  of  isolates  having  a 
specific zone diameter of inhibition (IZD measured in mm) relative to the total number of isolates 
tested, for each antimicrobial agent and in each food/animal category.  
  ‘Qualitative data’ consisted of the number of isolates out of the total number of isolates that were 
resistant to each antimicrobial agent in each food/animal category; qualitative data can be generated 
either from MIC determination or from disc diffusion testing. 
For  the  year  2011,  26  MSs  and  three  non-MSs  reported  data  on  antimicrobial  resistance  in  tested 
Salmonella  and  Campylobacter,  commensal  E. coli  and  commensal  enterococci  or  methicillin-resistant 
Staphylococcus aureus isolates from food-producing animals and/or food. Data on antimicrobial resistance in 
tested  Salmonella  and  Campylobacter  have  been  reported  on  a  mandatory  basis  under  Directive 
2003/99/EC and data on antimicrobial resistance in tested commensal E. coli and commensal enterococci or 
methicillin-resistant Staphylococcus aureus isolates have been reported by the MSs on a voluntary basis. An 
overview of the MSs and non-MSs reporting antimicrobial resistance data in 2011 is shown in Table MM3. 
Table MM3.  MSs reporting data in 2011 and description of data included in the report  
Bacteria 
Number of MSs and non-MSs 
reporting quantitative or 
qualitative data 
Data included in the report 
MIC dilution  Diffusion 
Salmonella  24 MSs + 2 non-MSs  97,602  11,441 
Campylobacter  20 MSs + 2 non-MSs  36,064  - 
Indicator E. coli  16 MSs + 2 non-MSs  123,662  1,298 
Indicator Enterococci  11 MSs + 2 non-MSs  69,166  1,848 
MRSA
1,2  1 MS +1 non-MS  450  - 
1. Methicillin-resistant Staphylococcus aureus 
2. In 2011, six MSs and one non-MS reported data on the occurrence of MRSA. 
In 2011, 12 % of quantitative Salmonella antimicrobial resistance data from animals and/or food included in 
the report were submitted by reporting MSs as disc diffusion data; the corresponding figure in 2010 was 
14 %. For E. coli, 1 % of quantitative data were obtained by disc diffusion, but these data were not included 
in the report as they were submitted only by one MS. For the purpose of this report, only quantitative dilution 
and quantitative disc diffusion data have been primarily considered. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Resistance data in Salmonella and Campylobacter 
Quantitative (MIC) results on antimicrobial resistance in Salmonella isolates from animals and food were 
reported by 20 MSs and one non-MS (Norway) in 2011. The information collected by these countries was in 
accordance with EFSA’s recommendations (EFSA, 2007); these data are described in Chapter 3. Norway 
reported results for only low numbers of isolates (fewer than 10); these data have been excluded from the 
analysis. 
In 2011, 17 MSs and two non-MSs (Norway and Switzerland) reported data on antimicrobial resistance in 
Campylobacter.  All  Campylobacter  results  were  reported  as  MIC  values  in  accordance  with  EFSA’s 
recommendations (EFSA, 2007). These data are described in Chapter 5. 
Resistance data in indicator bacteria 
For indicator (commensal) E. coli, a total of 12 MSs and two non-MSs (Norway and Switzerland) reported 
quantitative dilution (MIC) results from animals or meat derived from those animals: these data are described 
in Chapter 6. Some countries reported results for only low numbers of isolates (fewer than 10); these data 
have been excluded from the analysis. Hungary reported quantitative results for indicator E. coli isolates, 
tested  according  to  CLSI  recommendations  and  using  the  CLSI  disc  diffusion  method.  For  indicator 
enterococci  (E. faecalis  and  E. faecium),  in  total  10  MSs  and  two  non-MSs  (Norway  and  Switzerland) 
reported quantitative MIC data; these are described in Chapter 7. All countries reporting quantitative MIC 
data used the methods recommended by EFSA (EFSA, 2008a). 
Resistance data to third-generation cephalosporins 
In  relation  to  third-generation  cephalosporin  resistance  in  indicator  E.  coli  and  Salmonella  spp.,  EFSA’s 
recommendations suggest the use of cefotaxime alone to detect important types of resistance (EFSA, 2007). 
Most MSs reported results for cefotaxime; some also reported results for ceftazidime. Cefotaxime is likely to 
detect  the  presence  of  most  cefotaximases  (CTX-M  enzymes),  which  appear  to  be  currently  the  most 
prevalent  type  of  extended-spectrum  beta-lactamase  (ESBL)  enzymes  in  bacteria  isolated  from  food-
producing animals in the EU. The use of cefotaxime will also detect the presence of AmpC enzymes in 
Salmonella or E. coli. Some ESBLs are ceftazidimases rather than cefotaximases (particularly enzymes in 
the TEM and SHV families of ESBLs). Although testing both cefotaxime and ceftazidime is therefore optimal 
for  the  detection  of  all  ESBLs  and  AmpC  enzymes,  EFSA’s  guidelines  have  recommended  testing 
cefotaxime to detect all CTX-M enzymes mainly for reasons of affordability. 
Data on methicillin-resistant Staphylococcus aureus (MRSA) 
Data relating to methicillin-resistant Staphylococcus aureus prevalence were reported by six MSs and one 
non-MS (Switzerland). Among these, Switzerland reported data on resistance in MRSA isolates from pigs 
and cattle, and Belgium in MRSA isolates from broilers. The methods for collecting and testing samples for 
MRSA are not harmonised between MSs and as a result MSs may use differing procedures. Owing to the 
variety of methods employed by MSs, these are explained in detail within Chapter 8 to enable readers to 
better follow the procedures carried out by individual countries. 
There is an important difference between the methods used to isolate Salmonella, Campylobacter, E. coli 
and enterococci and that used to isolate MRSA. For the former group of organisms, there is no selective 
medium used to isolate from primary samples organisms possessing a particular resistance, whereas, for 
MRSA, antimicrobials are used to selectively isolate only those Staphylococcus aureus isolates which are 
resistant to methicillin. Some MSs may have sampled particular production types of animals (for example 
laying hens in Gallus gallus or veal calves in cattle), and this introduces another source of possible variation 
which may account for observed differences between MSs. 
11.3. Antimicrobials used for susceptibility testing in animals and food 
The antimicrobials incorporated in this summary analysis were selected based on their relative public health 
importance and as representatives of different antimicrobial classes, taking into account EFSA’s reports and 
recommendations on the harmonised monitoring and reporting of antimicrobial susceptibility data (EFSA 
2007, 2008a). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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11.3.1. Antimicrobials for susceptibility testing of Salmonella 
In 2011, both dilution and disc diffusion methods were used to test the susceptibility of Salmonella isolates 
from animals and food by MSs. Tables MM4 and MM5 show the antimicrobials selected by the different 
countries for susceptibility testing. Quantitative dilution results allowed MIC distributions to be reported for 
Salmonella  for  the  following  antimicrobials:  ampicillin,  apramycin,  cefotaxime,  ceftazidime,  ceftiofur, 
chloramphenicol,  ciprofloxacin,  colistin,  florfenicol,  gentamicin,  kanamycin,  nalidixic  acid,  neomycin, 
spectinomycin,  sulfonamides,  trimethoprim  and  tetracyclines.  For  further  information  on  reported  MIC 
distributions and number of resistant isolates, refer to the Level 3 tables published on the EFSA website. 
Data on Salmonella which were reported as disc diffusion data are presented in Appendix 1. Although results 
may not be directly comparable between MSs, it is anticipated that in most cases procedures will not have 
changed  markedly  over  time  within  a  country,  and  therefore  comparisons  of  the  proportion  of  resistant 
isolates over time in that country may be possible. 
Table MM4.  Antimicrobials selected for susceptibility testing of Salmonella isolates by MSs and one 
non-MS reporting quantitative data as MIC distributions, in 2011 
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Austria  ●    ●  ●    ●  ●  ●  ●  ●  ●  ●      ●  ●  ●  ● 
Belgium  ●    ●  ●    ●  ●  ●  ●  ●  ●  ●      ●  ●  ●  ● 
Denmark  ●  ●  ●    ●  ●  ●  ●  ●  ●    ●  ●  ●  ●  ●  ●  ● 
Estonia  ●    ●      ●  ●    ●  ●  ●  ●      ●  ●  ●  ● 
Finland  ●    ●      ●  ●    ●  ●    ●      ●  ●  ●  ● 
France  ●    ●  ●    ●  ●      ●    ●      ●  ●  ●  ● 
Germany  ●    ●  ●    ●  ●    ●  ●  ●  ●      ●  ●  ●  ● 
Greece  ●    ●      ●  ●    ●  ●    ●      ●  ●  ●  ● 
Hungary  ●    ●  ●    ●  ●      ●    ●      ●  ●  ●  ● 
Ireland  ●    ●  ●    ●  ●    ●  ●  ●  ●      ●  ●  ●   
Italy  ●    ●  ●    ●  ●    ●  ●  ●  ●      ●  ●  ●  ● 
Latvia  ●    ●      ●  ●    ●  ●    ●      ●  ●  ●  ● 
Netherlands  ●    ●  ●    ●  ●  ●  ●  ●  ●  ●      ●  ●  ●  ● 
Norway  ●    ●      ●  ●    ●  ●  ●  ●      ●  ●  ●   
Poland  ●    ●  ●    ●  ●    ●  ●    ●      ●  ●  ●  ● 
Portugal  ●    ●      ●  ●    ●  ●    ●      ●  ●  ●  ● 
Romania  ●    ●  ●    ●  ●  ●  ●  ●  ●  ●      ●  ●  ●  ● 
Slovakia  ●    ●  ●    ●  ●  ●  ●  ●  ●  ●      ●  ●  ●  ● 
Spain  ●    ●  ●    ●  ●  ●  ●  ●  ●  ●      ●  ●  ●  ● 
Sweden  ●    ●      ●  ●    ●  ●  ●  ●      ●  ●  ●  ● 
United Kingdom  ●    ●      ●  ●      ●    ●      ●  ●  ●  ● 
Note: Sulfonamides may include a variety of substances. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table MM5.  Antimicrobials  selected  for  susceptibility  testing  of  Salmonella  isolates  by  MSs 
reporting quantitative data as disc inhibition zones, in 2011 
Country 
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Romania  ●    ●      ●  ●      ●    ●      ●  ●  ● 
Spain  ●    ●      ●  ●      ●  ●  ●      ●  ●  ● 
Note: Sulfonamides may include a variety of substances. 
11.3.2. Antimicrobials for susceptibility testing of Campylobacter 
In 2011, all quantitative Campylobacter data were reported as MIC values, generated by dilution methods. 
Table  MM6  shows  the  antimicrobials  selected  by  the  different  countries  for  susceptibility  testing  of 
Campylobacter  isolates.  In this  report,  antimicrobial  resistance was  reported  separately  for  C. jejuni  and 
C. coli. 
MIC  distributions  were  analysed  for  the  following  antimicrobials:  ciprofloxacin,  chloramphenicol, 
erythromycin, gentamicin, nalidixic acid, streptomycin and tetracyclines. These antimicrobials were selected 
based on public health relevance and as representatives of different classes of antimicrobials. For further 
information  on  reported  MIC  distributions  and  number  of  resistant  isolates,  refer  to  the  Level  3  tables 
published on the EFSA website. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
 
EFSA Journal 2013;11(5):3196  324 
Table MM6.  Antimicrobials selected for susceptibility testing of Campylobacter isolates by MSs and 
non-MSs reporting quantitative data as MIC distributions, in 2011 
Country 
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Austria  ●  ●  ●  ●    ●  ●  ●  ●  ●  ●  ●    ●   
Belgium      ●  ●      ●  ●    ●    ●    ●   
Czech Republic    ●  ●  ●      ●  ●    ●    ●    ●   
Denmark      ●  ●      ●  ●    ●    ●    ●   
Estonia        ●      ●  ●    ●    ●    ●   
Finland        ●      ●  ●    ●    ●    ●   
France        ●      ●  ●    ●    ●    ●   
Germany      ●  ●      ●  ●    ●    ●    ●   
Hungary      ●  ●      ●  ●    ●    ●    ●   
Ireland      ●  ●      ●  ●    ●    ●       
Italy      ●  ●      ●  ●    ●    ●    ●   
Netherlands    ●  ●  ●  ●    ●  ●    ●  ●  ●  ●  ●  ● 
Norway        ●      ●  ●    ●    ●       
Poland        ●      ●  ●    ●    ●    ●   
Portugal      ●  ●      ●  ●    ●    ●    ●   
Romania      ●  ●      ●  ●    ●    ●    ●   
Spain      ●  ●      ●  ●    ●    ●    ●   
Sweden        ●      ●  ●    ●    ●    ●   
Switzerland      ●  ●      ●  ●    ●    ●    ●   
Note: Sulfonamides may include a variety of substances. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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11.3.3. Antimicrobials for susceptibility testing of Escherichia coli 
In 2011, both dilution and disc diffusion methods were used to test the susceptibility of E. coli isolates from 
animals and food. Tables MM7 and MM8 show the antimicrobials selected by the different countries for 
susceptibility testing. In this report, susceptibility data from animal isolates are presented. Owing to the very 
small number of countries reporting susceptibility data from food isolates, data were available from only three 
MSs and are described in the text. 
MIC  distributions  were  analysed  for  the  following  antimicrobials:  ampicillin,  apramycin,  cefotaxime, 
ceftazidime, ceftiofur, chloramphenicol, ciprofloxacin, colistin, florfenicol, gentamicin, imipenem, kanamycin, 
nalidixic acid, neomycin, spectinomycin, streptomycin, sulfonamides, trimethoprim and tetracyclines. These 
antimicrobials  were  selected  based  on  their  public  health  relevance  and  as  representatives  of  different 
antimicrobial classes. For further information on reported MIC distributions and number of resistant isolates, 
refer to the Level 3 tables published on the EFSA website. 
Table MM7.  Antimicrobials selected for susceptibility testing of Escherichia coli isolates by MSs and 
non-MSs reporting quantitative data as MIC distributions, in 2011 
Country 
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Austria  ●    ●      ●  ●      ●  ●    ●      ●  ●  ●  ● 
Belgium  ●    ●  ●    ●  ●  ●  ●  ● 
 
●  ●      ●  ●  ●  ● 
Denmark  ●  ●  ●    ●  ●  ●  ●  ●  ●      ●  ●  ●  ●  ●  ●  ● 
Estonia  ●    ●  ●    ●  ●  ●  ●  ●    ●  ●      ●  ●  ●  ● 
Finland  ●    ●      ●  ●      ●      ●      ●  ●  ●  ● 
France  ●    ●  ●    ●  ●    ●  ●      ●      ●  ●  ●  ● 
Germany  ●    ●  ●    ●  ●    ●  ●    ●  ●      ●  ●  ●  ● 
Ireland  ●    ●  ●    ●  ●    ●  ●    ●  ●      ●  ●  ●  ● 
Netherlands  ●    ●  ●    ●  ●    ●  ●    ●  ●  ●    ●  ●  ●  ● 
Norway  ●    ●  ●    ●  ●  ●  ●  ●    ●  ●      ●  ●  ●   
Poland  ●    ●  ●    ●  ●    ●  ●      ●      ●  ●  ●  ● 
Spain  ●    ●  ●    ●  ●  ●  ●  ●    ●  ●      ●  ●  ●  ● 
Sweden  ●    ●      ●    ●  ●  ●    ●  ●      ●  ●  ●  ● 
Switzerland  ●    ●  ●    ●  ●  ●  ●  ●    ●  ●      ●  ●  ●  ● 
Note: Sulfonamides may include a variety of substances. 
Table MM8.  Antimicrobials selected for susceptibility testing of Escherichia coli isolates by one MS 
reporting quantitative data as disc inhibition zones, in 2011 
Country 
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Hungary  ●     ●        ●  ●        ●        ●        ●  ●  ●  ● 
Note: Sulfonamides may include a variety of substances. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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11.3.4. Antimicrobials for susceptibility testing of enterococci 
In  2011,  for  enterococci,  only  susceptibility  data  from  dilution  methods  are  presented  by  MSs,  with  the 
exception of Hungary, which reported resistance data in E. faecalis derived from diffusion methods. Table 
MM9 shows the antimicrobials selected by the different countries for susceptibility testing. Only susceptibility 
data from animal isolates are presented as very few countries reported susceptibility data for enterococcal 
isolates from food. Data were available from only three MSs and are described in the text. 
MIC distributions were analysed  for the following antimicrobials: tetracycline, chloramphenicol, ampicillin, 
erythromycin,  streptomycin,  vancomycin,  quinupristin/dalfopristin  and  linezolid.  For  further  information  on 
reported MIC distributions and number of resistant isolates, refer to the Level 3 tables published on the 
EFSA website. 
Table MM9.  Antimicrobials selected  for  susceptibility  testing  of  isolates of  Enterococcus  faecium 
and Enterococcus faecalis, by MSs and non-MSs reporting quantitative data as MIC distributions, in 
2011 
Country 
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Austria    ●    ●  ●  ●  ●    ●      ●          ●    ●    ●    ●   
Belgium    ●    ●  ●    ●  ●  ●      ●          ●  ●  ●    ●    ●   
Denmark    ●    ●  ●    ●    ●  ●    ●        ●  ●  ●  ●  ●  ●  ●  ●   
Estonia    ●  ●  ●      ●    ●  ●    ●  ●            ●    ●    ●  ● 
Finland    ●    ●      ●    ●      ●              ●    ●    ●  ● 
France    ●    ●  ●  ●  ●    ●      ●          ●    ●    ●  ●  ●   
Ireland    ●    ●      ●    ●                    ●    ●    ●   
Netherlands    ●    ●  ●    ●  ●  ●      ●          ●  ●  ●    ●    ●   
Norway    ●  ●  ●      ●    ●  ●    ●  ●            ●        ●  ● 
Spain    ●    ●  ●    ●  ●  ●    ●  ●        ●  ●    ●    ●    ●   
Sweden    ●  ●  ●      ●    ●  ●    ●  ●            ●    ●    ●  ● 
Switzerland  ●  ●  ●  ●  ●    ●  ●  ●      ●    ●  ●    ●  ●  ●    ●    ●   
 
11.3.5. Antimicrobials for susceptibility testing of MRSA 
In 2011, Belgium reported data on susceptibility testing of MRSA isolates from broilers, and Switzerland from 
cattle and pigs. Details of the antimicrobials selected by Belgium and Switzerland are provided in Chapter 8. 
For further information on reported MIC distributions and number of resistant isolates, refer to the Level 3 
tables published on the EFSA website. 
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11.4. Data description and analysis 
11.4.1. Description and analysis of antimicrobial resistance data 
Methods to interpret, describe and analyse antimicrobial resistance data were presented in detail in the 
2004–2007 Community Summary Report on Antimicrobial Resistance (EFSA, 2010c). 
Overview tables of the resistance data reported 
Quantitative MIC data, generated by dilution methods recommended by EFSA, have been reported and 
analysed together; quantitative inhibition zone diameter (IZD) data, which constitute a relatively small fraction 
of  the  total  data  (12 %  of  the  quantitative  Salmonella  data),  have  not  been  included  in  the  analysis  of 
quantitative data and have been described separately in Appendix 1. The IZD data reported by MSs under 
Directive  2003/99/EC  for  the  years  2004–2007  were  interpreted  as  described  in  previous  Community 
Summary Reports. Some MSs reported antimicrobial resistance data as both quantitative and qualitative 
data; in that case, only the quantitative data have been included. Data generated from the antimicrobial 
susceptibility testing and reported as quantitative/qualitative by MSs, and data for which no details of the 
methodology  used  for  testing  were  provided,  have  been  described  in  the  overview  tables  of  individual 
chapters. 
MIC distributions, ECOFFs and occurrence of resistance 
For each combination of microorganism, antimicrobial and food or animal category tested, MIC distributions 
have been presented as frequency tables, giving the number of isolates tested having a given MIC at each 
test  dilution  (mg/L)  of  the  antimicrobial.  MIC  distributions  are  available  as  Level  3  tables  on  the  EFSA 
website. 
Quantitative MIC data were, wherever possible, interpreted using epidemiological cut-off values (ECOFFs) 
as listed in Decision 2007/407/EC (corresponding to those published by EUCAST at the time of publication of 
the Decision) and presented in Table MM10. Subsequent amendments by EUCAST to the ECOFFs have not 
yet  been  incorporated;  this  will  be  achieved  by  issue  of  a  revised  Decision.  An  isolate  was  defined  as 
‘microbiologically resistant’ (i.e. displaying a decreased susceptibility) to a selected antimicrobial when its 
MIC value was above the epidemiological cut-off value. A more sensitive MIC breakpoint or epidemiological 
cut-off value (i.e. a lower MIC breakpoint or epidemiological cut-off value) might be expected to result in 
more isolates being defined as clinically or microbiologically resistant, respectively; the number of isolates 
affected in that way will of course depend on the distribution of MIC results. 
The  occurrence  of  resistance  to  a  number  of  antimicrobials  was  determined  (giving  the  percentage  of 
isolates ‘microbiologically resistant’ out of those tested) for Salmonella, Campylobacter, indicator E. coli and 
enterococcal isolates from Gallus gallus, turkeys, pigs and cattle, and meat from Gallus gallus, pigs and 
cattle and are presented and analysed in tables on the occurrence of resistance in this report. These are the 
animal and food categories most frequently reported on by most MSs. Also, for the first time, data have been 
presented  at  production  type  level  where  possible.  Data  are  included  only  if  quantitative  MIC  data  are 
provided by more than four MSs or disc diffusion data are provided by more than two MSs for the bacterium–
animal/food category combination. An exception to this rule has nevertheless been made in the chapters on 
Salmonella serovars of public health importance (see below) and on MRSA. Data reported from fewer than 
10 tested isolates per combination and per MS are not included. Data are reported in separate chapters 
dedicated to each microorganism and in Appendix 1 for Salmonella data obtained from disc diffusion. In 
addition, the occurrence of resistance (i.e. resistance levels) in reporting MS groups was calculated as totals 
(the total number of resistant isolates out of the total number of tested isolates across reporting MSs), and 
not the weighted means. 
Resistance in Salmonella serovars of public health importance 
In this report, antimicrobial resistance in tested Salmonella isolates were aggregated to give a value for 
Salmonella spp. for each country and food/animal category for 2011. In addition, whenever sufficient data 
were transmitted by MSs for a particular food/animal category, the most prevalent  Salmonella serovars, 
S. Enteritidis and S. Typhimurium, were also reported separately for that food/animal category. An additional 
chapter has been included in this year’s report to describe the occurrence of antimicrobial resistance among EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Salmonella serovars of public health importance. In order to present a complete overview of the animal 
populations and food categories in which specific Salmonella serovars of public health importance have 
been recovered, data derived from the testing of fewer than 10 isolates and from fewer than four reporting 
countries, have been included. 
Data description 
Throughout the report, the following definitions apply: 
  level  or  occurrence  of  antimicrobial  resistance  means  the percentage  of  resistant  isolates  as  a 
proportion of the isolates tested of that microorganism. 
  MS reporting group means the MSs that provided data and were included in the relevant table of 
antimicrobial resistance for that bacterium–food or animal category–antimicrobial combination. 
Terms used to describe the antimicrobial resistance levels are: 
  rare:  ......................... <0.1 % 
  very low: .................. 0.1 % to 1 % 
  low: .......................... >1 % to 10 % 
  moderate: ................ >10 % to 20 % 
  high: ........................ >20 % to 50 % 
  very high:  ................. >50 % to 70 % 
  extremely high:  ........ >70 % 
These terms are applied to all antimicrobials. However, the significance of a given level of resistance will 
depend on the particular antimicrobial and its importance in human and veterinary medicine. 
Temporal trends in resistance 
Where the minimum criteria were met for the inclusion of data in this report (i.e. more than 10 isolates tested 
by a MS and more than four MSs reporting results for that antimicrobial, microorganism, food or animal 
category), then temporal trend graphs were generated showing the resistance to different antimicrobials over 
the 2005–2011 period, by plotting the level of resistance for each year of sampling. Only countries which had 
reported for four or more years in the 2005–2011 period were included. 
In order to assess the statistical significance of temporal trends, the proportions of resistance were modelled 
against time in a logistic regression. Results were provided only where there were five years or more of 
available  data  to  use  in  the  model,  and  where  the  likelihood  ratio  test  suggested  that  the  model  was 
meaningful. This analysis was carried out in SAS9.2 using the PROC LOGISTIC function for each country 
where  temporal  trend  data  were  presented  in  the  report.  The  PROC  LOGISTIC  function  uses  a  logit 
transform to model proportion of prevalence against year, and provides estimates for both intercepts and 
slope. Models resulting in a p value of <0.05 were considered to be significant. 
For  ciprofloxacin  and  nalidixic  acid,  resistance  trends  over  time  were  visually  explored  for  Salmonella, 
Campylobacter, indicator E. coli and enterococci by trellis graphs, using the lattice package in the R software 
(http://www.r-project.org). Graphs were created for those countries for which resistance data were available 
for four or more years, for at least one of the two antimicrobials. MS-specific resistance levels trend graphs 
use a unique scale and countries are shown in alphabetical order.  
Spatial analysis of resistance through maps 
MS-specific antimicrobial resistance levels for selected bacterium/food or animal category combinations were 
plotted  in  maps  for  2011,  using  ArcGIS  9.3.  In  the  maps,  resistance  levels  are  presented  with  colours 
reflecting the continuous scale of resistance to the antimicrobial of interest among reporting MSs, thus, there 
might  be  some  apparent  discrepancies  between  the  colours  and  resistance  levels  between  maps. 
Percentages shown  in  this  map  refer to countries  that reported quantitative MIC  data  for  more  than 10 
isolates in 2011. When quantitative 2011 data were not available, the 2010 level of resistance was used 
instead and referred by a footnote to the map. The countries labelled as ‘qualitative data’ therefore include 
those reporting IZD data, MIC data for fewer than 10 isolates, or purely qualitative data (as proportion of 
resistant isolates). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Table MM10.  Epidemiological cut-off values used to interpret MIC distributions (mg/L) for bacteria 
from animals and food – the given values define the microbiologically resistant isolates 
Antimicrobial agent 
Salmonella  E. coli  E. faecium  E. faecalis  C. jejuni  C. coli 
mg/L  mg/L  mg/L  mg/L  mg/L  mg/L 
Ampicillin  >4   >8  >4  >4       
Apramycin  >16  >16             
Avilamycin        >16  >8       
Cefotaxime  >0.5  >0.25             
Ceftazidime  >2  >0.5             
Ceftiofur  >2  >1             
Chloramphenicol  >16  >16  >32  >32  >16  >16 
Ciprofloxacin  >0.06  >0.03        >1  >1 
Erythromycin        >4  >4  >4  >16 
Florfenicol  >16  >16             
Gentamicin  >2  >2  >32  >32  >1  >2 
Linezolid        >4  >4       
Nalidixic acid  >16  >16        >16  >32 
Neomycin  >4  >8             
Spectinomycin     >64             
Streptomycin  >32  >16  >128  >512  >2  >4 
Sulfonamides  >256
1  >64             
Quinupristin/dalfopristin        >1          
Tetracyclines  >8  >8  >2  >2  >2  >2 
Trimethoprim  >2  >2             
Vancomycin        >4  >4       
1. Cut-off values wee not defined by EUCAST; instead cut-off values defined by the EU-RL on AMR (DTU) were used. 
11.4.2. Analysis of multi-resistance and co-resistance data 
As a consequence of the availability of antimicrobial resistance data at isolate-based level in an important 
number of MSs, the analysis of multi-resistance and co-resistance data becomes a feasible and important 
exercise, in the light of the public health relevance of the emergence of multi-resistant bacteria. As a matter 
of fact, the analysis and reporting on multi-resistance in the 2011 EUSR on antimicrobial resistance was 
previously recommended and endorsed by the Task Force on Zoonoses Data Collection at its meeting on 
AMR in March 2012.  
The  intention  is  to  focus  mainly  on  multi-resistance/co-resistance  patterns  involving  critically  important 
antimicrobials according to the bacterial species, such as cephalosporins, fluoroquinolones and macrolides, 
and  to  summarise  important  information  in  the  EUSR.  The  occurrence  of  the  isolates  of  a 
serotype/resistance pattern of interest is studied at MS level and at reporting MS group/EU level, as the 
overall picture for all MSs might show a more definite pattern of emergence and spread. In addition, the 
analysis of data may reveal the existence of new or emerging patterns of multi-resistance, particularly in 
Salmonella serotypes. 
11.4.2.1. Analysis of multi-resistance patterns 
Definitions 
For the purpose of this analysis, a multi-resistant isolate is one defined as resistant to at least three different 
antimicrobial  substances,  belonging  to  any  three  antimicrobial  families  listed  in  the  harmonised  set  of 
antimicrobials  included  in  the  EFSA  recommendations  (EFSA,  2007,  2008a).  Table  MM11  lists  those 
recommended antimicrobials.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Resistance to nalidixic acid and ciprofloxacin is addressed together: an isolate that is resistant to either of the 
two will be termed resistant to the combined antimicrobial ciprofloxacin/nalidixic acid, as the two substances 
belong to the same antimicrobial family.  
By contrast, a fully susceptible isolate is one defined as non-resistant to all of the antimicrobial substances 
included  in  the  set  of  substances  recommended  for  Salmonella,  Campylobacter,  indicator  E.  coli  and 
indicator enterococci. 
Table MM11.  Harmonised set of antimicrobials listed in the EFSA recommendations 
Zoonotic bacteria  Indicator bacteria 
Salmonella  C. coli/C. jejuni  E. coli  E. faecium/E. faecalis 
Ampicillin (AMP)  Ciprofloxacin (CIP)  Ampicillin (AMP)  Ampicillin (AMP) 
Cefotaxime (CTX)  Erythromycin (ERY)  Cefotaxime (CTX)  Chloramphenicol (CHL) 
Chloramphenicol (CHL)  Gentamicin (GEN)   Chloramphenicol (CHL)  Erythromycin (ERY) 
Ciprofloxacin (CIP)  Streptomycin (STR)  Ciprofloxacin (CIP)  Gentamicin (GEN) 
Gentamicin (GEN)  Tetracycline (TET)  Gentamicin (GEN)  Linezolid (LZD) 
Nalidixic acid (NAL)     Nalidixic acid (NAL)  Quinopristin/dalfopristin (Q/D) 
Streptomycin (STR)     Streptomycin (STR)  Streptomycin (STR) 
Sulfonamides     Sulfonamides  Tetracycline (TET) 
Tetracycline (TET)     Tetracycline (TET)  Vancomycin (VAN) 
Trimethoprim (TMP)     Trimethoprim (TMP) 
 
Data analysis 
The frequency and percentage of isolates that are considered susceptible/resistant to all of the antimicrobials 
tested were determined  for  Salmonella  (Salmonella  spp., S. Enteritidis,  S. Typhimurium and  monophasic 
S. Typhimurium),  Campylobacter  species,  indicator  E. coli  and  indicator  enterococcal  species  for  each 
country and each animal population/food category. Isolates for which no susceptibility data were provided for 
some of the antimicrobial substances were disregarded. Data analysis was presented for a particular country 
only when the number of tested isolates was at least 10, except for monophasic Salmonella Typhimurium. 
Summary indicators of multi-resistance 
To illustrate the relative proportions of multi-resistant isolates and the diversity of the resistance to multiple 
antimicrobials, graphical illustration was chosen. The percentages of isolates susceptible and resistant to 
one, two, three, etc., antimicrobials are shown using a composite bar graph displaying stacked bars, but only 
for certain combinations of bacterium–animal population or food category–MS of particular interest.  
The objective is first to give an overview of the situation on multi-resistance through summary indicators: 
  the proportion of fully susceptible isolates, 
  the proportion of multi-resistant isolates, 
  an index/indices of diversity, such as the entropy measure,
21 summarising the distributions of isolate 
frequencies and, thus, the diversity among the different categories of multi-resistance (resistance to 
one, two, three, etc., antimicrobials).  
The ‘summary indicators’ of multi-resistance can be calculated and reported yearly and, therefore, used to 
follow evolution of the multi-resistance situation across animal populations/food categories and MSs over 
time.  
Diversity of multi-resistance 
Resistance can be limited to resistance to only one or two antimicrobial substances, or resistance can be 
equally spread out from resistance from the lower to the higher number of antimicrobial substances. In other 
words, the frequencies across the categories resistant to one, two, three substances, and so on, can follow 
                                                 
21 Weighted or un-weighted entropy measures may be considered. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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different types of distributions: skewed to the right with higher frequencies for the lower numbers resistant; 
highly peaked or fully spread out; or even, at least in theory, with the higher frequencies for the larger 
numbers resistant. The entropy measure quantifies the degree of diversity of resistance. The standardised 
unweighted entropy takes values between 0 and 1. It takes the value 0 if all resistance is of one single type 
(e.g. resistance to exactly two antimicrobial substances) and takes the maximal value 1 if resistance to any 
number of antimicrobial substances is occurring equally often. The unweighted version does not take any 
order into account. So particular frequencies at the lower numbers resistant lead to the same entropy value 
when  having  these  particular  frequencies  at  the  higher  number  resistant.  The  weighted  entropy  takes 
higher values if resistance appears to higher numbers of antimicrobial substances. 
11.4.2.2. Analysis of co-resistance 
The co-resistance patterns of interest 
Co-resistance to cefotaxime and ciprofloxacin was estimated in Salmonella and E. coli isolates, as these two 
antimicrobials  are  of  particular  interest  in  human  medicine.  Co-resistance  was  addressed  using  both 
ECOFFs and clinical breakpoints in isolates of these bacteria. In C. jejuni and C. coli isolates, co-resistance 
to ciprofloxacin and erythromycin was estimated as these two antimicrobials are of particular interest in 
human medicine in the treatment of severe campylobacteriosis. The interpretative ECOFFs used to address 
co-resistance to ciprofloxacin and erythromycin were, for C. jejuni, CIP >1 mg/L and ERY >4 mg/L and, for 
C. coli,  CIP  >1 mg/L  and  ERY  >16 mg/L.  These  values  may  be  considered  as  very  similar  to  clinical 
breakpoints. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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APPENDIX 1.  ANTIMICROBIAL RESISTANCE IN SALMONELLA–QUALITATIVE DATA 
1.1. Introduction 
In 2011, two MSs reported on antimicrobial resistance in Salmonella from animals and food as quantitative 
disc diffusion data, which have been analysed as qualitative data and presented in this chapter. These disc 
diffusion data have been analysed using the breakpoints for resistance specified by the reporting MS and in 
accordance with the method used (Appendix Tables QSA1–QSA3). 
No  tables  were  generated  for  this  chapter  as  only  one  country  reported  qualitative  data  by  Salmonella 
species  and  sampling  origin.  Instead,  all  data  are  discussed  in  the  text.  Resistance  to  the  following 
antimicrobial agents are described in detail below: tetracyclines, chloramphenicol, ampicillin, sulfonamides, 
gentamicin, ciprofloxacin and nalidixic acid. 
Appendix Table QSA1.  Overview of MSs reporting qualitative data on Salmonella spp. from animals 
and food in 2011 
Origin 
Quantitative disk diffusion data 
Total number of  
MS reporting  Countries 
Gallus gallus (fowl)  1  MS: RO 
Turkeys  1  MS: RO 
Pigs  1  MS: RO 
Meat from broilers (Gallus gallus)  1  MS: ES 
Meat from pig  1  MS: ES 
 
Appendix Table QSA2.  Overview of MSs reporting qualitative data on Salmonella Typhimurium from 
animals and food in 2011 
Origin 
Quantitative disk diffusion data 
Total number of  
MS reporting  Countries 
Gallus gallus (fowl)  1  MS: RO 
Pigs  1  MS: RO 
Meat from pig  1  MS: ES 
Appendix Table QSA3.  Overview of  MSs reporting qualitative data on  Salmonella  Enteritidis  from 
animals and food in 2011 
Origin 
Quantitative disk diffusion data 
Total number of  
MS reporting  Countries 
Gallus gallus (fowl)  1  MS: RO 
Pigs  1  MS: RO EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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1.2. Antimicrobial resistance in Salmonella isolates from food (qualitative data) 
1.2.1. Meat from broilers (Gallus gallus) 
Resistance levels among Salmonella 
Only Spain reported qualitative data on resistance among Salmonella spp. from meat from broilers in 2011.  
It tested nine isolates for resistance to most antimicrobials but only eight for resistance to tetracyclines. 
These  isolates  were  fully  susceptible  to  chloramphenicol,  ciprofloxacin,  gentamicin,  sulfonamides  and 
tetracyclines. However, there was a high level of resistance to ampicillin (22.2 %) and nalidixic acid (44.4 %). 
1.3. Antimicrobial resistance in Salmonella isolates from animals (qualitative data) 
1.3.1. Fowl (Gallus gallus) 
Resistance levels among Salmonella 
Romania was the only country to report disc diffusion data for isolates of Salmonella from Gallus gallus. It 
reported data for 1,005 isolates of Salmonella spp. and 162 isolates of S. Enteritidis. The resistance levels 
reported for the former tended to be somewhat higher than in the latter. Resistance to sulfonamides was 
extremely high in both Salmonella spp. (95.9 %) and S. Enteritidis (90.2 %). Resistance to nalidixic acid was 
also very high in Salmonella spp. (57.5 %) but at a moderate level in S. Enteritidis (17.9 %). There was also 
a  high  level  of  resistance  to  ampicillin  among  Salmonella  spp.  (23.0 %)  but  only  a  moderate  level  of 
resistance  to  ciprofloxacin  (11.0 %)  and  gentamicin  (13.2 %),  and  a  low  level  of  resistance  to 
chloramphenicol (6.9 %). Among S. Enteritidis, there was only a low level of resistance to all four of these 
antimicrobials  (ampicillin  6.8 %;  chloramphenicol  1.9 %;  ciprofloxacin  1.2 %;  gentamicin  4.3 %).  No  data 
were reported concerning resistance to tetracyclines. 
1.3.2. Pigs 
Resistance levels among Salmonella 
Romania was also the only country to report disc diffusion data for isolates of Salmonella spp. from pigs. It 
reported data for 41 isolates of Salmonella spp. and eight isolates of S. Typhimurium. In both cases, there 
was 100 % resistance to sulfonamides. Resistance to ampicillin was also very high in both Salmonella spp. 
(53.7 %) and S. Typhimurium (50.0 %). Nalidixic acid resistance was at a very high level in Salmonella spp. 
(53.7 %) and at a high level in S. Typhimurium (25.0 %). Resistance to chloramphenicol and gentamicin was 
less common, with 22.0 % of Salmonella spp. and 12.5 % of S. Typhimurium expressing resistance to the 
former, and 12.2 % of Salmonella spp. and 12.5 % of S. Typhimurium expressing resistance to the latter. 
None  of  the  isolates  expressed  resistance  to  ciprofloxacin.  No  resistance  data  were  reported  for 
tetracyclines. 
1.3.3. Cattle (bovine animals) 
Resistance levels among Salmonella 
No data were reported for isolates of Salmonella spp. from cattle in 2011. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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1.4. Discussion 
Very few countries reported qualitative data for Salmonella in 2011. Furthermore, it is difficult to accurately 
compare the data collected using disc diffusion techniques and those deriving from dilution methods and 
collected quantitatively as MIC data. Therefore, as in previous years, a detailed analysis and interpretation of 
the results has not been undertaken. 
Romania and Spain both used CLSI disc diffusion methods to test the Salmonella isolates recovered from 
Gallus gallus, turkeys and pigs/meat from broilers and pigs respectively and interpreted the results using 
CLSI breakpoints. The results will not be directly comparable to the results obtained by MSs performing broth 
microdilution  MIC  determinations  and  applying  EUCAST  ECOFFs  to  interpret  those  results  and  have 
therefore been presented separately. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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APPENDIX 2.  MULTI-RESISTANCE 
Appendix Table MDR1.  Frequency  distribution  of  completely  susceptible  isolates  and  resistant  isolates  to  from  one  to  nine  antimicrobials,  in 
Salmonella spp. from meat from pigs in MSs reporting isolate-based data, 2011 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n  %  n  %  n  %  n  %  n  % 
Denmark (N=49)  9  18.4  4  8.2  4  8.2  6  12.2  19  38.8 
Estonia (N=22)  16  72.7  0  0  0  0  0  0  3  13.6 
Germany (N=115)  29  25.2  10  8.7  5  4.4  11  9.6  45  39.1 
Ireland (N=139)  37  26.6  13  9.4  6  4.3  21  15.1  30  21.6 
Italy (N=67)  18  26.9  15  22.4  4  6.0  7  10.5  11  16.4 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n  %  n  %  n  %  n  %  n  % 
Denmark (N=49)  7  14.3  0  0  0  0  0  0  0  0 
Estonia (N=22)  3  13.6  0  0  0  0  0  0  0  0 
Germany (N=115)  9  7.8  3  2.6  3  2.6  0  0  0  0 
Ireland (N=139)  15  10.8  15  10.8  2  1.4  0  0  0  0 
Italy (N=67)  7  10.5  2  3.0  3  4.5  0  0  0  0 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n = number of resistant isolates per category of susceptibility or multiple resistance. 
% = percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB = antimicrobial substance(s). 
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Appendix Table MDR2.  Frequency  distribution  of  completely  susceptible  isolates  and  resistant  isolates  to  from  one  to  nine  antimicrobials,  in 
Salmonella spp. from broilers in MSs reporting isolate-based data, 2011 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n  %  n  %  n  %  n  %  n  % 
Austria (N=90)  39  43.3  4  4.4  2  2.2  23  25.6  19  21.1 
Denmark (N=43)  34  79.1  5  11.6  1  2.3  0  0  2  4.7 
France (N=156)  94  60.3  27  17.3  0  0  9  5.8  21  13.5 
Germany (N=39)  24  61.5  3  7.7  2  5.1  2  5.1  6  15.4 
Ireland (N=63)  57  90.5  3  4.8  1  1.6  0  0  1  1.6 
Italy (N=54)  24  44.4  9  16.7  1  1.9  5  9.3  9  16.7 
Spain (N=40)  8  20.0  15  37.5  6  15.0  2  5.0  7  17.5 
United Kingdom (N=23)  12  52.2  5  21.7  3  13.0  0  0  2  8.7 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n  %  n  %  n  %  n  %  n  % 
Austria (N=90)  3  3.3  0  0  0  0  0  0  0  0 
Denmark (N=43)  1  2.3  0  0  0  0  0  0  0  0 
France (N=156)  4  2.6  1  0.6  0  0  0  0  0  0 
Germany (N=39)  1  2.6  0  0  1  2.6  0  0  0  0 
Ireland (N=63)  0  0  0  0  1  1.6  0  0  0  0 
Italy (N=54)  4  7.4  1  1.9  0  0  1  1.9  0  0 
Spain (N=40)  0  0  2  5.0  0  0  0  0  0  0 
United Kingdom (N=23)  0  0  0  0  1  4.4  0  0  0  0 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n = number of resistant isolates per category of susceptibility or multiple resistance. 
% = percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB = antimicrobial substance(s). 
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Appendix Table MDR3.  Frequency  distribution  of  completely  susceptible  isolates  and  resistant  isolates  to  from  one  to  nine  antimicrobials,  in 
Salmonella spp. from laying hens in MSs reporting isolate-based data, 2011 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n  %  n  %  n  %  n  %  n  % 
Austria (N=86)  77  89.5  7  8.1  0  0  1  0  1  1.2 
France (N=165)  141  85.5  11  6.7  2  1.2  2  1.2  6  3.6 
Germany (N=103)  89  86.4  2  1.9  2  1.9  0  0  7  6.8 
Italy (N=88)  47  53.4  19  21.6  4  1.6  5  5.7  8  9.1 
Spain (N=170)  112  65.9  45  26.5  4  2.4  3  1.8  4  2.4 
United Kingdom (N=12)  7  58.3  1  8.3  0  0  2  16.7  2  16.7 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n  %  n  %  n  %  n  %  n  % 
Austria (N=86)  1  1.2  0  0  0  0  0  0  0  0 
France (N=165)  3  1.8  0  0  0  0  0  0  0  0 
Germany (N=103)  2  1.9  0  0  0  0  1  1.0  0  0 
Italy (N=88)  3  3.4  0  0  2  2.3  0  0  0  0 
Spain (N=170)  1  0.6  1  0.6  0  0  0  0  0  0 
United Kingdom (N=12)  0  0  0  0  0  0  0  0  0  0 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n = number of resistant isolates per category of susceptibility or multiple resistance. 
% = percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB = antimicrobial substance(s). 
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Appendix Table MDR4.  Frequency distribution of completely susceptible isolates and resistant isolates to from one to nine antimicrobials, in Salmonella 
Enteritidis from laying hens in MSs reporting isolate-based data, 2011 
Country 
Susceptible to all  Resistant to 1 AMB   Resistant to 2 AMB   Resistant to 3 AMB  Resistant to 4 AMB 
n  %  n  %  n  %  n  %  n  % 
Austria (N=38)  35  92.1  3  7.9  0  0  0  0  0  0 
France (N=39)  39  100  0  0  0  0  0  0  0  0 
Germany (N=64)  64  100  0  0  0  0  0  0  0  0 
Italy (N=14)  9  64.3  3  21.4  0  0  0  0  1  7.1 
Spain (N=59)  21  35.6  34  57.6  2  3.4  2  3.4  0  0 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB   Resistant to 8 AMB   Resistant to 9 AMB 
n  %  n  %  n  %  n  %  n  % 
Austria (N=38)  0  0  0  0  0  0  0  0  0  0 
France (N=39)  0  0  0  0  0  0  0  0  0  0 
Germany (N=64)  0  0  0  0  0  0  0  0  0  0 
Italy (N=14)  1  7.1  0  0  0  0  0  0  0  0 
Spain (N=59)  0  0  0  0  0  0  0  0  0  0 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n = number of resistant isolates per category of susceptibility or multiple resistance. 
% = percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB = antimicrobial substance(s). 
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Appendix Table MDR5.  Frequency  distribution  of  completely  susceptible  isolates  and  resistant  isolates  to  from  one  to  nine  antimicrobials,  in 
Salmonella spp. from turkeys in MSs reporting isolate-based data, 2011 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n  %  n  %  n  %  n  %  n  % 
Austria (N=22)  6  27.3  7  31.8  1  4.6  2  9.1  2  9.1 
France (N=174)  64  36.8  36  20.7  8  4.6  14  8.1  19  10.9 
Germany (N=78)  24  30.8  6  7.7  2  2.6  13  16.7  12  15.4 
Ireland (N=14)  8  57.1  2  14.3  0  0  2  14.3  0  0 
Italy (N=27)  5  18.5  2  7.4  2  7.4  2  7.4  8  29.6 
Spain (N=154)  4  2.6  2  1.3  2  1.3  24  15.6  13  8.4 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n  %  n  %  n  %  n  %  n  % 
Austria (N=22)  1  4.6  3  13.6  0  0  0  0  0  0 
France (N=174)  29  16.7  4  2.3  0  0  0  0  0  0 
Germany (N=78)  18  23.1  3  3.9  0  0  0  0  0  0 
Ireland (N=14)  2  14.3  0  0  0  0  0  0  0  0 
Italy (N=27)  4  14.8  2  7.4  2  7.4  0  0  0  0 
Spain (N=154)  41  26.6  58  37.7  10  6.5  0  0  0  0 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n = number of resistant isolates per category of susceptibility or multiple resistance. 
% = percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB = antimicrobial substance(s). 
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Appendix Table MDR6.  Frequency  distribution  of  completely  susceptible  isolates  and  resistant  isolates  to  from  one  to  nine  antimicrobials,  in 
Salmonella spp. from fattening pigs in MSs reporting isolate-based data, 2011 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n  %  n  %  n  %  n  %  n  % 
Denmark (N=371)  183  49.3  52  14.0  18  4.9  24  6.5  68  18.3 
Estonia (N=17)  12  70.6  1  5.9  0  0  0  0  4  23.5 
Germany (N=614)  90  14.7  31  5.1  34  5.5  33  5.4  237  38.6 
Ireland (N=39)  15  38.5  2  5.1  0  0  0  0  8  20.5 
Italy (N=86)  27  31.4  7  8.1  3  3.5  3  3.5  33  38.4 
Spain (N=81)  18  22.2  8  9.9  4  4.9  13  16.1  22  27.2 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n  %  n  %  n  %  n  %  n  % 
Denmark (N=371)  20  5.4  6  1.6  0  0  0  0  0  0 
Estonia (N=17)  0  0  0  0  0  0  0  0  0  0 
Germany (N=614)  131  21.3  47  7.7  11  1.8  0  0  0  0 
Ireland (N=39)  3  7.7  7  18.0  3  7.7  1  2.6  0  0 
Italy (N=86)  7  8.1  2  2.3  2  2.3  2  2.3  0  0 
Spain (N=81)  5  6.2  6  7.4  2  2.5  3  3.7  0  0 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n = number of resistant isolates per category of susceptibility or multiple resistance. 
% = percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB = antimicrobial substance(s). 
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Appendix Table MDR7.  Frequency  distribution  of  completely  susceptible  isolates  and  resistant  isolates  to  from  one  to  nine  antimicrobials,  in 
Salmonella spp. from cattle in MSs and non-MS reporting isolate-based data, 2011 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n  %  n  %  n  %  n  %  n  % 
Estonia (N=15)  15  100  0  0  0  0  0  0  0  0 
Finland (N=11)  10  90.9  0  0  1  9.1  0  0  0  0 
Germany (N=146)  91  62.3  6  4.1  2  1.4  4  2.7  34  23.3 
Ireland (N=44)  17  38.6  1  2.3  0  0  4  9.1  8  18.2 
Italy (N=28)  14  50.0  1  3.6  1  3.6  2  7.1  4  14.3 
Spain (N=13)  11  84.6  1  7.7  1  7.7  0  0  0  0 
Sweden (N=24)  18  75.0  1  4.2  2  8.3  2  8.3  1  4.2 
Norway (N=12)  8  66.7  0  0  0  0  1  8.3  3  25.0 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n  %  n  %  n  %  n  %  n  % 
Estonia (N=15)  0  0  0  0  0  0  0  0  0  0 
Finland (N=11)  0  0  0  0  0  0  0  0  0  0 
Germany (N=146)  7  4.8  2  1.4  0  0  0  0  0  0 
Ireland (N=44)  13  29.6  1  2.3  0  0  0  0  0  0 
Italy (N=28)  3  10.7  2  7.1  0  0  1  3.6  0  0 
Spain (N=13)  0  0  0  0  0  0  0  0  0  0 
Sweden (N=24)  0  0  0  0  0  0  0  0  0  0 
Norway (N=12)  0  0  0  0  0  0  0  0  0  0 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n = number of resistant isolates per category of susceptibility or multiple resistance. 
% = percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB = antimicrobial substance(s). 
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Appendix Table MDR8.  Frequency  distribution  of  completely  susceptible  isolates  and  resistant  isolates  to  from  one  to  five  antimicrobials,  in 
Campylobacter jenuni from meat from broilers in MSs reporting isolate-based data, 2011 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB  Resistant to 5 AMB 
n  %  n  %  n  %  n  %  n  %  n  % 
Austria (N=84)  34  40.5  34  40.5  16  19.1  0  0  0  0  0  0 
Denmark (N=61)  53  86.9  2  3.3  6  9.8  0  0  0  0  0  0 
Germany (N=188)  52  27.7  49  26.1  82  43.6  5  2.7  0  0  0  0 
Italy (N=13)  1  7.7  4  30.8  8  61.5  0  0  0  0  0  0 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n = number of resistant isolates per category of susceptibility or multiple resistance. 
% = percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB = antimicrobial substance(s). 
 
Appendix Table MDR9.  Frequency  distribution  of  completely  susceptible  isolates  and  resistant  isolates  to  from  one  to  five  antimicrobials,  in 
Campylobacter jejuni from broilers in MSs and non-MSs reporting isolate-based data, 2011 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB  Resistant to 5 AMB 
n  %  n  %  n  %  n  %  n  %  n  % 
Austria (N=116)  33  28.5  65  56.0  18  15.5  0  0  0  0  0  0 
Denmark (N=43)  32  74.4  3  7.0  7  16.3  1  2.3  0  0  0  0 
Germany (N=59)  12  20.3  25  42.4  19  32.2  3  5.1  0  0  0  0 
Ireland (N=114)  38  33.3  44  38.6  31  27.2  1  0.9  0  0  0  0 
Spain (N=53)  2  3.8  5  9.4  38  71.7  6  11.3  2  3.8  0  0 
Norway (N=48)  44  91.7  4  8.3  0  0  0  0  0  0  0  0 
Switzerland (N=150)  71  47.3  51  34.0  22  14.7  4  2.7  1  0.7  1  0.7 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n = number of resistant isolates per category of susceptibility or multiple resistance. 
% = percentage of resistant isolates per category of susceptibility or multiple resistance. 
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Appendix Table MDR10.  Frequency  distribution  of  completely  susceptible  isolates  and  resistant  isolates  to  from  one  to  five  antimicrobials,  in 
Campylobacter coli from broilers in MSs and non-MS reporting isolate-based data, 2011 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB  Resistant to 5 AMB 
n  %  n  %  n  %  n  %  n  %  n  % 
Austria (N=48)  3  6.3  15  31.3  24  50.0  6  12.5  0  0  0  0 
Germany (N=25)  0  0  6  24.0  11  44.0  6  24.0  2  8.0  0  0 
Ireland (N=32)  13  40.6  11  34.4  7  21.9  1  3.1  0  0  0  0 
Spain (N=78)  0  0  1  1.3  22  28.2  27  34.6  24  30.8  4  5.1 
Switzerland (N=10)  5  50  2  20.0  2  20.0  0  0  1  10.0  0  0 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n = number of resistant isolates per category of susceptibility or multiple resistance. 
% = percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB = antimicrobial substance(s). 
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Appendix Table MDR11.  Frequency distribution of completely susceptible isolates and resistant isolates to from one to nine antimicrobials, in E. coli 
from broilers in MSs and non-MSs reporting isolate-based data, 2011 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n  %  n  %  n  %  n  %  n  % 
Austria (N=173)  24  13.9  53  30.6  34  19.7  22  12.7  23  13.3 
Denmark (N=134)  76  56.7  33  24.6  13  9.7  7  5.2  3  2.2 
Germany (N=246)  22  8.9  21  8.5  20  8.1  38  15.5  32  13.0 
Spain (N=101)  6  5.9  6  5.9  9  8.9  14  13.9  16  15.8 
Norway (N=244)  96  39.3  97  39.8  26  10.7  11  4.5  9  3.7 
Switzerland (N=176)  44  25.0  61  34.7  22  12.5  25  14.2  11  6.3 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n  %  n  %  n  %  n  %  n  % 
Austria (N=173)  11  6.4  3  1.7  3  1.7  0  0  0  0 
Denmark (N=134)  1  0.8  1  0.8  0  0  0  0  0  0 
Germany (N=246)  50  20.3  37  15.0  23  9.4  3  1.2  0  0 
Spain (N=101)  13  12.9  17  16.8  17  16.8  2  2.0  1  1.0 
Norway (N=244)  3  1.2  1  0.4  1  0.4  0  0  0  0 
Switzerland (N=176)  10  5.7  2  1.1  1  0.6  0  0  0  0 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n = number of resistant isolates per category of susceptibility or multiple resistance. 
% = percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB = antimicrobial substance(s). 
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Appendix Table MDR12.  Frequency distribution of completely susceptible isolates and resistant isolates to from one to nine antimicrobials, in E. coli 
from fattening pigs in MSs and non-MSs reporting isolate-based data, 2011 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n  %  n  %  n  %  n  %  n  % 
Austria (N=162)  51  31.5  33  20.4  33  20.4  21  13.0  11  6.8 
Denmark (N=157)  76  48.4  25  15.9  14  8.9  10  6.4  15  9.6 
Estonia (N=22)  6  27.3  5  22.7  3  13.6  1  4.6  3  13.6 
Germany (N=859)  204  23.8  122  14.2  73  8.5  105  12.2  94  10.9 
Spain (N=169)  6  3.6  12  7.1  8  4.7  24  14.2  34  20.1 
Norway (N=192)  103  53.7  56  29.2  14  7.3  6  3.1  5  2.6 
Switzerland (N=175)  59  33.7  28  16.0  14  8.0  25  14.3  21  12.0 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n  %  n  %  n  %  n  %  n  % 
Austria (N=162)  10  6.2  3  1.9  0  0  0  0  0  0 
Denmark (N=157)  13  8.3  4  2.6  0  0  0  0  0  0 
Estonia (N=22)  3  13.6  1  4.6  0  0  0  0  0  0 
Germany (N=859)  158  18.4  83  9.7  18  2.1  2  0.2  0  0 
Spain (N=169)  30  17.8  37  21.9  18  10.7  0  0  0  0 
Norway (N=192)  7  3.7  1  0.5  0  0  0  0  0  0 
Switzerland (N=175)  18  10.3  7  4.0  2  1.1  1  0.6  0  0 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n = number of resistant isolates per category of susceptibility or multiple resistance. 
% = percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB = antimicrobial substance(s). 
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Appendix Table MDR13.  Frequency  distribution  of  completely  susceptible  isolates  and  resistant  isolates  to  from  one  to  nine  antimicrobials,  in 
E. faecium from broilers in MSs and one non-MS reporting isolate-based data, 2011 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n  %  n  %  n  %  n  %  n  % 
Austria (N=72)  10  13.9  22  30.6  19  26.4  13  18.1  7  9.7 
Denmark (N=107)  55  51.4  32  29.9  17  15.9  2  1.9  1  0.9 
Spain (N=36)  0  0  0  0  6  16.7  11  30.6  9  25.0 
Switzerland (N=13)  1  7.7  5  38.5  4  30.8  2  15.4  1  7.7 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n  %  n  %  n  %  n  %  n  % 
Austria (N=72)  1  1.4  0  0  0  0  0  0  0  0 
Denmark (N=107)  0  0  0  0  0  0  0  0  0  0 
Spain (N=36)  9  25.0  1  2.8  0  0  0  0  0  0 
Switzerland (N=13)  0  0  0  0  0  0  0  0  0  0 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n = number of resistant isolates per category of susceptibility or multiple resistance. 
% = percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB = antimicrobial substance(s). 
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Appendix Table MDR14.  Frequency  distribution  of  completely  susceptible  isolates  and  resistant  isolates  to  from  one  to  nine  antimicrobials,  in 
E. faecium from pigs in MSs and non-MS reporting isolate-based data, 2011 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n  %  n  %  n  %  n  %  n  % 
Austria (N=61)  1  1.6  25  41.0  26  42.6  2  3.3  4  6.6 
Denmark (N=116)  19  16.4  20  17.2  25  21.6  19  16.4  28  24.1 
Spain (N=41)  1  2.4  2  4.9  4  9.8  7  17.1  25  61.0 
Switzerland (N=25)  5  20.0  6  24.0  8  32.0  5  20.0  1  4.0 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n  %  n  %  n  %  n  %  n  % 
Austria (N=61)  3  4.9  0  0  0  0  0  0  0  0 
Denmark (N=116)  5  4.3  0  0  0  0  0  0  0  0 
Spain (N=41)  2  4.9  0  0  0  0  0  0  0  0 
Switzerland (N=25)  0  0  0  0  0  0  0  0  0  0 
N = total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n = number of resistant isolates per category of susceptibility or multiple resistance. 
% = percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB = antimicrobial substance(s). 
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APPENDIX 3. LEVEL 3 TABLES 
Level 3 tables containing information on reported MIC distributions and data on the number of resistant 
isolates, are available on the EFSA website. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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APPENDIX 4. List of abbreviations and definitions, Member States and other reporting 
countries, definitions 
List of abbreviations  
Abbreviation  Definition 
AHVLA  Animal Health and Veterinary Laboratories Agency 
AMR  antimicrobial resistance 
AST  antimicrobial susceptibility testing 
BIOHAZ  EFSA Panel on Biological Hazards 
BSAC  British Society for Antimicrobial Chemotherapy 
CA-SFM  French Society for Microbiology 
CBP  clinical breakpoint 
CIA  critically important antimicrobial 
CLSI  Clinical and Laboratory Standards Institute 
CTX-M  cefotaximase 
Danmap  Danish Programme for surveillance of antimicrobial consumption and resistance in 
bacteria from animals, food and humans 
DIN  Deutsches Institut für Normung 
DNA  desoxyribonucleic acid 
DTU  Technical University of Denmark  
EC  European Commission 
ECDC  European Centre for Disease Prevention and Control 
ECOFF  epidemiological cut-off value 
EEA  European Economic Area 
EFSA   European Food Safety Authority 
EMA  European Medicines Agency 
ESBL  extended spectrum beta-lactamase 
ETEC  enterotoxigenic E. coli 
EU  European Union 
EUCAST  European Committee on Antimicrobial Susceptibility Testing 
EU-RL  European Union Reference Laboratory 
HACCP  Hazard Analysis and Critical Control Point 
HPA  Health Protection Agency (UK) 
IZD  Inhibition Zone Diameter 
MIC  Minimum Inhibitory Concentration 
MLSB  Macrolide–lincosamide–streptogramin B 
MRSA  Methicillin-resistant Staphylococcus aureus 
MS  Member State 
NCP  National Control Programme 
NRL  National Reference Laboratory 
PBP  Penicillin-binding protein 
PCR  Polymerase Chain Reaction 
SGRA-M  Subcommittee on methodology from the Swedish Reference Group for Antibiotics 
spp.  Species 
TESSy  The European Surveillance System 
VTEC  Vero(cyto)toxigenic E. coli 
WHO  World Health Organization EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Member States of the European Union and other reporting countries in 2011 
Member States of the European Union, 2011 
Member State  Country abbreviations 
Austria  AT 
Belgium  BE 
Bulgaria  BG 
Cyprus  CY 
Czech Republic  CZ* 
Denmark  DK 
Estonia  EE 
Finland  FI 
France  FR 
Germany  DE 
Greece  GR 
Hungary  HU 
Ireland  IE 
Italy  IT 
Latvia  LV 
Lithuania  LT 
Luxembourg  LU 
Malta  MT 
Netherlands  NL* 
Poland  PL 
Portugal  PT 
Romania  RO 
Slovakia  SK 
Slovenia  SI 
Spain  ES 
Sweden  SE 
United Kingdom  UK* 
* In text, referred to as the Czech Republic, the Netherlands and the United Kingdom 
 
Non-Member States reporting, 2011 
Country  Country abbreviations 
Iceland  IS 
Norway  NO 
Switzerland  CH EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
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Definitions 
Term  Definition and description 
‘Antimicrobial resistant isolate’.  In the case of quantitative data, an isolate was defined as ‘resistant’ to a 
selected antimicrobial when its MIC value (in mg/L) was above the cut-off 
value or the disc diffusion diameter (in mm) was below the cut-off value. 
The cut-off values used to interpret MIC distributions (mg/L) for bacteria 
from animals and food are shown in Table MM10. 
In the case of qualitative data, an isolate was regarded resistant when the 
country reported it as resistant using its own cut-off value or break point. 
‘Level of antimicrobial resistance’:  The percentage of resistant isolates among the tested isolates. 
‘Reporting MS group’:  Member States (MSs) that provided data and were included in the relevant 
table for antimicrobial resistance data for the bacteria–food/animal 
category–antimicrobial combination. 
Terms used to describe the 
antimicrobial resistance levels 
 
Rare:  < 0.1 % 
Very low:  0.1 % to 1 % 
Low:  >1 % to 10 % 
Moderate:  >10 % to 20 % 
High:  >20 % to 50 % 
Very high:  >50 % to 70 % 
Extremely high:  >70 % 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2011 
 
EFSA Journal 2013;11(5):3196  358 
APPENDIX 5. List of institutions contributing to AMR monitoring in animals and food 
List of institutions contributing to AMR monitoring in animals and food 
Member State  Institution 
Austria 
  Federal Ministry for Health 
  Austrian Agency for Health and Food Safety (AGES) 
Belgium 
  Veterinary and Agrochemical Research Centre (CODA-CERVA), Uccle 
  Institute of Public Health, Brussels 
  Federal Agency for the Safety of the Food Chain, Brussels 
Bulgaria 
  National Diagnostic and Research Veterinary Institute, Sofia 
  Bulgarian Food Safety Agency, Sofia 
Cyprus 
  Veterinary Services, Nicosia 
  Ministry of Agriculture, Nicosia 
Czech Republic 
  State Veterinary Institute, Prague and Olomouc 
  State Veterinary Administration of the Czech Republic, Prague 
Denmark 
  National Food Institute, Technical University of Denmark 
  Danish Veterinary and Food Administration 
Estonia 
  Estonian Veterinary and Food Laboratory, Tartu 
  Veterinary and Food Board, Tallinn 
Finland    EVIRA, Finnish Food Safety Authority, Helsinki 
France 
  ANSES, French Agency for Food, Environmental Occupational Health and Safety: 
Fougères Laboratory, Maisons-Alfort Laboratory, Ploufragan/Plouzané Laboratory 
  Ministère de l´agriculture, de l’alimentation, de la pêche, de la ruralité et de l’aménagement 
du terriroire, Direction Générale de l’Alimentation, Paris 
Germany    Federal Institute for Risk Assessment (BfR), Berlin 
Greece 
  Veterinary Laboratory, Chalkis 
  Ministry of Rural Development and Food, Athens 
Hungary 
  Central Agricultural Office, Veterinary Diagnostical Directorate, Budapest 
  Ministry of Rural Agriculture, Budapest 
Ireland 
  Central Veterinary Research Laboratory, Celbridge 
  Food Safety Authority of Ireland, Dublin 
Italy 
  Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana, Rome 
  Ministry of Health, Rome 
Latvia 
  Institute of Food Safety, Animal Health and Enviroment "BIOR", Animal Disease Diagnostic 
Laboratory, Riga 
  Food and Veterinary Service of Latvia, Riga 
Lithuania 
  National Food and Veterinary Risk Assessment Institute, Vilnius 
  State Food and Veterinary Service, Vilnius 
Luxembourg    Laboratoire de Médecine Vétérinaire, Luxembourg 
Malta    Ministry for Resources and Rural Affairs 
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List of institutions contributing to AMR monitoring in animals and food (continued) 
Member State  Institution 
Netherlands 
  Central Veterinary Institute, part of Wageningen UR (CVI), Lelystad 
  National Institute of Public Health and the Environment (RIVM), Bilthoven 
  Ministry of Agriculture, Nature and Food Quality 
  Animal Health Service, Deventer 
Poland 
  National Veterinary Research Institute, Pulawy 
  General Veterinary Inspectorate, WARSAW 
Portugal 
  Laboratório Nacional de Investigação Veterinária, Lisbon  
  Direcção Geral de Veterinária, Lisbon 
Romania 
  Institute for Diagnostic and Animal Heath, Bucharest 
  Institute for Hygiene and Veterinary Public Heath, Bucharest 
  National Sanitary Veterinary and Food Safety Authority, Bucharest 
Slovakia 
  State Veterinary and Food Institute, Dolny Kubin and Bratislava 
  State Veterinary and Food Administration of the Slovak Republic 
Slovenia 
  National Veterinary Institute, Veterinary Faculty, Ljubljana 
  Ministry for Agriculture and Environment, Veterinary Administration, Ljubljana 
Spain 
  Laboratorio Central de Sanidad Animal de Santa Fe, Granada 
  Laboratorio Central de Veterinaria de Algete, Madrid 
  VISAVET Health Surveillance Center, Complutense University, Madrid 
  Ministerio de Agricultura, Alimentación y Medio Ambiente 
  Agencia Española de Seguridad Alimentaria y Nutrición 
Sweden 
  National Veterinary Institute (SVA), Department of Animal Health and Antimicrobial 
Strategies, Uppsala 
  National Food Administration, Uppsala 
United Kingdom    Animal Health and Veterinary Laboratories Agency (AHVLA)  
 
Other reporting 
country  Institution 
Norway    Norwegian Veterinary Institute 
Switzerland 
  ZOBA–Centre for Zoonoses, Bacterial Animal Diseases and Antimicrobial Resistance–
Institute of Veterinary Bacteriology, Vetsuisse Faculty, University of Bern 
  Swiss Federal Veterinary Office 
 